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Abstract
The synthesis o f adenophostin A, a recently discovered exceptionally potent
agonist at the lD-myo-inositol 1,4,5-trisphosphate [Ins(l,4,5)P3] receptor, and a series
2+
of adenophostin A analogues is described. Structure-activity correlations for Ca 
release at the hepatocyte Ins(l,4,5)P3 receptor are described.
a-A nd /?-C-(hydroxymethyl)-1 -deoxy-D-glucopyranoside 3,4, 1'-
trisphosphates were designed and synthesised as monosaccharide analogues based on 
an originally described adenophostin A mimic (2-hydroxyethyl-cr-D-glucopyranoside- 
2,3',4'-trisphosphate), but with a shorter and less flexible side chain. The a-
94-trisphosphate was similar in potency for Ca release as Ins(l,4,5)P3 while the /?- 
trisphosphate was considerably weaker. Simplification o f the adenophostin A 
structure led to the design and synthesis o f [(3S,4R)-3-hydroxytetrahydrofuran-4-yl] 
a-D-xylopyranoside 3,3',4-trisphosphate (xylofuranophostin), a disaccharide-derived 
analogue in which the adenine and both hydroxymethyl moieties have been deleted. 
In order to explore the effect o f stereochemical variations on the biological activity of 
xylofuranophostin, and in particular the positioning of the non-vicinal phosphate 
group for potent activity, the synthesis o f three o f its diastereoisomers was 
undertaken. Further simplification would inevitably result in a substantial decrease in 
potency, and xylofuranophostin is therefore likely to represent the simplest possible
94 -structure for potent Ca -releasing activity in this type of carbohydrate-based 
analogue.
To enable the synthesis of adenophostin A and base-modified adenophostin A 
analogues a disaccharide intermediate, l,2 ,3 ,,4,-tetra-tri-0-acetyl-2,,5,6'-0-benzyl-3- 
O-a-D-glucopyranosyl-D-ribofuranose was synthesised. Vorbruggen condensation of 
this intermediate with 6-chloropurine/2,6-dichlorpurine led to the synthesis of a series 
of adenophostin A analogues elaborated at N-6 and C-2. Biological evaluation o f 
these compounds has shown N6-methyl adenophostin to be amongst the first totally 
synthetic compounds to approach the activity o f adenophostin A. By the introduction 
o f different sized molecules this study has revealed evidence o f a possible unoccupied 
and new receptor binding pocket for the Ins(l,4,5)P3R in complex with adenophostin
A. These results further demonstrate that a base-modification approach represents a 
powerful strategy to develop high potency ligands.
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Introduction Part a: Ca2+ and lns(1,4,5)P3
1.1 Intracellular Calcium Signaling
Intracellular calcium plays a crucial role in the control o f many cellular processes 
as diverse as cell proliferation, muscle contraction, secretion, metabolism and neuronal 
signaling[l]. In order to accomplish such varying feats the concentration o f intracellular 
Ca2+ must be regulated.
n  I
When the Ca concentration is low (10-100 nM) the cells are at rest but when 
raised to 500-1000 nM the cells are activated to perform their various functions. The 
concentration is finely regulated by various mechanisms related to physiological 
function.
94-  94 -One mechanism is the influx o f Ca via Ca channels, for example voltage- 
operated channels (VOCs), across the cell membrane. This mechanism takes advantage
94 -of the fact that there is a much larger concentration of Ca outside the cell than inside 
therefore producing a large electrochemical gradient favouring Ca2+ entry. Another 
mechanism is the release of Ca2+ from intracellular Ca2+ stores via intracellular Ca2+
9  .
release channels. Release from intracellular Ca stores is accomplished by small 
molecules, known as second messengers. These include D-myo-inositol 1,4,5- 
trisphosphate [Ins(l,4,5)P3, figure 1.1], cyclic adenosine diphosphate ribose (cADPR, 
figure 1.2) and nicotinic acid adenine dinucleotide phosphate (NAADP, figure 1.3)[2]. 
Ca2+ release from Ins(l,4,5)P3 receptor [Ins(l,4,5)P3R] is induced by the second 
messenger Ins(l,4,5)P3, while RyR is regulated by cADPR[3;4]. Both receptors share
94-many similarities and are modulated by cytoplasmic Ca concentrations, calmodulin and 
phosphorylation. The receptor for NAADP and the Ca2+ channel involved have not yet
09
been discovered. However, binding studies using [ PJNAADP revealed a single class of 
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Figure 1.2: Cyclic ADP-ribose
The rest o f the thesis will be concerned with Ins(l,4,5)P3, adenophostin 
(introduced in section 1.12) and their analogues.
1.2 Phosphoinositides and the origin of lns(1,4,5)P3
When the receptor on the surface o f the cell membrane is activated it triggers 
phospholipase C (PLC) enzymes[5] to break down the membrane-bound 
phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] into diacyl glycerol (DAG) and 
Ins(l,4,5)P3. The latter diffuses into the cytoplasm, binds to its receptor and releases 
stored Ca . Some PLC enzymes are regulated by G-nucleotide-binding proteins and 
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Figure 1.4: Hydrolysis o f phosphatidylinositol 4,5-bisphosphate by phospholipase C 
produces inositol 1,4,5-trisphosphate and diacylglycerol.
Phosphatidylinositol (Ptdlns) is synthesised from myo-inositol and CDP- 
diacylglycerol by a reaction that may take place in the endoplasmic reticulum. Recent 
evidence suggests that it may also be synthesized on the plasma membrane. In 
mammalian cells, myoinositol is either taken up from food or is provided by the 
dephosphorylation o f inositol phosphates. It is worth noting that myoinositol cannot 
cross the blood-brain barrier, so the brain must rely upon recycled myo-inositol. Plants 
can synthesize D-myoinositol-3-phosphate from D-glucose-6-phosphate.
The other substrate, CDP-DAG is formed from CTP and phosphatidic acid 
(PtdA), the latter originating either from de novo synthesized DAG, or from DAG 
produced by phospholipid hydrolysis by PLC. Once Ptdlns has been synthesized it may 
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Figure 1.5: Summary of the synthesis of phosphatidylinositol 4,5-bisphosphate.
1.3 P hospholipase C
There are eleven distinct isoforms of phosphoinositide-specific PLC, which are 
grouped into four subfamilies (J3, y, S, and s). This diverse group of enzymes differ in 
structure and tissue distribution. As mentioned earlier, PLC hydrolyses PtdIns(4,5)P2 to 
Ins(l,4,5)P3 and DAG in response to the activation of more than a hundred different cell 
surface receptors (Table 1.1).
All PLC isoforms contain X and Y domains, which form the catalytic core, as 
well as various combinations of regulatory domains that are common to many other 
signalling proteins. The presence of distinct regulatory domains renders them 
susceptible to different modes of activation, which is likely to be a highly regulated 
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Table 1.1: Plasma Membrane Receptors Increasing Intracellular Ca [7]
1.4 G-protein-linked receptors
As mentioned earlier, activation by G-protein linked receptors is one o f the two 
major mechanisms for the formation of Ins(l,4,5)P3. They are coupled to an energy- 
requiring (GTP) transducing mechanism which activates PLC to hydrolyse the lipid 
precursor PtdIns(4,5)P2 to give both DAG and Ins(l,4,5)P3.
In general, these receptors contain seven regions o f approximately twenty two to 
twenty four amino acids which form hydrophobic a-helices spanning the plasma 
membrane. The classes of G-protein involved in signal transduction from cell surface 
receptors are known as trimeric or heterotrimeric G-proteins. As their name suggests 
they are composed o f three subunits a, p  and y
5
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When at rest the three subunits are bound together and a molecule of GDP is 
bound to the a-subunit. When the receptor is activated by an agonist, a conformational 
change in the receptor is induced. This change stimulates the dissociation of bound GDP 
from the a-subunit. GTP then rapidly binds to the a-subunit (Go;). The Ga-GTP 
complex dissociates from the G/?y-complex and diffuses through the membrane until it 
encounters a molecule of PLCp  which it activates to produce Ins(l,4,5)P3 and DAG 
(Figure 1.6).
Activation o f PLC ceases when the GTP associated with the G-protein is 
hydrolysed to GDP by the intrinsic GTP-ase activity o f the G a  subunit. The Ga-GDP 
then dissociates from PLC and rejoins the G/?/complex therefore returning the G-protein 
to rest.
1.5 Tyrosine kinase-linked receptors.
The other pathway responsible for stimulating the release o f Ins(l,4,5)P3 begins 
with the tyrosine kinase receptors. The ligand-binding domain is found on the 
extracellular side o f the membrane, with usually a single span of the membrane leading 
to the catalytic domain on the cytoplasmic side. Like the G-protein linked receptors, 
these receptors also require energy as ATP is consumed not only as the two receptors 
interact (autophosphorylation) but also during the subsequent phosphorylation o f PLCy. 
The phosphoryl groups added to the receptor itself create binding sites for the SH2 
domains o f PLC^and so allow diffusion of PLCy to the membrane where it can associate 
with the receptor. Once association has occurred, phosphorylation activates the enzyme 
to produce Ins(l,4,5)P3 and DAG (figure 1.7).
DAG and Ins(l,4,5)P3 both have roles as second messengers. DAG can be 
degraded by lipases or it can be phosphorylated by DAG-kinases to phosphatidic acid 
(PtdOH). More importantly for cell signalling, DAG activates another family of 
enzymes, phospho-kinase C, which results in a cascade o f phosphorylations o f other 
proteins and enzymes. Massive amplification o f the original signal occurs because one 






















Figure 1.7: Activation of a tyrosine kinase receptor.
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1.6 The lns(1,4,5)P3 Receptor, its structure and regulation
The Ins(l,4,5)P3 receptor is a tetramer, composed of four subunits surrounding an 
anionic pore. Each subunit is a large protein with a molecular mass of about 300 kDa. 
Each subunit has three functionally distinct regions as follows.
• Ins(l ,4,5)P3 binding site domain at the N-terminal region.
• Six transmembrane helices towards the C~terminal which forms the ion channel 
pore.
• Large regulatory domain separating the two regions.
The transmembrane topology is thought to be as shown in Figure 1.8 and 
discussed further below.
HO
HO ? H 





Figure 1.8: Cross-section of a generalised Ins(l,4,5)P3 receptor. Ca2+ binding sites are 
depicted as orange circles, ATP-binding sites are shown as dark red circles, and 
phosphorylation sites are shown as cyan circles. Adapted from Thrower et al.[8]
The Ins(l,4,5)P3 receptor is a ligand gated Ca2+ channel, which responds to 
Ins(l,4,5)P3 produced when the cell surface receptors are activated. When Ins(l,4,5)P3 
binds to at least three and possibly all four subunits of the receptor (Figure 1.9), 
Ins(l,4,5)P3R undergoes a conformational change that opens the Ca2+ ion channel[9].
Chapter 1




Figure 1.9: Activation of the Ins(l,4,5)P3 receptor by Ins(l,4,5)P3.
A recent report involving electron microscopy of the Ins(l,4,5)P3R particles 
revealed two distinct structures with 4-fold symmetry; a windmill structure and a square 
structure (figure 1.10). They showed that Ca2+ reversibly promoted a transition from the 
square structure to the windmill structure with relocation of four peripheral Ins(l,4,5)P3- 
binding domains[10].
dom ain
dom ain ln s (1 ,4 ,5 )P 3-binding
dom ain
Figure 1.10: Proposed model for structural rearrangement within the Ins(l,4,5)P3R. 
Ins(l,4,5)P3 binding domain (light grey), channel domain (grey), and bridge domain 
(white). Black arrows indicate plausible domain movements.
Three distinct Ins(l,4,5)P3 isoforms have been identified termed IP3RI, IP3R2  
and EP3R 3 . For a recent review of the iso form-specific functions see Thrower et a /[8 ] .  
All three isoforms share 60-70% of the same homology with each other, partial 
homology with the ryanodine receptor and no significant homology with voltage-gated 
Ca2+ channels. All cells contain multiple receptor isoforms but one isoform may be 




FAM ILY PREDOMINANT TISSUE DISTRIBUTION
IP3R1 Cerebellum, uterus, peripheral tissue
IP3R2 Spinal cord, lung, hepatocytes, testis, spleen
IP3R3 Brain, gastrointestinal tract, kidney, pancreatic islets
Tab! e 1.2: Location o f Ins(l,4,5)P3 receptor isoforms.
In general Ins(l,4,5)P3 receptors are located in the membranes o f the ER; 
however in some tissues the Ins(l,4,5)P3 receptors have been found in the plasma 
membrane and nuclei[ll]. This could indicate that in some cell types, Ins(l,4,5)P3
94 -receptors may have a role in Ca entry from outside the cell.
The study o f Ins(l,4,5)P3 signalling has been complicated further by the fact that 
the different Ins(l,4,5)P3 receptor isoforms can combine to form mixed tetramers 
therefore providing a mechanism for generating greater diversity o f Ins(l,4,5)P3 
receptors[12].
1.6.1 The lns(1>4,5)P3 receptor binding domain
Early studies indicated that the large N-terminal region o f the Ins(l,4,5)P3 
receptor incorporates six hundred and fifty amino acid residues, thought to contain the 
sequence that forms the 3-D structure o f the Ins(l,4,5)P3 binding sites. Finally the 
Ins(l,4,5)P3 binding site of the Ins(l,4,5)P3R is thought to have positive charges to 
facilitate ionic interaction with negative charges on the three phosphate groups of 
Ins(l,4,5)P3. More recent studies, involving deletion mutagenesis o f the N-terminal 
region of the Ins(l,4,5)P3R, have mapped the amino acid residues essential for ligand 
binding activity. Three basic residues, Arg 265, Lys 508 and Arg 511 are critical for 
specific binding, while Arg 568 is important in regulating the binding specificity for 
various inositol polyphosphates[13].
The binding affinity o f Ins(l,4,5)P3 for the N-terminal segment varies between 
different receptor isoforms. Two different groups have found different rank orders for 
the binding affinity of Ins(l,4,5)P3 to the receptor isoforms[14-16].
10
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1.6.2 The lns(1,4,5)P3 receptor transmembrane domain
Recently, it has been experimentally proven that there are six transmembrane 
spanning regions, thus projecting the C-terminus o f the protein into the cytoplasm[17]. 
A hydrophobic region between the fifth and sixth transmembrane domain has been 
proposed to form a hairpin loop that is partially embedded in the membrane. This may 
function as part o f the ion-conducting pore (P-domain) o f the Ca channel. Negatively 
charged amino acids around the P-domain may concentrate Ca ions around the pore.
Furthermore, the transmembrane-spanning segments are also thought to be 
required for the oligomerization of the four Ins(l,4 ,5)P3 receptor subunits.
1.6.3 The lns(1,4,5)P3 receptor regulatory domain
The regulatory domain separates the Ins(l,4 ,5)P3 binding domain from the 
transmembrane domain. As shown in figure 1.8, the domain contains binding sites for 
various modulators o f the channel such as ATP, Ca2+, Calmodulin (CAM) and 
phosphorylation sites for several protein kinases.
The homology among different Ins(l,4 ,5)P3R subtypes is the lowest in the 
regulatory domain, suggesting the operation o f differential regulation in different 
subtypes[18].
1.6.4 Three dimensional structure of the type 1 lns(1,4,5)P3 receptor.
The first 3-D structure o f IP3RI has very recently been reported [19]. Purified 
receptors were shown to be functional by Ins(l,4 ,5)P3 binding and Ca2+ efflux assays 
were used to obtain the images. The 24 A resolution structure takes the shape of an 
uneven dumbbell with one end larger than the other. The bulky large end probably 
corresponds to the cytoplasmic domain. The smaller end has structural features 
indicative o f the membrane-spanning domain. A central opening in this domain, which 




1.7 lns(1,4,5)P3 induced Ca2+ release
A feature o f the Ins(l,4,5)P3R is its Ca2+ induced Ca2+ release (CICR) property.
9 +This is caused by a positive effect of Ca at the low concentration range, (above resting 
cytoplasmic Ca2+) on channel opening, while high Ca2+ levels (//M range) cause 
inactivation.
9 -1-Ins(l,4,5)P3 determines the concentration o f Ca at which the Ins(l,4,5)P3 
channels open. Ca2+ increases without the presence o f Ins(l,4,5)P3 cannot activate 
channel opening. Lns(l,4,5)P3 concentration does not necessarily determine the amount 
o f Ca2+ that is released, rather it is determined by the amount o f Ca2+ in the Ca2+ store 
and the inactivation of the channel by Ca2+ and Ins(l,4,5)P3.
1.8 Capacitative Ca2+ entry
9 +  9 +When internal Ca stores are depleted, Ca influx through the plasma membrane 
occurs, this is known as capacitative Ca2+ entry or store operated Ca2+ influx channel 
(SOC). This idea was introduced when Ca2+ influx was found to be increased even in the 
absence o f increased Ins(l,4,5)P3 levels after emptying o f the intracellular Ins(l,4,5)P3
2 ”f"sensitive Ca stores. Two major questions need to be answered in the field of 
capacitative Ca2+ entry;
1. What is the mechanism by which the depleted stores signal the Ca2+ entry 
channel?
2. What is the molecular entity that is responsible for Ca2+ entry through 
SOC?
Models have been proposed to explain Ca2+ influx. One model hypothesizes that 
a diffusible molecule is released after Ca2+ stores are depleted, and that it stimulates Ca2+
2“Pinflux via Ca channels on the plasma membrane. Numerous second messengers have
9 -4-been proposed to initiate Ca influx, including small G proteins, pertussis toxin- 
sensitive G proteins, cGMP, various lipids, tyrosine phosphorylation and Ins(l,4,5)P3. 
The most interesting candidate second messenger is Ca2+ influx factor (CIF). It has been 
isolated as an acid extract from Jurkat T cells and partially characterised as a pH stable 
small anionic phosphorylated molecule that induces Ca2+ influx[20]. CIF is probably 
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Figure 1.11: Capacitative Ca2+ entry. The depletion of endoplasmic reticulum Ca2+ 
stimulates the entry of Ca2+ through the plasma membrane. Two theories are depicted in 
the figure; conformational coupling and a diffusible Ca2+ influx factor (CIF).
The second model postulates that internal Ca2+ release channels conformationally 
couple to the plasma membrane Ca2+ channel, SOC also referred to as CRAC (Ca2+ 
release activated Ca2+ channels). The idea is that the cytoplasmic head of the 
Ins(l,4,5)P3R communicates with two Ca2+ channels, one in the ER and the other in the 
plasma membrane. Ins(l,4,5)P3 binding will induce a conformational change which 
creates the channel that releases Ca2+ from the store. Once the store is empty the 
receptor changes the conformation leading to the opening of the CRAC on the plasma 
membrane[21]. In summary, the conformational coupling hypothesis considers that 
Ins(l,4,5)P3R controls the mobilisation of both the internal and external Ca2+. These two 
dominant theories of capacitative Ca2+ entry, conformational coupling and CIF are 
summarised schematically in figure 1.11.
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1.9 Metabolism of Inositol phosphates
Once produced, Ins(l,4,5)P3 is metabolized extremely quickly, in order to 
terminate its action and return the cell to rest. Two enzymes catalyse the conversion of 
Ins(l,4,5)P3 in cells. 5-Phosphatase cleaves the phosphate group at position 5 and 3- 
kinase catalyses ATP-dependent phosphorylation of Ins(l,4,5)P3 at position 3. The 
important features of Ins(l,4,5)P3 metabolism are detailed in figure 1.12, however this is 
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Figure 1.12: Metabolism of inositol phosphates. Adapted from Potter and
Lampe[22].
Ins(l,4,5)P3 is dephosphorylated at position 5 to produce Ins(l,4)P2, which in 
turn, is further dephosphorylated at position 1 to give Ins(4)P. Several 5-phosphatases
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have been indentified. Some of these enzymes are involved in the dephosphorylation of 
inositol lipids rather than inositol phosphates.
Ins(l,4,5)P3 can be phosphorylated at the 3-position by Ins(l,4,5)P3 3-kinase to 
form Ins(l,3,4,5)P4. Three isoforms (A, B and C) of 3-kinase have been cloned[23]. 
Ins(l,3,4,5)P4 is then metabolised by the same 5-phosphatase as Ins(l,4,5)P3 to give 
Ins(l,3,4)P3. This can then be dephosphorylated via two different routes, via Ins(3,4)P2 
and Ins(l,3)P2. Although many of these metabolic intermediates are believed to be 
biologically inactive, it is quite possible that some are involved in the synthetic routes by 
which higher phosphates, such as Ins(l,3,4,5,6)P5 and InsPc are synthesised.
1.10 Structure-Activity Relationships at lns(1,4,5)P3 Receptors
Over the last couple of decades there has been considerable interest in 
establishing structure-activity relationships for the Ins(l,4,5)P3 receptor. This has 
recently been covered in two comprehensive reviews [22],[24] and only a short summary 
will be presented here. The interaction of Ins(l,4,5)P3 with the receptor is highly 
stereospecific, with the D-isomer being over 1000-fold more potent than the L-isomer. 
The relative importance of the functional groups Ins(l,4,5)P3 are summarised in figure 
1.13. Each ring position of Ins(l,4,5)P3 will now be considered.
Axial 2-hydroxyl, equatorial 3 hydroxyl: 












Figure 1.13: Relative importance of the functional groups of Ins(l,4,5)P3 to its Ca2+




The equatorial 1-phosphate is less important than the 4- and 5-phosphates. 
However, as Ins(4 ,5)P2 binds considerably more weakly than Ins(l,4 ,5)P3, the 1- 
phosphate must contribute to receptor binding[24]. The 1-phosphate may be replaced 
with an axial phosphate or a phosphate more distant from the ring without major loss o f 
activity. Large groups are also tolerated and this fact has been exploited by attaching 
photoaffinity ligands and fluorescent labels to the 1-phosphate o f Ins(l,4 ,5)P3.
Inoue et al.[25] recently described a 1-position modified Ins(l,4 ,5)P3 analogue 
with remarkable binding affinity. Modification of this 1-phosphate with the dye 
molecule malachite green (Figure 1.14) resulted in a compound with a IQ of 1.17 nM in 
the Ins(l,4 ,5)P3-binding domain o f human type-1 Ins(l,4 ,5)P3 receptor. In the same 
study the corresponding binding of Ins(l,4 ,5)P3 (IQ 195nM) was found to be 167-fold 
weaker. Since then this group has synthesised more analogues (Figure 1.14) to 
investigate the importance o f steric factors and charges[26]. The authors concluded that 
linking a hydrophobic moiety to the 1-phosphate o f Ins(l,4 ,5)P3 enhances the binding of 
Ins(l,4 ,5)P3 analogues to the receptor with considerable latitude of substituent structure. 
For strong interaction with the receptor, a cationic charge adjacent to the 1-phosphate of 
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The axial 2-hydroxyl is the least important part o f Ins(l,4 ,5)P3. It can be deleted,
changed to equatorial or replaced with fluorine with only slight effect on activity,
2+
therefore suggesting that it is not very important for binding or for Ca release [22]. 
Position 3
The equatorial 3-hydroxyl enhances binding, but is less important than the 6- 
hydroxyl. Stereochemical inversion of C-3 causes loss o f activity[27], while increasing 
the steric bulk of the equatorial 3-position produces a series o f Ins(l,4 ,5)P3 analogues 
with progressively decreasing activity at the Ins(l,4 ,5)P3R. However D-3-C-trifluoro- 
methyl-myo-inositol 1,4,5-trisphosphate, which retains the equatorial 3-hydroxyl, but has 
an axial 3-trifluoromethyl group, has almost the same potency as Ins(l,4 ,5)P3. This 
suggests that bulky substituents in the 3-axial position can be efficiently accommodated 
in the Ins(l,4,5)P3R[22].
Positions 4 and 5
The 4,5-bisphosphate is the most crucial part o f Ins(l,4 ,5)P3 as it is essential for 
activity. The two phosphate groups are vicinal and diequatorial. It has recently been 
suggested that the 5-phosphate is the dominant partner in receptor interaction as 
replacement of the 4-phosphate with phosphorothioate has less effect than replacing the
5-phosphate[24].
Position 6
The hydroxyl group at position 6 is the most sensitive of the three 
unphosphorylated hydroxyl groups in the cyclitol to modification. It is thought to make 
a major contribution as 6-deoxy- inositol 1,4,5-trisphosphate was found to be a very 
weak agonist at the Ins(l,4,5)P3R[28]. The 6-hydroxyl group may be able to hydrogen 
bond to an amino acid residue on the receptor. Alternatively it may form an 
intramolecular hydrogen bond to the 1- or 5-phosphate group. Either way, the hydrogen 
bonds may be important in defining the receptor recognising properties o f Ins(l,4 ,5)P3. 
The receptor probably cannot tolerate steric bulk at this position as substitution with 




A partial agonist is an agent that will occupy the receptor but will produce a 
response somewhat less than the maximum possible. Some Ins(l,4 ,5)P3 analogues can
9+bind to the Ins(l,4 ,5)P3R but are not able to mobilise the full Ca stores, these are 
referred to as class I partial agonists. The first analogue found to exhibit this activity was 
the naturally occurring Ins(l,3 ,4 ,6)P4 (Figure 1.15)[29]. It is thought to adopt a binding 
orientation which efficiently mimics Ins(l,4 ,5)P3 with the exception o f presenting an 
axial 3-phosphate and an additional phosphate in the equatorial 2-position.
Phosphorothioate groups at positions usually substituted with phosphate groups 
were prepared originally as they were stable to the metabolising enzymes Ins(l,4 ,5)P3 3- 
kinase and Ins(l,4 ,5)P3 5-phosphatase. Two o f these analogues from the Potter group D-
6-deoxy-Ins(l,4 ,5)PS3 (7) and L-c/»>o-Ins(2 ,3 ,5)PS3 (Figure 1.15) have been shown to be 
partial agonists[22]. These compounds are C-3- or C-6- modified analogues of 
Ins(l,4 ,5)P3, respectively, in addition to carrying phosphothioate groups rather than 
phosphates in the 1-, 4- and 5-positions. The replacement of oxygen with sulphur to 
form the phosphorothioate group results in considerable disturbance in charge 
distribution with an increased negative charge on the sulphur and reduced negative 
charge on the remaining oxygen. These changes in charge distribution appear to have 
subtle effects in the interactions o f the compounds with the receptor[30].
Studies then concentrated on finding the key elements to partial agonist activity. 
It was noted that modifications o f the 3-hydroxyl resulted in a decreased efficacy. One 
o f the best partial agonists described so far is the 3-fluorinated 4,5-phosphorothioate 
analogue o f Ins(l,4 ,5)P3 [3F-Ins(l)P(4 ,5)PS2, (Figure 1.15)][30], which retained a 
relatively high affinity for the Ins(l,4 ,5)P3 binding site, accompanied by a significant 
loss in both potency and intrinsic activity for Ca2+ mobilisation. The retention o f the 1- 
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Figure 1.15: Class I partial agonists at Ins(l,4 ,5)P3 receptors.
Some analogues can mobilise the full Ca2+ store, however at a much slower rate 
than Ins(l,4 ,5)P3; this has been defined as class II partial agonist[31]. These analogues 
include a series o f 3-position modified Ins(l,4 ,5)P3 analogues and Ins(2 ,4 ,5)P3 (Figure 
1.16).
D-3,6-dideoxy-/7?yo-lns(1,4.5)P3
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No good antagonist o f the Ins(l,4 ,5)P3R has been found in spite of many efforts 
using the inositol backbone to create inhibitory analogues. For several years heparin and 
decavanadate were the only known Ins(l,4 ,5)P3R antagonists. Indeed they can stop
9-1-Ins(l,4 ,5)P3 induced Ca release in cell free systems or when injected into cells. 
However they are both non-selective and they can bind to a number o f proteins to inhibit 
their functions. They are therefore not ideal for use as pharmacological agents.
Xestospongins have recently been isolated from the Australian sponges of
• • 9+Xestspongia and were shown to inhibit Ins(l,4 ,5)P3-induced Ca release in cell free 
systems as well as in cells. Xestospongin C (Figure 1.17) was the most potent. However 
xestospongins also block ryanodine receptors, but only at thirty times higher 
concentrations[24].
Another antagonist at the Ins(l,4 ,5)P3R is 2-aminoethoxydiphenylborate (2- 
APB)(Figure 1.17). It has been found to inhibit Ins(l,4 ,5)P3 action in platelets and 
neutrophils. Unlike xestospongins, 2-APB does not appear to block Ca2+ release from 
the ryanodine receptor[32].
Both xestospongins and 2-APB are considered to have the advantage o f being 
cell-permeable, non-competitive agonists at the Ins(l,4 ,5)P3R, as they are thought to bind 
to the Ins(l,4 ,5)P3R at a site other than the Ins(l,4 ,5)P3 binding site.
OH NH2
2-APBXestospongin C




The effects of phosphoinositides are mediated primarily by direct interaction with 
a large number of downstream effector proteins, and these protein-lipid interactions 
involve numerous, specific lipid-binding modules, including the pleckstrin homology 
(PH), FYVE and ENTH domains (recently reviewed in [33]) and PX domain[34]. Since 
there are x-ray structures of Ins(l,4 ,5)P3 to the PH domains, a short summary about PH 
domains follows.
1.11.1 Structure of the PH domain
The pleckstrin homology (PH) domain is a structural protein of around one 
hundred amino acids that was first identified in 1993, occurring as an internal repeat in 
the phosphoprotein pleckstrin. Since then it has been found in more than one hundred 
different proteins involved in cellular signalling, cytoskeletal organisation, regulation of 
intracellular membrane transport and modification o f membrane phospholipids. 
Examples include some protein kinases, all phospholipase C isoforms, and the 
phosphoinositide 3-kinase p i 10^ subunit[35].
Although the primary sequence o f PH domains varies considerably, their 
secondary structure is quite similar, this being one of the criteria for a PH domain. It is 
formed by a seven stranded antiparallel ^-sheet with a strong bend that results in an 
orthogonal sandwich. There are six loops connecting the /?-strands, three of these have 
been termed variable loops as they are variable in length and sequence. The domain has 
a characteristic C-terminal a-helix which blocks one end of the twisted sheet.
The PH domain has been found in proteins expressed in mammals and unicellular 
eukaryotes but not in plants or bacteria. Their amino acid sequences are diverse, the only 
distinguishing characteristic o f the PH domain sequence is a single almost invariant 
tryptophan residue in the C terminus o f the domain. One side o f the domain, including 
the variable loops, is a positively charged surface, made up o f lysines, arginines and 





The majority o f PH domain-containing proteins appear to have a functional 
requirement to be membrane associated. It is believed that PH domains function as 
membrane adapter/tethers, linking the host protein to the membrane surface often by 
binding to phosphoinositides. Most PH domains bind to phosphoinositides or inositol 
phosphates with a broad range o f specificity and affinity, some o f these are summarised 
in table 1.3.
PROTEIN LIGAND AFFINITY
Pleckstrin Ptdftis(4,5)P2 13.4 /uM.
/^-Spectrin g-PtdIns(4,5)P2 40 juM
PLC-61 g-PtdIns(4,5)P2 0.46 jlM
Ptdftis(4,5)P2 1.7 /M .
D-Ins(l,4,5)P3 210 nM
PL C-r Ins(l,3,4,5)P4 1-2 jlM
Dynamin g-PtdIns(4 ,5)P2 4.3 fJM
Dynamin D-Ins(l,4 ,5)P3 1.23 mM
Table 1.3: Summary o f proposed ligands for some PH domains[36‘.
O f particular interest is the interaction o f PLC-<Si with Ins(l,4 ,5)P3 and 
PtdIns(4 ,5)P2. It is believed that PLC-<Si uses its PH domain to bind PtdIns(4 ,5)P2 in the 
cell membrane. The catalytic domain o f PLC then hydrolysises PtdIns(4 ,5)P2, to give 
free Ins(l,4 ,5)P3, which then inhibits the binding o f further PtdIns(4 ,5)P2 to the PH 
domain.
1.11.3 X-ray crystal structures of lns(1,4,5)P3
In 1995 two groups independently published x-ray crystal structures of 
Ins(l,4 ,5)P3 bound to PH domains[37;38]. For the first time this enabled us to see the 
conformation o f Ins(l,4 ,5)P3 at one o f its binding sites.
The x-ray structure o f Ins(l,4 ,5)P3 at the spectrin domain shows direct hydrogen 
bonds between Ins(l,4 ,5)P3 and five amino acids. The 4- and 5-phosphate groups are
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anchored by salt bridges to positively charged amino acids, and by hydrogen bonds to 
Tyr23 and Tyr69. The 1-phosphate forms a single hydrogen bond to Ser22, and is most 
likely to be exposed to solvent. The upper face of the molecule, including the area 







Figure 1.18: Schematic representation of the Ins(l,4,5)P3 binding site of /2-spectrin. 
Adapted from Hyvonen et al. [38]
The X-ray structure of Ins(l,4,5)P3 at the PLC-<5i PH domain shows direct 
hydrogen bonding between the bound Ins(l,4,5)P3 and seven amino acids. Two lysine 
chains (Lys30 and Lys57) each hydrogen bond with both the 4- and 5-phosphate groups 
of Ins(l,4,5)P3. Additional interactions with the side chains of Arg56 plus additional 
hydrogen bonds via water molecules (not shown) ensure that the 5-phosphate of 
Ins(l,4,5)P3 is completely buried. The 4-phosphate forms hydrogen bonds to the 
sidechains of Lys30, Lys32 and Lys57 and a water molecule. The 1-phosphate forms a 
single hydrogen bond to Trp36[37] (Figure 1.19).
The complex formed between PLC-<Si PH domain and Ins(l,4,5)P3 is two 
hundred fold more stable than the complex between spectrin PH domain and 
Ins(l,4,5)P3. This is not surprising as there are seven hydrogen bonds, involving five 
amino acids between Ins(l,4,5)P3 and spectrin, while there are twelve hydrogen bonds, 
involving nine amino acids, between Ins(l,4,5)P3 and PLC-^ PH domain. In fact there 
are more interactions between the 5-phosphate and PLC-<5i PH domain than there are 
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Figure 1.19: Schematic representation of the Ins(l,4,5)P3 binding site of PLC-<5j PH 
domains. Adapted from Ferguson et al.[37]
These studies show the interaction of Ins(l,4,5)P3 with the binding sites of PH 
domains. The results are in very good agreement with the conclusions reached about 
Ins(l,4,5)P3R binding. However, the Ins(l,4,5)P3 binding site of these PH domains do 
not necessarily resemble the Ins(l,4,5)P3R. For example neither study showed any 
interactions of the 6-hydroxyl group of Ins(l,4,5)P3 with the binding site of the PH 
domain, yet this is a very important feature in the Ins(l,4,5)P3R. However, as many of 
the structure-activity relationships are the same for Ins(l,4,5)P3R similar interactions and 
spatial relationships may be involved.
1.12 Radixin FERM domain
Radixin is a member of the ezrin/radixin/moesin (ERM) family of proteins, 
which function as cross-linkers between plasma membranes and actin filaments. The 
cross linking is regulated by PtdIns(4,5)P2. Recently, the Hakoshima group published a 
x-ray crystal structure of Ins(l,4,5)P3 bound to the radixin FERM domain[39]. The 
domain is responsible for membrane binding and it consists of three sub-domains.
Ins(l,4,5)P3 binds in a basic cleft that is different from those found in PH 
domains. Three lysine chains (Lys60, Lys63 and Lys278) and one asparagine (Asn62) 
contact the three phosphate groups of Ins(l,4,5)P3. The 1-phosphate group is exposed to
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solvent, which enables PtdIns(4 ,5)P2 to reach the binding site from the membrane 
surface. The 4-phosphate group intrudes into the cleft, whereas the 5-phosphate group 
resides at the molecular surface.
1.13 Adenophostin A and B
Adenophostin A and B (Figure 1.20) were first isolated in 1993 from the cultured 
broth o f Penicillium brevicompactum SANK 11991 and SANK 12177[40]. They are 
potent Ins(l,4 ,5)P3R agonists, which bind to Ins(l,4 ,5)P3R, and induce Ca2+ release from 
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Figure 1.20: The structures of adenophostin A and adenophostin B
Their structures were first elucidated using a range o f techniques including NMR, 
MS, elemental analysis and enzymatic degradation[41]. The structures were later 
confirmed by the first total synthesis of adenophostin A[42].
Adenophostins were originally found to have activities 100-fold more potent than
^  I
Ins(l,4 ,5)P3 at releasing Ca from cerebellar microsomes[40]. Most subsequent papers 
only report a 10-fold increase in activity[43]. In addition, both adenophostins were 
found to inhibit [3H ]Ins(l,4 ,5)P3 binding in a more potent manner than Ins(l,4 ,5)P3 with 
a high positive cooperativity[44]. Their effect could be totally blocked by heparin.
Both adenophostins are resistant to phosphorylation and dephosphorylation by 
Ins(l,4 ,5)P3-metabolising enzymes, Ins(l,4 ,5)P3 3-kinase and Ins(l,4 ,5)P3 5-
phosphatase. They do not bind to Ins(l,3 ,4 ,5)P4 receptors[44] and in both functional and 
radioligand binding assays of all three Ins(l,4 ,5)P3R subtypes they bind with about 10- 
fold greater affinity than Ins(l,4 ,5)P3[43].
When the structures of the adenophostins were first published it was surprising as 
they seemed so different from Ins(l,4 ,5)P3. However on closer examination, the 
resemblances to Ins(l,4 ,5)P3 became apparent. The 3" and 4" -bisphosphate and adjacent 
2" -hydroxyl can be superimposed on the 5 and 4-equatorial bisphosphate and 6-hydroxyl
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ofIns(l,4,5)P3, respectively. This structural motif is an essential part of all Ins(l,4,5)P3R 
agonists. A third phosphate group is not essential for activity in inositol phosphates but 
greatly enhances it. In adenophostins the third phosphate group is in the 2' position of 
the ribose ring; when removed it causes a 1000-fold reduction in activity[40]. The 
adenosine group of the adenophostins is the most surprising feature of these molecules. 
Finally, the charge distribution on the phosphate groups of adenophostin A at 
physiological pH is virtually identical with that in the equivalent phosphate groups of 
Ins(l,4,5)P3; therefore, it may be concluded that the exceptional activity of adenophostin 
A cannot be explained by a difference in the ionisation state of its phosphate groups in 







Figure 1.21: Structures of Ins( 1,4,5)P3 compared to Adenophostin A.
Although there are several common characteristics between Ins(l,4,5)P3 and 
adenophostins, the exceptional ability of the adenophostins to mobilise Ca2+ through the 
Ins(l,4,5)P3 receptor could not be explained. Thus further information about the 
structure activity relationships of adenophostins was needed, in particular about the 
adenine ring. In Chapter 2 and the rest of the thesis, we will look at the synthesis and the 












2 Introduction-chemical synthesis and biological effects 
of adenophostin and analogues.
2.1 Synthetic Considerations
The synthesis o f Ins(l,4 ,5)P3 analogues from chiral carbohydrate starting 
materials is an attractive prospect as inositol phosphate chemistry is difficult and time 
consuming[22]. There is great attraction in focusing upon adenophostin A as a surrogate 
o f this key signalling molecule, not only because o f its exceptional potency but also 
because o f the greater synthetic ease in dealing with readily available chiral 
carbohydrates as synthetic starting materials. The remainder o f this chapter will 
introduce the synthesis o f carbohydrate based analogues. Many published analogues will 
be reviewed and some structure activity relationships will be considered.
Several problems are inherent to the preparation o f polyphosphates from either 
















Deprotection of hyroxyl 
and phosphate protecting groups 
followed by purification
Polyphosphate
Figure 2.1: Steps in the synthesis o f polyphosphates.
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Protecting groups need to be chosen wisely in order to facilitate later 
incorporation of phosphate groups at selected positions. The most popular temporary 
and permanent hydroxyl protecting groups are acetyl, allyl, benzoyl, benzyl, 
butanediacetal (BDA), isopropylidene, /?-methoxybenzyl, pivaloyl and Si-based 
protecting groups..
The phosphorylation o f the free hydroxyls o f a suitably protected carbohydrate is 
usually performed using a P111 reagent. The resulting phosphite ester is immediately 
oxidised to give the protected phosphate ester. Examples o f phosphoramidites used in 
the synthesis o f carbohydrate analogues are given in figure 2.2. They are activated by a 
weak acid (177-tetrazole). The oxidation o f phosphite triesters is usually effected with 
tert-butyl hydroperoxide (/BuOOH) or m-chloroperoxybenzoic acid (mCPBA).
a
^  ,^ — NEt2
___0
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r =c h 2c h 2s o 2c h 3
Figure 2.2: Phosphitylating reagents.
In order to avoid migration of protected phosphate esters to adjacent free 
hydroxyl groups it is essential to deblock the phosphate groups before the alcohols. 
Benzyl groups are convenient as benzyl phosphate esters are cleaved more rapidly than 
the benzyl ethers therefore deprotection in one step is possible. Benzyl groups are 
usually removed by hydrogenolysis. When base sensitive phosphitylating reagents are 
used, a two stage deprotection is usually required. The final compounds may be purified 
by anion-exchange chromatography or HPLC.
2.2 Minimal Structures
Adenophostin analogues that lacked the adenine base o f the adenophostins or 
similar structure have been termed minimal structure analogues. These compounds can 
be split into two categories; those based on a single ring "monosaccharide'’ derivatives 
and those based on two rings "disaccharide" derivatives. As two o f the chapters in this 
thesis are about minimal structure analogues the biological results and structure activity
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relationships o f the following compounds will be discussed in the introduction of 
chapters 2 and 3 to explain the rationale of the compounds described in the chapters.
2.2.1 Monosaccharide analogues
The first monosaccharide analogue prepared was (2-hydroxyethyl)- a - D -  
glucopyranoside-2’,3,4-trisphosphate [Glc(2 ',3 ,4)P3]. It is structurally based on the a- 
glucoside moiety of adenophostin A and can be visualised as adenophostin A with the 
majority of the adenosine moiety excised. Two groups independently reported the 
synthesis o f this analogue almost simultaneously.
Jenkins and Potter[46] started the synthesis with the known allyl 
glucopyranoside, regioselective benzylation at positions 2 and 6 was achieved using tin 
stannylene methodology (Figure 2.3). Temporary acetal protection of the 2,3 triol with 
an isopropylidene group allowed oxidative cleavage o f the double bond followed by 
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Figure 2.3: Route to Glc(2 '3 ,4)P3.
The other group Wilcox and Gigg[47;48] only communicated their synthesis; 
their extensive biology and structure activity relationships will be discussed in chapter 2 .
At a similar time another series o f compounds was reported by Moitessier et 
al[49]. These compounds were based on the sugar D-xylose and contained the same
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hydroxyethyl side chain as the compound described above but with both a  and p  
stereochemistry. They also synthesised the a  and p  compounds with propyl side chains. 
The synthesis was similar to that described above for Glc(2 ',3,4)P3; thus after appropriate 
protection, ozonolysis o f the double bond in the side chain, followed by reductive work 
up with sodium borohydride gave the precursors for the expected hydroxyethyl 
xylosides. The corresponding 3-hydroxypropyl derivatives were obtained by 
hydroboration o f the double bond in 2.6. The four triols were phosphitylated and 
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Figure 2.4: Route to the a-xylose analogues 2.11 and 2.12.
A few years later the same group published the synthesis of the 2-deoxy analogue 
2.23[50]. This time, the allyl D-xyloside was submitted to acetal formation by reaction 
with butanedione in the presence o f a catalytic amount of camphorsulfonic to give an 
equal amount o f 2.13 and 2.14 which could be separated. The double bond in 2.13 was 
cleaved by ozonolysis to give, after reduction, the primary alcohol which was protected 
as the trityl derivative. The C-2 hyroxyl group was then converted into its methyl
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xanthate, the protecting groups were removed and replaced with acetyls to give 2.19, 
which was deoxygenated using the Barton-McCombie method. 2.20 Was deprotected to 
give triol 2.21. Phosphitylation and oxidation gave the protected trisphosphate, which 




























Scheme 2.1: Synthetic route to 2-deoxy-a-D-f/zreo-pentopyranoside.
Reagents and conditions: i) MeC(OMe)2C(OMe)2Me, CSA, MeOH, (MeO^CH, reflux 
90 min; ii) O3, CH2Cl2/MeOH, -70  °C, 90 min then NaBH4; iii) TrCl, DMAP, 
pyridine, 80 °C, 30 h; iv) NaH, CS2, THF then Mel; v) 95% aq. TFA-CH2C12 (1:1), rt, 
10 min; vi) Ac20 , pyridine; vii) BU3S11H, AIBN, toluene; viii) NaOMe, MeOH; ix) 
(CNCH2CH20 )2PN'Pr2, l//-tetrazole, CH2C12, rt, 4h then /BuOOH, O °C; KOH, MeOH, 
40 °C, 2.5 h:
In Chapter 3, the synthesis and biological evaluation o f a  and ft C-glycosides will 
be described and other C-glycoside Ins(l,4 ,5)P3 analogues will be compared.
2.2.2 Conformationally restricted analogues
The first conformationally restricted analogue o f Ins(l,4 ,5)P3 was designed and 
synthesised in this laboratory[51]. The cyclic phosphate analogue in which the 
phosphate group equivalent to the 4-phosphate o f Ins(l,4 ,5)P3 was tethered via a 
methylene group to the equivalent carbon at position 3 in Ins(l,4 ,5)P3. Unfortunately 
this compound was inactive but inspired the synthesis o f carbohydrate based 
conformationally restricted analogues. The spirophostins[52] were designed to study in
32
Chapter 2
detail the effect o f the position o f the 2' phosphate in adenophostin A. Chain elongation 
of the protected thioethylglucoside gave a mixture o f diastereoisomers which was 
subjected to spiroketalization. Separation o f the intermediate spiroketals, followed by 
phosphorylation and deprotection afforded the spirophostins (2.27 and 2.28).
MeO B n aMeO B n a
SEt OH HO'BnO.BnO
OMeOMe
2 .2 4 2 .2 7  R 1 = H, R = 0 P 0 3
2 .2 8  R 1 = 0 P 0 32', R2 = H
2 .2 5  R 1 = O H , R  = H
2 .2 6  R 1 = H, R2 = O H
Figure 2.5: Synthesis o f spirophostins.
Both spirophostins are approximately equipotent with respect to their 
Ins(l,4 ,5)P3R binding and Ca2+ release properties. They are both less potent than 
Ins(l,4 ,5)P3 and adenophostin A. At a similar time a report was published from this 
laboratory describing bicyclic[53] analogues o f Ins(l,4 ,5)P3 (Figure 2 .6), these analogues 
were designed to place their non-vicinal phosphate groups in regions o f space more 
distant from the inositol ring than are normally accessible to the 1-phosphate group of 
Ins(l,4 ,5)P3. Interestingly even though the molecules constrain the non-vicinal 
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Disaccharides offer plenty o f scope as frameworks for the synthesis of novel 
polyphosphates, but the difficulties of protecting the hydroxyl groups selectively are 
often much greater than those encountered with simple inositols. There are two main 
methodologies for synthesising disaccharide polyphosphates.
The first method is to choose an existing disaccharide with the required anomeric 
configuration, selectively protect some o f its hydroxyl groups, phosphorylate the 
unprotected positions and then deprotect. However as many disaccharides are not 
available, precise target structures may not be accessible. Three compounds have been 






Figure 2.7: Disaaccharide polyphosphates
The second method is more adaptable; it relies on the selective protection o f the 
hydroxyl groups in two monosaccharides and the coupling o f the two together. This 
method has the advantage that any desired disaccharide polyphosphate can be assembled. 
A number o f compounds have been synthesised in this manner.
The first disaccharide synthesised was called ribophostin (Scheme 2.2)[55]. It 
was prepared to mimic the structure o f adenophostin A, but with the adenine removed. 
The glycosyl imidate was prepared in six steps from D-glucose using similar protecting 
group manipulations as described for Gluc(2 ',3 ,4)P3. The methyl riboside was prepared 
in several steps from D-ribose by a series o f protecting group manipulations to mask all 
the hydroxyl groups except the 3 position.
Coupling o f 2.29 and 2.30 was achieved under standard Schmidt conditions using 
TMSOTf as promoter resulting in a 4:1 cc.fi mixture o f anomers. After removing the 
PMB protecting groups the a  anomer was isolated. 2.32 a  was phosphorylated to 2.33, 











Bni IMe BnO OR OH
ribophostin2.31 a,fi R = PMB  
2.32a,fi R = H 
2.33 R = P (0 )(0 B n )2
HO OPMB
2.30
Scheme 2.2.: Synthetic route to ribophostin.
Reagents and conditions: i) Me3Si0 S02CF3, Et2 0 , 3 A sieves, rt, 10 min; ii) DDQ, 
CH2CI2-H 2O (10:1), rt, 1 h, (56%); iii)(BnO)2PNPr'2, l//-tetrazole, rt, 30 min, then 
MCPBA, -78  °C to rt, 10 min, (82%); iv) H2, Pd-C, 40 psi, 16 h, (70%):
The Matsuda group designed and synthesised a number o f glycosyl- 
tetrahydrofuran trisphosphates. A fluoroglycoside donor was used to couple to a number 
of tetrahydrofuran derivatives (Figure 2.8)[56].




AIIO OHHO OAII HO OAII
Figure 2.8:Glycosyl donor and acceptors
Glycosidation reactions o f the fluoroglycoside donor with the different acceptors 
using TMSOTf as a catalyst gave the corresponding a-glycoside as the main product. 
After protecting group manipulations the corresponding triols were isolated. 
Phosphorylation was achieved by the classical phosphoramidite methodology to provide 
after deprotection the three corresponding trisphosphates (Figure 2.9).
OH OHOH OP03‘
OH
Figure 2.9: More disaccharide polyphosphates.
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The Potter group also synthesised furanophostin [57] in a similar manner to the 
four disaccharide analogues described in chapter 4.
One interesting application of disaccharide polyphosphates was to construct 
clustered disaccharide polyphosphates[58;59]. These were designed to help study the 
Ins(l,4 ,5)P3-binding events to the tetrameric receptor. The disaccharide (described in 
chapter 5) was elaborated to 2.34. This was used in a coupling reaction with different 
iodobenzene derivatives to give the fully protected precursors. Deacetylation, 













Figure 2.10: Synthesis of clustered disaccharide polyphosphates.
2.3 Base containing analogues
Several adenophostin analogues which retain the purine base have been 
synthesised. This section deals with the chemistry o f these analogues, as well as some of 
their structure activity relationships.
2.3.1 Total synthesis of adenophostin A
Three total syntheses o f adenophostin A have been reported so far. The first total 
synthesis was completed by the Sankyo group[42] whose aim was to provide definitive 
proof of the chemical structure o f adenophostin A. Briefly, glycosylation o f a 
regioselectively protected glucosyl bromide donor derivative with a regioselectively 
protected adenosine-based acceptor using silver perchlorate and ^-collidine as promoters 
gave the basic backbone in 48% yield (figure 2.11). The remainder o f the synthesis 
consisted of protecting group manipulations to selectively protect the two primary
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alcohol positions and the amino group o f the adenine. Subsequent phosphorylation and 












More recently our group[60] adopted a similar but more efficient strategy. This 
was based on glycosidation o f a regioselectively protected adenosine-based acceptor 
with a regioselectively protected glycosyl phosphite donor. The a-coupled product was 
the sole product. Deprotection o f the acid sensitive groups with TFA in dichloromethane 
led to the required triol. Selective phosphitylation, without amino group protection, was 
achieved using a stoichiometric amount o f imidazolium triflate instead o f tetrazole as the 
phosphoramidite activator. Subsequent oxidation and deprotection by catalytic 
hydrogenation gave adenophostin A. (See figure 2.15, strategy 1)
The third approach, used by van Straten et al[6l], involved a very different 
convergent approach whereby the adenine base was introduced onto a disaccharide 
intermediate using Vorbriiggen condensation methodology. This kind of approach will 
be discussed in more detail in chapter 5.
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2.3.2 Molecular Modelling of adenophostin A
Early modelling studies by Takahashi et al [44] and Wilcox et al [48] indicated 
that the vicinal equatorial 4"- and 3"-bisphosphates and the a-glucoside ring of 
adenophostin A can be superimposed on the vicinal equatorial 4- and 5-bisphosphates of 
the wyo-inositol ring o f Ins(l,4 ,5)P3. The modelling demonstrated that the 2'-phosphoryl 
group o f adenophostin A relative to the 3" and 4"-bisphosphate motif might be slightly 
more extended than the corresponding positions o f Ins(l,4 ,5)P3, suggesting that the high 
potency o f adenophostin might be due to the optimal positioning of the 2 '-phosphoryl 
group.
Later Hotoda et al[62] suggested a putative conformation o f adenophostin A at 
the Ins(l,4 ,5)P3R. Their suggestion is based upon molecular mechanics calculations and 
NMR experiments in solution. They found the following;
• The glucose moiety adopts a chair conformation with two equatorial phosphoryl 
groups;
• The ribose ring prefers the south (CT-endo) conformation rather than north (C3'- 
endo);
• The N-glycosyl linkage was found to be in the syn orientation, which may be 





Figure 2.12: North and south ribose conformations.
n h2
n h 2syn anti
HOHO
Figure 2.13: Syn and anti conformations o f adenophostin A.
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They proposed that their model indicates the possibility that the relative position of 
the 2'-phosphate group of adenophostin A is optimal for the recognition by the 
Ins(l,4,5)P3R.
The model[48] is inconsistent with the Hotoda model[62]. The Wilcox 
conformation was compactly folded and the N-glycosyl linkage was anti. This 
conformation is inconsistent with Hotoda's NOE data observed between H-8 and H-T 
and H-8 and H-2'. Furthermore, when Hotoda modelled the Wilcox conformer it was 
found to be less stable than their model. Finally the Hotoda model is consistent with our 
model, based on molecular dynamics simulation of adenophostin A. [60].
Figure 2.14: Comparison of conformations of X and Y. Left: structure of Ins(l,4,5)P3 
taken from X-ray crystal structure of the phospholipase C-^l pleckstrin homology 
domain complex with Ins(l,4,5)P3. Right: representative energy-minimised conformer 
of adenophostin A obtained from molecular dynamics simulations at 300 K.[60]
2.3.2 Adenophostin A analogues by total synthesis.
The two distinct types of approaches to the synthesis of adenophostin A have led 
to the synthesis of two main classes of analogues. Substitution of the glycosyl donor in 
the first methodology by a different sugar-derived donor has led to two congeners 
modified at glucose. While replacing the adenine base in the second strategy has led to a 
whole series of nucleobase-modified adenophostin A mimics. The two strategies are 
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BnO I /  0AcBnO' HO
may lead to base 
modified analogues
Figure 2.15: The two strategies for the synthesis of adenophostin A and analogues.
2.3.4 Carbohydrate modified analogues
The glucopyranosyl bisphosphate moiety was replaced with mannopyranosyl 
bisphosphate and xylopyranosyl bisphosphate units respectively[63]. Evaluation of the 
analogues showed manno-adenophostin to be about twelve fold less potent than 
adenophostin while xy/o-adenophostin is only two fold less potent than 
adenophostin[43].





Figure 2.16: Strucures of ma««o-adenophostin and ry/o-adenophostin.
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2.3.5 Base modified analogues
Many base-replaced analogues have been synthesised[64;65]. We will take a 
closer look at these compounds in Chapter 4.
2.3.6 Flexible analogues
Several analogues in which the ribose or the glucose have been cut up in different 











2.40 R=CH2OH 2.41 R -H , R ^=O PC V'
2.42 R 1= 0 P 0 32', R2=H
Figure 2.17: Flexible analogues o f adenophostin A.
The synthesis of acyclophostin[66] commenced with the condensation of 2.44 
with the glucopyranosyl trichloroacetimidate donor (2.43). The glycosidation under 
controlled addition of excess TMSOTf proceeded smoothly to give the a-compound 
exclusively (2.45). Protecting group manipulations gave the corresponding triol which 
was phosphitylated with 7VW-diisopropyl-bis-[2-methylsulfonyl] ethyl phosphoramidite 
(MSE). It was subsequently oxidised with tert-butyl hydroperoxide to give the fully 
protected trisphosphate. Removal of the base labile groups in 2.46 with NaOH, followed 
















t )P (0 )(0 M S E )2BnO
2.46
Acyclophostin
Scheme 2.18: Synthesis o f acyclophostin.
A second compound 2.38 which lacked the C-l"-C-2" was prepared in the same 
report. Condensation o f the adenosine donor with arabinitol acceptor under the influence 
of TMSOTf led to the isolation o f the dimer. Protecting group manipulations gave the 













The same group then reported the synthesis o f two more analogues of 
adenophostin A in which the ribosyl-2-phosphate unit is replaced by either a glycol or a 
glycerol[67]. Both syntheses took the same route; briefly, glycosidation o f the glycosyl 
donor with the respective glycol and glycerol acceptors led to the «-linked compounds. 
The adenine was then introduced by Vorbriiggen condensation with the bis-trimethylsilyl 
derivative of N6-benzoyl adenine in the presence of a catalytic amount of TMSOTf. The 
resulting compounds were then submitted to routine protecting group manipulations to 













Scheme 2.20: Route to 2.39 and 2.40.
The biological results o f these compounds and a couple o f related compounds 
were published in a subsequent paper[68]. Replacement o f the glucose moiety by a 
bisphosphorylated polyol, as in the acyclic analogue had a detrimental effect. The 
opening of the ring presumably allows too much conformational mobility around the 
essential bisphosphate and neighbouring hydroxyl group.
The substantial decrease in the affinity o f the bisphosphate analogue 2.39, 2.40 
parallels the massive decrease in affinity o f adenophostin after the removal of its 2 ' 
phosphate[41].
Interestingly, acyclophostin exhibited unusual activity. It bound to hepatic 
membranes with appreciably higher affinity than Ins(l,4 ,5)P3, yet it was marginally less 
potent in causing Ca2+ mobilisation. Further investigation demonstrated that
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acyclophostin was in fact a pH dependent partial agonist; it was found to be a partial 
agonist at high pH (8.3) and a full agonist at pH 7. It was speculated that the pH 
dependent efficacy o f acyclophostin was either the result o f a conformational change 
related to the pKa o f the 2'-phosphate and the lack of conformational restriction from a 
furanoside ring, or that acyclophostin may differ from Ins(l,4 ,5)P3 in the residues 
involved in its binding and Ca release at the Ins(l,4 ,5)P3 receptor.
The Chapleur group recently reported the synthesis o f the acyclophostin related 
compounds 2.41 and 2.42[69]. The two compounds differ only by the stereochemistry at 
the C-2 of the propyl tether between the xylose ring and the adenine.
Asymmetric dihydroxylation o f the dibenzoate gave the diol in an 8:1 mixture of 
diastereoisomers. Activation of the primary alcohol as the tosylate and the reaction with 
the sodium anion o f adenine led to a mixture o f N-7 and N-9 regioisomers. The N-9 
isomer was isolated, and the benzoates removed to give the tr io l. The resulting triol was 
phosphitylated followed by in situ oxidation o f the corresponding phosphites gave the 
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Scheme 2.21: Routes to compounds 2.41 and 2.42.
The second isomer was synthesised via a different route. It commenced with the 
deallylation o f compound 2.47 to provide the free hemiacetal. Activation of the free 
hemiacetalic hydroxyl was acheived via the Schmidt procedure. The imidates were then 
reacted with enantiomerically pure (R)(+) glycidol using TMSOTf as promotor to give a 
mixture of anomeric glycosides. The a-anomer was isolated and the epoxide ring was 
opened with the adenine anion. The remainder o f the synthesis was identical to that 
described above for compound 2.42.
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These compounds were tested for Ca2+ release from permeabilised hepatocytes. 
Compound 2.41 was about five times weaker at releasing Ca2+ than Ins(l,4 ,5P3 while 
compound 2.42 was 10 times weaker. The significance o f the biological results o f these 
two compounds will be discussed in chapter 3.
2.3.7 Conformationally restricted analogues
A paper recently appeared in which the authors described the synthesis and 
biological evaluation o f a 5',6" tethered analogue o f adenophostin A called cyclophostin, 
as well as its de-adeninylated analogue cycloribophostin [70]. The compounds were 
prepared via ring closing metathesis o f a carbohydrate dialkene, followed by coupling of 
2.48 to 6-N-benzoyl adenine or propargyl alcohol, respectively. The compounds were 









Scheme 2.22: Ring closing metathesis-approach towards cyclophostin and
cycloribophostin.
Cyclophostin is approximately five fold more potent at releasing Ca2+ than 
Ins(l,4 ,5)P3. In contrast, the potency o f cycloribophostin is greatly reduced, confirming 
that the adenine is important in achieving adenophostin like activity. NMR spectroscopy 
and molecular modelling o f these analogues showed that the 5',6" tether induces a C-3'- 




Two photoaffinity derivatives have recently been reported[71]. In compound 
2.49, the chemically stable /?-benzoyldihydrocinnamoyl (BZDC) photoprobe is joined 
directly by an amide bond to the 5'-position, while in 2.50 it is tethered to an 
aminopropyl spacer at the anomeric centre of the ribosyl moiety.
The usual Vorbriiggen type condensation o f 2.51 with N -6 benzoyl adenine gave 
the backbone. The standard protecting group manipulations were applied, followed by 
phosphorylation and deblocking yielded 2.49. Condensation o f the amino derivative 
2.52 with /7-benzoyldihydrocinnamoyl (BZDC) photoprobe proceeded in a 













Scheme 2.23: Route to photoaffinity compound 2.49.
Glycosidation of the disaccharide with 3-(benzyloxycarbonylamino)-l-propanol 
under the influence o f SnCU led to the exclusive formation o f the ^-aminopropyl 
derivative. Usual deacetylation and subsequent phosphorylation gave the trisphosphate 
in 77% yield. Hydrogenolysis afforded derivative 2.53 which underwent a condensation 


























3 C-Glycosides as monosaccharide analogues
3.1 Introduction
Adenophostin A can be viewed as a phosphorylated glucose glycosidically 
linked at its Imposition to an adenosine at the 3'-position. As previously mentioned in 
the introduction, adenophostin analogues that lack the adenine base or a similar 
structure were termed minimal structure analogues, and these could be split into 
monosaccharides and disaccharides. The minimal structure analogues were designed 
to show the functional consequences of systematically trimming the adenosine. All 
were based on carbohydrates with the exception of 6-deoxy-6-hydroxymethyl-5cy//o- 




Figure 3.1: 6-deoxy-6-hydroxymethyl-5cy//o-Ins( 1,2 ,4)P3 and scyllo-Ins( 1,2 ,4)P3
3.1 May be considered as an inositol based analogue of the adenophostin A 
glucose motif, with the 4,5-bisphosphate o f Ins(l,4 ,5)P3 being equivalent to the 3",4"- 
bisphosphate o f adenophostin A. Therefore, the position o f Ins(l,4 ,5)P3 most likely to 
correspond to the bulky 5"-hydroxymethyl group of adenophostin A is the 3-hydroxyl 
o f Ins(l,4 ,5)P3. 3.1 Was designed to explore the effect o f introducing such a group 
into an Ins(l,4 ,5)P3 structure.
Biological evaluation o f racemic 3.1 in permeabilised rabbit platelets found
9+that it exhibited equal potency in Ca release to Ins(l,4 ,5)P3, and in binding assays in 
rat cerebellar membranes 3.1 was found to be equipotent to Ins(l,4 ,5)P3. This 
observation implies that the CH2OH component is tolerated by the Ins(l,4 ,5)P3R 
despite the additional steric bulk.
It must be noted that 3.1 differs from Ins(l,4 ,5)P3 in two ways; it is not only 
modified at the 3-hydroxyl position but the 2-position is equatorial as opposed to 
axial. Therefore it was also tested against scy//o-Ins(l,2 ,4)P3 and was found to be 
significantly more potent at releasing Ca from rabbit platelets and in binding. We
49
Chapter 3
can conclude, at least in scyllo-analogues of Ins(l,4 ,5)P3, that replacement o f the 
secondary hydroxyl group at the 3 position (6 position in scy//oinositol) with an 
hydroxymethyl group enhances affinity for the Ins(l,4 ,5)P3R.
As mentioned in chapter 2, the first carbohydrate analogue synthesised was 
G1uc(2 '3 ,4)P3, (3.3)[46;47]. 3.3 Could be visualised as a truncated version o f
adenophostin A where the 2' and 3' carbons o f the ribose ring and their terminal 
phosphate group are retained but the remainder o f the adenosine residue is excised. It 
was found to be a full agonist at the Ins(l,4 ,5)P3R of rabbit platelets, but ten-fold 




A comprehensive biological study o f 3.3 was carried out by another 
group[48]. It was found to be a full agonist for Ca2+ release in SH-SY5Y 
neuroblastoma cells and MDCK cells, being only 10-12 fold weaker than 
Ins(l,4 ,5)P3. Furthermore, in binding assays o f pig cerebellum 3.3 had only 5-fold 
lower affinity compared with Ins(l,4 ,5)P3. Like adenophostin A, 3.3 was shown to be 
unaffected by both 3-kinase and 5 phosphatase enzymes. Molecular modelling 
indicated that the vicinal equatorial 4 and 3-phosphates and the a-glucoside ring of 
3.3 can be almost perfectly superimposed on the analogous structural moieties of both 
adenophostin A and Ins(l,4 ,5)P3. A molecular dynamics simulation was used to 
explore the position o f the 2'-phosphate group in adenophostin A and the 2'-phosphate 
in 3.3, which confirmed that in 3.3 the conformationally flexible hydroxyethyl 
phosphate was likely to adopt an extended conformation therefore preventing the 2 '- 
phosphate from accurately mimicking either the 1-phosphate o f Ins(l,4 ,5)P3 or the 2'- 
phosphate o f adenophostin A.
Shortly afterwards, another group published the synthesis o f more analogues 
similar to 3.3 but based on xylopyranosides (figure 3.3)[49]. It was found that three 
o f the mimics showed comparable activity to 3.3 releasing approximately the same 
amount of intracellular Ca2+ from permeabilised hepatocytes. However the potency
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o f these analogues was ten fold lower than that of Ins(l,4 ,5)P3, with the larger and 
more flexible /?-hydroxypropyl mimic having a much lower potency. Biological 
evaluation o f 3.3 and the xylopyranosides in the same assay would be interesting to 
determine the contribution o f the hydroxymethyl group to the activity. This point has 
been considered in more recent studies and will be discussed further in chapter 3.
'!KS=2U _..
'O P 0 3
n=2 or 3 n=2 or 3
Figure 3.3: Xylopyranoside based minimal structures.
Later a report appeared on a synthesis o f 2-deoxy derivative of 
Gluc(2'3,4)P3[50]. Not surprisingly, this molecule was some 2,000-fold less potent 
than Ins(l,4 ,5)P3 in mobilising intracellular Ca2+, showing the expected parallel with 
the deletion of the 6-hydroxyl group of Ins(l,4 ,5)P3.
Figure 3.4: 2-deoxy derivative o f Gluc(2’3,4)P3.
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3.2 Synthesis of the C-glycosides
The lower affinities of compounds (figures 3.2-3.4) compared with 
Ins(l,4 ,5)P3 were thought to be due to the conformational flexibility o f the side chain 
preventing the third phosphate from achieving an optimal binding position on the 
receptor. We therefore envisaged that it would be of interest to design a 
monosaccharide polyphosphate Ins(l,4,5)P3 mimic, having the third phosphate closer 
to the ring and using a less flexible chain. It is clearly impractical to attempt synthesis 
o f the chain-shortened version of Gluc(2 '3 ,4)P3, therefore a C-glycoside derivative 
was an attractive target. On the basis o f all the above considerations, in the present 
work, we designed the syntheses o f a  and /£-C-(hydroxymethyl)-l-deoxy-D- 
glucopyranoside 3,4, l'-trisphosphate analogues (1 and 2) based on Gluc(2 '3 ,4)P3 but 
with a shorter side chain. In 1 and 2, the third phosphate is attached to a carbon centre 




Figure 3.5: a  and /?-C-(hydroxymethyl)-l-deoxy-D-glucopyranoside 3,4, l'-
trisphosphate analogues
3.2.1 Synthesis of D-glucopyranose intermediate
The glucopyranose intermediate was produced by Fischer glycosidation with a 
slight modification o f the method previously reported[46]. Thus D-glucose was 
reacted with allyl alcohol in the presence o f HC1, which was generated in situ by 
careful addition of acetyl chloride, to give a mixture o f pyranosides from which the a  
anomer was isolated in 31% yield. Regioselectively protected 2,6-dibenzyl-D- 
glucopyranose has already been prepared and reported in our laboratory[46]; however 
another method was sought, as this method involved stannylene mediated direct 
dibenzylation of positions 2 and 6 in 3. Although this methodology was fairly 
successful on a small scale (44% on 2 g), when scaled up the yield reduced 
dramatically (15% on 35 g). Moreover, stannylene mediated dibenzylation requires 
extensive purification of the product by flash chromatography therefore limiting the
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scale o f the synthesis. This led to the investigation o f an alternative route. Although 
the proposed route was longer it was hoped that the overall yield would be higher and 






Figure 3.6: Route to the BDA protected derivative 6.
A modification o f a selective pivaloylation method described in the 
literature[73] was used to selectively acylate the 2 and 6-hydroxyls o f 3. This 
particular report was concerned with regioselective acylation o f a selection of 
carbohydrates and treatment o f methyl or-D-glucopyranoside was shown to give the 
2,6-di-O-pivaloyl derivative in high yield (83%). Treatment o f 3 with pivaloyl 
chloride (trimethylacetylchloride) at 0°C gave one major product which was shown to 
be the 2,6-di-O-pivaloyl derivative from the COSY NMR spectrum (which
indicated typically deshielded doublet o f doublets at <5h 4.61 with coupling constants J
3.9 Hz and 9.8 Hz, corresponding to H-2, Sn 4.42 and 4.33 with coupling constants J
1.9 Hz, 4.9 Hz and 12.2 Hz, corresponding to H-6).
The protection of the remaining /raws-diequatorial hydroxyl groups at 
positions 3 and 4 was initially achieved by heating 4 under reflux with butane-2,3- 
dione, catalytic camphorsulphonic acid and excess trimethyl orthoformate for 3 h. 
This gave one major product (5), which, after purification, was identified as the 
corresponding butane diacetal (BDA) in 62.5% yield. The family o f 1,2-diacetals (eg. 
BDA) have recently become very important protecting groups in carbohydrate 
chemistry and are extensively reviewed in [74]. Unfortunately, upon scale-up the 
yield of the reaction reduced dramatically due to the migration o f the pivaloyl groups 
under acidic conditions. After the pivaloyl groups were removed using NaOH, the 
overall yield of the required product was poor (28%) over two steps.
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5.8 5.6 5.4 5.2 5.0 4.8 4.6 4.4 4.2 4.0 3.8
Figure 3.7: Part of the 1H NMR spectrum of 4 indicating the deshielded acylated 
positions of H-2 and H-6 .
A slightly different strategy was adopted in which positions 3 and 4 of 4 were 
protected by an isopropylidene acetal using 2-methoxypropene in THF in the presence 
of a catalytic amount of p-toluenesulphonic acid. When 4 was used crude, a second 
product was formed during this reaction, presumably from some 2,3-di-0-pivaloyl 
ester formed in the preceeding step. Athough the impurity was not fully 
characterised, 13C NMR identified this product as allyl 2,3-dipivaloyl-4,6-0- 
isopropylidene-a-D-glucopyranoside on the basis of characteristic Sc values of 
isopropylidene quaternary carbons (<5c 101.92, characteristic of a 6 -membered ring) 











Figure 3.8: 400 MHz 13C NMR chemical shift values for isopropylidene Cs in 7 and 
7b.
Conversion of 7 into the known allyl 2,6 -di-0-benzyl-a-D-glucopyranoside 
was then straightforward. The 2,6-di-0-pivaloyl derivative 7, was saponified by 
heating at reflux with NaOH pellets in methanol. The resulting free 2- and 6 - 
hydroxyls were alkylated using benzyl bromide and sodium hydride in DMF; the
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product of this reaction was used without purification. Finally, the isopropylidene 
group was removed by stirring the crude intermediate with 10% 1M aqueous HC1 in 
methanol for 30 min, and crystallisation from ether-hexane gave pure 10 (67% yield 
over five steps). This was found to be the most convenient and efficient method to 
produce 10 in multigram quantities. Similar reactions on D-xylose to produce 
selective allyl 2-O-benzyl-a-D-xylopyranoside (chapter 4), confirmed the general 
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Scheme 3.1: Synthetic route to the D-glucopyranose intermediate.
Reagents and conditions: iXCH^CCOCl, pyridine, 0°C, 2.5 h; ii) 2- 
methoxypropene, PTSA, THF, 30 min; iii) NaOH, MeOH, reflux, 1 hour; iv) NaH, 
BnBr, DMF, 0°C, 90 min; v)l M HCl-MeOH, 1:10, rt, 30 min (67%, over 5 steps), 
vi) NaH, PMBC1, DMF, rt, 12 h (77%); vii) PdCl2, MeOH, rt, 4 h (71%). All = allyl, 
Piv = (CHsXCCO, (Pivaloyl), PMB = />-methoxybenzyl, Bn = benzyl.
The diol 10 was easily converted in high yield into 11, a selectively protected 
intermediate without the labile trans isopropylidene group. In the synthesis of 
Ins(l,4 ,5)P3 analoguesp-methoxybenzyl groups are often used to mask the hydroxyls 
designated for phosphorylation towards the end of a synthetic route, because they are 
easily removed in the presence of other protecting groups such as benzyl ethers[22]. 
This approach has been adopted here also. Thus, / 7-methoxybenzylation with sodium 
hydride and /?-methoxybenzyl chloride in DMF gave the fully protected product 11. 
The allyl glycoside was then cleaved by stirring 11 vigorously with palladium 
chloride in MeOH for 4 h to give 12. The reaction becomes increasingly acidic as the 
reaction proceeds, and must be neutralised before work-up to prevent the formation of 
side products if  acid-labile groups such as />-methoxybenzyl ethers are present. This 
method represents a more convenient and higher yielding cleavage o f the allyl 
glycoside than that reported in the literature[76].
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3.2.2 Synthesis of the C-glycosides
With 12 in hand, attention now turned to the synthesis of the exo-methylene 
derivative. Oxidation of 12 using oxalyl chloride and DMSO in dichloromethane 
(Swem oxidation) proceeded smoothly to give 13 with a yield of 67%. The IR 
spectrum displayed the characteristic C=0 stretching at 1755 cm'1, while !H NMR









Figure 3.9: Part of the 400 MHz !H NMR of lactone 13.
Elaboration to the exo-methylene derivative 14 was carried out by the Tebbe 
reaction[77]. The product was obtained in 65% yield after purification by flash 
chromatography. The Tebbe reagent was chosen over the Wittig to synthesis the exo­
methylene sugars as it gives better product yields, particularly when the lactone 
substrate is hindered[78].
The a  and /? epimers of the C-glucosylmethanol derivatives were then 
synthesised by hydroboration reactions[77]. Hydroboration using 9-BBN produced 
y6-2,6-di-0-benzyl-3,4-di-0-(p-methoxybenzyl)-D-glucopyranosylmethanol (17) 
exclusively. The structure of 17 was difficult to assign from the *H NMR spectrum 
due to the protons of the benzyl having a similar influence on the chemical shifts of 
the protons H-T and H-6 . However a 1H-13C NMR correlation experiment allowed 
assignment of H-l' and H- 6  due to the downfield shift of the benzylated C- 6  in the 13C 
NMR spectrum. A small sample was also converted into the acetate and the resulting 
downfield shift of the H-T protons confirmed the assignment. Hydroboration of 14
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with borane-THF complex produced a mixture of a- and /?-isomers 15 and 17 in an 
approximate ratio o f 1:2. The two products could not be separated by flash 
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Scheme 3.2: Route to triols 16 and 18.
Reagents and conditions: i) a. Oxalyl chloride, CH2CI2, -78  °C, b. Me2SO added 
dropwise, c. (12) in CH2CI2 added dropwise, d. NEt3 (67%); ii) Pyridine, THF, 
Tebbe reagent (l.leq ) added dropwise -45°C for 30 min 65%); iii) 9-BBN, THF 
0°C, 3 h (58%) or BH3-THF, 0°C, 2 h (74%); iv) CF3COOH, CH2C12 (80%);
Removal of the PMB protecting groups using 10% TFA in DCM furnished a 
separable mixture o f the corresponding triols 16 and 18 in good yields.
3.2.3 Phosphorylation and Deprotection
The phosphitylating reagent chosen for the synthesis was
bis(benzyloxy)diisopropylaminophosphine. This reagent was prepared by the
literature procedure[79]. In brief, 7V,7V-diisoproylamine was added dropwise to an 
ethereal solution of phosphorus trichloride at -78°C. The product was isolated and 
purified by distillation under reduced pressure to give 19 which was stored as a 
crystalline solid at -20°C. Benzyl alcohol was then added to a solution o f 19 in 
triethylamine and dichloromethane. After purification the phosphitylating reagent 
was obtained as a clean sample Sp 149.03 ppm.
Figure 3.10: Route to the phosphitylating reagent.
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The two triols were treated identically in the rest of the synthesis but for the 
purpose o f this discussion when NMR values are quoted it is the a-anomer being 
referred to. Phosphitylation was carried out at rt using 2 equivalents o f 
phosphitylating reagent per hydroxyl group and three equivalents of 1/7-tetrazole, in a 
small volume of dry dichloromethane. A mixture of phosphitylating reagent and 1H- 
tetrazole was stirred for 30 min; the mixture turned cloudy indicating the 
phosphitylating agent-tetrazoiide intermediate had been formed. The triol was added 
and after 30 min, TLC indicated complete conversion into the trisphosphite. After 
oxidation with mCPBA and work-up, the 31P NMR spectrum of 21 revealed three 
phosphate signals at 0.21, -0.594 and -1.07ppm, corresponding to the phosphorus 
atoms o f the trisphosphate.
Deblocking o f the eight benzyl protecting groups was achieved using 
hydrogenation over a palladium catalyst. The products were purified using ion- 
exchange chromatography on Q Sepharose Fast Flow resin eluting with a 0-1 mol
 o
dm gradient of triethylammonium hydrogen carbonate, pH 7. The phosphate- 
containing fractions were detected and combined, and the total amount of compound 












Scheme 3.3: Synthetic route to a  and /?-C-(hydroxymethyl)-l-deoxy-D- 
glucopyranoside 3,4, l'-trisphosphate analogues.
Reagents and conditions: i) a. (BnO)2PNPr'2, li/-tetrazole, b. mCPBA, -78 °C to rt 
(78%); ii) H2, Pd-C, 50 psi, MeOH-H20 , 24 h.
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The structure of the product was identified as the required triethylammonium 
salt of the trisphosphate (1) on the basis of its 31P NMR spectrum which showed three 
signals, and its 'H NMR spectrum in CD3OD. The accurate negative FAB mass 
spectrum showed a mass consistent with that predicted for [M-H]“.
Figure 3.11 : 162 MHz 31P NMR spectrum of the triethylammonium salt of 1 in 
CD3OD.
3 . 3  B i o l o g i c a l  R e s u l t s
The ability of a sample of each of the analogues to release Ca2+ from 
permeabilised hepatocytes was compared with that of a sample of Ins(l,4 ,5 )P3. The 
results are shown in Table 3.1.
Maximally effective concentrations (10 //M) of Ins(l,4,5)P3 and 1 released the
same fraction of the intracellular Ca2+ stores, 47 ± 2% (n = 5) and 42 ± 5% (n = 3) 
respectively; half-maximal effects (EC50) occurred with 144 ± 6 nM and 2.41 ± 
0.17pM, respectively (figure 3.12) . At a concentration of 10 juM, 2 released only 19 
± 3% (n = 5) of the stores. Higher concentrations of 2 were not examined, but its 
inability to antagonise the response to a submaximal concentration of Ins(l,4,5)P3 
(table 3.2) suggest that it is not a partial agonist. The results are therefore consistent 
with 9 being a full agonist with an EC50 of about 10//M. Thus, trisphosphate 1 was 
similar in potency to Gluc(2 '3 ,4 )P3 and the xylose equivalent, while 2 was 
considerably weaker, this will be discussed below.
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ECS0 It % release 
with 10pM
n
Ins(l,4,5)P3 144 ± 6  nM 1 .6 8  ±0.26 47 ± 2 5
1 2414 ± 173 nM 4.99 ± 1.84 42 ± 5 3
2 nd nd 19 ± 3 5
Gluc(2'3,4)P3 a 1867 ± 64 nM 2.76 ±0.10 47 ± 3 3
Table 3.1: 45Ca2+ release data for Ins(l,4,5)P3, Gluc(2'3,4)P3, 1 and 2 from
permeabilised hepatocytes.
The EC50 values and Hill coefficients (h) were separately determined for n 
independent experiments by fitting results to logistic equations. Results are shown as 
means ± S.E.M.
Data for Gluc(2'3,4)P3 obtained in an independent study [54] when Ins(l,4,5)P3 had 
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Ins(l,4,5)P3 (150 nM) 22 ± 4
2 (10 pM) 21 ± 2
with 2 (10 pM)
38 ± 1
Table 3.2: 45Ca2+ release data for combined stimulation with Ins(l,4,5)P3 and 2 from 
permeabilised hepatocytes.
The percentage o f the intracellular Ca2+ stores released by a submaximal 
concentration o f Ins(l,4,5)P3 alone or in combination with 2 are shown. Results are 
shown as means ± S.E.M for 3 independent experiments.
3.4 Conclusions
Previous studies [54;56] have clearly demonstrated that sugar-based 
polyphosphates (see chapter 4) are able to approach the potency o f Ins(l,4,5)P3 but 
not o f adenophostin. Such molecules possess a glucopyranosyl 3,4-bisphosphate with 
an auxiliary phosphate which is accommodated in an optimal position for binding 
using a second ring as in adenophostin. A challenge therefore is to explore the 
possibility o f optimal positioning of the third phosphate without the need for the 
second ring. This would also be useful in the design o f related molecules since it 
would avoid problems of coupling strategies (see chapters 4 and 5).
It is encouraging to see that the C-glycoside mimics prepared here (1 and 2) do 
possess Ins(l,4,5)P3 like Ca2+ mobilising activity, although neither has attained the 
activity o f disaccharide analogues (chapter 4). The differential potencies o f 1 and 2 
are o f interest and indicate that 1 presents the auxiliary phosphate group in a more 
favourable position. However, a comparison of the activity o f 1 with that of 
G1c(2'3,4)P3 (figure 3.2) indicates that both molecules possess similar potency, 
implying no significant advantage o f 1 over Glc(2'3,4)P3 in binding to the Ins(l,4,5)P3 
receptor.
Moitessier et al [49] synthesised 2', 3, 4-trisphosphates o f (2-hydroxyethyl) 
a  and /?-D-xylopyranosides and 3', 3, 4-trisphosphates o f (2-hydroxypropyl) a  and fi- 
D-xylopyranosides. It was found that three o f the mimics were comparable and 
released approximately the same amount of intracellular Ca2+, roughly with ten fold 
lower potency than Ins(l,4,5)P3) with only the larger and more flexible p~ 
hydroxypropyl mimic having a much lower potency. On the basis o f these results it
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might be reasoned that the C-glycosides with a less flexible chain should both behave 
similarly while, based upon the structure o f Ins(l,4 ,5)P3 one might expect the /? 
modified C-glycoside to have higher potency. However, on examination of molecular 
models this is clearly not the case. The differential activity o f 1 and 2 can be 
qualitatively explained by the fact that the a-C-glycoside phosphate group in 1 could 
readily access some o f the conformational space described by the 1-phosphate of 
Ins(l,4 ,5)P3. While this is not impossible for the y0-C-glycoside phosphate group in 2, 
it does seem to be more difficult and we also cannot exclude a potentially disfavour 
able steric or electronic interaction o f the extra CH2 group with the receptor protein. 
The results show that the anomeric oxygen atom in Glc(2 '3 ,4)P3 is not essential for 
biological activity and confirm that the three-dimensional location of the third 
phosphate group plays an important role in strong binding to the receptor.
These C-glycoside based polyphosphate analogues represent steps in 
designing high potency ligands using insights gained from the adenophostins and are 
worthy o f further development.
3.5 Further C-glycoside analogues.
Several other C-glycoside analogues have been reported by the Shuto group 
since this work was carried out. Compounds 3.4 and 3.5 have only been reported as a 
communication[81]. Although the biological evaluation o f these compounds has not 
been reported, the subsequent paper[82] where the synthesis of 3.6 was described 
suggests that the length of the side-chain in 3.4 and 3.5 may be too long to allow the 







Figure 3.13: Further C-glycosides.
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The binding affinity o f 3.6 to the Ins(l,4 ,5)P3R in calf cerebellum was found 
to be only about 2-fold lower than Ins(l,4 ,5)P3. It is worth noting that this is 
considerably better than the O-glycoside equivalent [Gluc(2 '3 ,4)P3]. The different 
activity between the C-glycoside and Gluc(2 '3 ,4)P3 may not be due to the property of 
the glycosidic linkage, since the side-chain length of 3.6 is also different from 
G1uc(2'3,4)P3.
C-glycoside adenophostin A C-glycoside base substituted adenophostin A
Figure 3.14: C-glycoside adenophostin A derivatives.
Finally, the same group has prepared a C-glycosidic analogue of adenophostin 
A and an C-glycoside analogue where the purine m otif has been replaced by a much 
smaller pyrimidine (uracil) (Figure 3.14)[83]. The ability o f the compounds to release
2 j
Ca from permeabilised hepatocytes was compared. The C-glycosidic adenophostin 
A was the most active compound with EC50 o f 77 ± 7 nM while the base substituted 
adenophostin A was dramatically lower (378 ± 87 nM)[84]. As the C-glycosidic 
adenophostin A is less active than adenophostin A it suggests that the oxygen may 
influence the relative position of the 2 '-phosphate, due to the steric and electronic 










As already discussed in chapter 3, minimal structure analogues were designed and 
synthesised to determine whether the adenine component o f the adenophostins was 
essential for activity. All the monosaccharide analogues had lower affinity than 
Ins(l,4 ,5)P3; This lower affinity was thought to be due, at least in part, to the 
conformational flexibility o f the ethylphosphate side chain in figure 4.1 [48]. 
Consequently, various phosphorylated disaccharides incorporating a D-glucopyranosyl 
3,4-bisphosphate moiety with an a-glycosidic linkage to a second sugar containing one 





Figure 4.1: Glc(2 ',3 ,4)P3 (4.1) and the xylopyranoside equivalent (4.2).
The first series o f disaccharide polyphosphates [54] were based on a ,a l-trehalose 
and sucrose, both o f which are readily available naturally occurring starting materials 
(figure 4.2). All three of the synthetic analogues, sucrose 3,4,3'-trisphosphate 
[Sucr(3 ,4 ,3 ')P3], «,«'-trehalose 3,4,3',4'-tetrakisphosphate [Trehal(3 ,4 ,3 ',4 ')P4] and a ,d -  
trehalose 2,4,3',4'-tetrakisphosphate [Trehal(2,4,3',4') P4], contain the same
phosphorylated glucose component, identical to that found in the adenophostins. The 
third phosphate was on a second ring in a more rigid conformation than in Glc(2 ',3 ,4)P3. 
Although molecular modelling indicated that the positioning o f the third phosphate may 
not have been ideal, these were easily accessible from existing disaccharides avoiding 








T re h a l(3 ,4 I3 ,I4 ,)P 4T re h a l(2 )4 13 ',4 ,)P 4
Figure 4.2: Disaaccharide polyphosphates.
These analogues together with adenophostin A, Ins(l,4 ,5)P3 and Glc(2 ',3 ,4)P3
•7
underwent biological testing to determine their potencies in both [ H]Ins(l,4 ,5)P3 
binding and 45Ca2+ mobilisation from rat hepatocytes. They had the following rank order 
which was the same in both binding assays and 45Ca2+ release, adenophostin 
A>Ins(l,4,5)P3>Trehal(2,4,3,,4,)P4> Glc(2,,3,4)P3«Trehal(3,4,3,,4,)P4>Sucr(3,4,3,)P3.
Trehal(2,4,3’,4')P4 is an asymmetrical regioisomer o f Trehal(3,4,3',4')P4 in which a 
single phosphate is relocated to a position two carbons removed from the glycosidic 
oxygen. Trehal(2,4,3',4')P4, gave the better result with a potency 10-fold lower than 
Ins(l,4 ,5)P3, suggesting that the positioning o f the 2-phosphate group must be better than 
either o f the 3 or 4-phosphates. It was also reasoned that the alteration in the substitution 
pattern on one glucose residue may influence the conformation about the glycosidic 
linkage.
These findings together with the biological data from Glc(2 ',3 ,4)P3 suggested that 
the precise orientation and position o f the phosphate group needed to be controlled in 
some way. On the basis o f these considerations, methyl 3-0-(a-D-glucopyranosyl)-/?-D- 
ribofuranoside 2,3',4' trisphosphate (ribophostin figure 4.3) [54;55] was designed to 
restrict the conformation o f the side chain of Glc(2 ',3 ,4)P3 by introducing a 
ribofuranoside ring, as in the adenophostins. The potency of ribophostin in Ca2+ release 
assays was similar to that o f Ins(l,4 ,5)P3, but still about 20-fold less than that of 
adenophostin A. The lower affinity o f ribophostin suggests that the adenine component 







Sucr(3,4,3')P3 was found to be 25-fold less potent in Ca2+ release than ribophostin, 
which is surprising as it is structurally quite similar to ribophostin. The authors 
suggested several reasons why it should be so much weaker; i). Steric hindrance from 
one or both hydroxymethyl groups on the fructofuranoside in Sucr(3,4,3')P3 interfering 
with binding, ii) Overlapping anomeric effects about the glycosidic linkage, not present 
in ribophostin, influence the conformation about the glycosidic linkage, iii). The 
presence of a quaternary furanosyl anomeric centre may lead to increased flexibility 
about the fructofuranosyl linkage.
Simplification of ribophostin led to the synthesis of l-0 -[(3 ,5',4,R)-3- 
hydroxytetrahydrofuran-4-yl] - a-D-glucopyranoside 3,4,3 '-trisphosphate (furanophostin, 
figure 4.4)[57] which lacks both the O-methyl and the 4-hydroxymethyl moieties but 
retains the rigidity o f the five-membered ring. Again, the activity o f furanophostin was 
found to be similar to Ins(l,4,5)P3 and to ribophostin in Ca2+ release assays.
OH
Figure 4.4: Furanophostin.
At a similar time the Matsuda group published the synthesis o f furanophostin[56] 
and some related compounds shown in figure 4.5. Biological testing of furanophostin in 
binding to porcine cerebellum, showed a comparable affinity to Ins(l,4,5)P3 itself in this 
assay, thus confirming the conclusions from the 45Ca2+ release assays, that furanophostin 
is almost equipotent to Ins(l,4,5)P3. 4.3 Has a structure midway between furanophostin 
and ribophostin; it contains a hydroxymethyl group analogous to the ribophostin 4- 
hydroxymethyl, but like furanophostin lacks the l-O-methyl group. It has a similar 
binding affinity to furanophostin indicating that the 4-hydroxymethyl motif does not 
increase affinity for the Ins(l,4,5)P3 receptor towards that o f adenophostin A, and neither
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does it seem necessary for Ins(l,4,5)P3-like activity. Compound 4.4 which lacks the 
third phosphate group of 4.3, was, as expected on parallel studies o f Ins(l,4,5)P3 almost 
inactive. Compound 4.5, a regioisomer of 4.3, showed about 20-fold lower potency than 
4.3, which suggested that the binding of the compounds depends on the three- 
dimensional location o f the third phosphate group.
OH
OH OHOH O P 0 3‘
4.3 4.4 4.5 OH
Figure 4.5: Furanophostin-related disaccharide polyphosphates.
In the last chapter we designed and synthesised a  and ft- D-
glucopyranosylmethanol 3,4,l'-trisphosphate analogues based on Gluc(2',3,4)P3 but with 
a shorter side chain (chapter 3)[85]. In these molecules the third phosphate group is 
attached to a carbon centre fixed in the a  and /^-positions. However, biological 
evaluation showed that the a-C-analogue was only comparable to Gluc(2',3,4)P3, while 
the y^-C-analogue was even weaker. This finding suggests that the second ring of 
ribophostin and furanophostin is required for greater affinity.
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4.2 Synthesis of xylofuranophostin and its diastereoisomers.
In the present work we have taken the simplification o f furanophostin a step 
further by replacing the glucopyranosyl 3,4-bisphosphate structure in furanophostin with 
the xylopyranosyl equivalent to give 23. In order to explore the effect o f stereochemical 
variations on the biological activity o f 23, and in particular the positioning o f the non- 
vicinal phosphate group for potent activity, we have also synthesised three of its 
diastereoisomers 24, 25 and 26. The series of trisphosphates 23 to 26 may be regarded as 
conformationally restricted analogues of the original xylopyranoside-based[49] analogue
4.2 (figure 4.1) and its /Minked equivalent.
2' 0 3PO ^ O
2-o 3p o - ^ ^ | / \
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Figure 4.6: Xylofuranophostin and its diastereoisomers.
4.2.1 Discussion
We planned to synthesise the target compounds using glycosidation reactions 
with glycosyl donor and tetrahydrofuran derivatives shown in scheme 4.2. A typical 
route is shown in figure 4.7. We designed a phosphite donor as it is easy to prepare in 
quantitative yield and a colleague (Dr. R. D. Marwood) has successfully employed the 












Figure 4.7: Route to xylofuranophostin and its f l - e pimer.
4.2.2 Synthesis of the donor
Although the required regioselectively-protected D-xylopyranose 33 had already 
been prepared and reported[76], the overall yield from allyl a-D-xylopyranoside (27) was 
restricted by the unavoidable formation of two butane diacetal protected regioisomers in 
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Figure 4.8: Literature route to fully protected D-xylopyranose.
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A different route was therefore investigated, with the aim o f increasing the 
overall yield o f 27 while reducing the need for time-consuming purifications by column 
chromatography. Thus, Fischer glycosidation o f xylose by a modification of the 
previously described method [76] gave the allyl xyloside (27) as colourless crystals in 
41% yield over three crops. It was found that the reaction mixture could be satisfactorily 
neutralised by addition o f solid NaHCC>3, avoiding the need for more expensive 
Amberlite IR-45 (OH') resin. Furthermore, adding diisopropyl ether to the crystallisation 
mixture immediately before filtration facilitated the isolation o f the crystalline product 
and consequently the yield was significantly improved from that reported o f 28% to 
41%.
The next step involved the selective acylation at position 2 o f xylose using the 
trimethylacetyl chloride (pivaloyl chloride). Selective protection o f alcohols to give the 
corresponding pivaloyl esters has mainly been used for esterifying the primary hydroxyl 
groups in the presence o f secondary hydroxyl groups. A literature search revealed that 
the 2-OH is the most reactive o f all the secondary hydroxyl functions in the a-D- 
glucopyranosides. It was therefore reasoned that the 2-OH in the xylose derivative 
would also be the most reactive[73]. Therefore, a modification o f a selective 
pivaloylation method described in this report was used to selectively acylate the 2- 
hydroxyl of 27. After several systematic changes relating to equivalents of pivaloyl 
chloride, temperature and reaction time, the best conditions were established. Thus, 
treatment of 27 with pivaloyl chloride at -20°C in pyridine did indeed give one major 
product, although other minor products were shown to be present by TLC, presumably 
the di-pivaloyl esters. The required 2-O-pivaloyl ester 34 could be isolated by 
crystallisation in 53% yield, without the need for purification by chromatography. The 
major product was identified as 2-0-pivaloyl derivative from the ^ - 'H  COSY NMR 
spectrum, which indicated a typically deshielded doublet o f doublets at <Sh 4.62 with 
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Figure 4.9: Part of 400 MHz ]H and 2D 'H COSY NMR spectra of 34 indicating the 
deshielded acylated position of H-2.
As in chapter 2, for the synthesis of allyl 2,6-di-O-benzyl-a-D-glucopyranoside, 
the protection of the remaining Jra«s-diequatorial hydroxyl groups at positions 3 and 4 
was initially achieved by refluxing 34 with butane-2,3-dione, catalytic camphorsulphonic 
acid and excess trimethyl ortho formate for 3 h. This gave one major product (35), 
which, after purification, was identified as the corresponding butane diacetal (BDA) in 
8 6 % yield. Unfortunately, when the reaction was scaled up the yield reduced 
dramatically due to the migration of the pivaloyl groups under acidic conditions. After 
the pivaloyl groups were removed by NaOH, the overall yield of the required product 









Figure 4.10: Route to BDA derivative 28.
The same strategy was then adopted as in chapter 3. Thus the trans-diequatorial 
hydroxyl groups at positions 3 and 4 were protected using 2-methoxypropene in THF in 
the presence o f a catalytic amount of /7-toluenesulphonic acid to give one major product. 
Since a colleague (Dr. R. D. Marwood) carried out this reaction at a similar time and 
identified the major product to be the 3,4-O-isopropylidene derivative, the crude material 
obtained from the reaction was carried forward to the next step.
Conversion into the known allyl 2-O-benzyl-a-D-xylopyranoside was then 
straightforward, with each intermediate being isolated for identification. The pivaloyl 
ester was removed using saponification by heating at reflux with NaOH pellets in 
methanol to give the free 2-hydroxyl. Benzylation o f the 2-hydroxyl was achieved using 
sodium hydride and benzyl bromide in DMF. Finally, the isopropylidene group was 
removed by stirring 38 with 1 M HC1 in MeOH for 30 min to give allyl 2-O-benzyl-a-D- 
xylopyranoside (31) in high yield (76% over the 4 steps from 27) after purification by 
flash chromatography followed by crystallisation. 31 Has been prepared previously but 
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Scheme 4.1: Synthetic route to the D-xylopyranose intermediate.
Reagents and conditions: i) AllOH, HC1, reflux, 16 h; ii) (C H ^ C O d , pyridine, -40  
°C, 2.5 h; (53%); iii) 2-methoxypropene, PTSA, THF, 30 min; iv) NaOH, MeOH, reflux, 
1 h; v) NaH, BnBr, DMF, 0 °C, 90 min; vi)l M HC1 (10%), MeOH, rt, 30 min (76%, 
over 4 steps), vii) a) NaH, PMBC1, DMF, rt, 12 h (84%); viii) PdCl2, MeOH, 0 °C to 
room temp, 4 h (90%). All = allyl, Piv = ( d ^ C C O ,  (Pivaloyl), PMB = p- 
methoxybenzyl, Bn = benzyl
The diol 31 was easily converted in high yield into 2-0-benzyl-3,4-bis-0-(p- 
methoxybenzyl)- a,^-D-xylopyranose (32), a selectively protected intermediate without 
the labile trans isopropylidene group. Thus, reaction with sodium hydride and p- 
methoxybenzyl chloride in DMF gave the fully protected product. The allyl protection at 
the anomeric position was then removed by stirring vigorously with a catalytic amount of 
palladium chloride in MeOH to give xylopyranose 33. Finally, 33 was converted into 
the phosphite donor (39) with 1/7-tetrazole and bis(methoxy)(diethylamino) phosphine in 
dichloromethane, which was used without further purifcation.
PMRO---- V " - ---- 9
PMBCH-^-*,,* ' ^ \ ,
BnO 0H
PMBO-----V""-— 9
' p m b o -~ * -* ,,,,,' ^ A ,
BnO OP(OMe)2
33 Dnu 39
Figure 4.11: Conversion to the phosphite donor.
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4.2.3 Synthesis of the acceptor
The acceptors (40 and 41) were prepared by Dr. A. M. Riley. Although the 
structure is simple, the synthesis required optical resolution o f an enantiomeric 
intermediate, and the conversion o f one enantiomer into a compound for which the 
absolute configuration was already known. The route followed is outlined in scheme 
4.2.








Scheme 4.2: Synthetic route to glycosyl acceptors (+)-40 and (—)-41.
Reagents and conditions: i) a) /?-methoxybenzylidene dimethyl acetal (1.05 equiv.), 
pT SA , DMF, 70 °C; b) DIBAL-H (2.5 equiv.), CH2CI2, -78  °C; 90 % yield for two steps; 
ii) (-)-(iS)-camphanic chloride, pyridine, 0 °C to rt, (80 % yield; iii) NaOH, MeOH, 
reflux, 94-97 %; iv) a) NaH, BnBr, DMF; b) CF3COOH, CH2C12; 87 % yield for two 
steps.
4.2.4 Glycosidation and deprotection
With suitable glycosyl phosphite donor and acceptors in hand, the glycosidation 
was carried out under established conditions favouring a-stereoselectivity i.e. room 
temperature in a mixture o f 1,4-dioxane and toluene[86]. The crude glycosyl phosphite 
was coupled to each of the two enantiomeric alcohols in the above manner using zinc 
chloride and silver perchlorate as promoters. The glycosylation [87] of (+)-(3R,4S)-4-p- 
methoxybenzyloxy-tetrahydrofuran-3-ol (40) [20] and o f (-)-(31S',4R)-4-p-
methoxybenzyloxy-tetrahydrofuran-3-ol (41) [57] with the di-OMe phosphite gave a
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total o f four diastereoisomeric products 42-45. It is interesting to note that, in each case, 
a mixture o f a  and /?-coupled products was formed using this xylopyranosyl phosphite 
glycosyl donor, whereas only the a-coupled product was detected when the same 
conditions were applied to the analogous glucopyranosyl phosphite in the synthesis of 
furanophostin [57].




RO" 3’S4 'R OR
OR 3 'R4'S,BnO
42 and 43 R=PMB 44 and 45 R=PMB
46 and 47 R=H 48 and 49 R=H
Scheme 4.3: Synthetic route to the diastereoisomers.
Reagents and conditions: i) AgC104, ZnCl2, dioxane, toluene, 4A sieves, glycosyl 
acceptor, (70-76%); ii) CF3COOH, CH2C12 (18-34%);
The a  and /?-epimers could not be separated at this stage, therefore it was decided 
to proceed with the deprotection of the /?-methoxybenzyl groups in the hope that the 
anomeric mixture o f triols could be separated. Thus, the PMB ethers where removed 
using 10% trifluoroacetic acid in dichloromethane. In both cases TLC showed the 
appearance o f two new spots, allowing the chromatographic separation of the 4'S,3'R 
anomers (48 and 49). Subsequent crystallisation furnished the pure triols for 
phosphorylation. Unfortunately, compounds 46 and 47 could still not be fully separated, 
so the mixture o f products was converted into its corresponding acetate by reaction with 
acetic anhydride and pyridine. The products were then separated by flash 
chromatography to give the a  and p  analogues. The P  product was further purified by 
crystallisation. 51 Was then deprotected by stirring with methanolic ammonia overnight 
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Figure 4.13: Part of 400 MHz ]H and 2D *H COSY NMR spectra of 51.
The lH-!H NMR spectrum of 50 exhibited a doublet at 4.92 ppm with a 
characteristically axial-equatorial coupling constant of J  3.2 Hz, while the 'H -’H NMR 
spectrum of 51 exhibited a deshielded doublet at 4.44 ppm. There was no sign of cross 
over contamination by the other isomer in either NMR (Figures 4.12 and 4.13).
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4.2.5 Phosphorylation and Deprotection
Phosphitylation of each triol was achieved in the usual way with bis(benzyloxy) 
(diisopropylamino)phosphine and l//-tetrazole in dichloromethane to give the 
trisphosphite intermediates. Oxidation at reduced temperature with wCPBA then gave 
the fully protected trisphosphates 52-55 respectively. 31P NMR spectroscopy confirmed 
the presence of three phosphate groups in each compound.
RO V '" '"  4 'R l — i 3 'S
BnO ”0  OR
RO-—
ro- ^ - ^ A ^
BnO 1 P R
3 'R
a  stereochemistry 
46 R=H
P  stereochemistry « stereochemistry 
47 R=H i—  48 R=H
52 R=P(0)(0Bn)2 , i C
P  stereochemistry 
i— 49 R=H
53 R=P(0)(0Bn)2 *— 54 R=P(0)(0Bn)2 1— 55  R=P(0)(0Bn)2
23 24 25 26
Figure 4.14: Phosphorylation and deprotection.
Figure 4.15: 162 MHz 31P NMR spectrum of protected 23.
Deprotection by hydrogenation over palladium on carbon yielded the target 
trisphosphates 23-26 respectively, which were purified by ion-exchange chromatography 
on Q Sepharose Fast Flow resin and isolated as their tri ethyl ammonium salts. Finally, 
each trisphosphate was accurately quantified by total phosphate assay.
The structures of the products were identified as the required triethylammonium 
salts of the trisphosphates (23-26) on the basis of their corresponding 31P NMR and *H-
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'H COSY NMR spectra in CD3OD. All the accurate negative FAB mass spectra showed 




















Figure 4.17: Part of 400 MHz NMRspectrum of 24 in CD3OD.





Stereochemistry E C 5 0 h n % release with 
10 pm
Ins(l,4,5)P3 144 ± 6 nM 1.68±0.26 5 4 7 1 2
23 a,3'S, 4'R 487 ± 58 nM 2.51 ± 1.00 3 51 ± 5
24 J3,3'S, 4'R nd nd 5 3 1 3
25 a,3%  4'S nd nd 5 1 2 1 2
26 P,3 %  4'S 2694 ± 276 
nM
1.7810.43 3 4 6 1 2
Table 4.1: 45Ca2+ release data for Ins(l,4 ,5)P3, 23, 24, 25 and 26 in permeabilised 
hepatocytes.
The EC50 values and Hill coefficients (h) were separately determined for n independent 
experiments by fitting results to logistic equations. Results are shown as means ± S.E.M.
Biological evaluation o f the analogues by a collaborator using the method
described in the experimental section indicated that maximally effective concentrations
2+of Ins(l,4,5)P3, 23 or 26, released the same fraction o f the intracellular Ca stores (47 ± 
2%, 51 ± 5% and 46 ± 2% respectively, Figure 4.18 and Table 4.1). Furthermore, the 
combined application of 10 juM Ins(l,4 ,5)P3 with 10 juM o f either 23 or 26 released no
'ji
more Ca than either o f the agonists applied alone. The concentration o f 23 required to 
cause half-maximal Ca2+ release (EC50) was only 3-4 fold higher than that for 
Ins(l,4,5)P3, while 26 was considerably weaker. The responses to both agonists were 
positively co-operative. Interestingly, there was no significant interaction between 24 
(the ^-epimer of 23) and Ins(l,4 ,5)P3 receptors; even at 10 juM 24 failed to cause
^  I
significant Ca mobilisation and nor did it affect the response to a submaximal 
concentration o f Ins(l,4 ,5)P3 (Table 2). Finally, the results for 25 are consistent with it 
being a very low affinity full agonist (EC50 > 10//M): alone at 10 juM it released less than 
50% of the Ins(l,4 ,5)P3-sensitive Ca2+ stores (Table 4.1) and its effects were 
approximately additive with a submaximal concentration o f Ins(l,4 ,5)P3 when added in 






Ins(l,4,5)P3 (150nM) 22 ± 4 3
24 (lOpM) 4 ± 4 3
Ins(l,4,5)P3 (150nM) with 24 (lOpM) 30 ± 3 3
25 (lOpM) 13 ± 3 3
Ins(l,4,5)P3 (150nM) with 25 (lOpM) 34 ± 1 3
Table 4.2: 45Ca2+ release data for combined stimulation with Ins(l,4 ,5 )P3, 24 and 25 in 
permeabilised hepatocytes.
The percentage of the intracellular Ca2+ stores released by a submaximal concentration of 
Ins(l,4,5)P3 alone or in combination with 24 and 25 are shown. Results are shown as 
means ± S.E.M for 3 independent experiments.
Release (%)
lns(1,4,5)P3
100 - * 23 
° 26
50-
C 9 8 7 6 5 4
-log{[Ligand], M}
Figure 4.18: Effects of Ins(l,4 ,5 )P3 and xylopyranosides 23 and 26 on 45Ca2+ release 
from the Ins(l,4 ,5 )P3-sensitive Ca2+ stores of permeabilised hepatocytes.
These results demonstrate that both 23 and 26 behave as full agonists in this assay 
and that diastereoisomer 23 has a potency in Ca2+ release assays similar to that of 
Ins(l,4,5)P3, ribophostin and furanophostin. This shows that the 5-hydroxymethyl 
moiety of the glucose ring in ribophostin and furanophostin is not essential for potent
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activity at Ins(l,4 ,5)P3 receptors, although the very gradually decreasing potency in the 
series ribophostin>furanophostin>23 suggests that each hydroxymethyl group in 
ribophostin may have a slight enhancing effect on activity. The results also confirm that, 
at the receptor binding site, the orientation of ribophostin and furanophostin relative to 
that ofIns(l,4,5)P3 is such that the 5-hydroxymethyl group o f the glucose moiety mimics 
the 3-hydroxyl o f Ins(l,4 ,5)P3. Had an inverted binding orientation been involved [in 
which case the 5-hydroxymethyl group would be equivalent to the 6-OH of Ins(l,4 ,5)P3] 
then a dramatic difference in activity between the glucopyranoside-based analogues 
(ribophostin, furanophostin) and their xylopyranoside-equivalent (23) would have been 
expected, analogous to the large difference between Ins(l,4 ,5)P3 and 6-deoxy- 
Ins(l,4 ,5)P3. The fact that 23 (similar to ribophostin and furanophostin) is still 10 to 100- 
fold less potent than the adenophostins supports previous arguments that the adenine 
component o f the adenophostins plays a pivotal role in their activity. The similar 
activities of Ins(l,4 ,5)P3, ribophostin and furanophostin suggest that 23, with its single 
hydroxyl group, is the minimal structure for potent agonism in a simple carbohydrate- 
derived agonist of Ins(l,4 ,5)P3 receptors. Because this remaining OH group is equivalent 
to the crucial 6-OH of Ins(l,4 ,5)P3, its removal would undoubtedly result in a dramatic 
decrease in potency. Indeed, while this work was in progress a report appeared [50] on a 
synthesis of the 2-deoxy derivative o f 4.2. This molecule, having no remaining hydroxyl
94-group, was some 2000 fold less potent than Ins(l,4 ,5)P3 in mobilising intracellular Ca , 
showing the expected parallel with deletion o f the 6-OH group o f Ins(l,4 ,5)P3[22].
4.4 Molecular modelling
Clearly, the stereochemical differences between analogues 23, 24, 25 and 26 have 
a significant effect on the recognition o f these molecules by Ins(l,4 ,5)P3 receptors. The 
structural simplicity o f 23-26 suggested that a molecular modelling approach (which was 
carried out by Dr. A. M. Riley), might be used to account for the impact of 
stereochemical variation on their potencies. It is important to appreciate, however, that 
modelling of adenophostin A [48;62] and even o f the simpler analogues 23-26 presents 
many difficulties, including those o f simulating the combined influence of charged 
phosphate groups, solvent, counter-ions, pseudorotational equilibria in five-membered 
rings, and anomeric effects associated with the glycosidic linkage. It is also likely that
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the conformation of these molecules is sensitive to the ionisation state [45;88] of the 
three phosphate groups under physiological conditions. With these reservations in mind, 
a consideration of predicted low-energy conformations of 23-26 can be used to suggest 
qualitative explanations for their differing potencies.
In s (1 ,4 ,5 )P 3
Figure 4.19: X-ray crystal structure of Ins(l,4 ,5 )P3 derived from its complex with the 
PH domain of phospholipase C-5] compared with low energy conformers of 
diastereoisomers 23-26 as determined by molecular modelling experiments.
The most stable conformers found for 23-26 are shown in Figure 4.19, together 
with the conformation of Ins(l,4 ,5 )P3 identified in an X-ray crystallographic study of the 
PH domain of phospholipase C-£i in complex with Ins(l,4 ,5 )P3 [37]. For 
diastereoisomer 23, a particularly well-defmed global minimum energy conformation 
was identified, similar to that reported for adenophostin A.* In this conformer, the 
tetrahydrofuranyl ring is positioned below the plane of the xylopyranosyl ring, 
presumably in an orientation that avoids steric clashes with the receptor binding pocket 
and does not disrupt binding of the 3'-phosphate group. This phosphate group is located 
in a similar region of space to the 1-phosphate group of Ins(l,4 ,5 )P3, although in a 
slightly more extended position. Thus, as has been suggested for adenophostin A
Tt should be noted, however, that this conformation of 23 resembles a 3'-endo 
conformation of adenophostin A whereas, on the basis of !H NMR evidence, the 2'-endo 
form of adenophostin A is thought to predominate in solution. It has been suggested that 
the 2'-endo conformation might be essential to the high potency of adenophostin A [10].
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[48;62;89], the non-vicinal phosphate in 23 may be held close to some ideal position for 
optimal interaction with the region of the receptor binding site that normally 
accommodates the 1-phosphate group o f Ins(l,4 ,5)P3. As in the case o f adenophostin A 
[62] a local minimum conformer o f 23 (corresponding to a T-endo conformation of 
adenophostin A) with slightly higher energy and a different puckering o f the five- 
membered ring was also found.
In low energy conformations of the other diastereoisomers 24-26, the 3'- 
phosphate group is held in different regions o f space relative to the xylopyranosyl ring. 
Presumably the 3 '-phosphate groups in the less active isomers 24-26 are, to different 
degrees, less able to interact effectively with the Ins(l,4 ,5)P3 receptor binding pocket, 
and can only approach the ideal position and orientation at greater energetic costs than 
can the 3'-phosphate group in 23. The almost negligible activity of 24 is striking, 
particularly when it is compared to that of the relatively potent ^-linked analogue 26. A 
possible explanation for this difference, in addition to the factors already discussed, is 
that in low energy conformations of 24 such as that shown in Figure 4.19, regions o f the 
hydrophobic tetrahydrofuranyl ring may interfere with binding to the receptor.
4.5 Conclusions
The synthesis o f a series of novel tetrahydrofuranyl xylopyranoside-based 
trisphosphates related to the adenophostins and to Ins(l,4 ,5)P3 has been described. The 
most active member of the series (23) is of comparable potency to Ins(l,4 ,5)P3 and to the 
previously described ribophostin and furanophostin, from which 23 is a logical 
development. Further simplification would inevitably result in a substantial decrease in 
potency, and analogue 23 is therefore likely to represent the simplest possible structure 
for potent Ca2+-releasing activity in this type o f carbohydrate-based analogue. The 
weaker activities of the other three diastereoisomers 24, 25 and 26 may be related to the 
effect o f differing stereochemistry at three stereogenic centres or the spatial positioning 
of the non-vicinal phosphate group and tetrahydrofuranyl ring.
85
Chapter 4
4.6 Further xylose-based analogues
Several other xylose-based analogues have been reported since this work 
commenced, including xy/o-adenophostin (figure 4.20), in which the glucose of 
adenophostin A has been replaced by xylose. Ay/o-adenophostin was only 1.9 ± 0.6 fold 





Recently, two further xylose based analogues have been published which differ 
only in the stereochemistry at C-2 o f the propyl tether between the xylose ring and 
adenine (figure 4.21). As would be expected from our results, the two compounds show 
strikingly different biological results. The effects o f these analogues and Ins(l,4 ,5)P3 on 
[3H]Ins(l,4 ,5)P3 binding and 45Ca2+ mobilisation from rat hepatocytes which 
predominantly express type 2 Ins(l,4 ,5)P3 receptors were recently compared. The data 
indicated that the order o f potency was Ins(l,4 ,5)P3>4 .6>4 .7 . 4.6, which has an absolute 
configuration at C-2' identical to adenophostin, has a much higher activity compared to 
4.7.
NH
4.6 R -H , R^=OPCV'
4.7 R1= 0 P 0 32\  R2=H











Synthesis of adenophostin A and its analogues.
5.1 Introduction
As previously discussed in chapters 3 and 4 the biological activity of 
analogues that lack the adenine base synthesised so far has not exceeded that of 
Ins(l,4 ,5)P3. In an endeavour to ascertain the features o f the adenine base crucial for 
adenophostin A-like activity, our group have recently reported the synthesis and 
biological results o f several adenophostin A analogues where the nucleobase motif 
has been replaced by both natural and unnatural surrogates [43;65]. All the modified 
analogues were evaluated for Ca2+ mobilising activity in permeabilised hepatocytes 









Figure 5.1: Base modified analogues
Replacement o f the pyrimidine ring o f the adenine by a benzene ring (5.1) 
reduced potency by approximately 4 fold, and complete removal reduced the potency 
of the analogue imidophostin (5.2) to almost that o f Ins(l,4 ,5)P3. Even replacement 
o f the purine moiety (adenine) o f adenophostin A with a much smaller pyrimidine 
(uracil 5.3) caused the potency to decrease by approximately 2 fold. Finally, 
replacement of the entire adenine moiety of adenophostin A with unrelated single 
(5.4) or double (5.5, 5.6) aromatic rings with a /?-C-ribosyl glycosidic linkage
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produced ligands with activities comparable to adenophostin A and greater than 
Ins(l,4,5)P3.
Thus, all these compounds are more potent than Ins(l,4 ,5)P3, and some have 
activity close to adenophostin A; however when the stereochemistry of the C- 
glycosidic linkage o f 5.4 was changed to a  from p  the activity decreased dramatically 
to 10 times weaker than Ins(l,4 ,5)P3.
It has now seems clear that in order to maintain the potency of adenophostin A 
an adenine base/base surrogate with a ^ -linkage to the ribose is required[43].
5.2 Synthesis of a versatile disaccharide building block
5.2.1 Discussion
The versatile disaccharide 56 (figure 5.2) has previously been utilised in the 
synthesis o f adenophostin and its analogues. It is an excellent intermediate as it has 
orthogonal protecting groups. Furthermore, the acetates at positions one and two are 
a prerequisite for the Vorbriiggen condensation (figure 5.2). Several syntheses o f this 
[58;59;64;65] and similar [61] disaccharides[71] have been published differing 
mainly in the glycosidation step and protecting group manipulations leading up to the 
glycosidation.
Benzyl protecting groups at positions 5 and 6' provide 
a stable set of protecting groups which allow  
for a one-step deprotection of final compound.
BnO.
BnO
Acetates at positions 3' and 4' 
provide an "orthogonal" set 
which can be deprotected 
under mild conditions.
A c O '^ r ^ ^ ° \
AcO—
BnO I • -
OAc
Acetate at position 1 is a 
prerequisite for Vorbruggen  
condensations.
Benzyl protecting group at 2-position  
part of an "orthogonal" set and aids the  
formation of a-linked glycoside.
Acetate at position 2 is necessary for 
Vorbruggen condensations and  
provides part of an set of protecting 
groups for deprotection and 
subsequent phosphorylation.
Figure 5.2: Versatility and synthetic utility of protected disaccharide donor (56).
In our laboratory we have previously utilised two different types of 
glycosidation procedure. Trichloroacetimidate methodology was used in the synthesis
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o f ribophostin[55], it was chosen as the literature reported high a  selectivity in the 
glycosidation reaction[90]. Furthermore the trichloroacetimidate glycosyl donor 
could be prepared from a protected glucopyranose already in hand[46]. Unfortunately 
the desired /2-glycoside was only obtained in moderate yield (48%), accompanied by a 
notable amount o f the a-anomer. The glycosidation reaction proceeded smoothly to 
give predominantly the a-D-glucopyranosyl isomer however /2-D-glucopyranosyl 
isomer constituted ca. 20% of the isolated product.
Phosphite methodology has been used in the synthesis o f the 
disaccharide[64;65] and all the other analogues requiring glycosidation[57;63;91] 
including adenophostin[60]. It was chosen as model glycosidations using phosphite 
donors had been reported by Watanabe et al[92] with good a-selectivity and good 
yields. The phosphite donors were easy to prepare from the same glucopyranose used 
in the trichloroacetimidate route, and in quantitative yield.
Certain disadvantages o f the phosphite methodology (e.g. preparation o f the 
phosphite donor in situ each time) prompted us to explore an alternative strategy 
employing a thioglycoside donor. This approach has a number of attractive features; 
the thioglycoside offers sufficient temporary protection at the anomeric centre thus 
avoiding temporary protecting groups while the other hydroxyls are being 
protected[93]. Furthermore the donor is a crystalline solid rather than an oil which is 
a definite advantage when working with air sensitive reagents. The thioglycoside has 
relative stability to various reaction conditions and is conveniently activated with 
electrophilic reagents. Another attractive feature o f thioglycosides as glycosyl donors 
is that they are readily converted into most other glycosyl donors. Finally, another 
group has recently reported the synthesis o f the disaccharide using thioglycoside 
donors for the glycosidation which required fewer reaction steps than the synthesis of 
the phosphite donor[59].
5.2.2 Synthesis of the donor
The thiogylcosode donor was prepared on a large scale following the 
published procedures. Briefly, fully acetylated glucose was reacted with ethanethiol 
is the presence of a Lewis acid to produce the thiogylcoside 57. The /^-configuration 
o f the thioglycoside was easily identifiable from the !H NMR spectrum, which
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presented a doublet at Su 4.50 with a characteristically large coupling constant o f J  
9.9 Hz corresponding to H -l\  Longer reaction times led to an increase in a- 
configured product.
The selective 2,6 dipivaloylation methodology developed in chapter 3 to 
improve the yields o f selectively protected donor was not attempted as there is 
evidence that in the absence o f an adjacent axial function, the secondary 3-OH is 
more reactive than the 2-OH towards pivaloylation[73].
ho.^OR
RO












Figure 5.3: Route to the glycosyl donor 62.
After the acetates were removed, the protection o f the fraws-diequatorial 
hydroxyl groups at positions 3 and 4 was achieved by refluxing 58 with butane-2,3- 
dione, catalytic camphorsulphonic acid and excess trimethyl orthoformate for 6 h. 
The two regioisomers were separated and the BDA derivative 60 was identified. The 
remaining 2 and 6 positions were alkylated with benzyl bromide and sodium hydride 
in DMF. This donor was initially used in the glycosidation step (see below), although 
it was later found to be more convenient to convert it into the 3,4-di-O-acetate. Thus 
cleavage o f the BDA protection in 61 was accomplished by heating at reflux for a 
short time in a mixture of acetic acid and water. The mixture was concentrated and 
co-evaporated under reduced pressure with pyridine and then acetylated with an 
excess of acetic anhydride in pyridine to give the glycosyl donor 62.
5.2.3 Synthesis of the acceptor
The desired acceptor was easily prepared from commercially available 1,2-0- 
isopropylidene-a-D-xylofuranose following procedures already published[64]. The 5-
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O-benzyl ether was synthesised in one step by the regioselective ring opening of a 
3,5-O-dibutylstannylene derivative with benzyl bromide. An 87% yield o f benzylated 
products was isolated containing 90% of the desired 5-O-benzyl regioisomer as 
indicated by ]H NMR. Inversion of configuration at C-3to give the ribofuranoside 
acceptor was achieved by oxidation of this position with acetic anhydride and DMSO, 
followed by reduction of the 3-ulose intermediate with NaBtLi.
BnlBnO'BnO'HO'
Figure 5.4: Synthesis of glycosyl acceptor
5.2.4 Glycosidation
Glycosidation of ribose acceptor (64) with glucose donor (62) in the presence 
o f the promoter NIS and catalytic amount of triflic acid proceeded in a stereoselective 
fashion to afford a-linked disaccharide in 68 % yield. Formation o f the required 1,2 
cis linkage was confirmed by the H-l" resonance in the jH NMR spectrum, which 
appeared as a deshielded doublet at Sa 5.82 with a characteristically axial-equatorial 
coupling constant of J  3.9 Hz. Glycosidation o f the ribose acceptor (64) and glucose 
donor (61) was also carried out to reduce the number o f steps in the synthesis; 
although the reaction was successful the yield was slightly lower. Furthermore the 
glycosidation of the acceptor with the acetylated donor also has the advantage o f 
producing a crystalline product.
Cleavage o f the cw-isopropylidene acetal was accomplished by stirring with 
TFA for 10 min at rt to yield the corresponding czs-diol (66). The 1,2-di-O-acetate 
was then prepared by treatment with acetic anhydride, in order to meet the 
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Figure 5.5: Two routes to the disaccharide intermediate (56).
5.3 Synthesis of adenophostin A
5.3.1 Vorbruggen condensation and deprotection
Synthesis of nucleosides via the reaction o f silylated heterocyclic bases with 
peracetylated sugars in the presence of Friedel-Crafts catalysts is now well 
established. Vorbruggen et al. first used TMSOTf as the catalyst 1981 [94]; 
previously SnCU had been used, but it was difficult to remove in the work up. 
TMSOTf was found to be a better catalyst because it was easily removed in the work 














Figure 5.6: Route to triol 69.
Vorbruggen condensation reaction o f disaccharide 56 with silylated N-6- 
benzoyl-adenine in the presence of catalytic TMSOTf proceeded smoothly. TLC 
during the course o f the reaction revealed the formation of two products. Initially the 
lower spot was the major one, but over time saw full conversion to the higher. The 
compound was identified by its ]H NMR spectrum which exhibited a deshielded 
doublet at 6.42 ppm with a characteristically axial-axial coupling constant of J  5.5 Hz 
corresponding to H-T o f a ^-substituted product (68).
The acetyl groups and benzoyl group were simultaneously removed with 
excess lithium hydroxide in water/methanol overnight yielding the corresponding triol 
(69) which was purified by flash chromatography.
5.3.2 Phosphorylation and deprotection
Selective phosphitylation o f the free hydroxyls without the prior protection of 
the adenine N-6-position, was then attempted by the published procedure with a 
mixture o f bis(benzyloxy)(diisopropylamino)phosphine and imidazolium triflate in 
DCM[60;63]. Monitoring the reaction by TLC indicated that the reaction never went 
to completion and some over-phosphitylation occurred. The reaction mixture was 
cooled to -78°C before being oxidised with mCPBA. The reaction was quenched at
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this temperature to avoid any possible oxidation o f the adenine base. The yield was 
low as the expected product of this reaction (71) was extremely difficult to isolate.
A review of the literature found that the original adenophostin synthesis by 
Hotoda et a/[42] made use o f 4,4'-dimethoxytritylation (DMTr) protection at the 
amino group of the adenine and the two primary hydroxyl groups. Since the primary 
hydroxyls are protected in 69, only the amino group of the adenine needed protecting 
in this instance. Thus 69 was dissolved in dry pyridine and subsequent addition o f 







Figure 5.7: Phosphitylation and deprotection.
Subsequent phosphitylation of the triol with 1/f-tetrazole and
bis(benzyloxy)(diisopropylamino)phosphine in dichloromethane gave the
trisphosphite. The reaction mixture was cooled to -78°C  and oxidised with mCPBA, 
to give the fully protected trisphosphate, which was immediately deprotected with 
acetic acid to give 71 in 85% yield. 31P NMR spectrum of the purified product (71) 
confirmed the presence o f three phosphate groups. In addition, the presence of the 
free unphosphorylated N-6-position NH2 was substantiated by the presence o f a broad 







Figure 5.8: Part of the ]U NMR spectrum of 71 clearly indicating the free N6- 
amine of adenine and part of the 31P NMR (insert) indicating three protected 
phosphate groups.
Deprotection of this adenophostin precursor was achieved via catalytic 
transfer hydrogenation[60;63]. A solution of 71 was refluxed in a mixture of 
methanol, water and cyclohexene with 20% palladium hydroxide for 3 h. The free 
acid was then converted into the sodium salt. 31P NMR exhibited three resonances 
from the three deprotected phosphates and the !H NMR spectrum of adenophostin A 











Figure 5.9: 400MHz *H NMR spectrum of the free acid of adenophostin A in 
D2O and part of the 31P NMR (insert) indicating three protected phosphate groups.
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5.4 N-6 Base-Modified Adenophostins
5.4.1 Introduction
In order to explore the base-modification approach further we decided to 
synthesis a series o f N -6 base modified compounds for the following reasons. The 
most active totally synthetic adenophostin A analogue so far published is 
purinophostin[64] where the amino group has simply been removed from the adenine; 
this suggested that, although a purine ring (or equivalent) is necessary for high 
potency, the 6-amino constituent does not contribute greatly to the activity of 
adenophostin A. Furthermore, previous results for the activity o f the hypoxanthine 
analogue[42], prepared by the deamination of natural material, indicated that it too 




Figure 5.10: Literature N -6 substituted analogues.
The N -6 base-modified analogues are elaborated versions o f adenophostin A 
designed to explore predominately the introduction of a range o f different sized 
hydrophobes. The synthesis o f these modified analogues is versatile and is an 
extension o f the general methodology for synthesising base substituted compounds.
In the literature there are many examples o f N -6 substituted analogues of 
adenosine; most o f the syntheses described begin with 6-chloropurine as the 
heterocyclic base to gain easy access to any kind o f N -6 monosubstituted adenosine 
analogue[95] and references therein. Substituting the benzoyl-adenine with 6- 
chloropurine in the Vorbruggen reaction with the disaccharide led to a versatile 
adenophostin intermediate capable o f undergoing nucleophilic substitution with a 
range of nucleophiles. From this intermediate a variety o f novel analogues has been
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synthesised. It may also be possible to synthesise adenophostin by substituting the 
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Figure 5.11: potential products from substitution reactions.
5.4.2 Vorbruggen Condensation
Condensation o f dissacharide (56) and 6-chloropurine yielded the key 
intermediate 2',3",4"-tri-0-acetyl-2",5',6"-tri-0-benzyl-3'-0-a-D-glucopyranosyl-6- 
chloro-l-/?-D-ribofuranosidepurine (73). For the condensation reaction a modified 
Vorbruggen reaction was used[96]. The mixture o f protected disaccharide and base 
was treated with TMSOTf and DBU in acetonitrile at 60 °C for 1 h. DBU is used not 
only as a nucleophilic base but it increases the solubility of 6-chloropurine. TMSOTF 
acts as a catalyst to convert the 1,2-di-O-acyl ribofuranoside into an electrophilic 1,2- 
acyloxonium salt. As an excess of TMSOTf was used, the meticulous drying o f 
reagents and solvents necessary for the success o f the Vorbruggen coupling could be 
dispensed with. The product was isolated in excellent yield (89%) by flash 
chromatography and identified by its ^  NMR spectrum which exhibited a deshielded
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doublet at 6.41 ppm corresponding to H-1' of a J3-substituted product. Finally, the 
positive ion FAB mass spectrum for this compound exhibited a peak at m/z 846 
corresponding to the compound, and showed a characteristic isotope pattern for 
chlorine.












Figure 5.12: 400 MHz *H NMR spectrum of 73 in CDCI3 indicating the anomeric 
positions.
5.5 Synthesis of 6-OMe adenophostin
With the versatile 6-chloro intermediate (73) in hand attention turned to the 
first substituted product. The 6-methoxy compound was attempted first, as the 
literature revealed that NaOMe[97] was used for the synthesis of the adenosine 
equivalent 6-methoxy analogue from the known 6-chloropurine riboside. Since
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catalytic NaOMe is known to remove acetate protecting groups no prior deprotection 
was required.
The 6-chloro derivative (73) was easily converted into the 6-methoxy triol. 
Thus 73 was treated with two equivalents o f NaOMe for 30 min at 65 °C to give after 






Figure 5.13: 6-methoxy triol 74.
5.5.1 Phosphorylation and deprotection
Triol 74 was reacted with a pre-formed complex between l//-tetrazole and 
bis(benzyloxy)(diisopropylamino)phosphine in dichloromethane. The resulting 
tnsphosphite was oxidised with twCPBA to the trisphosphate. The P NMR spectrum 











Deprotection o f 75 to give the methoxy analogue o f adenophostin A was 
achieved with catalytic transfer hydrogenation in a similar manner to adenophostin. 
However complete deprotection took 31 hours compared to 3 hours needed to 
deprotect adenophostin and the corresponding N-substituted analogue precursors.
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This is possibly due to the electron donating effects of the methoxy group or to 
coordination o f the oxygen with the palladium. The free acid was then converted into 
the sodium salt. XH NMR of the white solid product indicated complete loss o f all the 
benzyl groups, and 31P NMR exhibited three resonances from the three deprotected 
phosphates. Quantification was carried out with the Briggs phosphate assay.
5.6 Synthesis of N6-cyclopentyl-adenophostin
The majority o f the literature procedures for synthesising N6-substituted 
adenosine analogues have used the commercially available 6-chloropurine riboside as 
the starting material. It was therefore decided that the base labile acetates o f 73 
should be removed prior to the nucleophilic displacement o f the chlorine with the 
cyclopentylamine. Thus the base labile acetates o f 73 were removed using catalytic 
NaOMe in methanol. Unfortunately a side product was produced which, not 
surprisingly, was identified as the 6-methoxide substituted triol 74 on the basis o f 
TLC with an authentic sample o f 74 and !H NMR. The 6-chloro triol was then heated 
with cyclopentylamine and triethylamine at 80 °C for 3 hours. This reaction 








78 R = H
73 R = Ac
79 R = 0 P (0 )(0 B n )2




Figure 5.15: Route to N6-cyclopentyl-adenophostin 80.
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5.6.1 Phosphorylation and deprotection
Triol 77 was phosphitylated with a pre-formed complex between 1/7-tetrazole 
and bis(benzyloxy)(diisopropylamino)phosphine in dichloromethane. The resulting 
trisphosphite was oxidised with mCPBA at -78°C to give the trisphosphate. The 31P 
NMR spectrum of the purified product exhibited three singlets corresponding to the 
three dibenzyloxyphosphate groups at 0.15, -0.66 and -0.79ppm.
Complete deprotection was achieved with catalytic transfer hydrogenation. 
79 Was heated at 65 °C in a mixture o f cyclohexene, methanol and water with 20% 
palladium hydroxide on carbon for 3 hours. After removal o f the catalyst by filtration 
the product was converted to its sodium salt. The structure o f the product was 
identified as the sodium salt o f the trisphosphate 80 on the basis o f its 31P NMR 
spectrum which showed three signals at 3.28, 2.56 and 1.59 ppm, and by its !H NMR 
in D2O indicated complete loss of benzyl groups. The accurate negative ion FAB 
mass spectrum showed a mass consistent with that predicted for [M-H]~. The 
compound was quantified by Briggs phosphate assay.
5.7 Synthesis of N-6 methyl, dimethyl and cyclohexyl- 
adenophostins
Due to the previous problems o f the acetate deprotection in the presence o f the 
chlorine (see cyclopentyl) it was decided that it would be better to substitute the 
chlorine first. The first compound attempted was the N -6 methyl-substituted 
compound 85. Thus 73 was heated with triethylamine and methylamine hydrochloride 
at 60 °C overnight. Initially using 3 equivalents o f methylamine hydrochloride and 6 
equivalents of triethylamine, the product could be isolated, although the reaction did 
not go to completion. The structure o f 81 was established on the basis o f its ]H NMR 
spectrum in CDCI3 which showed the appearance o f an NH signal at 5.87 ppm and 
NCH3 signal at 3.19 ppm. When the equivalents were raised to 7 and 14 respectively, 
all starting material disappeared but an inseparable side product appeared. As the 
reactants are fairly nucleophilic it was presumed that the side product formed was a 
partially deprotected product, therefore the mixed products were treated with catalytic 
amount o f NaOMe to produce only the desired product.
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Substitution by the dimethylamine went to completion within 2 h and no 
deprotection occurred. However substitution with cyclohexylamine required longer 
reaction times and some acetate deprotection occurred. The products were fully 
deprotected using catalytic amount of NaOMe in methanol to give the triols 87 and 91 




H-2’ h -3" H - f IMeH-1'
Figure 5.16: Part of the 'H NMR spectrum of 81 clearly indicating the NHMe, the 





81, 85, 89 R"= Ac, R -M e, R=H
82, 86, 90 R" = H
83, 87, 91 R" = 0P (0 )(0B n)2
81,82, 83 R=H, R -M e
85, 86, 87 R=R-M e





84 R=H, R'=Me 
88 R=R'=Me 
92 R=H, R=cyclohexyl
Figure 5.17: Route to trisphosphates
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5.7.1 Phosphorylation and deprotection
The triols 82, 86, 90 were phosphitylated in the usual way with a pre-formed 
complex between l//-tetrazole and bis(benzyloxy)(diisopropylamino)phosphine in 
dichloromethane. The trisphosphites were oxidised with mCPBA at -78°C to give the 
fully protected intermediates. The 31P NMR spectrum of the purified products 
exhibited three singlets corresponding to the three dibenzyloxy phosphate groups. ]H 
coupled 31P NMR spectrum of 83 in CDC13 exhibited the protected ring phosphates as 
a sextet at -0.23 ppm and two overlapping sextet at -1.05 ppm.
Figure 5.18: 162MHz 'H-coupled 31P NMR spectrum of 83 in CDC13.
Unfortunately, the dimethyl compound (8 6 ) contained some impurities which 
could not be entirely removed by column chromatography with various eluents. As 
the impurities did not contain phosphorus, as judged by 31P NMR spectroscopy, the 
crude material was deprotected. The target trisphosphate was obtained pure after 
HPLC.
Deprotection of all three compounds was achieved with catalytic transfer 
hydrogenation as described for the synthesis of adenophostin. The compounds were 
quantified by Briggs phosphate assay, samples were examined by HPLC and the 
resulting HPLC traces are shown below in Figure 5.19.
T*
Figure 5.19: HPLC traces of 84, 88 and 92.
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5.8 Synthesis of N-6 methyl-2-OMe-adenophostin
In order to elaborate the adenine moiety further a synthesis of a 2,6 
disubstituted adenophostin analogue was attempted. In the literature there are many 
examples of N-6 , N-2 disubstituted analogues o f adenosine; starting from 2,6- 
dichloropurine as the heterocyclic base to gain access to many analogues. 
Furthermore it has been demonstrated that the 6-chlorine atom is much more reactive 
than the 2-chlorine atom in the adenosine derivative; it is logical to presume that the 
chlorine atoms in the corresponding adenophostin derivative should show a similar 
difference in reactivity[97]. Thus, monosubstitution o f the 2,6 dichloropurine 
derivative by a nucleophilic reagent should yield a 6-substituted product, which after 
isolation, should be capable o f undergoing further substitution of the 2-position with a 
variety o f nucleophilic reagents.
5.8.1 Vorbruggen Condensation
The method employed to prepare 2',3",4"-tri-0-acetyl-2",5',6"-tri-0-benzyl-3'- 
0-a-D-glucopyranosyl-2,6-dichloro-l-/?-D-ribofuranosidepurine (93) is similar to that 
used in the synthesis of 73. and involves a modified Vorbruggen reaction. Thus a 
mixture o f protected disaccharide and 2,6-dichlorpurine was treated with TMSOTf 
and DBU in acetonitrile at 60 °C for 1 h. The reaction was difficult to follow as there 
was no change in R f value from the starting material to product when TLC was 
carried out in a variety o f solvents; however, the product was isolated in good yield 
(67%) by flash chromatography and identified by *H NMR spectrum which exhibited 
a deshielded doublet at 6.37 ppm corresponding to H-1' o f a /?-substituted product and 













Figure 5.21: 400 MHz ]H NMR spectrum of 93 in CDCI3 indicating the anomeric 
positions and H-8 .
5.8.2 Substitution reactions
With the 2,6-dichloro-derivative in hand attention then turned to substitution 
reactions. Initially the 2,6-dimethyl compound was attempted. Thus, 93 was refluxed 
with a large excess of methylamine hydrochloride and triethylamine in 
dichloromethane and ethanol overnight. TLC showed all starting material had 
disappeared and the formation of several inseparable products. The crude material 
was subjected to FAB mass spectrometry unfortunately there was no peak 
corresponding to the disubstituted product. The reaction time was reduced to 4 h and 
one major product was isolated and identified as 6 -NMe, 2-chloro derivative on the 
basis of its 'H NMR and FAB mass spectrum.
It was then decided that 2-methoxy substitution would be attempted with the 
simultaneous removal of the acetate protecting groups. Thus 2 equivalents of NaOMe 
were added to a solution of 94 in methanol and heated at 65 °C overnight. The 
product was identified as 95 by ]H NMR and FAB mass spectrometry which still 
exhibited a characteristic isotope pattern for chlorine. It was therefore reasoned that 
more forcing conditions were required for substitution. Thus 95 was refluxed with a 
very large excess of NaOMe in methanol overnight. The product was identified as the 










OMe Bni OMeHO' BnO'
RO'
ORBnOHO
96  R = H
97  R= 0 P (0 ) (0 B n )2
Figure 5.22: Route to 6-NMe, 2-OMe adenophostin.
5.8.3 Phosphorylation and deprotection
The triol (96) was phosphitylated with
bis(benzyloxy)(diisopropylamino)phosphine and l//-tetrazole, following the usual 
procedure. Oxidation with mCPBA at -78°C gave the trisphosphate triester (97). The 
31P NMR spectrum of the purified product exhibited three singlets at 0.04, -0.58 and 
-0.79 ppm corresponding to the three dibenzyloxy phosphate groups.
Deprotection using catalytic transfer hydrogenation as described for the 
synthesis o f adenophostin removed all benzyl protecting groups. The compound was 
purified by HPLC to give the free acid (98), which was quantified by Briggs 
phosphate assay.
5.9 Synthesis of N6-noradamantylamino adenophostin
The synthesis o f noradamantane adenophostin was attempted as the 
noradamantyl group represents a very large hydrophobe. Initially, the substitution
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was attempted on 72 with 3-noradamantanamine hydrochloride, unfortunately the 
reaction never went to completion and product could not be seen by TLC using 
variety o f eluents. The 6-chlorine atom in 93 seemed more reactive than in 72 so the 
substitution was attempted. Thus 93 was reacted with noradamantanamine 
hydrochloride and triethylamine in dichloromethane and ethanol at 60°C overnight. 













Figure 5.23: Route to noradamantane adenophostin
The acetates of 99 were carefully removed using NaOMe in methanol and 
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Figure 5.24: part of 400 MHz ’H NMR spectrum of 100 in CDCI3.
5.9.1 Phosphorylation and deprotection
Phosphitylation of 100 with l//-tetrazole and
bis(benzyloxy)(diisopropylamino) phosphine in dichloromethane went smoothly to 
give the trisphosphite which was oxidised to the trisphosphate with mCPBA. The 31P 
NMR spectrum exhibited three characteristic singlets corresponding to the three 
protected phosphate groups.
Deprotection removed all the benzyl protecting groups and the 2 chlorine atom 
on the adenine. Thus 101 was heated at reflux in a mixture of water, methanol and 
cyclohexene with 20% palladium hydroxide on carbon for 2 h. After removal of the 
catalyst by filtration the crude product was converted to its sodium salt. 'H NMR 
spectroscopy indicated complete loss of all the benzyl protecting groups and a singlet 
at 8.03 ppm corresponding to H-2. Quantification was only carried out by the Briggs 




The analogues were biologically tested for Ca2+ mobilisation in permeabilised 
hepatocytes by a collaborator according to the method described in the experimental 
section. I participated in some of the biological testing. The results are shown in 
Table 5.2. Since the analogues were tested in different experiments, the EC50 values 
with respect to the adenophostin (EC5o=10 nM) values for the individual experiment 
are given for each analogue. The N6-methyl (84), N6-cyclopentyl (80) and N6- 
dimethyl (88) analogues were shown to be the most active compounds with an EC50 
ratio with respect to adenophostin A o f approximately 0.80 (<1 is less active than 
adenophostin A). The N 6-noradamantane (102) and the methoxy (76) analogues also 
had similar potencies o f approximately 0.55 with respect to adenophostin A. The 
cyclohexyl (92) analogue was slighter lower (0.41) and N6-methyl, 2-methoxy (98) 
analogue was the weakest (0.18). Thus, all these compounds are more potent than 
Ins(l,4 ,5)P3 and some have activities close to adenophostin A.
Furthermore in the functional studies maximum concentrations of 
adenophostin A and most o f the analogues released the same fraction o f the 
intracellular Ca2+ stores (=34%). Unusually, two compounds (92 and 102) released a 
bigger percentage of the intracellular Ca2+ stores (186 ± 21%, 147 ± 9% respectively) 
in paired controls with Adenophostin A. This is the first time an analogue has 
released a bigger percentage o f the intracellular Ca2+ stores, since the cyclopentyl (80) 
analogue did not release the extra amount but the cyclohexyl (92) and noradamantane 
(102) analogues did, it seems that as the size of the molecule is increased the ability to 
release Ca2+ is affected.
EC50I1M h n % release EC50 wrt 72
Ins(l,4,5)P3 185 ± 17.90 2.29 ± 0.30 11 35 ± 1.2 0.07
76 18.80 ± 1.90 3.85 ± 1.50 5 34.08 ± 2.64 0.57
80 12.98 ± 1.61 2.15 ±0.06 5 35.40 ± 1.8 0.81
84 13.24 ±2.30 2.12 ±0.44 5 37.03 ± 2.0 0.84
88 19.42 ±2.09 2.15 ±0.06 4 38.57 ± 1.96 0.82
92 49.0 ± 5 .0 2.33 ±0.14 6 62.0 ± 4.7 0.27
98 82.06 ± 1.57 8.82 ± 1.57 5 34.21 ± 1.04 0.18
102 34.32 ± 2.04 2.14 ±0.22 6 49.21 ±2.10 0.55




The EC50 values and Hill coefficients (h) were separately determined for n 
independent experiments by fitting results to logistic equations. Results are shown as 
means ± S.E.M.
Figure 5.25: Effects of modifying the adenosine moiety of adenophostin A. In this 
figure the EC50 of each of the analogues is compared with that determined for 
adenophostin A (2) in parallel experiments to give a potency ratio. Ratios <1 denote 
agonists less potent than adenophostin A.
QSAR studies were attempted on the seven analogues and adenophostin A by 
Mr. James Robinson. QSAR attempts to find a consistent relationship between the 
variations in values of molecular properties (descriptors) and the biological activity. 
A good QSAR should only contain, at most, a third of the number of descriptors to the 
number of compounds. Energy minima structures were calculated for the eight 
compounds, using the Merck Forcefield implemented in MOE and descriptors were 
calculated. Principal component analysis was performed to derive three PCA 
columns. Partial least squares analysis calculation using the 3 PCA columns resulted 
in a correlation coefficient of 0.82 and a cross validated coefficient of 0.54. A trend is 
shown; however, nothing may be quantitatively inferred. With eight compounds and 
three descriptors the excel spreadsheet data is over fitted. However, it does show there 
is an underlying relationship between the molecular properties of the compounds and 
the biological activities. More compounds are needed to establish a firm relationship.
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R2 = 0.8211
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Figure 5.26: QSAR relationship of the seven analogues and adenophostin A.
The energy minima structure was calculated for adenophostin A using MOE, 
using the Merck Forcefield, MMFF94. Pharmacophore points were chosen based on 
things like aromatic interactions, hydrogen bond donors and acceptors etc. All the 
analogues (76, 80, 84, 88, 92, 98, 102) were also fitted to the MOE and they are all 
shown in figure 5.27.
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Figure 5.27: Adenophostin A and analogues (76, 80, 84, 88, 92, 98, 102) overlayed in 




Figure 5.28: Adenophostin A and analogues (76, 80, 84, 88, 92, 98, 102) overlayed in 
their energy minima structures. The diagram clearly indicates different hydrophilic 
(red) and hydrophobic (green) regions.
Analysis with methods such as CoMFA, CoMSIA and HQSAR also failed to 
find suitable QSAR relationships as attaining suitable alignments for the molecules 




These results further demonstrate that a base-modification approach represents 
a powerful strategy to develop high potency ligands. They also show that elaboration 
of the adenine ring can indeed produce highly potent compounds. This study, 
exploring predominantly the introduction of a range of different sized hydrophobes, 
has revealed evidence of a possible unoccupied and new receptor binding pocket for 
the Ins(l,4,5)P3R in complex with adenophostin A. Alternatively the binding site 
may be exposed at the surface of the receptor allowing the large bulk. However, this 
seems unlikely as even the large hydrophobic adamantane (102) derivative (see 
modelling fig) has only a slight reduction in potency. The surface of the receptor is 
likely to be solvated and therefore repel the hydrophobes. Furthermore, by the 
introduction of a range of different sized hydrophobes we have shown that it is
94-possible to release a greater fraction of the intracellular Ca stores. Further work 
needs to be carried out in order to fully understand these effects.
AdA The adamantane derivative
Figure 5.29: molecular modelling
Even though the 2-substituted analogue (98) synthesised here has low potency, 
further 2-modifications need to be carried out to establish whether this site offers 
similar potential to that at N-6 for reporter group exploitation. Further 2 
modifications need to be carried out to determine establish if the decrease in activity 
is due to conformation, steric or electronic effects.
A useful method for the preparation of a wide variety of 6-substituted and 2,6- 
disubstituted analogues has been developed. The chemistry needs to be expanded to 
introduce further hydrophobic groups as well as acidic and basic motifs to determine
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weather there is a new binding pocket in the receptor. Some ideas for future work 












Recent developments and general conclusions
6.1 Recent developments
6 .1 .1  B io lo g ic a l  a d v a n c e s
Since the discovery o f the adenophostins biologists have been working hard to 
determine whether the adenophostins are simply higher affinity analogues of 
Ins(l,4,5)P3. Adenophostin A is 10-fold more potent at releasing Ca2+ than 
Ins(l,4,5)P3 from internal stores in most functional analyses, whether performed on 
permeabilised cells, microsomes, planar lipid bilayers, or purified receptors 
reconstituted into liposomes. Apart from this difference adenophostin A was believed 
to interact with the Ins(l,4,5)P3R in a manner identical with that for Ins(l,4,5)P3.
New evidence is currently emerging that suggests that adenophostin A may 
behave differently from Ins(l,4,5)P3. There are a few subtle differences in the 
responses evoked by adenophostin A and Ins(l,4,5)P3; Adenophostin A has more 
positively co-operative interactions in binding assays than Ins(l,4,5)P3; Elementary 
Ca2+ release events, Ca2+ puffs, evoked by adenophostin A decay more rapidly than 
those evoked by Ins(l,4,5)P3. Until recently, these effects were assumed to be a 
consequence o f the ligand dissociating from the Ins(l,4,5)P3R more slowly than 
Ins(l,4,5)P3 dissociates. However a recent report showed only a 1.9-fold slower rate 
o f dissociation for adenophostin A than Ins(l,4,5)P3 from the Ins(l,4,5)P3R. The 
authors speculated that adenophostin A may have an approximately 10-fold faster rate 
of association with the Ins(l,4,5)P3R than does Ins(l,4,5)P3[98].
A study very recently published found that under physiological conditions of 
weak intracellular Ca2+ buffering (0.1 mM EGTA), Ins(l,4,5)P3 often fails to activate 
any detectable store-operated Ca2+ current ( I c r a c )  [99], while adenophostin A 
consistently activates the current under similar conditions. The analogues manno- 
adenophostin and ribophostin were also tested and it emerged that ribophostin acts in 
the same way as adenophostin. If the higher affinity o f adenophostin A than that of 
Ins(l,4,5)P3 for the Ins(l,4,5)P3R is the main factor underlying its ability to activate
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I c r a c  in weak Ca2+ buffer, then neither ribophostin nor /wawno-adenophostin should 
activate the current in weak buffer, because these analogues have similar affinities to 
that ofIns(l,4 ,5)P3 for the Ins(l,4,5)P3R. Two possible mechanisms were suggested 
to account for the preferential activation o f I c r a c  by adenophostin A and ribophostin 
in weak buffer in comparison to Ins(l,4,5)P3. These were; i. different extents o f store 
depletion brought about by different gating properties of the occupied Ins(l,4,5)P3R 
or ii. a novel action of adenophostin A and ribophostin in addition to their actions on 
the Ins(l,4,5)P3R.
In a recent study it was suggested that ATP affects the activation o f the 
Ins(l,4,5)P3R by adenophostin A[100]. In the presence of 0.5 mM cytoplasmic free 
ATP the opening o f the Ca channel is indistinguishable from Ins(l,4,5)P3 activation, 
although the functional affinity o f the channel is higher for adenophostin A. However 
in the absence of ATP both the efficacy and affinity of adenophostin A are 
significantly reduced. Furthermore, adenophostin A is only a partial agonist under 
these conditions. The absence o f free ATP did not appear to affect the efficacy and 
affinity o f Ins(l,4,5)P3. The authors suggested that the binding of ATP produces an 
allosteric conformational change in the ligand-binding site that enhances the binding 
o f adenophostin A to the channel. The 1-phosphoryl group of Ins(l,4,5)P3 interacts 
equally well when ATP is present or absent. In the presence o f ATP, the 2'- 
phosphoryl group o f adenophostin A can bind to the same phosphoryl group binding 
site in the receptor that Ins(l,4,5)P3 interacts with, therefore making adenophostin A 
indistinguishable from Ins(l,4,5)P3. However in the absence of ATP the 2'- 
phosphoryl group of adenophostin A cannot interact in the same way, therefore 
reducing its efficacy and affinity. The authors also showed that the low affinity 
adenophostin analogues furanophostin and ribophostin acitvated the Ins(l,4,5)P3R in a 
similar way to adenophostin A in either the presence or absence o f ATP. It has been 
proposed that interactions between the adenine o f adenophostin A and the 
Ins(l,4,5)P3R enhance the affinity o f adenophostin A. As adenophostin A and ATP 
share a common adenine moiety in their molecular structures the authors considered 
that an interaction o f adenophostin A with an ATP binding site in the Ins(l,4,5)P3R 
might contribute to high affinity binding. However, their results showed no evidence 
for ATP being an antagonist competing with adenophostin A for the same binding site 
in the Ins(l,4,5)P3R; thus it was concluded that ATP and adenophostin must bind to 
distinct binding sites in the Ins(l,4,5)P3R.
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Ins(l,4,5)P3 and adenophostin A binding is competitive, and adenophostin A 
binds with greater affinity than Ins(l,4 ,5 )P3 to each of the Ins(l,4 ,5 )P3R subtypes. 
For type 1 and 2 receptors the preference for adenophostin A is greater (7-8 fold) than 
for type 3 receptor (3 fold). Recently, our biological collaborators [101] have shown 
that N-terminal fragments of the type 1 receptor bind Ins(l,4 ,5 )P3 with significantly 
higher affinity than the full length receptor (figure 6 .1), but this is not matched by a 
proportionate increase in their affinity for adenophostin A. In full length receptors, 
residues lying C-terminal to the Ins(l,4 ,5 )P3-binding core are likely to impede access 
of the Ins(l,4 ,5 )P3 to its receptor. It was suggested that adenophostin A may be 
capable of deflecting this inhibitory region to allow less restricted access to the 
binding pocket and so bind with higher affinity by virtue of more rapid association 
with the Ins(l,4,5)P3R.
b in d in g  







) 57'  R5R568,
b in d in g  *  
d o m ain  2
Ins(l,4,5)Pj
2-o3P O -\A l—I2
2' 0 3 P 0 ~ \ ^ » - \ l ^ 0 P 0 3 ‘ 
5 OH
OH
Figure 6.1: Residues 226-576 form the minimal Ins(l,4 ,5 )P3 binding core of the type 
1 receptor and within this region several conserved Arg and Lys residues are essential. 
Both IP3 and AdA bind to the same binding pocket formed by residues from 2 distinct 
domains (bold); the two are linked by residues that include the SI splice site (dotted). 
Arg-568, in the second of the core domains, is probably essential for recognition of 
the 1-phosphate of IP3 and the analogous 2'-phosphate of AdA. Access of both 
ligands to the binding pocket is partially occluded by residues (dashed) towards the N- 
terminal. C-terminal residues (thin line) also occlude access to the receptor, but it has 
been suggested that the adenosine moiety of AdA can bind to this region to displace it 
and allow fast access of the remainder of the molecule to the core binding 
domain[1 0 1 ]
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At present there are two major explanations to account for the 10-fold greater 
potency of adenophostin for the Ins(l,4,5)P3R; i. the adenosine may force the 2'- 
phosphate into a position that allows it to bind more effectively than the 1 -phosphate 
ofIns(l,4,5)P3 and/or ii. there may be a direct interaction between the elements of the 
adenine ring and the Ins(l,4,5)P3R that contribute to the high affinity.
6.2 Structure-activity relationship work
Along with the synthesis of adenophostin A, the syntheses of thirteen 
adenophostin A analogues have been presented in this thesis. Their biological 
evaluation in direct comparison with our synthetic adenophostin A and Ins(l,4,5)P3 
has allowed several important conclusions to be drawn concerning the structure- 
activity relationships of adenophostin A at the Ins(l,4,5)P3 receptor. These are 
summarised in Figure 6.2.
5"-Hydroxymethyl
Deletion has a minimal effect on
4'-Hydroxymethyl
Does not seem to be important for 
binding or Ca2+ release, at least in 





Is crucial for adenophostin A-like activity, 
although the N-6 amine is not vital.
N-6 can be elaborated with large hydrophobic groups 
with some loss of activity.
C-2 can be elaborated with loss of activity.
Figure 6.2: The properties of some of the structural features of adenophostin A 
involved in activity at the Ins(l,4,5)P3 receptor.
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From these results and others it is now well established that the 3",4"- 
bisphosphate and 2"-hydroxyl group of adenophostin A may effectively mimic the 
critical 4,5-bisphosphate and 6-hydroxyl groups o f Ins(l,4,5)P3. Combining the 
results in figure 6.2 and the results from the literature it is possible to further refine 
these structure activity relationships as shown in figure 6.3.
Tolerant of substantial changes 
to aromatic ring systems.
5"-position has minima! effect on activity 
(similar to 3-hydroxyl of lns(1,4,5)P3.
3",4"-bisphosphate mimics 
the 4,5-bisphosphate of 
lns(1,4,5)P3.




2'-phosphate group not essential 
for activity but has an 
"enhancing" effect (similar to 
1-phosphate of lns(1,4,5)P3).
‘ Deletion of 2'-phosphate 
leads to 2000-fold reduction 
in activity.
‘ Ribofuranosyl ring optimal, 
rigid ring structure is 
essential.
*ln the absence of adenine, 
the 4'-hydroxymethyl is not 
required for lns(1,4,5)P3-like 
activity.
Ribose
*«-D-glucopyranose structure is 
a good bioisostere of the 
myo-inositol backbone of lns(1,4,5)P3. 
‘ Open ring structure not tolerated. 
‘ Bisphosphate essential for 
adenophostin A-like activity. 
‘ Equatorial 2"-hydroxyl required 
for adenophostin A-like activity. 
‘ Absence of 5"-hydroxymethyl leads 






‘ Not necessary for lns(1,4,5)P3-like 
activity, but adenine or a substitute 
base structure is essential for activity 
to approach that of adenophostin A. 
‘ Adenine may be replaced by inosine 
or purine with only a marginal loss of 
activity.
‘ The amino group may be elaborated 
to 6-NHMe, 6-NMe2, 6-NHcyclopentyl 
with only marginal loss of activty. 
‘ Substitution at C-2 with OMe results 
in a 5-6 fold loss of activity.
‘ The amino group may be elaborated 
to a large hydrophobic group with 
slight loss of activity.
‘ Substitution with uracil, 
benzimidazole or 4-methyl anisole 
results in a 3-4 fold loss of activity. 
‘ The imidazole ring of adenine on its 
own is not sufficient to engender 
adenophostin A-like activity. 
‘ Inversion of the nucleosidic bond 
leads to a severe reduction in activity 
when adenine is substituted for 
4-methyl anisole.
Figure 6.3: Summary of the structure-activity relationships o f adenophostin A at the 
Ins(l,4>5)P3 receptor.
From the above considerations it is possible to propose a binding model for 
adenophostin A at the Ins(l,4,5)P3 receptor. The 3",4"-bisphosphate, adjacent
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equatorial 2"-hydroxyl, and well positioned accessory 2-phosphate of adenophostin A 
comprise the basic structural motif that elicits similar activity to that of Ins(l,4,5)P3, 
and thus probably binds in a similar way to the analogous motif of Ins(l ,4,5)P3. For 
the activity to approach that of adenophostin A an adenine base (base substitute) is 
vital. The interaction with the adenine base may involve all/some/none of the 
hydrogen bonds shown in by the dotted lines figure 6.4 alternatively the interaction 
maybe a hydrophobic one, as even with the introduction of large hydrophobic groups, 
the potency is still greater than Ins(l,4,5)P3. There may therefore be an extra binding 
pocket around the adenine, alternatively it may be fairly open to the solvent. Relating 
the increased bulk on adenophostin A to Ins(l,4,5)P3, a number of analogues with a 
bulky substituent on the C-2 of the inositol ring have been reported[102]. The 
biological activities of these compounds in a number of systems were only marginally 
weaker than Ins(l,4,5)P3. The bulky substitutuent probably occupies the same area in 













Figure 6.4: Two proposed receptor sites; A. Proposed pocket surrounding the 




Since the discovery o f adenophostin A, syntheses o f analogues have given us 
a better understanding of the structural requirements o f adenophostin A that contribute 
to its exceptional activity; however further research needs to be carried out in order to 
refine these ideas. The enhanced activity is probably the result o f an additional 
contribution o f the adenine.
We have already established the existence of a possible binding pocket around 
the N-6 position of adenine; this needs further exploration by designing more novel 
ligands using the 6-chloro intermediate. To obtain more information about the 
possible existence for a binding pocket further substitutions are required with a range 
o f different properties for example hydrophobic, acidic and basic groups. A strategy 
was recently published to introduce fluorescent probes into adenosine derivatives. 
The approach involved an extension of the chemistry described for the synthesis o f 
the 6-substituted compounds as above. Thus 6-chloropurine riboside was reacted with 
the appropriate mono N-Boc-protected diamine. Subsequent deprotection o f the N- 
Boc group afforded free primary amines which were used in the condensation reaction 
with the fluorescent tag[103]. Another approach has been to introduce fluorescent 
labels in the 2-position starting from a guanosine nucleotide [104]. An extension of 
this strategy could be applied to adenophostin A analogues by altering the protecting 
group to provide the free primary amine in the final deprotection step, which could 
then be used to create a wide variety o f probes and tags. The probes would be 
invaluable as a pharmacological tools for studying the complex Ca2+ pathways and 
perhaps novel assets for the location and characterization o f Ins(l,4,5)P3R. Such an 
approach can also be used to explore further the SAR o f adenophostin at the N6 and 2 
positions. Extensive generation o f modified compounds has previously been severely 
limited by the long chemistry required for each modification. The whole process 
could be radically improved if  key intermediates modified with pendant amino or 
sulphurhydryl groups at the N6 and 2-positions could be prepared in large quantity in 
the fully deprotected forms. It would then be a relatively simple matter using 
established conjugation chemistry to attach in one step a variety of hydrophobic, 
acidic and basic motifs to fully explore the potential offered for activity augmentation 











Versatile intermediate for attaching probes
Figure 6.5: Suggested route to versatile intermediate.
Furthermore, an investigation o f conformational restriction about the 
nucleosidic bond would be interesting. The 8-bromo derivative should be accessible 
directly from adenophostin A and will place the adenine in the syn-configuration, 
while modifications will enable the synthesis of an anti-configured derivative. 









0 P 0 3‘HO
etheno (fluorescent)
Figure 6.6: Two conformationally restricted analogues and a fluorescent
analogue.
Recently, a strategy has been reported for constructing potent ligands for 
proteins with multiple binding sites[105] The approach involves the synthesis of 
polymer-linked dimers (PLDs) in which two molecules of the natural ligand are 
joined by a polymer chain of variable length Applying this approach to tetrameric 
cyclic nucleotide gated ion channels (CNG channels), it was possible to create PLDs 
of cGMP whose potency was 1000-fold greater than cGMP itself. This methodology 
might be applicable to Ins(l,4,5)P3 receptors which, like CNG channels, are known to 
be tetrameric ion channels with a separate ligand binding site on each subunit. Recent 
studies o f Ins(l,4,5)P3 receptors using quick-freeze deep-etch electron 
microscopy[106;107] have estimated the width o f the tetrameric complex to be from 
12 and 20 nm; the locations of the Ins(l,4,5)P3 binding sites are not known. However, 
by using a convergent synthetic methodology to construct a range o f PEG-linked 
Ins(l,4,5)P3 dimers it should be possible to cover a range o f distances between 
Ins(l,4,5)P3 binding sites up to, and possibly exceeding 12 nm. If  it is possible to 
identify a particular size of dimer that gives enhanced affinity for the receptor, not 
only will this provide a new strategy for developing potent Ins(l,4,5)P3 receptor 
ligands, but also structural information on the location o f the Ins(l,4,5)P3 binding
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sites in the tetrameric complex. This strategy has recently been employed in the 
synthesis of Ins(l,4,5)P3 dimers[108]. Previously, carbohydrate-based Ins(l,4,5)P3 
mimics were attached to a small hydrophobic hub to create bivalent and tetravalent 
analogues[58;59]. It should be possible to construct more effective dimers by using a 
more rigid linker (e.g. polypeptide) of the appropriate length, and to extend the 
methodology to produce dimers of adenophostin A by using the methodology of 
substituting the 2 or 6 positions of the adenine.
Linker
Figure 6.7: Adenophostin A dimers could target multiple 
receptor binding sites.
Finally it would be useful to synthesise further base substituted compounds; 
since uridophostin (figure 6.8) was the most potent compound other than those with 
elaborated adenine bases, it may be useful to synthese the following series based on 
uridophostin.
With a greater understanding of the properties of the base it should be possible 
to design analogues of adenophostin A which are more effective modulators of the 





















Chemicals were purchased from Acros, Aldrich, Sigma and Fluka. DMF was 
distilled from barium oxide under reduced pressure and then stored over 4 A molecular 
sieves. Pyridine was dried over potassium hydroxide pellets, distilled and then stored 
over potassium hydroxide pellets. Dichloromethane and acetonitrile were dried over 
calcium hydride, distilled and then stored over 4 A molecular sieves. 1,4-Dioxane, 
dimethyl sulphoxide (DMSO), ethanol, diethyl ether, THF and toluene were purchased in 
anhydrous form. Ins(l,4 ,5)P3 was purchased from American Radiolabeled Chemicals. 
TLC was performed on precoated plates (Merck aluminum sheets silica 60 F254, Art. No. 
5554). Products were visualised under U.V. light and by dipping into phosphomolybdic 
acid in MeOH followed by heating or by dipping into anisaldehyde in ethanol followed 
by heating. Flash chromatography was carried out on Silica gel (particle size 40-63 
pm). *H and 13C NMR spectra were recorded on JEOL JMN GX-270 or EX-400 NMR 
spectrometers. Unless otherwise stated, chemical shifts were measured in ppm relative 
to internal tetramethylsilane. 31P NMR chemical shifts were measured in ppm and 
denoted positive downfield from external 85% H3PO4.
Melting points were determined using a Reichert-Jung Therm Galen Kofler block 
and are uncorrected.
Microanalysis was carried out at the University o f Bath Microanalysis Service. 
Low resolution mass spectra were recorded at the University o f Bath Mass Spectrometry 
Service using +ve and -v e  fast atom bombardment (FAB) with m-nitrobenzyl alcohol as 
the matrix. High resolution accurate mass spectra were recorded at the University of 
Bath Mass Spectrometry Service.
Optical rotations were measured at ambient temperature using an Optical Activity 
Ltd AA-10 polarimeter in a cell volume o f 1 mL or 5 mL and specific rotations are given 
in 10' 1 deg mL g '1. Ion exchange chromatography was performed on an LKB-Pharmacia 
Medium Pressure Ion-Exchange Chromatograph using
Sepharose Q fast flow resin and gradients of triethylammonium bicarbonate as
eluent.
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HPLC analysis was carried out on a Dynamax model SD-200 with reverse phase 
column: APEX ODS II 5\i S/N 7121103. A gradient o f 0.05M TEAA buffer containing 
0.1% tetrabutylammoniumhydrogen sulphate and acetonitrile was used as eluent at 0.9 
mL/min, with a UV detector set at 259 nm.
HPLC purification was carried out on a Hewlett Packard series chromatograph 
with a strong anion exchange resin AGMP1 size 3 mm x 150 mm. A gradient o f 150 
mM TFA buffer was used as eluent at 1 mL/min, with a UV detector set at 259 nm.
Synthetic phosphates were assayed by adaptations o f the Briggs phosphate[80] 
test as follows. For the qualitative test, 200 pL aliquots o f the ion exchange column 
fractions were pipetted into a test tube and 4 drops of conc. sulfuric acid added to each 
tube, which was then heated to an oven at 200°C for 1 hour. The tubes were allowed to 
cool and water (200 pL) was added to dissolve the residue. An aliquot (400 pL) o f a 
solution o f ammonium molybdate (5 g) in water (40 ml) and conc. sulphuric acid (16 ml) 
was added, followed by an aliquot (200 pL) of a solution of quinol (200 mg) in water (40 
ml) and two drops of conc. sulphuric acid, then finally an aliquot (200 pL) of a solution 
o f sodium sulphite (8 g) in water (40 ml) was added. The mixture was heated to boiling 
for 10 seconds. A blue colour indicated the presence of inorganic phosphate.
For the quantitative assay the mixtures treated as above were transferred to 
volumetric flasks and made up to 10 mL with water. The UV absorbances at 340nm 
were recorded using 3 mL quartz cells. Concentration was calculated from a standard 
curve compiled from UV absorbance values o f known concentrations o f KH2PO4 treated 
as above and measured at 340nm.
The method used by our collaborators for the biological testing was as follows: 
Hepatocytes were isolated by collagenase digestion o f the livers o f male Wistar rats and 
stored at 4 °C in Eagles medium supplemented with 26 mM NaHCC>3 and BSA (2% w/v) 
for up to 24 h. The Eagles medium was removed and the cells were resuspended in a 
cytosol-like medium (CLM: KC1, 140 mM, NaCl, 20 mM, 2 mM MgCh, lm M  EGTA, 
300pM CaCh, 20mM Pipes, pH7.0) where they were permeabilised by incubation with 
saponin (10 /ig/mL). They were subsequently loaded to steady state (5 min at 37°C) with 
45Ca2+ in a cytosol-like medium containing ATP (1.5 mM), creatine phosphate (5 mM) 
creatine phosphokinase (5 units/mL) and FCCP (10 juM). After 5 min, thapsigargin 
(1.25 ^M ) was added to the cells to inhibit further Ca2+ uptake (by inhibiting the activity 
of the SERCA pump), 30s later the cells were added to appropriate concentrations o f the
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agonists and after a further 60s the 45Ca2+ contents of the stores were determined by rapid 
filtration. Concentration-response relationships were fitted to a four parameter logistic 
equation using Kaleidegraph software (Synergy Software, PA) from which the maximal 
response, half-maximally effective agonist concentration (EC50) and Hill slope (h) were 
determined. All results are expressed as means ± SEM.
7.2 Synthesis of Bis(benzyloxy)diisopropylaminophosphine
N,N-Diisopropylaminodich!orophosphine (19).
Dry N,A-diisopropylamine (141 mL, 1.4 mol) in dry diethyl ether (150 mL) 
n— p c i2 wag a(j^e(j d r o p w i s e  to a stirred solution o f phosphorus trichloride (44 mL, 
0.32 mol) in dry diethyl ether (100 mL) at -78  °C. More dry diethyl ether 
(300 mL) was added and the mixture was stirred overnight at room temperature. The 
precipitated amine salt was then filtered and washed with 300 mL of diethyl ether and 
concentrated to give an oil. The crude mixture was distilled, b.p. 62-63 °C at 7 mmHg 
(lit b.p. 62-63 °C[79]) to give the title compound (57 g, 89%). The product was stored at 
-20  °C.
‘H NMR (270 MHz; CDCI3) *  3.97 (septet, 2 H ,/6 .5  Hz, 2 x (CH3)2CHN) 1.33 (d, 12 
H ,/6 .9  Hz, 2 x (C //3)2C(H)N-PC12); 3IP NMR (1.09 MHz, CDC13), *172.88:
Bis(benzyloxy)diisopropylaminophosphine (20).
\  A mixture o f 19 (14.44g, 0.072 mmol) in dry dichloromethane (160 mL)
/ \  _  /-0Bn
 / N P\ 0Bn and dry triethylamine (21.1 mL, 0.151 mmol) was stirred at -78  °C.
Anhydrous benzyl alcohol (14.8 mL, 0.14 mmol) was added dropwise 
and stirred for a further 2h. The amine salt was filtered and washed with a further two 
portions of dichloromethane (40 mL). The organic portion was then washed with satd 
aq. NaHCCb (150 mL) and H2O (150 mL). The organic layer was dried (MgS04), 
filtered and concentrated under reduced pressure to leave a yellow oil, which was 
purified by flash chromatography on silica using hexane-triethylamine (10:1) as eluent 
to give the title compound (20.1 g, 81%) as a colourless oil.
‘H NMR (270 MHz; CDCI3) *  7.47-7.33 (m, 10 H, AiH), 4.92-4.78 (m, 4 H, 2 x 
C //2Ar), 3.85-3.76 (m, 2 H, 2 x (CH3)2CHNPOCH2Ar and 1.20 (d, 12 H, J  7.0 Hz, 2 x 
(C7/ 3)2CHNPOCH2Ar); 31P NMR (1.09 MHz, CDCI3), *149.03:
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7.3 Synthesis of the C-Glycoside trisphosphates
Allyl -a-D-glucopyranoside (3).
Acetyl chloride (4 mL, 70 mmol) was added dropwise to allyl alcohol 
HC \  (500 mL, 7.33 mol) and the mixture was stirred at RT for 15 min. D-HC
h o oaii glucose (100 g, 0.56 mol) was added and the mixture was refluxed 
heated at for 3 h. The mixture was cooled, neutralised with NaHCCb (10 g), filtered and 
concentrated under reduced pressure to give a viscous orange syrup. It was purified by 
flash chromatography on silica using ethyl acetate-methanol (9:1) as eluent to give a 
white compound. This was crystallised from hot acetone (500 mL) to give the title 
compound (37.3 g, 30.5%).
m.p. 94-96 °C; Lit m.p. 99-100 °C[46]; 'H  NMR (270 MHz; CDC13) <5h 6.01-5.89 (m, 1 
H, CH2C//=CH2), 5.33 (d, 1 H, 3J  17.2 Hz, C H iC H ^H ci^w ns), 5.25 (d, 1 H, }J  10.4 
Hz, ^C H ^T /c isH m n s), 4.94 (d, 1 H, J li2 3.8 Hz, H -l), 4.25^1.02 (m, 2 H, 
C //2CH=CH2), 3.85-3.65 (m, 4 H, H-3, H-5, H-6a, H-6b), 3.53 (dd, 1 H, J2,1 3.8 Hz, J2i
9.9 Hz, H-2) and 3.38 (t, 1 H, 9.7 Hz, H-4):
Allyl 2,6-di-O-trimethylacetyl-a-o-glucopyranoside (4).
A solution of 3 (5.0 g, 22 mmol) was dissolved in dry pyridine (50 mL)
oaii (5.6 mL, 45 mmol) was added dropwise over 1 h. Stirring was 
continued for a further 1 h. The mixture was poured into ice water (200 mL) and 
extracted with diethyl ether (200 mL). The organic solution was washed successively 
with 1 M HCL (200 mL) and sat. aq. NaHC03 solution (200 mL), dried (MgSCU) and 
concentrated under reduced pressure to give crude 4, which was used in the next step 
without further purification. A small sample was subjected to flash chromatography on 
silica using diethyl ether-hexane (3:1) as eluent to give the title compound as an oil.
[a]20D +90.6 (c 1.2, CHCI3); 'H  NMR (400 MHz; CDCI3) Sa 5.89-5.79 (m, 1 H,
under N2. The solution was cooled to 0 °C and trimethylacetyl chloride
CH2CT=CH2), 5.28 (dd, 1 H, 1 /1 .5  Hz, 3J  17.1 Hz, CH2CH=CHcu7/,ra„), 5.17 (dd, 1 H, 
2/ 0 .9  Hz, V  10.3 Hz, CH2CH=C//c„H,ra„), 5.02 (d, 1 H, JU2 3.9 Hz, H -l), 4.61 (dd, 1 H,
72 , i  3.9 Hz, J2,3 9.8 Hz, H-2), 4.42 (dd, 1 H, J6a,5 4.9 Hz, / 6a,6b 12.2 Hz, H-6a), 4.33 (dd, 1 
H, J 6b>3 1.9 Hz, J6bM 12.2 Hz, H-6b), 4.19^1.14 (m, 1 H, Cf/2CH=CH2), 4.09-3.92 (m, 3 
H, H-3, CH2CH=CH2), 3.85-3.80 (m, 1 H, H-5), 3.38 (t, 1 H, Jv =Jt,s 9.3 Hz, H-4) and
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1.22 (s, 18 H, 2 x C(0)C(Ctf3)3); 13C NMR (67 MHz; CDC13) <5b 179.40, 178.45 (2 x 
C(0)C(CH3)3), 133.42 (CH2CH=CH2), 117.59 (CH2CH=CH2), 95.09 (C-l), 72.76, 
71.50, 70.76, 69.09,(4 x CH), 68.40 (CH2CH=CH2), 63.22 (C-6), 38.97 (C(0)C(CH3)3), 
27.21 (C(0)C(CH3)3) and 27.07 (C(0)C(CH3)3); MS: (FAB) m/z 799.6 [(2M+Na)+, 
85%], 777.6 [(2M+H)+, 59%], 411.3 [(M+Na)+, 20%]; Anal. Calcd for Ci9H320 8: C, 
58.75; H, 8.30%. Found: C, 58.80%; H 8.32%.
(2'S,3'S) allyl 3,4-di-0-(2',3'-dimethoxybutane-2',3'-diyl)-2,6-di-0- 
trimethylacetyl-a-D-glucopyranoside (5).
A solution of 4 (1.78 g, 4.58 mmol), trimethyl orthoformate (4.2 ml, 
38 mmol) butane-2,3-dione (1.43 mL, 16.3 mmol) and CSA (20 mg,
and showed the presence o f one product. The mixture was allowed to cool to RT and 
triethylamine was added until the mixture was neutralised. The mixture was 
concentrated under reduced pressure and the syrup thus obtained was subjected to flash 
chromatography on silica using dichloromethane-acetone (20 :1) as eluent to give the 
title compound (1.78 g, 62.5 %) as an oil.
'H  NMR (400 MHz; CDC13) <5k 5.90-5.76 (m, 1 H, CH2CH=CH2), 5.23 (dd, 1 H, V  1.6
18 H, 2 x C(0)C(Ctf3)3); 13C NMR (67 MHz; CDC13) <5fc 178.14, 178.24 (2 x
C(0)C(CH3)3), 133.59 (CH2CH=CH2), 117.24 (CH2CH=CH2), 99.72, 99.65 (BDA 
OCCH3OCH3) 95.18 (C-l), 72.779 (CH), 70.48 (CH2CH=CH2), 68.30,67.70, 66.90,(3 x 
CH), 62.11 (C-6), 48.09,47.73 (2 x OCH3), 38.77 (C(0)C(CH3)3), 27.06 (C(0)C(CH3)3), 
27.23 (C(0)C(CH3)3) and 17.73, 17.58 (2 x CH3); MS: (FAB) m/z 525.4 [(M+Na)+,
0.086 mmol) in methanol (10 mL) was heated under reflux for 3 h, 
when TLC (diethyl ether) showed consumption o f starting material
OM e
Hz, V  17.2 Hz, CH2CH=CHa^ raM5), 5.15 (dd, 1 H, 2J  1.6 Hz, V  10.4 Hz, 
CH2CU=CHcisHtrans), 5.10 (d, 1 H, J h2 3.9 Hz, H -l), 4.73 (dd, 1 H, J2A 3.9 Hz, J2,3 10.6 
Hz, H-2), 4.45 (dd, 1 H, J6a,5 2.2 Hz, J6a>6h 11.7 Hz, H-6a), 4 .27 ^ .1 9  (m, 1 H, H-3 or H- 
4), 4.17-3.89 (m, 4 H, H-5, H-6b, CH2CH=CH2), 3.73-3.60 (m, 1 H, H-3 or H-4), 3.31 
(s, 3 H, OCH3), 3.24 (s, 3 H, OCH3% 1.30 (s, 3 H, CH3), 1.21 (s, 3 H, CH3) and 1.20 (s,
68%]:
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(2'S,3'S) Allyl 3,4-di-0-(2',3'-dimethoxybutane-2',3'-diyl)-a-D- 
glucopyranoside (6).
0H A solution o f crude 5 (2.85 g, 5.76 mmol), NaOH (0.93 g,
-o 23 mmol) in methanol (100 mL) was heated under reflux for 1 h.
h o  I The mixture was cooled, neutalised with solid CO2. The solvents
OAII
were evaporated off under reduced pressure and the residue was 
partitioned between diethyl ether (100 mL) and water (60 mL). The aqueous layer was 
back-extracted with diethyl ether (100 mL) and the combined organic fractions were 
dried (MgS04), filtered and concentrated under reduced pressure to give an oil which 
was subjected to flash chromatography on silica using diethyl ether as eluent. (545 mg, 
28% over 2 reactions).
[a]20D= +299 (c 0.7, CHC13); ]H NMR (400 MHz; CDCI3) <Sh 5.92-5.84 (m, 1 H, 
CH2C//=CH2), 5.29 (dd, 1 H, 2J  1.6 Hz, V  17.2 Hz, CH2CH=CH„s//,ra„), 5.22 (dd, 1 H, 
2J  1.3 Hz, V  10.3 Hz, CH2CH=C7/asH,ra„), 4.96 (d, 1 H, JU2 3.8 Hz, H -l), 4.25^4.10 (m, 
2 H, Cff2CH=CH2), 3.98-3.90 (m, 1 H, H-3 or H-4), 3.84-3.71 (m, 5 H, H-2, H-3 or H- 
4, H-5, H-6a, H-6b), 3.31 (s, 3 H, OCH3), 3.26 (s, 3 H, OCH}), 1.34 (s, 3 H, CH3) and
1.30 (s, 3 H, CH3); 13C NMR (67 MHz; CDC13) Sc 133.00 (CH2CH=CH2), 118.00 
(CH2CH=CH2), 99.62, 99.61 (BDA OCCH3OCH3) 97.67 (C-l), 70.29, 69.87 (2 x CH), 
68.74 (CH2CH=CH2), 65.96, (CH), 61.55 (C-6), 48.02, 47.97 (2 x OCH3), and 17.76, 
17.66 (2 x CH3); MS: (FAB) m/z 357.3 [(M+Na)+, 15%]; Anal. Calcd for Ci5H260 8 C, 
53.88; H, 7.84%. Found: C, 54.0; H, 7.95%:
Allyl 2,6-di-0-trimethylacetyl-3,4-0-isopropylidene-a-D- 
glucopyranoside (7).
p iv o ^  A solution of crude 4 (8.82 g, 22.0 mmol), 2-methoxypropene
A (5.5 mL, 56 mmol) and /?-toluenesulphonic acid (100 mg) in THF 
Piv0 oaii (100 mL) was stirred for 2 h at RT under N2. TLC diethyl ether- 
hexane (1:1) indicated consumption o f starting material. Diethyl ether (250 mL) was 
added and the mixture was washed with sat. aq. NaHCC>3 solution (250 mL). The organic 
layer was dried (MgS04 ) and filtered, and a few drops of EtsN were added before the 
organic layer was concentrated under reduced pressure. The product o f this reaction was 
used directly in the next step without purification. A small sample was purified by flash
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chromatography on silica using diethyl ether-hexane (1:2) as eluent to give the title 
compound for analysis.
[a]20o +114 (c 1.2, CHC13); 'H  NMR (400 MHz; CDC13) <5h 5.92-5.78 (m, 1 H,
3 H, isopropylidene CHi), 1.23 (s, 9 H, (C (0)C(C//3)3) and 1.22 (s, 9 H, (C(0)C(C//3)3); 
13C NMR (67 MHz; CDC13) <5fc 177.98 (2 x C(0 )C(CH3)3), 133.39 (CH2CH=CH2),
117.80 (CH2CH=CH2), 111.00 (isopropylidene C(CH3)2), 95.32 (C-l), 72.98, 71.50,
(2 x isopropylidene CH3, 2 x (C(0)C(CH3)3); MS: (FAB) m/z 429.0 [(M+H)+, 97%]; 
Anal. Calcd for C22H360 8 C, 61.66%; H, 8.47%. Found: C, 61.90%; H, 8.35%.
Allyl 2,6-di-O-benzyl-a-D-glucopyranoside (10).
CO2. Following concentration in vacuo the residue was partitioned between diethyl ether 
(100 mL) and water (50 mL). The aqueous layer was back-extracted with diethyl ether 
(10 mL) and the combined organic fractions were dried (MgSCU), filtered and 
concentrated under reduced pressure. The oil obtained was dissolved in dry DMF 
(40 mL) and was stirred at 0 °C with NaH (2.25 g of a 60 % w/w dispersion in mineral 
oil, 56 mmol) and benzyl bromide (6.1 mL, 56 mmol) was added slowly. The mixture 
was stirred at RT for 90 min. Water (50 mL) was added and stirring continued for 60 
min. The solvents were evaporated under reduced pressure and the residue was 
dissolved in diethyl ether (200 mL). The extract was washed with water (500 mL), dried 
(MgSC>4), filtered and concentrated under reduced pressure. The oil was dissolved in 
methanol (50 mL) and stirred with 1 M HC1 (5 mL) for 30 min. TLC diethyl ether- 
hexane (1:2) indicated consumption o f starting material. Solid NaHCOs was added until 
the mixture reached neutral pH. The solvents were evaporated off and the residue was 
partitioned between dichloromethane (100 mL) and water (50 mL). The aq. layer was 
back extracted with CH2CI2 (200 mL) and the combined organic layers were dried 
(MgSC>4), filtered and concentrated under reduced pressure. The product was
CH2C//=CH2), 5.28 (dd, 1 H, V  1.7 Hz, 3J  17.2 Hz, CH2CH=CH„S/ / Ira„), 5.20-5.17 (m, 
2 H, H -l, CH2CH=C//„SH,„„J, 4.83 (dd, 1 H, J 2,i 3.7 Hz, J2l,  10.6 Hz, H-2), 4.37 (dd, 1 
H, J6a,5 2.2 Hz, J6a,6b 11.9 Hz, H-6a), 4.20-4.10 (m, 1 H, H-6b), 4.18-3.91 (m, 4 H, H-3, 
H-5, Cff2CH=CH2), 3.37-3.30 (m, 1 H, H 4 ), 1.44 (s, 3 H, isopropylidene CHi), 1.42 (s,
70.68, 69.76 (4 x CH), 69.84 (CH2CH=CH2), 63.50 (C-6), 27.00,27.16, 26.40 and 26.70
OAII
A solution of crude 7 (9.77 g, 22 mmol), NaOH (3.6 g, 90 mmol) in 
methanol (50 mL) was heated under reflux for 1 h. The mixture was 
cooled to RT and the pH was adjusted to 8 by careful addition of solid
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crystallised from diethyl ether-hexane to give the title compound (6.1 g, 67% over the 
previous 5 steps from 3).
[a ]20D +76.3 (c 0.8, CHC13); Lit [a f°D +76.4 (c 0.8, CHC13)[46]; m.p. 75-77 °C; Lit 
m.p. 74-77 °C[46]; 'H  NMR (270 MHz; CDCI3) A  7.36-7.26 (m, 10 H, ArCH), 5.94- 
5.83 (m, 1 H, CH 2Ctf=CH 2), 5.31 (dd, 1 H, 2J=  1.6, 3J=17.2, CH 2 CH=CHcisflrtrans), 5.23 
(dd, 1 H, 2J  1.6 Hz, 3J  10.3 Hz, CH2 CH=C7/„sH trans), 4.84 (d, 1 H, J,,2 3.5 Hz, H -l),
4.67, 4.62 (AB, 2 H, J ab 12.1 Hz, ArCff20 ), 4.59, 4.54 (AB, 2 H, J ab 12.1 Hz, 
ArC/720 ), 4.18-4.11 (m, 1 H, CHHCH=CH2), 3.98-3.90 (m, 2 H, H-3 CHHCH=CH2), 
3.78-3.68 (m, 3 H, H-5, H-6a, H-6b), 3.62 (t, 1 H, J 4,3=J4l5 9.2 Hz, H-4) and 3.38 (dd, 1 
H, J 2>, 3.5 Hz, J 2,3 9.5 Hz, H-2):
Allyl 2,6-Di-0-benzyl-3,4-di-0-(p-methoxybenzyl)-a-D- 
glucopyranoside (11).
A solution of 10 (6 g, 15 mmol) in dry DMF (40 mL) was stirred
BnO~-^
pmbo^ A ^ ^ 0 S0C^ um hydride (2.39 g, 60 mmol) and /7-methoxybenzyl
g^ol chloride (8.1 mL, 60 mmol) at RT for 3 h. Methanol (30 mL) was
OAII
added and stirring continued for 15 min. The solvents were 
concentrated under reduced pressure and the residue was dissolved in diethyl ether. The 
organic solution was washed with water, dried (MgSO,*), filtered and concentrated under 
reduced pressure. The residue was subjected to flash chromatography on silica using 
hexane-ethyl acetate (19:1) as eluent to give the title compound as an oil.
'H  NMR (270 MHz; CDC13) <5h 7.34-7.25 (m, 12 H, ArCH, H-2 o f PMB ring, H-6 of 
PMB ring), 7.04 (d, 2 H, J 8 .6  Hz, H-2 and H-6 o f PMB ring), 6.90-6.78 (m, 4 H, 2 x 
H-3 o f PMB rings, 2 x H-5 o f PMB rings), 5.93-5.91 (m, 1 H, CH2Ctf=CH2), 5.29 (d, 1 
H, 3J=17.2, CH2CH=CHclJ / trans), 5.19 (d, 1 H, 3J=10.3, C ^ C H C ^ H ^ ) ,  4.92-4.36 
(m, 9 H, 4 x ArCtf20 , H -l), 4.12-3.97 (m, 3 H, H-3, CH2CH=CH2), 3.80 (s, 3 H, 
OCHi), 3.79 (s, 3 H, OCH}) and 3.72-3.51 (m, 5 H, H-2, H-4, H-5, H-6a and H-6b):
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2 ,6 - D i - 0 - b e n z y l - 3 l4 - d i - 0 - ( p - m e th o x y b e n z y l ) - a - d - g lu c o p y r a n o s id e
(12).
11 (5.5 g, 8.6 mmol) In methanol (50 mL) was stirred vigorously
BnO~-__
X, n with PdCh (304 mg, 1.7 mmol) for 3 h. TLC dichloromethane- 
pmbo—v ^ ^ \ ^  acetone (10:1) showed consumption o f the starting material. Et3N
BnO  OH 17 ^
(1 mL) was added to neutralise the reaction. It was filtered through Celite, the solvents 
were evaporated off and the residue was subjected to flash chromatography on silica 
using dichloromethane-acetone (10:1) as eluent to give a pale yellow oil which was 
crystallised from diethyl ether to give the title compound as a white solid (3.59 g,
70.5 %).
'H  NMR (270 MHz; CDCI3) <5h 7.35-7.25 (m, 12 H, ArC/7, H-2 o f PMB ring, H -6 PMB 
ring), 7.07-7.04 (m, 2 H, H-2 o f PMB ring, H -6 o f PMB ring), 6.87-6.78 (m, 4 H, 2 x H- 
3 o f PMB rings, 2 x H-5 o f PMB rings), 5.21 (t, 0.5 H, / 2 .6  Hz, H -la), 4 .88 ^ .3 9  (m,
8.5 H, H -1a  4 x A rC ftO ), 3.92 (t, 0.5 H, JX2=JX 4 9 3 Hz, H-3a or H-3/;), 3.79 (s, 3 H, 
OCHi), 3.78 (s, 3 H, O C//3), 3.67-3.53 (m, 5.5 H, 0.5 x H-2a, H-3a or H-3/;, H-4, H-5, 
H-6a, H-6b) and 3.44-3.30 (m, 0.5 H, H-2/;):
2 ,6 - D i - 0 - b e n z y l - 3 ,4 - d i - 0 - ( p - m e th o x y b e n z y l ) - a - D - g lu c o n o - 1 ,5 - la c to n e  
(1 3 ) .
Dry dichloromethane (1 mL) was placed into a 100 mL flask under 
Bn° ^ \  at atmosphere o f N2. A solution o f oxalyl chloride in dry
p M B °-----
p m b o — dichloromethane (1.7 mL, 3.4 mmol of 2 M  solution) was injected
BnO
and the flask was cooled to -78  °C. Anhydrous dimethyl sulphoxide 
(0.5 mL, 7 mmol) dissolved in dry dichloromethane was added dropwise (care evolution 
o f gas) and stirring was continued for 5 min. A solution o f 12 (2.0 g, 3.3 mmol in 2 mL 
dry dichloromethane) was added dropwise and stirring was continued for 20 min. Et3N 
(1.8 mL, 13 mmol) was added dropwise and the reaction was stirred for a further 5 min, 
then the mixture was allowed to heat up to RT. The mixture was stirred with water 
(40 mL) for 10 min, then dichloromethane (80 mL) was added. The organic layer was 
separated and the aqueous layer was re-extracted with dichloromethane (80 mL). The 
combined organic layers were washed successively with sat. aq. NaCl (80 mL), 1% HC1 
(80 mL) and 10% aq. NaHC(>3 (80 mL), dried and concentrated under reduced pressure.
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The residue was subjected to flash chromatography on silica using diethyl ether-hexane 
(1:1) as eluent to give the title compound as an oil (1.33 g, 67%).
[a]20D +64.7 (c 0.5, CHC13); IR; u 1755cm’1 (carbonyl); !H NMR (400 MHz; 
CDC13;) <5h 7.39-7.07 (m, 14 H, AiCH, 2 x H-2 o f PMB ring, 2 x H-6 o f PMB ring), 
6.86-6.80 (m, 4 H, 2 x H-3 of PMB ring, 2 x H-5 o f PMB ring), 4.98 (AB, 1 H, Jab
11.42 Hz, 0.5 x A rC//20 ), 4.67^1.40 (m, 8 H, H-5, 3.5 x ArCtf20), 4.09 (d, 1 H, J2,3 6.2 
Hz, H-2), 3.95-3.85 (m, 2 H, H-3, H-4), 3.79 (s, 3 H, OCH3\  3.78 (s, 3 H, OCi/3), 3.69 
(dd, 1 H, J6b,6a 10.8 Hz, J6b,5 2.3 Hz, H-6b) and 3.63 (dd, 1 H, J6si>5 3.5 Hz, J6&,6b 10.8 Hz, 
H-6a); 13C NMR (100 MHz; CDC13) *  169.54, 159.54 (2 x C-4 o f PMB ring), 137.81, 
137.16 (2 x C-l o f Bn ether ring) 129.93, 129.91, 128.86, 128.81,128.68, 128.58, 
128.30, 128.01 (ArCH), 114.06 (C-3, C-5 o f PMB ring), 80.90, 78.49, 77.74 and 77.70 
(4 x CH), 75.95, 74.05, 73.86, 73.70, (4 x ArCH20), 68.56 (C-6) and 55.64 (OCH3); 
MS: (FAB) m/z 621.1 [(M+Na)+, 22%], 597.1 [(M), 35 %], m/z calcd for C36H380 8 
598.2566: Found m/z 598.2518:
2,6-Anhydro-3,7-di-0-benzyl-4,5-di-0-(p-methoxybenzyl)-1-deoxy-D- 
glucohept-1-enitol (14).
To a solution o f 13 (1.07 g, 1.8 mmol) in dry toluene (3.5 mL)
and dry THF (1.5 mL), pyridine (26 /AS) was added. The mixture 
ch2 wag cooie(i _45 °£  Tebbe Reagent (3.9 mL, 2 mmol) was
added slowly. The mixture was stirred at -40  °C to -45 °C for 1 h then at 0 °C for a 
further 30 min. It was then cooled to -10  °C to -15  °C and NaOH (1 mL, 15 % w/v) was 
added. The cooling bath was removed and the reaction mixture was diluted with diethyl 
ether (50 mL). The inorganic residue was removed by filtration through Celite and the 
filter cake was washed with excess diethyl ether. The solvents were evaporated off 
under reduced pressure and the residue was subjected to flash chromatography on silica 
using diethyl ether-hexane (1:3) as eluent to yield the title compound which was 
recrystallised from hexane (691 mg, 65.1%).
m.p. 52-54 °C; [a ]20D +42.8 (c 0.5, CHCI3); 'H  NMR (400 MHz; CDCI3) A  7.36-7.03 
(m, 14 H, ArCH, 2 x H-2 o f PMB ring and 2 x H -6 o f PMB ring), 6.86-6.77 (m, 4 H, 2 
x H-3 of PMB ring, 2 x H-5 of PMB ring), 4.81-4.39 (m, 11 H, H-6, H2-l', 4 x
PM BO ^
PMBO-
ArCtf20), 3.93 (d, 1 H, J3>4 7.2 Hz, H-3), 3.79 (s, 3 H, OCH3), 3.77 (s, 3 H, OCff3) and
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3.74-3.71 (m, 4 H, H-4, H-5, H2-7); UC NMR (100 MHz; CDCI3) <5fc 159.24, 156.36 (2 
x C-4 o f PMB ring), 137.93 (2 x C-l o f Bn ether ring), 130.55, 130.29 (2 x C-l o f PMB 
ring), 129.54, 128.43, 128.35, 127.88, 127.75, 127.62, (ArCH), 113.79, 113.75 (2 x C-3 
o f PMB ring, 2 x C-5 o f PMB ring), 94.61 (C-l), 84.44, 78.98, 78.57, 77.47 (4 x CH),
74.08, 73.50, 73.77 (4 x ArCH20 ), 68.78 (C-l) and 55.25 (OMe); MS: (FAB) m/z 597.2 
[(M+H)+, 20%], m/z calcd for C37H40O7 [M+H]+ 597.2852 found m/z 597.2833; 
Anal.Calcd for C37H40O7 C, 74.47; H, 6.75%. Found: C, 74.30; H, 6.75%:
a  and /?-2,6 di-0-benzyl-3,4-di-0-(p-methoxybenzyl)-D- 
glucopyranosylmethanol (15 and 17).
To compound 14 (570 mg, 0.9 mmol) was added a 1.0 M 
solution of BH3-THF in THF (2.9 mL, 2.9 mmol) at 0 °C. It was
OH stirred for 2 h and allowed to heat up to RT. H2O2 (0.9 mL, 
30%) was added and stirring was continued for 30 min. Water 
(10 mL) and diethyl ether (20 mL) were added. The organic 
0H layer was washed with sat. aq. NaCl (10 mL), dried (MgSCU), 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica using diethyl ether-hexane (2 :1) as eluent to give the title 








9-BBN (0.5 M in THF, 1.68 mL, 0.8 mmol) was added to 14
BnO-—_
Q (100 mg, 0.2 mmol) at 0 C and the mixture was stirred for 3 h.
p m b o - A ^ ^ / ^ o h  H2O2 (3 mL, 30%) and 5% aq. KOH were added. The product
BnO
was extracted into diethyl ether and washed with sat aq. NaCl, dried (MgS04), filtered 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica using ethyl acetate-hexane (4:6) as eluent to give the title 
compound as an oil (60 mg, 58%).
[a ]20D +4.5 (c 0.2, CHCI3); 'H  NMR (400 MHz; CDCI3) (5k 7.72-7.04 (m, 14 H, 10 x 
ArCH, 2 x H-2 o f PMB ring, 2 x H -6 o f PMB ring), 6.90-6.80 (m, 4 H, 2 x H-3 o f PMB 
ring, 2 x H-5 PMB ring), 4.88^1.84 (AB, 3 H, Jab 12.0 Hz, 1.5 x ArCH20 ), 4.75, 4.66 
(AB, 2 H, Jab 12.0 Hz, ArCH20 ), 4.59, 4.54 (AB, 2 H, JAB 10.5 Hz, ArCH20 ), 4.48 
(AB, 1H, Jab 10.5 Hz, 0.5 x ArCH2Q), 3.86 (dd, 1 H, J2 .3  Hz, J  12.0 Hz, H-lt>), 3.79 (2
139
x s, 6 H, 2 x OCHi), 3.74-3.60 (m, 4 H, H -l'a, H-3, H-6a, H-6b), 3.57-3.51 (2 x t, 2 H, 
H-2, H-4), 3.45 (ddd, 1 H, H-5) and 3.34 (ddd, 1 H, H -l); 13C NMR (100 MHz; 
CDC13) Sc 159.41, 159.31 (2 x C-4 o f PMB rings), 138.20, 138.07 (2 x C-l Bn ether 
ring), 130.93, 130.39 (2 x C -l o f PMB ring), 129.81, 129.58, 128.71, 128.64, 128.23,
128.08, 127.96, (ArCH), 114.09, 114.06 (2 x C-3 o f PMB ring, 2 x C-5 o f PMB ring),
87.05 (C-3), 79.52 (C-l), 78.94, 78.42, 78.27 (C-5, C-4, C-2), 75.66, 75.34, 75.59, 73.78 
(4 x ArCH20 ), 69.44 (C-6), 62.45 (C-l') and 55.64 (OCH3); MS: (FAB) m/z 637.2 
[(M+Na)+, 80%], 615.2 [(M+H)+, 10%], m/z calcd for C37H4208 [M+H]+ 615.2957 
found m/z 615.2895; Anal. Calcd for C37H420 8: C, 72.29; H, 6.89%. Found: C, 72.10; H 
6.89%:
a  and p-2,6 di-O-benzyl-D-glucopyranosylmethanol (16 and 18).
The mixture o f 15 and 17 (87 mg, 0.14 mmol) was dissolved in 
Bn0^  dichloromethane (10 mL), TFA (1 mL) was added and the mixture
"oh was stirred for 20 min. TLC diethyl ether-hexane (7:3) showed 
that the reaction had gone to completion. Sat. aq. NaHC03 
(50 mL) was added to neutralise the reaction. The products were 
extracted with dichloromethane (2 x 50 mL), the organic layer was 
dried (MgSC>4), filtered and concentrated under reduced pressure 
to give a white solid. It was purified by flash chromatography on silica using ethyl 
acetate-hexane (8:2) as eluent to give 18 (20.5 mg, 39%)
mp 68-70 °C; [a]20D+6.3 (c 0.2, CHC13); 'H  NMR (400 MHz; CDC13) Sh 7.38-7.25 (m, 
10 H, ArCH), 4.78, 4.72 (AB, 2 H, Jab 11.4 Hz, ArCH20 ), 4.57, 4.54 (AB, 2 H, Jab 
12.0 Hz, ArCH20 ), 3.87 (dd, 1 H, J 2.3 Hz, H -l'a ), 3.70-3.67 (m, 3 H, H-6a, H-6b, H- 
11)), 3.64-3.40 (m, 4 H, H-2, H-3, H-4, H-5) and 3.39-3.32 (m, 1 H, H -l); 13C NMR 
(100 MHz; CDCI3) *  138.24,137.64 (2 x C -l o f Bn ether ring). 128.79,128.70, 128.26, 
128.23, 128.15, 128.03 (ArCH), 79.28, 78.70, 77.62, (3 x CH), 76.99, 75.00 (2 x 
ArCH20 ), 73.98 (CH), 72.16 (CH), 70.50 (C-6) and 62.39 (C-l'); MS: (FAB) m/z 397.2 
[(M+Na)+, 73%], 375.2 [(M+H)+, 34%], m/z calcd for C2)H260 6 [M+H]+ 375.1807 
found m/z 375.1805:
Further elution gave 16 (22 mg, 41.2%)
[a]20D +5.6 (c 0.17, CHC1]); ‘H NMR (400 MHz; CDC13) Sh 131-1.20  (m, 10 H, 
ArCH), 4.64, 4.63 (AB, 2 H, Jab 11.7 Hz, ArCH20 ), 4.58, 4.54 (AB, 2 H, Jab 12.0 Hz,
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A rC//20 ), 4.17 (ddd, 1 H, J U2 5.9 Hz, Ji.ra 4.1 Hz, Ji.it, Hz, 9.1 Hz, H -l), 3.90 (dd, 1 H, 
Jv*,n 12.3 Hz, J ra,i 4.1 Hz, H-l'a), 3.77 (dd, 1 H, Jit,.,* 12.3 Hz, J )W 9.1 Hz, H-l'b), 
3.73-3.63 (m, 5 H, H-3, H-4, H-5, H-6a, H-6b) and 3.60 (dd, 1 H, J 2,i 5.9 Hz, J 2,3 9.4 Hz, 
H-2); 13C NMR (100 MHz; CDCI3) Sc 137.60, 137.53 (2 x C-l o f Bn ether ring). 
128.82, 128.68, 128.40, 128.21, 128.12, 128.03 (ArCH), 78.53, 77.62 (2 x CH), 74.60,
74.05 (2 x ArCH20 ), 73.53 (CH), 72.14 (C-6), 71.86 (CH), 70.83 (CH) and 58.79 (C -l’); 
MS: (FAB) m/z 397.2 [(M+Na)+, 80%], 375.2 [(M+H)+, 59%], m/z calcd for C2iH260 6 
[M+H]+375.1807 found m/z 375.1810:
/A2,6-di-0-benzyl-D-glucopyranosylmethanol 3,4,1- 
tris(dibenzylphosphate) (22)
Bn0'~-N A mixture o f bis(benzyloxy)(diisopropylamino)
<B(Sfe(S o ) P o X i « ^ x ^ ^ OP(0)(OBn)2 phosphine (276 mg, 0.8 mmol), tetrazole (84 mg, 1.2 
Bn°  mmol) and dry dichloromethane (5 mL) was
vigorously stirred at RT for 30 min under N2, whereupon 18 (50 mg, 0.13 mmol) was 
added and stirring was continued for 30 min. The mixture was cooled to 0 °C and 
raCPBA (460 mg, 1.6 mmol) was added. The mixture was stirred at RT for 10 min, then 
was diluted with dichloromethane (50 mL). The solution was washed successively with 
10% (w/v) aq. Na2SC>3 (25 mL), sat. aq. NaHCC>3 (25 mL) and sat. aq. NaCl (25 mL), 
dried (MgSCU), filtered and concentrated under reduced pressure. The concentrate was 
purified by flash chromatography on silica using ethyl acetate-hexane (6:4) as eluent to 
give the title compound as an oil (137 mg, 99.1%).
[a]20D -5.5 (c 1.8, CHCI3); ‘H NMR (400 MHz; CDC13) <Sh 7.46-7.04 (m, 40 H, AiCH), 
5.09-4.72 (m, 13 H, 6.5 x ArC//20 ), 4.70-4.63 (m, 1 H, H-3), 4.55-4.48 (m, 1 H, H-4), 
4.44 (AB, 1 H, Jab 11.1 Hz, 0.5 x AiCH20), 4.40 (AB, 1 H, Jab 12.3 Hz, 0.5 x 
ArOT20 ), 4.30-4.20 (m, 2 H, H -l'a, 0.5 x A rC ftO ), 4 .1 2 ^ .0 7  (m, 1 H, H -l’b), 3.79 
(dd, 1 H, J 6a,5 1.5 Hz, J 6a,6b 11.1 Hz, H-6a), 3.66 (dd, 1 H, J 6b,5 5.3 Hz, J 6b,6a 11.1 Hz, H- 
6b), 3.65-3.51 (m, 2 H, H-2, H-5) and 3.46-3.43 (m, 1 H, H -l); 13C NMR (100 MHz; 
CDCI3) Sc 138.24, 137.76 (2 x C-l Bn ether ring),136.20-135.79 (6 x C-l o f Bn ester 
rings), 128.73, 128.68, 128.61, 128.54, 128.47, 128.42, 128.38, 128.23, 128.12, 128.09,
127.79, 127.73, 127.62 (ArCH), 74.63, 73.47, 70.16, 70.10, 69.85, 69.66, 69.00 and 
66.19 (CH2); 31P NMR (109 MHz; CDC13) <5p 0.02, -0.19, -0.79; MS: (FAB) m/z 1177.6
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[(M+Na)+, 32%], 1155.6 [(M+H)+, 81%], m/z calcd for C63H65O15P3 [M+H]+l 155.3614 
found m/z 1155.3628:
a-2,6-di-0-b e n z y l - D - g lu c o p y r a n o s y lm e th a n o l  3,4,1 
t r i s ( d i b e n z y l p h o s p h a t e )  (2 1 ) .
A mixture o f bis(benzyloxy)(diisopropylamino)
(Bno^(pgo^^~ ^ ^  phosphine (232 mg, 0.67 mmol), tetrazole (71 mg, 1.00
BnO I mmol) and dry dichloromethane (5 mL) was vigorously
0P(0)(0Bn)2
stirred at RT for 30 min under N2, whereupon 16
(42 mg, 0.11 mmol) was added and stirring was continued for 30 min. The mixture was 
cooled to 0 °C and mCPBA (460 mg, 1.6 mmol) was added. The mixture was stirred at 
RT for 10 min, then was diluted with dichloromethane (50 mL). The solution was 
washed successively with 10% (w/v) aq. Na2SC>3 (25 mL), sat. aq. NaHCC^ (25 mL) and 
sat. aq. NaCl (25 mL), dried (MgS04), filtered and concentrated under reduced pressure. 
The concentrate was purified by flash chromatography on silica using ethyl acetate- 
hexane (6:4) as eluent to give the title compound as an oil (90.5 mg, 78%).
[a]20D +7.7 (c 1.81, CHCI3); ’H N M R (400 MHz; CDCI3) Sh 7.35-7.16 (m, 40 H,
CDCI3) Sc 138.15, 137.31 (2 x C-l o f Bn ether ring), 135.91-135.84 (6 x C-l of Bn
[(M+H)+, 85%], m/z calcd for C63H65O15P3 [M+H]+l 155.3614 found m/z 1155.3648:
ArCtf), 5.11-4.86 (m, 12 H, 6 x ArC7/20 ), 4.81-4.76 (m, 1 H, H-3), 4.67-4.61 (m, 1 H, 
H-4), 4.57 (AB, 1 H, JAB 11.7 Hz, 0.5 x A rC //20 ), 4.44-4.29 (m, 4 H, H -l'a, 1.5 x 
A rC//20 ), 4.14-4.04 (m, 2 H, H -l, H-IT?), 3.98-3.94 (m, 1 H, H-5), 3.70-3.64 (m, 2 H, 
H-6a, H-2) and 3.58 (dd, 1 H, J6ht5 2.9 Hz, J6b>6a 10.8 Hz, H-6b); 13C NMR (100 MHz;
ester rings), 128.73, 128.71, 128.65, 128.62, 128.54, 128.41, 128.16, 128.14, 128.13, 
127.81, 127.63 (ArCH) 77.66, 77.55 (2 x CH), 73.84, 73.50 (2 x CH2), 73.35, 71.80,
71.71, (3 x CH), 69.92, 69.76, 69.71, 69.65, 68.14 and 64.10 (CH2); 31P NMR (162 
MHz; CDCI3) Sp 0.21, -0.594, -1.07; MS; (FAB) m/z 1177.6 [(M+Na)+, 32%], 1155.6
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a-D-glucopyranosylmethanol 3,4,r-trisphosphate (1)
10% Palladium on activated charcoal (50%, 200 mg ) was 
added to a solution o f compound 21 (90 mg, 0.08 mmol) in 
methanol (20 mL) and water (5 mL) and the mixture was
0P0:}2 hydrogenated at 50 psi at RT for 24 h, after which it was
filtered and washed well with de-ionised water and methanol. The filtrate was
concentrated under reduced pressure to give a glassy clear solid. The residue was
dissolved in de-ionised water and purified by ion exchange chromatography on Q 
Sepharose Fast Flow resin, eluting with a gradient of TEAB buffer (0-1 M), pH 8 . The 
triethylammonium salt o f 1 was eluted between 80 and 92%. TEAB fractions containing 
compound 1, as judged by phosphate assay, were combined and concentrated to give a 
residue from which MeOH (3 x 100 mL) was evaporated to give the title trisphosphate 
as its triethylammonium salt (58 pinole, 72.5%).
[a]20D +19.8 (c 0.9, MeOH); ‘H NMR (400 MHz; CD3OD) <Sh 4.35 (q, 1 H . / 8.8 Hz, H- 
3), 4.26-4.12 (m, 3 H, H -l, H -l'a, H -l’b), 4.10-4.05 (q,l H, J 8.8 Hz, H-4), 3.90 (dd, 1 
H, 76a,5 4.1 Hz, J 6a,6b 12.6 Hz, H-6a), 3.86-3.79 (m, 2 H, H-2, H-5) and 3.72(dd, 1 H, J6bj5
2.1 Hz, -/6b,6a 12.6 Hz, H-6b ) ;31P NMR (162 MHz; CD3OD)<5p 2.70,2.11,2.10; (FAB) 
m/z 867.0 [(2M-H)”, 80%], 433.1 [(M-H)‘ , 100 %], m/z calcd for C7H 16O 15P3 [M-H]“ 
432.9657 found m/z 432.9694:
/ ( - D - g lu c o p y r a n o s y lm e th a n o l  3,4,1 ' - t r i s p h o s p h a t e  (2)
10% Palladium on activated charcoal (50%, 200 mg ) was
added to a solution o f compound 22 (90 mg, 0.08 mmol)
OPO
h o  3 in methanol (20 mL) and water (5 mL) and the mixture
was hydrogenated at 50 psi at RT for 24 h, after which it was filtered and washed well 
with de-ionised water and methanol. The filtrate was concentrated under reduced 
pressure to give a glassy clear solid. The residue was dissolved in de-ionised water and 
purified by ion exchange chromatography on Q Sepharose Fast Flow resin, eluting with a 
gradient o f TEAB buffer (0-1 M), pH 8 . The triethylammonium salt o f 2 was eluted 
between 80 and 92%. TEAB fractions containing compound 2, as judged by phosphate 
assay, were combined and concentrated to give a residue from which MeOH (3 x 
100 mL) was evaporated to give the title trisphosphate as its triethylammonium salt (69 
pmole, 86.3%).
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[a]20c -3 .7  (c 1.3, MeOH); ‘H NMR (400 MHz; CD3OD) Sh 4.22-4.15 (m, 2 H, H-3, H- 
l'a), 4.09-3.96 (m, 2 H, H-4, H-lt>), 3.86 (dd, 1 H, J 6a,5 3.8 Hz, / 6a,6b 12.6 Hz, H-6a),
3.77 (dd, 1 H, / 6b>5 1.8 Hz, / 6b,6a 12.6 Hz, H-6b), 3.50 (t, 1 H, / 2,i=2,3 8.8 Hz, H-2), 3.43-
3.39 (m, 1 H, H-5) and 3.36-3.29 (m, 1 H, H -l); 31P NMR (162 MHz; CD3OD) dp -  
5.90, -5.85, -5.38; MS; (FAB) m/z 433.1 [<M-H)“, 100 %], m/z calcd for C7H K A 5P3 
[M -H]+432.9657 found m/z 432.9684:
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7.4 Synthesis of Xylopyranoside trisphosphates
Allyl a-D-xylopyranoside (27)
Allyl alcohol (1 L) and acetyl chloride (6.0 mL) were stirred together
Hcrr'V—
H for 30 min, after which time D-xylose (100.0 g, 0.67 mol) was added.
HO I
0AH The mixture was heated at reflux for 16 h and then cooled to room 
temperature. Solid NaHCCh (7.00 g) was slowly added, and stirring continued for 30 
min. The mixture was then filtered and the filtrate was concentrated under reduced 
pressure, leaving an off-white solid. The solid was dissolved in minimal ethanol (700 
mL) and the solution was kept at -20°C for 24 h. Diisopropyl ether was added 
immediately before the collection of the title compound over three crops as white fluffy 
crystals (52.25 g, 41%).
mp 100-103 °C; Lit mp 101-103 °C[76]; [a]20D+140 (c 3.19, CHC13); Lit [a f°D +149 
(c 3.2, CHC13)[76]; !H NMR (D20 ; 270 MHz) A  6.01-5.88 (m, 1 H, CH2Ctf=CH2), 
5.34 (d, 1 H, 3J  17.4 Hz, CH2CH=CH„SH „„S), 5.18 (d, 1 H, V  10.3 Hz, 
CH2CH=CH„sHm„s), 4.91 (d, 1 H, J,,2 3.5 Hz, H -l), 4.20-4.13 (m, 2 H, C //2CH=CH2) 
and 3.76-3.49 (m, 5 H, H-2, H-3, H-4, H-5a, H-5b):
Allyl 2-O-trimethylacetyl a-D-xylopyranoside (34).
A solution o f 27 (10.0 g, 52.6 mmol) in dry pyridine (200 mL) was 
stirred at -40  °C under N2. Trimethylacetyl chloride (6.8 mL, 55.2
PivO I
0AN mmol) was added dropwise over 1 h. The mixture was stirred at -4 0  °C 
for a further 90 min. The reaction was quenched with water (100 mL) and was allowed 
to reach RT and extracted with diethyl ether (100 mL). The organic layer was washed 
with 1 M HC1 (100 mL) and sat. aq. NaHCCb solution (100 mL), dried (MgS04), filtered 
and concentrated to give an oil which was dissolved in hexane and refrigerated at -2 0  °C. 
The title compound was collected as crystals over 3 crops (7.6 g, 53%). 
mp 76-77 °C; [a]20D +154 (c 1.7,CHC13); ]H NMR (CDC13; 400 MHz) <5k 5.89-5.77 (m, 
1 H, CH2CH=CH2), 5.29 (dd, 1 H, 2J 1.5 Hz, 3J 17.0 Hz, CH2CH=CHclsHtrans), 5.18 (dd, 1 
H, 2J 1.5 Hz, 3J 11.7 Hz, CH2CH=CHcisHtrans), 4.96 (d, 1 H, Ju  3.7 Hz, H -l), 4.62 (dd, 1 
H, J2,i 3.7 Hz, J2,3 9.9 Hz, H-2), 4.20-4.15 (m, 1 H, 0.5 x CH2CH=CH2), 3.96-3.91 (m, 2 
H, H-3, 0.5 x CH2CH=CH2), 3.75-3.60 (m, 2 H, H-4, H-5a), 3.60-3.54 (m, 1 H, H-5b), 
3.17 (d, 1 H, J 13.3 Hz, OH), 2.97 (d, 1 H, J 9.5 Hz, OH) and 1.22 (s, 9 H, 
C(0)C(CH3)3); 13C NMR (CDC13; 67 MHz) Sc 178.60 (C(0)C(CH3)3), 133.57
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(CH2CH=CH2), 117.51 (CH2CH=CH2), 95.28 (C-l), 73.07, 72.14, 70.44 (C-2, C-3, C-4),
68.39 (CH2CH=CH2), 61.42 (C-5), 38.89 (C(0)C(CH3)3) and 27.08 (C(0)C(CH3)3); MS: 
(FAB) m/z 571.4 [(2M+Na)+, 62%], 549.4 [(2M+H)+, 50 %], 297.2 [(M+Na)+, 28%],
275.3 [(M+H)+, 20%]; Anal. Calcd for Ci3H220 6 C, 56.92; H, 8.08%. Found: C, 56.90;
H, 8.08%:
(2'S,3'S) Allyl 3,4-di-0-(2 ',3,-dimethoxybutane-2,J3,-diyl)-2-0- 
trimethylacetyl-a-D-xylopyranoside (35).
Me9 A solution o f (34) (250 mg, 0.91 mmol)l, trimethyl orthoformate
(0.39 ml, 3.64 mmol) butane-2,3-dione (0.16 mL, 1.8 mmol) and
PivO I
OMe 0AN CSA (20 mg, 0.086 mmol) in methanol (10 mL) was heated under 
reflux for 3 h, when TLC (diethyl ether) indicated consumption of starting material and 
showed the presence of one product. The mixture was cooled to RT and triethylamine (1 
mL) was added.. The mixture was concentrated under reduced pressure and the syrup 
obtained was subjected to flash chromatography on silica using dichloromethane- 
acetone (20:1) as eluent to give the title compound (347 mg, 86%) as an oil.
'H  NMR (400 MHz; CDC13) &  5.90-5.75 (m, 1 H, CH2Ctf=CH2), 5.27 (dd, 1 H, 2J  2.9 
Hz, V  17.2 Hz, CH2CH=CHasH „ „ ) , 5.15 (dd, 1 H, 2J  1.6 Hz, 3J  10.4 Hz, 
CH2CH=C7/mH,ra„), 5.08 (d, 1 H, J ia 3.7 Hz, H -l), 4.70 (dd, 1 H, J2,1 3.7 Hz, J2,i 10.4 
Hz, H-2), 4.19-4.11 (m ,1 H, 0.5 x CH2CH=CH2), 3.94-3.54 (m, 5 H, H-3, H-4, H-5a, 
H-5b, 0.5 x CH2CH=CH2), 3.30 (s, 3 H, OCH}), 3.27 (s, 3 H, OCtf3), 1.29 (s, 3 H, C tf3),
I.20 (s, 3 H, C a n d  1.20 (s, 9 H, C (0)C (C tf3)3); 13C NMR (67 MHz; CDC13) Sc
177.71, (C(0)C(CH3)3), 133.70 (CH2CH=CH2), 117.09 (CH2CH=CH2), 99.82, 99.54 
(BDA OCCH3OCH3), 95.48 (C-l), 70.68, 68.41 (2 x CH), 68.40 (CH2CH=CH2), 67.35 
(CH), 59.58 (C-5), 49.70, 47.65 (2 x OCH3), 38.77 (C(0)C(CH3)3), 27.06 
(C(0)C(CH3)3), and 17.81, 17.55 (2 x CH3); MS: (FAB) m/z 411.2 [(M+Na)+, 55%], 
389.2 [(M+H)+ 64%], m/z calcd for Ci9H310 8, [M+H]+ 388.2097 found 388.2062:
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(2,S,3,S) Allyl 3 ,4-d i-0-(2,,3'-dimethoxybutane-2,,3'-diy|)-a-D- 
xylopyranoside (28).
MeQ A solution o f crude 35 (3 g, 7.7 mmol), NaOH (0.61 g, 15 mmol) in
—'"'C\ methanol (50 ml) was heated under reflux for an hour. The mixture
hoI was cooled to room temperature, solid CO2 was added until the
OMe 0AN
solution was adjusted to pH8 . The solvents were removed under 
reduced pressure and the residue was partitioned between diethyl ether (50 mL) and 
water (30 mL). The aqueous layer was back-extracted with diethyl ether (50 mL) and 
the combined organic fractions were dried (MgS04), filtered and concentrated under 
reduced pressure. The syrup crystallised as fine needles from light petroleum to give the 
title compound (800 mg, 34%, over 2 steps).
mp 94-96 °C; Lit mp 98-99 °C[76]; 'H  NMR (270 MHz; CDC13) <5h 5.92-5.84 (m , 1 H, 
CH2CH=CH2), 5.30 (dd, 1 H, 2J3 .2  Hz, 3J  17.2 Hz, CH2CH=CHcistf,„„ ), 5.22 (dd, 1 H, 
2J  1.5 Hz, V  10.2 Hz, CH2CH=CHc,sHIrOTS), 4.90 (d, 1 H, J U2 3.8 Hz, H -l), 4.05^1.01 (m, 
2 H, CH2CH=CH2), 3.89-3.55 (m, 5 H, H-2, H-3, H-4, H-5a, H-5b) 3.33 (s, 3 H, OCtf3),
3.27 (s, 3 H, OCHy), 1.35 (s, 3 H, CH2), 1.30 (s, 3 H, CH2):
Allyl 3,4-0-isopropylidene-2-0-trimethylacetyl-a-D-xylopyranoside 
(36)
A solution of 34 (5.0 g, 18 mmol) in THF (50 mL) was stirred with
pivo^ p-toluenesulphonic acid (20 mg) and 2-methoxypropene (3.49 mL, 
36 mmol) at RT for 30 min under N2. TLC (ethyl acetate) indicated consumption of 
starting material and showed the presence o f one product. The mixture was diluted with 
diethyl ether (50 mL) and washed with sat. aq. NaHCCh (30 mL). The organic layer was 
dried (MgS04) and filtered, a few drops o f EtsN were added before the organic layer was 
concentrated under reduced pressure. The residue was used directly in the next step 
without purification. A small sample was purified for analysis by flash chromatography 
on silica using diethyl ether-hexane (1:7) as eluent.
[a ]D20 +143 (c 0.4, CHCI3); 'H  NMR (400 MHz; CDCI3) 8H 5.90-5.80 (m, 1 H, 
CH2CH=CH2), 5.29 (d, 1 H, 3J 17.3 Hz, CH2CH=CHcisCHtrans), 5.19 (d, 1 H, 3J 10.2 Hz, 
CHzCHCHcisCH,™,), 5.16 (d, 1 H, J ,,2 3.8 Hz, H -l), 4.82 (dd, 1 H, J2,i 3.8 Hz, J2,3 9.0 
H-2), 4.21-4.16 (m, 1 H, 0.5 x CH2CH=CH2), 3.96-3.90 (m, 3 H, H-3, H-5a, 0.5 x
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CH2CH=CH2), 3.76 (d, 1 H, 3J 10.2 Hz, H-5b), 3.54-3.48 (m, 1 H, H-4), 1.46 (s, 6 H, 2 
x isopropylidene CH3) and 1.23 (s, 9 H, C(0 )C(CH3)3); 13C NMR (100.4 MHz; CDCI3) 
8c 177.96 (C(0)C(CH3)3), 133.50 (CH2CH=CH2), 117.83 (CH2CH=CH2), 110.86 ( 
isopropylidene C(CH3)2), 95.10 (C-l), 75.75 (C-2), 74.12 (C-3), 72.88 (C-4), 68.96 
(CH2CH=CH2), 61.27 (C-5), 38.77 (C(0)C(CH3)3) and 27.10, 26.81, 26.54 (2 x 
isopropylidene CH3, C(0)C(CH3)3); MS: (FAB) m/z 315 [(M+H)+, 49%]; Anal. Calcd 
for C i6H260 6 C, 61.13; H, 8.34%. Found: C, 61.00; H, 8.29%:
Allyl 3,4-O-isopropylidene-a-D-xylopyranoside (37).
A solution of crude 36 (5.72 g, 18.0 mmol) and NaOH (1.46 g,
36 mmol) in MeOH (100 mL) was heated under reflux for 1 h. The
HO I
oaii mixture was cooled to RT and neutralised by careful addition o f solid 
CO2. The solvents were evaporated off under reduced pressure and the residue was 
partitioned between diethyl ether(100 mL) and water (50 mL). The aqueous layer was 
back-extracted with diethyl ether (100 mL) and the combined organic fractions were 
dried (MgS04). A few drops o f EtsN were added before the organic layer was 
concentrated under reduced pressure. The residue was used directly in the next step 
without purification. For analytical purposes, a small sample was purified by flash 
chromatography on silica using diethyl ether-hexane(l:l) as eluent.
[a ]D20 +133 (c 0.4, CHCI3); *H NMR (400 MHz; CDCI3) 8H 5.97-5.87 (m, 1 H, 
CH2CH=CH2), 5.32 (d, 1 H, 3J 17.3 Hz, CHzCH^HcisCHtrans), 5.24 (d, 1 H, 3J 10.2 Hz, 
CH2CH=CHcisCHtrans), 4.95 (d, 1 H, J i,2 3.8 Hz, H -l), 4.28-4.23 (m, 1 H, 0.5 x 
CH2CH=CH2), 4.07-4.02 (m, 1 H, 0.5 x CH2CH=CH2), 3.94 (t, 1 H, J3,4 9.7 Hz, J3)2 4.4 
Hz, H-3), 3.83 (dd, 1 H, J2)i 3.8 Hz, J2)3 4.4 Hz, H-2), 3.74-3.66 (m, 2 H, H-5a, H-5b), 
3.44-3.38 (m, 1 H, H-4), 2.43 (d, 1 H, J 10.8 Hz, 2-OH) and 1.46, 1.45 (2s, 6 H, 2 x 
isopropylidene CH3); 13C NMR (100.4 MHz; CDC13) 8C 133.35 (CH2CH=CH2), 118.07 
(CH2CH=CH2), 110.70 (isopropylidene C(CH3)2), 97.50 (C-l), 79.3 (C-2), 73.6, 71.9 (C- 
4, C-3, C-2), 68.84 (CH2CH=CH2), 61.57 (C-5) and 26.73, 26.40 (2 x isopropylidene 
CH3); MS: (FAB) m/z 231 [(M+H)+, 100%]; Anal. Calcd for for C n H 1805: C, 57.38; H, 
7.94%. Found C, 57.10; H, 7.94%:
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Allyl 2-0-benzyl-3,4-0-isopropylidene-a-D-xylopyranoside (38).
^  solution of crude 37 (4.18 g, 18 mmol) in dry DMF (25 mL) was
b oai i  s^ rre(  ^ a t  0  °c with NaH (760 mg of an 60% w/w dispersion in 
mineral oil, 19 mmol) and benzyl bromide (2.17 mL, 19 mmol) was added slowly under 
N2. The mixture was stirred at RT for 90 min, after which time TLC (diethyl ether- 
hexane 1:2) showed complete consumption o f starting material. Water (25 mL) was 
added carefully and stirring continued for 1 h. The solvents were evaporated under 
reduced pressure and the residue was dissolved in diethyl ether (50 mL). The extract 
was washed with water (25 mL), dried (MgSC>4), filtered and concentrated under reduced 
pressure. The product o f this reaction was used directly in the next step without 
purification. A small sample was purified for analysis by flash chromatography on silica 
using diethyl ether-hexane (1:9) as eluent.
[a ]D20 +30.6 (c 0.5, CHC13); 'H  NMR (400 MHz; CDC13) 6H 7.39-7.24 (m, 5H, ArCH), 
5.96-5.86 (m, 1 H, CH2CH=CH2), 5.34 (d, 1 H, 3J 17.3 Hz, CH2CH=CHcisCHtrans), 5.21 
(d, 1 H, 3J 10.2 Hz, 0.5 x CH2CH=CHcisCHtrans), 4.86-4.83 (m, 2 H, H -l, 0.5 x
OCH2Ar), 4.64 (AB, 1 H, J ab 12.3 Hz, 0.5 x OCH2Ar), 4.20-4.15 (m, 1 H, 0.5 x
CH2CH=CH2), 4.00-3.91 (m, 2 H, H-3, 0.5 x CH2CH=CH2), 3.86 (dd, 1 H, J5a,5b 9.7 Hz, 
J5a,4 4.7 Hz, H-5a), 3.73 (dd, 1 H, J5b,5a9.7 Hz, H-5b), 3.65 (dd, 1 H, J2,, 3.5 Hz, J2,3 10.2 
Hz, H-2), 3.41-3.35 (m, 1 H, H-4) and 1.47, 1.46 (2s, 6 H, 2 x isopropylidene CH3); 13C 
NMR (100.4 MHz; CDCI3) 5C 138.05 (C-l o f benzyl ether ring), 133.69 (CH2CH=CH2), 
128.26, 127.86, 127.62 (ArCH), 117.80 (CH2CH=CH2), 110.54 (isopropylidene 
C(CH3)2), 96.24 (C-l), 77.91, 77.90, 74.10 (C-4, C-3, C-2), 71.8 (OCH2Ar), 68.44 
(CH2CFNCH2), 61.09 (C-5) and 26.82, 26.43 (2 x isopropylidene CH3); MS: (FAB) m/z 
321 [(M+H)+, 14%]; Anal. Calcd for Ci8H24 0 5: C, 67.48; H, 7.55%. Found C, 67.40%; 
H, 7.53%:
Allyl 2-O-benzyl-a-o-xylopyranoside (31)
ho_ —Q A solution of 38 (5.86 g, 18 mmol) in MeOH (25 mL) was stirred with
B^ol 1M  HC1 (2.5 mL) for 30 min. TLC (diethyl ether-hexane 4:1)
OAII
indicated consumption o f starting material. Solid NaHCOs was added 
until the mixture was neutral. The solvents were evaporated off and the residue was 
partitioned between dichloromethane (50 mL) and water (25 mL). The aqueous layer
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was back extracted with dichloromethane (100 mL) and the combined organic layers 
were dried (MgSCU), filtered and concentrated under reduced pressure. The syrup 
obtained was subjected to flash chromatography on silica using diethyl ether-hexane (4:1 
then 1:0) as eluent to give the title compound as a colourless syrup (3.87 g, 76% over the 
previous 4 steps) which slowly crystallised.
mp 46-47 °C (from diisopropyl ether); Lit oil[76]. [o c ]d 20 +115 (c 2.3, CHCI3); Lit [a]o20 
+113 (c 2.3, CHC13)[76]; !H NMR (CDCI3; 270 MHz). Sh 7.36-7.24 (m, 5 H, ArCH), 
5.95-5.81 (m, 1 H, CH2CH=CH2), 5.31 (dd, 1 H, 2J 1.6 Hz, 3J 17.2 Hz, 
CH2CH=CHcisHtrans), 5.18 (dd, 1 H, 2J 1.5 Hz, 3J 10.4 Hz, CHzCHCHdsHtra™), 4.78 (d, 1 
H, J i,2 3.5 Hz, H -l), 4.67, 4.61 (AB, 2 H, J ab 11.9 Hz, ArCH20 ), 4.17-4.06 (m, 1 H, 0.5 
x CH2CH=CH2), 3.92-3.83 (m, 2 H, 0.5 x CH2CH=CH2,H-3), 3.62-3.43 (m, 5 H, H-4, 
H-5 a, H-5b, 2 x OH) and 3.31 (dd, 1 H, J2ji 3.5 Hz, J2j3 9.5 Hz, H-2):
Allyl 2-0-benzyl-3,4-bis-0-(p-methoxybenzyl)-a-D-xylopyranose (32).
A solution o f 31 (4.1 g, 14 mmol) in dry DMF (60 mL) was stirred 
B n o l wilh NaH (1.58 g of an 60% w/w dispersion in mineral oil, 40 mmol)
11 OAII
and />-methoxybenzyl chloride (8.0 mL, 59 mmol) at rt for 3 h. 
Methanol (30 mL) was added and stirring continued for 15 min. The solvents were 
concentrated under reduced pressure and the residue was dissolved in diethyl ether. The 
organic solution was washed with water, dried (MgS04), filtered and concentrated under 
reduced pressure. The residue was subjected to flash chromatography on silica using 
hexane-ethyl acetate (19:1) as eluent to give the title compound as an oil.
'H  NMR (CDCb; 270 MHz) A  7.37-7.22 (m, 9 H, ArCH, 2 x H-2 o f PMB ring, 2 x H -6 
of PMB ring), 6.87-6.83 (m, 4 H, 2 x H-3 o f PMB ring, 2 x H-5 o f PMB ring), 5.97-
5.85 (m, 1 H, CH2CH=CH2), 5.31 (dd, 1 H, 2J 1.5 Hz, 3J 17.2 Hz, CH2CH=CHC]SHlra„s),
5.03 (d, 1 H, 3J 10.3 Hz, CH2CH=CHcisHtrans), 4.84, 4.79 (AB, 2 H, J ab 10.4 Hz, 
ArCH20 ), 4.71 (d, 1 H, J u  3.4 Hz, H -l), 4.77, 4.64 (AB, 2 H, Jab 12.2 Hz, ArCH20 ),
4.68, 4.54 (AB, 2 H, Jab 11.2 Hz, ArCH20 ) , 4.18-4.11 (m , 1 H, 0.5 x CH2CH=CH2), 
4.00-3.96 (m, 1 H, 0.5 x CH2CH=CH2), 3.93-3.86 (m, 1 H, H-3), 3.79 (s, 3 H, OCH3),
3.78 (s, 3 H, OCH3), 3.53-3.49 (m, 3 H, H-4, H-5a, H-5b) and 3.43 (dd, 1 H, J2,i 3.4 Hz, 
J2l3 9.5 Hz, H-2):
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2-0-benzyl-3,4-bis-0-(p-methoxybenzyl)-a-D-xylopyranose (33).
q A solution of allyl 2-0-benzyl-3,4-bis-0-(p-methoxybenzyl)-«-Z)-
PMB0^ V 0h xylopyranoside 32 (6.87 g, 13.2 mmol) in MeOH (60 mL) was 
cooled to 0°C and PdCl2 (0.47 g, 2.64 mmol) was added. The flask was fitted with a 
drying tube, the cooling bath removed and the reaction mixture was stirred vigorously 
for 4 h, after which time TLC (diethyl ether-hexane 3:2) indicated almost complete 
conversion of starting material into a product. The reaction mixture was quenched with 
triethylamine and filtered through a Celite pad. The filtrate was concentrated and the 
dark brown residue was subjected to flash chromatography on silica using diethyl ether- 
hexane (3:2) as eluent to yield the title compound (mixture o f a  and p  anomers) as a 
white solid (5.72 g, 90%).
]H NMR (CDC13; 400 MHz:D20  exchange) 7.34-7.23 (m, 9 H, ArCH), 6.87-6.83 (m, 
4 H, 2 x H-3 of PMB ring, 2 x H-5 of PMB ring), 5.09 (d, 0.5 H, Ji,2 3.7 Hz, H -la ), 
4.89—4.54 (m, 6.5 H, H -ip , 3 x ArCH20 ), 3.82 (s, 3 H, OCH3), 3.80 (s, 3 H, OCH3), 
3.92-3.50 (m, 3.5 H, H-3, H-4a, H-5a, H-5b), 3.45 (dd, 0.5 H, J2a,ia 3.7 Hz, J2a>3a 8.9 
Hz, H-2a) and 3.30-3.21 (m, 1 H, H-2p, H-4P):
1 -0 -[(3 ,S,4,R)-3-(p-methoxybenzyloxy)tetrahydrofuran-4-yl] 2-O- 
benzyl 3,4-di-0-(p-methoxybenzyl)-« and /?-D-xylopyranosides (42 
and 43).
To a stirred mixture o f 33 (2.0 g, 4.6 mmol) and lH-tetrazole
PM B O '
pmbo- ^— I \ (440 mg, 6.25 mmol) in dichloromethane (10 mL) was added
BnO O OPMB
bis(methoxy)(diethylamino)phosphine (0.9 mL, 5.4 mmol). 
After 20 min, TLC (ethyl acetate-toluene 1:4) indicated complete conversion into 
product. The reaction mixture was partitioned between diethyl ether (100 mL) and water 
(75 mL). The resulting ethereal layer was washed with brine (75 mL), dried (MgSCU), 
filtered and concentrated under reduced pressure to give crude 2-0-benzyl-3,4-bis-O-(p- 
methoxybenzyl)-D-xylopyranosyl dimethyl phosphite 39 [63] as a colourless oil (2.38 g), 
which was used without further purification. A solution o f the dimethyl phosphite (2.38 
g), (+)-(3R,4S)-4-/?-methoxybenzyloxy-tetrahydrofuran-3-ol 40 [57] (747 mg, 3.3 mmol) 
and 4 A molecular sieves (3 g) in dioxane-toluene (21 mL:7 mL) was stirred for 2 h 
under N2. Zinc chloride (679 mg, 4.99 mmol) and silver perchlorate (2.04 g, 9.88 mmol) 
were added to the reaction mixture which was stirred in the dark for a further 2 h, TLC
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(toluene-ethyl acetate 4:1) showed consumption o f the starting material. NaHCC>3 (3 g), 
ethyl acetate (100 mL) and water (75 mL) were added to the mixture and it was stirred 
vigorously for a further 30 min. The mixture was filtered through a Celite pad and the 
organic layer was washed with brine (100 mL), dried (MgS04), filtered and concentrated 
under reduced pressure. The oil obtained was subjected to flash chromatography on silica 
using ethyl acetate-hexane (7:3) to give an anomeric mixture of the title compounds 
which could not be separated at this stage (1.60 g, 70%):
1-0 -[(3 ,R,4,S)-3-(p-methoxybenzyloxy)tetrahydrofuran-4-yl] 2-O- 
benzyl 3,4-bis-0-(p-methoxybenzyl)-a ^nd /?-D-xylopyranosides (44 
and 45).
To a stirred mixture of 33 (2.0 g, 4.6 mmol) and 1H-  
tetrazole (440 mg, 6.25 mmol) in dichloromethane (10 mL) 
was added bis(methoxy)(diethylamino)phosphine (0.9 mL,
5.4 mmol). After 20 min, TLC (ethyl acetate-toluene 1:4) 
indicated complete conversion into product. The reaction mixture was partitioned 
between diethyl ether (100 mL) and water (75 mL). The resulting ethereal layer was 
washed with brine (75 mL), dried (MgS04 ), filtered and concentrated under reduced 
pressure to give crude 2-0-benzyl-3,4-bis-0-(p-methoxybenzyl)-d-xylopyranosyl 
dimethyl phosphite as a colourless oil (2.38 g), which was used without further 
purification. A solution o f the dimethyl phosphite (2.38 g), (-)-(3S,4R)-4-/?- 
methoxybenzyloxy-tetrahydrofuran-3-ol (41) [57] (747 mg, 3.3 mmol) and 4 A molecular 
sieves (3 g) in dioxane-toluene (21 mL:7 mL) was stirred for 2 h under N2. Zinc 
chloride (679 mg, 4.99 mmol) and silver perchlorate (2.04 g, 9.88 mmol) were added to 
the reaction mixture which was stirred in the dark for a further 2 h, TLC (toluene-ethyl 
acetate 4:1) showed consumption of the starting material. NaHCC>3 (3 g), ethyl acetate 
(100 mL) and water (75 mL) were added to the mixture and it was stirred vigorously for 
a further 30 min. The mixture was filtered through a Celite pad and the organic layer 
was washed with brine (100 mL), dried (MgS04), filtered and concentrated under 
reduced pressure. The oil obtained was subjected to flash chromatography on silica using 
ethyl acetate-hexane (7:3) to give an anomeric mixture o f the title compounds which 
could not be separated at this stage (1.75 g, 76%):





1-0 -[(3 ,S,4,R)-3-hydroxytetrahydrofuran-4-yl]-2-0-benzyl-a-D- 
xylopyranoside (46) and 1-0-[(3'S,4'R)-3-hydroxytetrahydrofuran-4- 
yl] 2-O-benzyl-^-D-xylopyranoside (47).
n A solution o f the mixture o f 42 and 43 (1.60 g, 2.32 mmol) and 
TFA (2 mL) in dichloromethane (20 mL) was stirred for 20 min, 
B n o 0  0H t l c  (dichloromethane-acetone 10:1) showed consumption of 
starting material. Sat. aq. N aHC03 was added to neutralise the reaction. The mixture 
was extracted with ethyl acetate (4 x 100 mL) and the combined organic extracts were 
dried (MgSCU), filtered and concentrated under reduced pressure. The oil obtained was 
subjected to flash chromatography on silica using ethyl acetate-methanol (20:1) to give a 
mixture o f the title compounds (341 mg, 45%). 46 (261 mg, 35 %) Crystallised from 
ethyl acetate-hexane (261 mg, 34%).
mp 119-120 °C (EtOAc-hexane); [a f° D +87.2 (c 0.5, CHC13); *H NMR (CDC13; 400 
MHz;D20  exchange) Sh 7.37-7.26 (m, 5 H, ArCH), 4.77 (d, 1 H, Ji,2 2.9 Hz, H -l), 4.75, 
4.71 (AB, 2 H, Jab 11.7 Hz, ArCH20 ), 4.26-4.25 (m, 1 H, H-3'), 4.11-4.07 (m, 1 H, H- 
4'), 3.96 (dd, 1 H, J5Vr 5.9 Hz, Js-a.s-b 9.4 Hz, H-5'a), 3.91-3.88 (m, 2 H, H-3, H-2'a), 3.80 
(dd, 1 H, J5-b(4- 4.4 Hz, J5v>'a 9.4 Hz, H-5t>), 3.72-3.68 (m, 1 H, H-2T)), 3.65-3.51 (m, 3 
H, H-4, H-5 a, H-5b) and 3.35 (dd, 1 H, J2j3 8.8 Hz, J2,i 2.9 Hz, H-2); 13C NMR (CDC13; 
100.4 MHz) Sc 137.34 (C-l of benzyl ether ring), 128.92, 128.73, 128.68 (3 x Ar), 98.82 
(C-l), 79.40, 79.00 (2 x CH), 74.59 (CH2), 73.78 (CH), 73.13 (CH2), 71.11 (CH), 71.11 
(ArCH20 ), 70.28 (CH) and 62.41 (C-5); MS: (FAB) m/z 349.2 [(M+Na)+, 22%], 327.2 




benzyl-a-D-xylopyranoside (50) and 
acetoxytetrahydrofuran-4-yl] 3,4-di-0-acetyl-2-0-benzyl-/?-D- 
xylopyranoside (51).
The mixture o f compounds (46, 47) (90 mg, 0.27 mmol) was 
dissolved in acetic anhydride (0.16 mL, 1.65 mmol) and 
pyridine (1 mL) and stirred overnight. The mixture was 
concentrated under reduced pressure from toluene (3 x 10 mL). The products were 
purified by flash chromatography on silica using diethyl ether-hexane (5:2) as eluent to 
give 50 (13 mg, 10%).
[a]20D +63.8 (c 0.19, CHC13); *HNMR (CDCh; 400 MHz) <5k 7.35-7.28 (m, 5 H, 
ArCH), 5.43 (t, 1 H, J 3,2=J3,4 9.7 Hz, H-3), 5.28-5.25 (m, 1 H, H-3'), 4.92 (d, 1 H, J ,,2 3.2 
Hz, H -l), 4.90-4.84 (m, 1 H, H-4), 4.68, 4.51 (AB, 2 H, Jab 12.3 Hz, ArCH20 ), 4 .35-
4.30 (m, 1 H, H-4’), 4.06 (dd, 1 H, J ? 5.8 Hz, J 2.a,2V 9.9 Hz, H-2 ’a), 3.97 (dd, 1 H, J5X4‘
6.1 Hz, J 5.a,5n, 9.1 Hz, H-5'a), 3.90-3.81 (m, 2 H, H-2'b, H-51)) 3.75 (dd, 1 H, J 5a,4 5.9 Hz, 
J 5a,5b 10.8 Hz, H-5a), 3.54 (t, 1 H, J 5b,4=J5b.5a 10.8 Hz, H-5b), 3.46(dd, 1 H, J 23 9.7 Hz, 
J 2jl 3.2 Hz, H-2), 2.02 (s, 3 H, CH3CO), 1.99 (s, 3 H, CH3CO) and 1.91 (s, 3 H, CH3CO); 
13C NMR (CDCI3; 100.4 MHz) 5c 171.07, 170.22 (3 x OCOCH3), 137.99 (C-l o f benzyl 
ether ring), 128.58, 128.03, 127.87 (3 x Ar), 97.49 (C-l), 77.17, 76.13 (2 x CH), 73.28,
71.34, 71.18 (2 x CH2, 2 x ArCH20 ), 70.93, 70.77, 69.72 (3 x CH), 59.38 (C-5), 21.36,
21.20,21.09 (3 x CH3CO); MS: (FAB) m/z 475.2 [(M+Na)+, 15%]:
Further elution gave 51 (81 mg, 65%) w hich crystallised from diethyl ether-hexane. 
mp 108-110 °C; [a]20D-21.9 (c 0.91, CHC13); ‘H NMR(CDC13; 400 MHz) 8.02-7.25 
(m, 5 H, ArCH), 5.26-5.22 (m, 1 H, H-3’), 5.14 (t, 1 H, J 3,2=J3,4 9.4 Hz, H-3), 4.92-4.85 
(m, 1 H, H-4), 4.80,4.61 (AB, 2 H, J ab 12.3 Hz, ArCH20 ), 4.50-4.44 (m, 2 H, H -l, H- 
4’), 4.09-3.99 (m, 3 H, H-5a, H-2’a, H-5’a), 3.88-3.84 (m, 2 H, H-2Tj, H-5'b), 3.40 (dd, 1 
H, J 2,3 9.4 Hz, J 2,1 7.0 Hz, H-2), 3.28 (dd, 1 H, J 5b,4 9.4 Hz, J 5b,5a 11.7 Hz, H-5b), 2.11 (s, 
3 H, CH3CO), 2.01 (s, 3 H, CH3CO) and 1.95 (s, 3 H, CH3CO); 13C NMR (CDC13; 100.4 
MHz) 5c 170.06, 169.75, 169.66 (3 x OCOCH3), 137.40 (C-l o f benzyl ether ring), 
128.17, 127.76, 127.56 (3 x Ar), 102.96 (C -l), 78.07, 77.05 (2 x CH), 74.22 (CH2), 
72.54, 72.06 (2 x CH), 70.18, 70.06 (2 x ArCH20 ), 69.10 (CH), 62.44 (C-5), 20.97, 
20.76, 20.73 (3 x CH3CO); MS: (FAB) m/z 475.1 [(M+Na)+, 10%], 451.1 [(M+H)+, 
9%], m/z calcd for C22H28Oi0, [M+H]+ 453.1760 found 453.1729:
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1 -0 -[(3 ,S,4,R)-3-hydroxytetrahydrofuran-4-yl] 2-0-benzyl-(3-d- 
xylopyranoside (47).
A j  A solution o f 51 (50 mg, 0.11 mmol) and concentrated ammonia 
(0.75 mL) in methanol (4 mL) was stirred at rt overnight. The 
mixture was concentrated under reduced pressure from
BnO r
dichloromethane (3 x 10 mL). The products were purified by flash chromatography on 
silica using ethyl acetate-methanol (20:1) as eluent to give (30 mg, 83%).
[a f°D +8.33 (c 0.6, CHCI3); 'H  NMR (CDCI3; 400 MHz) 5k 7.34-7.26 (m, 5 H, ArCH), 
4.85, 4.65 (AB, 2 H, Jab 11.4 Hz, ArCH20 ), 4.45 (d, 1 H, J xa 7.0 Hz, H -l), 4.25-4.19 
(m, 2 H, H-4', H-3'), 3.98-3.94 (m, 3 H, H-5a, H-2'a, H-5'a), 3.80-3.77 (m, 2 H, H-2b, 
H-5'b), 3.63-3.62 (m, 1 H, H-4), 3.52-3.45 (m, 1 H, H-3), 3.30-3.23 (m, 4 H, H-2, H-5b,
2 x OH) and 3.18 (broad s, 1H, OH); 13C NMR (CDC13; 100.4 MHz) 5c 137.96 (C-l of 
benzyl ether ring), 128.84, 128.36, 128.22 (Ar), 104.02 (C-l), 81.43, 80.63 and 75.75 (3 
x CH), 74.96, 73.29 (CH2), 71.04 (CH), 70.19 (ArCH20 ), 69.51 (CH) and 65.60 (C-5); 
MS: (FAB) m/z 349.1 [(M+Na)+, 18%], 327.1 [(M+H)+, 20%], m/z calcd for Ci6H220 7, 
[M+H]+327.1443 found 327.1455:
1 -0-[(3'R,4'S)-3-hydroxytetrahydrofuran-4-yl] 2-O-benzyl-a-o- 
xylopyranoside (48) and 1-0-[(3'R,4'S)-3-hydroxytetrahydrofuran-4- 
yl] 2-0-benzyl-/j-D-xylopyranoside (49).
h o —^ A solution of the mixture o f 44 and 45 (1.75 g, 2.50 mmol) and
H 0  _ V ^ Q  p U I  -TVT-. A / f \  T  \  ---------------------^1--------------- t \  T  \    ™
Q
consumption o f starting material. Sat. aq. NaHCOs was added to neutralise the reaction.
Bno °\ /0H TFA (2 mL) in dichloromethane (20 mL) was stirred for 20
min, TLC (dichloromethane-acetone 10:1) showed
The mixture was extracted with ethyl acetate (4 x 100 mL) and the combined organic 
extracts were dried (MgS04), filtered and concentrated under reduced pressure. The oil 
obtained was subjected to flash chromatography on silica using ethyl acetate-methanol 
(20:1) to give the title compound 48 which was crystallised from ethyl acetate-hexane 
(145 mg, 18%).
mp 144-145 °C; [a ]20D +132 (c 0.2, CDC13); ‘H NMR (CDC13; 400 MHz) 5k 7.35-7.25 
(m, 5 H, ArCH), 4.74 (d, 1 H, A ,2 3.5 Hz, H -l), 4.66, 4.57 (AB, 2 H, Jab 11.4 Hz, 
ArCH20 ), 4.25-4.22 (m, 1 H, H-3'), 4.16-4.12 (m, 1 H, H-4'), 3.99-3.89 (m, 2 H, H-3, 
H-5'a), 3.85 (dd, 1 H, J1%s 5.6 Hz, J2Va 9.4 Hz, H-2'a), 3.76-3.72 (m, 2 H, H-2b, H- 
5b), 3.63-3.46 (m, 3 H, H-4, H-5a, H-5b) and 3.33 (dd, 1 H, J 2.3 9.4 Hz, J2,i 3.5 Hz, H-
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2); 13C NMR (CDCI3; 67 MHz) <5fc 137.28 (C-l o f benzyl ether ring), 128.63, 128.43 
(ArCH), 95.08 (C-l), 79.44, 76.53 (2 x CH), 74.79 (CH2), 73.49 (CH), 72.57 (CH2), 
71.40, 69.63 (2 x CH), 68.89 (ArCH20 )  and 61.85 (C-5); MS: (FAB) m/z 349.2 
[(M+Na)+, 30%], 327.2 [(M+H)+, 28%]; Anal. Calcd for Ci6H2207  C, 58.88; H, 6.79%. 
Found: C, 58.70; H, 6.79%:
Further elution gave compound 49 which was crystallised from EtOAc-hexane (155 mg, 
19%);
mp 166-167 °C; [a]20D -28.3 (c 0.4, MeOH); 'H N M R  (CD3OD; 400 MHz) (5k 7.43-
7.27 (m, 5 H, ArCH), 4.95, 4.81 (AB, 2 H, Tab 11.1 Hz, ArCH20 ), 4.55 (d, 1 H, J u  7.6 
Hz, H -l), 4.31-4.23 (m, 2 H, H-2'a and H-5'a), 3.98-3.94 (m, 1 H, H-3' or H-4'), 3.90-
3.86 (m, 2 H, H-3, H-2b or H-5'b), 3.80-3.76 (m, 1 H, H-3’ or H-4'), 3.63 (dd, 1 H, J 4.1 
Hz, Jgem 9.1 Hz, H -2b or H-5b), 3.57-3.46 (m, 2 H, H-4, H-5a) and 3.30-3.21 (m, 2 H, 
H-2, H-5b); 13C NMR (CDC13; 67 MHz) Sc 140.21 (C-l o f benzyl ether ring), 129.70, 
129.54 and 128.96 (Ar), 105.10 (C-l), 83.02, 80.18, 78.02 (3 x CH), 75.98, 73.66 (2 x 
CH2), 72.23 (ArCH20 ), 72.13, 71.60 (2 x CH) and 67.17 (C-5); MS: (FAB) m/z 349.2 
[(M+Na)+, 24%], 327.2 [(M+H)+, 28%]; Anal. Calcd for Ci6H220 7 requires C, 58.88; H, 
6.79%. Found: C, 58.50; H, 6.80%:
1 -0-[(3'S,4'R)-3-hydroxytetrahydrofuran-4-yl] 2-O-benzyl-a-o- 
xylopyranoside 3,4,3'-tris(dibenzylphosphate) (52).
.0. A mixture o f bis(benzyloxy)(diisopropylamino)
(OBn)2(0 )P O ^V ---- {  J
(0Bn)2(0)P0- ^ ^ ^ i p h o s p h i n e  (518 mg, 1.50 mmol), l//-tetrazole (158
BnO 1/ OP(0)(OBn)2
0 mg, 2.25 mmol) and dry dichloromethane (5 mL) was
vigorously stirred at rt for 30 min under N2, whereupon triol 46 (83 mg, 0.25 mmol) was 
added and stirring was continued for 30 min. The mixture was cooled to -78  °C and 
mCPBA (863 mg, 60%, 3.0 mmol) was added. The mixture was stirred at rt for 10 min 
and was diluted with dichloromethane (50 mL). The solution was washed successively 
with 10% (w/v) aq. Na2SC>3, sat. aq. NaHCOs (25 mL) and brine (25 mL), dried 
(MgSC>4), filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica using ethyl acetate-hexane (8 :2) as eluent to give the title 
compound as an oil (279 mg, 99%).
[a f°D +0.3 (c 1.9, CHCI3); *H NMR (CDC13; 400 MHz) Sh 7.39-7.04 (m, 35 H, ArCH), 
5.06-4.66 (m, 16 H, H -l, H-3, H-3', 6.5 x ArCH20), 4.47^1.31 (m, 2 H, H-4, 0.5 x
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AiCH20 ), 4.12-4.08 (m, 1 H, H-4’), 3.96-3.84 (m, 4 H, H-5a, H-5b, H-2'a, H-5'a), 3.79 
(dd, 1 H, J 5-b,4.5.3 Hz, J5T,,5'a 9.4 Hz, H-5t>) and 3.49-3.43 (m, 2 H, H-2, H-2%); 13C 
NMR (CDC13; 67 MHz) <5fc 137.59 (C-l o f benzyl ether ring), 136.02-135.50 (C-l of 
benzyl ester rings), 128.50, 128.50, 128.48, 128.41, 128.61, 128.22, 128.13, 128.06, 
127.94, 127.88, 127.71, 127.60, 127.49 (ArCH), 95.68 (C-l), 77.09, 75.35, 75.26, 74.03 
and 73.93 (5 x CH), 71.97, 69.99 (2 x CH2), 68.91- 69.71 (ArCH20 )  and 59.69 (C-5); 
31P NMR (CDC13; 162 MHz). S? -0.70, -0 .62 and 0.11; MS: (FAB) m/z 1128.9
[(M+Na)+, 60%], 1107.0 [(M+H)+, 98%], m/z calcd for C58H6i0 16P3 [M+H]+ 1107.3250 
found m/z 1107.3233:
1 -O-KS'S^'RJ-S-hydroxytetrahydrofuran^-yl] 2-0-benzyl-/?-D- 
xylopyranoside 3,4,3'-tris(dibenzylphosphate) (53).
A mixture o f bis(benzyloxy)(diisopropylamino)
o
\  j  phosphine (191 mg, 0.55 mmol), 1/7-tetrazole (58
(0Bn)2(0)P0—v '9. o op(OHOBn), mg5 0.83 mmol) and dry dichloromethane (5 mL)
Bno was vigorously stirred at rt for 30 min under N2,
whereupon triol 47 (30 mg, 0.09 mmol) was added and stirring was continued for 30 
min. The mixture was cooled to -78 °C and mCPBA (317 mg, 60%, 1.1 mmol) was 
added. The mixture was stirred at RT for 10 min, then was diluted with dichloromethane 
(50 mL). The solution was washed successively with 10% (w/v) aq. Na2SC>3, sat. aq. 
NaHCCb (25 mL) and brine (25 mL), dried (MgSCU), filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica using 
ethyl acetate-hexane (8:2) as eluent to give the title compound as an oil (89 mg, 87%). 
[ a f \  -10.4 (c 1.4, CHC13); ‘H N M R  (CDC13; 400 MHz) <5h 7.34-7.02 (m, 35 H, 
ArCH), 5.14-4.75 (m, 14 H, H-3’, 6.5 x A rC //20 ), 4.58^1.49 (m, 2 H, H-3, 0.5 x 
A1CH2O), 4.39 (d, 1 H, J ,,2 7.0 Hz, H -l), 4.35^1.31 (m, 1 H, H-4’), 4.30-4.23 (m, 1 H, 
H-4), 4.19 (m, 1 H, H-5a), 3.93-3.85 (m, 3 H, H-5'a, H-2'a, H-2'b), 3.74 (dd, 1 H, 4.
6.5 Hz, H-5'b) and 3.28-3.23 (m, 2 H, H-2, H-5b); 13C NMR (CDC13; 100.4 MHz) 
137.89 (C-l o f benzyl ether ring), 136.64-135.12 (C-l o f benzyl ester ring), 128.83,
128.80, 128.75, 128.61, 128.59, 128.46, 128.23, 128.21, 128.12, 128.03, 127.97, 127.91,
127.81 (Ar), 103.09 (C-l), 79.55, 79.26, (2 x CH), 76.40 (CH2), 74.58, 73.86, 71.36 (3 x 
CH), 70.10 (CH2), 68.87-70.04 (7 x ArCH20 )  and 63.42 (C-5); 31P NMR (CDC13; 162
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MHz) Sp -0.76, -0.60 and -0.43; MS: (FAB) m/z 1129.1 [(M+Na)+, 60%], 1107.2 
[(M+H)+, 83%], m/z calcd for C58H610 i6P3 [M+H]+ 1107.3238 found m/z 1107.3238:
1 -0-[(3'R,4'S)-3-hydroxytetrahydrofuran-4-yl] 2-O-benzyl-a-o- 
xylopyranoside 3,4,3,-tris(dibenzylphosphate)(54).
(0Bn)2(0)P0^ v ^ °  A mixture o f bis(benzyloxy)(diisopropylamino)
(0Bn)2(0)P0- ^ - ^ A  phosphine (539 mg, 1.56 mmol), 177-tetrazole (164
°\ /0P0(0Bn)2 mg? 2.34 mmol) and dry dichloromethane (5 mL) was
o vigorously stirred at rt for 30 min under N2,
whereupon trio! 48 (85 mg, 0.26 mmol) was added and stirring was continued for 30 
min. The mixture was cooled to -78 °C and mCPBA (898 mg, 60%, 3.12 mmol) was 
added. The mixture was stirred at rt for 10 min, then was diluted with dichloromethane 
(50 mL). The solution was washed successively with 10% (w/v) aq. Na2SC>3, sat. aq. 
NaHCC>3 (25 mL) and brine (25 mL), dried (MgSOzi), filtered and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica using 
ethyl acetate-hexane (8:2) as eluent to give the title compound as an oil (210 mg, 73%). 
[a] 20D +9.4 (c 0.3, CHCI3); *H NMR (CDC13; 400 MHz) Sh 7.40-7.13 (m, 35 H, AiCH), 
5.16-4.87 (m, 13 H, H -l, 6 x ArCH20 ), 4.82^1.77 (m, 1 H, H-3'), 4.69-4.66 (m, 2 H, H- 
3, 0.5 x A rC//20), 4.49-4.40 (m, 2 H, H-4, 0.5 x A rC//20 ), 4 .1 8 ^ .1 0  (m, 1 H, H-2'a), 
4.03-3.92 (m, 2 H, H-5a, H-5b), 3.91-3.85 (m, 3 H, H-2T), H-4', H-5'a), 3.74 (dd, 1 H, 
Jyb ,4' 6.3 Hz, Jyb 5-a 9.1 Hz, H ^ T d )  and 3.51 (dd, 1 H, J2,i 3.5 Hz, J2,3 9.7 Hz, H-2); 13C 
NMR (CDCI3; 100.4 MHz) Sc 137.80 (C-l o f benzyl ether ring), 136.13-134.49 (6 x C- 
1 o f benzyl ester rings), 132.95, 130.17, 128.72, 128.70, 128.63, 128.55, 128.43, 128.36, 
128.29, 128.22, 128.16, 128.01, 127.83 (Ar), 96.90 (C-l), 78.53, 77.99, 76.32, 76.26, 
75.92 (5 x CH), 74.14, 73.87 (CH2) 70.79-70.79 (OCH2Ar) and 60.33 (C-5); 31P NMR 
(CDCI3; 109 MHz)<5jj -0.55, -0.80 and -0.95; MS: (FAB) m/z 1129.3 [(M+Na)+, 60%],
1107.3 [(M+H)+, 80%], m/z calcd for CsgHeiOiePs (M +l)+ 1107.3250 found m/z 
1107.3252:
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1 -0 -[(3 ,R,4,S)-3-hydroxytetrahydrofuran-4-yl] 2-0-benzyl-/?-D- 
xylopyranoside 3,4,3,-tris(dibenzylphosphate) (55).
A mixture o f bis(benzyloxy)(diisopropylamino)
(0Bn)2(0 )P 0 — V " " " ' '  'v
(OBnfecojpo-^^ , ( n phosphine (260 mg, 0.75 mmol), liT-tetrazole (79
^  mg, 1.13 mmol) and dry dichloromethane (5 mL)
was vigorously stirred at rt for 30 min under N2, whereupon triol 49 (40 mg, 0.13 mmol) 
was added and stirring was continued for 30 min. The mixture was cooled to -78  °C and 
wCPBA (260 mg, 60%, 1.5 mmol) was added. The mixture was stirred at rt for 10 min, 
then was diluted with dichloromethane (50 mL). The solution was washed successively 
with 10% (w/v) aq. Na2SC>3, sat. aq. NaHCC>3 (25 mL) and brine (25 mL), dried 
(MgSCU), filtered and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica using ethyl acetate-hexane (8 :2) as eluent to give the title 
compound as an oil (107 mg, 79%).
[a]20D -10.8 (c 1.2, CHCI3); ‘H N M R (CDC13; 400 MHz) Sa 7.37-7.04 (m, 35 H, 
ArC//), 5.02—4.71 (m, 14 H, H-3\ 6.5 x ArCtf20 ), 4.61-4.52 (m, 3 H, H -l, H-3, 0.5 x 
ArC7/20 ), 4.37-4.29 (m, 1 H, H-4), 4.23 (dd, 1 H, J2^ 5 3 ,  10.2, H-2'a), 4.10 (dd,
1 H, J5aA 5.3, J 5a,5b 12.0, H-5a), 3.97-3.89 (m, 2 H, H-4', H-5'a), 3.82-3.78 (m, 2 H, H- 
2 \  H^T)), 3.40-3.36 (m, 1 H, H-2) and 3.14 (dd, 1 H, J5b)4 9.4, J5b,5a 12.0, H-5b); 13C 
NMR (CDC13; 100.4 MHz) Sc 138.11 (C-l of benzyl ether ring), 136.13-135.71 (6 x C- 
1 o f benzyl ester ring), 128.88, 128.82, 128.80, 128.75, 128.61, 128.56, 128.44, 128.41,
128.34, 128.32, 128.25, 128.22, 128.20, 128.05, 128.00, 127.89, 127.59 (ArCH), 102.86 
(C-l), 79.20, 79.10 (2 x CH2), 76.32, 76.26, 75.58, 75.54 and 74.29 (5 x CH), 73.79-
69.43 (7 x ArCH20 )  and 62.89 (C-5); 31P NMR (CDC13; 162 MHz) Sp -0.25, -0.83 and -  
1.07; MS: (FAB) m/z 1129.4 [(M+Na)+, 42%], 1107.4 [(M+H)+, 80%], m/z calcd for 
C58H6iO i6P3 [M+H]+ 1107.3250 found m/z 1107.3232:
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1 -0 -[(3 ,S,4,R)-3-hydroxytetrahydrofuran-4-yl] a-D-xylopyranoside 
3,4,3'-trisphosphate (23).
10% Palladium on activated charcoal (200 mg) was added to a 
°23.1 solution of compound 52 (94 mg, 0.084 mmol) in methanol
an atmosphere o f hydrogen at 50 psi at rt for 24 h. The suspension was filtered and 
washed well with de-ionised water. The combined filtrate was concentrated to a glassy 
clear solid. The residue was dissolved in de-ionised water (300 mL) and purified by ion 
exchange chromatography on Q Sepharose Fast flow resin, eluting with a gradient of 
TEAB buffer (0-1 M), pH 8 . The triethylammonium salt o f 8 eluted between 68% and 
82%. Fractions containing the title compound, as judged by phosphate assay, were 
combined and evaporated to give a residue from which methanol (3 x 100 mL) was 
evaporated under reduced pressure to give the title trisphosphate as its triethylammonium 
salt (0.071 mmol, 85%).
[a]20D +30.2 (c 1.3, MeOH); *H NMR (D20 ; 400 MHz) <3k 4.99 (d, 1 H, Ji)2 3.5 Hz, H-
NMR (D20 ; 162 MHz) Sp 1.05 and 0.89 (2P); MS: (FAB) m/z 475.1 [(M-H)“, 100 %], 
m/z calcd for C9H 18Oi6P3 [M-H]“ 474.9807 found m/z 474.9801:
1 -0 -[(3 ,S,4,R)-3-hydroxytetrahydrofuran-4-yl] /?-D-xylopyranoside 
3,4,3'-trisphosphate (24).
n 10% Palladium on activated charcoal (200 mg) was added 
to a solution of compound 53 (72 mg, 0.064 mmol) in
24 h. The suspension was filtered and washed well with de-ionised water. The 
combined filtrate was concentrated to a glassy clear solid. The residue was dissolved in 
de-ionised water (300 mL) and purified by ion exchange chromatography on Q 
Sepharose Fast flow resin, eluting with a gradient o f TEAB buffer (0-1 M), pH 8 . The 
triethylammonium salt o f 8 eluted between 68% and 82%. Fractions containing the title 
compound, as judged by phosphate assay, were combined and evaporated to give a
o OP°32 (20 mL) and water (5 mL) and the mixture was shaken under
1), 4.61-4.58 (m, 1 H, H-3'), 4.29^1.25 (m, 1 H, H-4’), 4.22-4.14 (m, 1 H, H-3), 3.97- 
3.91 (m, 1 H, H-4), 3.90-3.82 (m, 2 H, H-2'a, H-5'a), 3.75-3.67 (m, 3 H, H-2T>, H ^ t) , 
H-5a), 3.58 (dd, 1 H, J2,i 3.5 Hz, J2)3 8.8 Hz, H-2) and 3.52-3.45 (m, 1H, H-5b); 31P
methanol (20 mL) and water (5 mL) and the mixture was 
shaken under an atmosphere o f hydrogen at 50 psi at rt for
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residue from which methanol (3 x 100 mL) was evaporated under reduced pressure to 
give the title trisphosphate as its triethylammonium salt (0.049 mmol, 77%).
[ a f° D -17.7 (c 1.2, MeOH); ]H NMR (CD3OD; 400 MHz) <5J, 4.60-4.54 (m, 1 H, H-3'),
4.42-4.37 (m, 2 H, H -l, H-4'), 3.97-3.92 (m, 3 H, H-5a, H-5b, H-3), 3.88-3.83 (m, 2 H, 
H-2'a, H-5'a), 3.73-3.69 (m, 2 H, H-2b, H-5'b), 3.38-3.34 (m, 1 H, H-2) and 3.31-3.23 
(m, 1 H, H-4); 31P NMR (CD3OD; 162 MHz) <$> 0.81, 1.05, 1.20; MS: (FAB) m/z 475.1 
[(M-H)“, 100%], m/z calcdforC 9H 180 16P3 [M -H]“ 474.9807 found m/z 474.9801:
1 -0-[(3'R,4'S)-3-hydroxytetrahydrofuran-4-yl] a-o-xylopyranoside 
3,4,3'-trisphosphate (25).
10% Palladium on activated charcoal (200 mg) was added to 
a solution o f compound 54 (110 mg, 0.099 mmol) in 
o p o 32' methanol (20 mL) and water (5 mL) and the mixture was
K y  shaken under an atmosphere of hydrogen at 50 psi at rt for 24 
o
h. The suspension was filtered and washed well with de­
ionised water. The combined filtrate was concentrated to a glassy clear solid. The 
residue was dissolved in de-ionised water (300 mL) and purified by ion exchange 
chromatography on Q Sepharose Fast flow resin, eluting with a gradient of TEAB buffer 
(0-1 M), pH 8 . The triethylammonium salt o f 8 eluted between 68% and 82%. 
Fractions containing the title compound, as judged by phosphate assay, were combined 
and evaporated to give a residue from which methanol (3 x 100 mL) was evaporated 
under reduced pressure to give the title trisphosphate as its triethylammonium salt (0.641 
mmol, 65%).
[af°D  +40.8 (c 1.5, MeOH); ‘H NMR (D20 ; 270 MHz) <Sh 4.79 (d, 1 H, J 1>2 3.7 Hz, H- 
1), 4.57-4.53 (m, 1 H, H-3'), 4.23^1.10 (m, 2 H, H-3, H-4'), 3.95-3.63 (m, 7 H, H-4, H- 
5a, H-5b, H-5'a, H-5b, H-2'a, H-2b) and 3.50 (dd, 1 H, J ,,2 3.7 Hz, J2,% 9.2 Hz, H-2); 31P 
NMR (D20 ; 109 MHz) ^  0.34 and 0.80 (2P); MS: (FAB) m/z m/z 475.1 [(M-H)“, 100 
%], calcd for C9H i80i6P3 [M-H]“ 474.9807 found m/z 474.9802:
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1 -0 -[(3 ,R l4 ,S)-3-hydroxytetrahydrofuran-4-yl] /?-D-xylopyranoside 
3,4,3-trisphosphate (26).
10% Palladium on activated charcoal (200 mg) was
2-
added to a solution o f compound 55 (94 mg, 0.084 mmol) 
in methanol (20 mL) and water (5 mL) and the mixture 
was shaken under an atmosphere o f hydrogen at 50 psi at rt for 24 h. The suspension 
was filtered and washed well with de-ionised water. The combined filtrate was 
concentrated to a glassy clear solid. The residue was dissolved in de-ionised water (300
mL) and purified by ion exchange chromatography on Q Sepharose Fast flow resin,
eluting with a gradient o f TEAB buffer (0-1 M), pH 8 . The triethylammonium salt o f 8 
eluted between 68% and 82%. Fractions containing the title compound, as judged by 
phosphate assay, were combined and evaporated to give a residue from which methanol 
(3 x 100 mL) was evaporated under reduced pressure to give the title trisphosphate as its 
triethylammonium salt (0.071 mmol, 85%).
[ > ] 20d  -21.1 (c 0.52, MeOH); ‘H NMR (CD3OD; 400 MHz) <5k 4.81—4.78 ( m ,  1 H, H- 
3'), 4.54 (d, 1 H, J u2 7.6 Hz, H -l), 4.45^1.40 (m, 1 H, H-4'). 4.30-4.19 (m, 1 H, H-2'a),
4.08-4.06 (m, 1 H, H-3), 3.98-3.92 (m, 1 H, H-5’a), 3.86 (dd, 1 H, J2\ y  3.5, / 2v «  9.6, 
H-2t>), 3.73 (dd, 1 H, J5%* 6.2, Js„& 8 .8 , H-5'b), 3.44-3.34 (m, 2 H, H-2, H-4) and
3.08-3.01 (m, 3 H, H-5a, H-5b, OH); 31P NMR (CD3OD; 162 MHz) S? 0.71, 1.32 and 
1.47; MS: (FAB) m/z 950.9 [(2M-H)-, 68%], 475.1 [(M-H)~, 100 %], m/z calcd for 
C9H 18O 16P3 [M-H]“ 474.9807 found m/z 474.9815:
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7.5 Synthesis of adenophostin and analogues
7.5.1 Synthesis of disaccharide 
Ethyl 2,3,4,6-tetra-0-acetyl-1-thio-a-z>glucopyranoside (57a) and 
Ethyl 2,3,4,6-tetra-0-acetyl-1-thio-/?-D-glucopyranoside (57).
Sugar (10.0 g, 26 mmol) was dissolved in chloroform (200 mL) and
Q A C
S  cooled to 0 °C, ethanethiol (2.1 mL, 28 mmol) followed by
BF3.(C2Hs)20  (16.3 mL, 128 mmol) was added slowly. The icebath
AcO
+  o a c  was allowed to heat up and the mixture was stirred for 2 h. The
AcO— react ion mixture was washed with H2O (100 mL), satd aq NaHCC>3 
A c 0 SEt x 100 mL), dried (MgSCLi), filtered and concentrated under
reduced pressure. Purified by flash chromatography on silica using diethyl ether-hexane 
(1:1) as eluent to give 57a (150 mg, 1.5%), which was then crystallised from ethanol, 
m.p. 94-96 °C; Lit m.p 91-93 °C[109]; NMR (400 MHz; CDC13) <5h 5.69 (d, 1 H, J ia
5.9 Hz, H -l), 5.36 (t, 1 H, J3>2=J3A 9.8 Hz, H-3), 5.07-5.02 (m, 2 H, H-2, H-4), 4.46-
4.42 (m, 1 H, H-5), 4.30 (dd, 1 H, J 6&>5 4.7 Hz, J6&,6b 12.5 Hz, H-6a), 4.08 (dd, 1 H, J6b,5
2.1 Hz, J6bj6a  12.5 Hz, H-6b), 2.63-2.50 (m, 2 H, SCtf2CH3), 2.09 (s, 3 H, C //3CO), 2.07 
(s, 3 H, C //3CO), 2.04 (s, 3 H, C //3CO), 2.02 (s, 3 H, CH3CO) and 1.27 (t, J  7.4 Hz, 
SCH2C7/3):
Further elution gave 57 (9.5 g, 94%) which was crystallised from ethanol. 
m.p.80-82 °C; Lit m.p 82-83 °C; *H NMR (270 MHz; CDC13) <5h 5.23 (t, 1 H, J3A=3,2 9.3 
Hz, H-3), 5.12-5.0 (m, 2 H, H-2, H-4), 4.50 (d, 1 H, J x,2 9.9 Hz, H -l), 4.25 (dd, 1 H, J6a,5
4.9 Hz, J6a)6b 12.5 Hz, H-6a), 4.13 (dd, 1 H, J6b>5 2.4 Hz, J6b)6a 12.5 Hz, H-6b), 3.74-3.68 
(m, 1 H, H-5), 2.78-2.64 (m, 2 H, S C //2CH3), 2.08 (s, 3 H, CH3CO), 2.06 (s, 3 H, 
C//3CO), 2.03 (s, 3 H, C//3CO), 2.01 (s, 3 H, CH3CO) andl.27 (t, 3 H, J  7.5 Hz, 
SCH2CF/3):
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(2'S,3'S) Ethyl 3,4-di-0-(2,J3'-dimethoxybutane-2,,3'-diyl)-1 -\h\o-J3-D- 
glucopyranoside (59).
pressure. It was purified by flash chromatography on silica using diethyl ether-hexane 
(1:1) as eluent which gave the title compound and its regioisomer as white foams. 59
3 H, CH3\  1.17 (t, 3 H, J 1 3  Hz, SCH2Ctf3):
Further elution gave 2,3 (1.6 g, 37%):
(2'S,3'S) Ethyl 2,6-di-O- benzyl 3 ,4-d i-0-(2,,3,-dimethoxybutane-2,J3'- 
diyl)-1 -thio-/?-D-glucopyranoside (61).
to RT and stirred for 3 h. The excess sodium hydride was destroyed with methanol (10 
mL); and the reaction mixture was diluted with diethyl ether (100 mL) and H20  (100 
mL). The aqueous phase was extracted with diethyl ether and the organic extracts were 
washed with H20 , dried (MgSCU), filtered and concentrated under reduced pressure. The 
compound was purified by crystallisation from hexane to yield the title compound (970 
mg, 91%).
87-89 °C; Lit (white solid) !H NMR (400 MHz; CDC13) <5h 7.52-7.20 (m, 10 H, ArC/7), 
4.83 (AB, 2 H, JAB 10.5 Hz, AiCH2), 4.58 (AB, 2 H, JAB 12.1 Hz, AiCH2), 4.46 (d, 1 H, 
J x>2 9.8 Hz, H -l), 3.86 (t, 1 H, J 3)2=J3)4 9.4 Hz, H-3), 3.78-3.59 (m, 4 H, H-4, H-5, H-6a,
OM e
+
57 (5.0 g, 12.7 mmol) was deacetylated with NaOMe (35 mg, 
0.64 mmol) in methanol (30 mL). When TLC (ethyl acetate) 
showed complete conversion o f SM the reaction was neutralised 
with Dowex® 50WX4-50 ion-exchange resin and filtered.
O M e
SEt Trimethyl orthoformate, butane-2,3-dione and CSA were added 
and the mixture was heated until reflux. After 6 h, Et3N was 
added and the mixture was concentrated under reduced
(1.35 g, 31.3%)
'H  NMR (400 MHz; CDCI3) &  4.29 (d, 1 H, J u  9.5 Hz, H -l), 3.75 (dd, 1 H, J 6a,5 2.6 
Hz, J6a,6b 12.1 Hz, H-6a), 6.63-3.41 (in, 5 H, H-2, H-3, H-4, H-5, H-6b), 3.19 (s, 3H, 
OCH}), 3.13 (s, 3 H, OCHi), 2.65-2.59 (m, 2 H, SC7/2CH3), 1.22 (s, 3 H, C f t) ,  1.18 (s,
Sodium hydride (289 mg o f an 60% w/w dispersion in mineral
OM e
o oil, 7.23 mmol) was added to a cooled solution (0 °C) o f 59
lo (700 mg, 2.06 mmol) in DMF (10 mL) and benzyl bromide 0.49
mL, 4.55 mmol) was added slowly. It was allowed to warm up
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H-6b), 3.48 (t, 1 H, H-2), 3.29 (s, 3 H, OCHi), 3.20 (s, 3 H, OCHi), 2.81-2.65 (m, 2 H, 
SC //2CH3), 1.35 (s, 3 H, CHi), 1.30 (t, 3 H, J 7.4 Hz, SCH2CHs) and 1.29 (s, 3 H, CH):
E th y l 3,4-di-0-acetyl-2,6-di-0-benzyl-1-thio-/i-D-glucopyranoside (62)
61 (1.89 g, 3.64 mmol) was dissolved in 80% aq. AcOH (10 mL)
SEt and heated at reflux for 1 h. The mixture was concentrated under 
BnO reduced pressure and co-evaporated with pyridine ( 3 x 1 0  mL). The
mixture was dissolved in acetic anhydride (1.38 mL, 14 mmol) and pyridine (5 mL) and 
stirred overnight. The mixture was concentrated under reduced pressure from toluene (3 
x 10 mL). The product was isolated as white needles after crystallisation from diethyl 
ether-hexane (5:2, v/v), (1.3 g, 73%).
m.p. 108 °C; Lit m.p 108 °C[71]; *H NMR (400 MHz; CDC13) <Sh 7.52-7.27 (m, 10 H, 
ArH), 5.18 (t, 1 H, J3>2=3A 9.4 Hz, H-3), 4.99 (t, 1 H, H-4), 4.86 (AB, 1 H, JAB 10.9 Hz, 
0.5 x OCtf2Ar), 4.58-4.47 (m, 4 H, J l>2 9.8 Hz, H -l, 1.5 x O C//2Ar), 3.66-3.45 (m, 4 H, 
H-2, H-5, H-6a, H-6b), 2.84-2.71 (m, 2 H, SCtf2CH3), 1.90 (s, 3 H, C tf3CO), 1.89 (s, 3 
H, C tf3CO),and 1.33 (t, 3 H, J 1 A  Hz, SCH2Ctf3); MS: (FAB) m/z calcd for C26H320 7S 
[M+H]+ 488.1868 found m/z 488.1838:
5 - 0 - B e n z y l - 1 ,2 - O - i s o p r o p y l id e n e - a - D - x y lo f u r a n o s e  (6 3 ) .
BnO^A o ^  mixture o f 1,2-0-isopropylidene-a-D-xylofuranose (5.64 g, 29.7
H * mmol), dibutyltinoxide (8.1 g, 32.6 mmol),
IT
Oy- tetrabutylammoniumbromide (9.5 g, 29.7 mmol), benzyl bromide (5.3 
mL, 44.5 mmol) and acetonitrile (300 mL) was heated under reflux for 24 h via a soxhlet 
thimble containing 3 A molecular sieves. After this time the milky suspension had 
become a pale yellow solution. The solution was cooled, Et3N (50 mL) was added and 
the mixture was heated under reflux for a further 1 h. The mixture was cooled, diethyl 
ether (200 mL) and satd aq. N aHC03 (200 mL) were added and stirred vigorously for 1 h 
followed by filtration through celite to remove the tin residues. The diethyl ether was 
separated and dried (MgS04), filtered and concentrated under reduce pressure. It was 
purified by flash chromatography on silica using ethyl acetate-hexane (1:1) as eluent to 
give a white solid which was crystallised from hexane to give the title compound. (7.26 
g, 87%).
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m.p.64 °C; Lit m.p 60-62 °C [110]; 'H  NMR (400 MHz; CDC13) Sh 7.39-7.28 (m, 5 H, 
ArCH), 5.96 (d, 1 H, J ,2 3.7 Hz, H -l), 4.63,4.57 (AB, 2 H, Jab 12.1, OCH2Ai), 4.49 (d, 
1 H, J2,1 3.7 Hz, H-2), 4.29-4.23 (m, 2 H, H-3, H-4), 3.95-3.88 (m, 2 H, H-5a, H-5b), 
3.66 (br s, 1 H, OH-3), 1.47 (s, 3 H, isopropylidene C //3) and 1.31 (s, 3 H, 
isopropylidene CH3):
5 - 0 - B e n z y l - 1 ,2 - O - i s o p r o p y l i d e n e - a - D - r i b o f u r a n o s e  (6 4 ) .
BnO^A o ^  solution of 63 (5 g, 17.8 mmol) in dry DMSO (20 mL) was added
\  dropwise to a solution o f acetic anhydride (40 mL) in dry DMSO (30
HO mL) and the solution was stirred under N2 at 23 °C overnight. The
reaction mixture was then added to a vigourously stirred solution o f satd 
aq. NaHCOs (300 mL) at 0 °C and stirring was continued for 1 h. The mixture was 
extracted with dichloromethane and the combined extracts were dried (MgS04), filtered 
and concentrated under reduced pressure. The yellow oil was dissolved in ethanolyTLO 
(1:1, 200 mL) and NaBH4 (742 mg, 19.6 mmol) was added in portions and stirring was 
continued for 1 h. The mixture was partially evaporated and the aq. layer was extracted 
with dichloromethane, dried (MgS04), filtered and concentrated under reduced pressure. 
It was purified by flash chromatography on silica using chloroform as eluent to give the 
title compound which was crystallised from hexane (2.52 g, 50.5%). 
m.p.80-82 °C; Lit m.p 81—83°C[111]; *H NMR (400 MHz; CDC13) Sn 135-129  (m, 5 H, 
ArC//), 5.81 (d, 1 H, J l>2 3.9 Hz, H -l), 4.60 (s, 2 H, O C//2Ar), 4.56 (t, 1 H, H-2), 3.96- 
3.89 (m, 2 H, H-3, H-4), 3.79 (dd, 1 H, J5aA 10.9 Hz, J5&)5b 2.7 Hz, H-5a), 3.64 (dd, 1 H, 
J5b)4 4.7 Hz, H-5b), 2.33 (d, 1 H, J9.1  Hz, OH-3), 1.56 (s, 3 H, isopropylidene CHi) and 
1.37 (s, 3 H, isopropylidene CH}):
( 2 " S ,3 " S )  5 - 0 - B e n z y l - 3 - 0 - [ 2 ,,6 '- d i - 0 - b e n z y l - 3 ,,4 ,- d i - 0 - ( 2 ,,,3 " -  
d im e th o x y - b u ta n e - 2 " ,3 " - d iy r ) a - D - g lu c o p y r a n o s y l ] - 1 ,2 - 0 -  
i s o p r o p y l i d e n e - ^ D - r ib o f u r a n o s id e  (6 7 )
Acceptor (64) (350 mg, 1.25 mmol) and donor (61) (973 mg,
1.87 mmol) were dissolved in anhydrous diethyl ether (20 mL). 
Activated 4A molecular seives were added and the mixture was 
stirred under argon. NIS (476 mg, 2.11 mmol) and a catalytic 
amount o f TfOH (10 pL) were added. After stirring for 15 min., TLC (diethyl ether- 
hexane 2:1) showed complete disappearence o f acceptor. The reaction mixture was
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filtered though celite and the filtrate was diluted with ethyl acetate, washed with satd aq. 
Na2S2C>3 (15 mL, 1 M) and satd aq. NaHCC>3 (15 mL), dried (MgSC^), filtered and 
concentrated under reduced pressure. It was purified by flash chromatography on silica 
using diethyl ether-hexane (2:3) as eluent to yield the title compound as an oil (560 mg, 
61%).
*H NMR (400 MHz; CDC13) 7.22-7.41 (m, 15 H, ArCH), 5.79 (d, 1 H, J lj2 3.9 Hz, H- 
1), 5.19 (d, 1 H, J\\2 ' 3.9 Hz, H-l'), 4.78, 4.75 (AB, 2 H, JAB 12.1 Hz, OGtf2Ar), 4.70 (t, 1 
H, J2,3=J2,l 3.9 Hz, H-2), 4.60 (AB, 1 H, Jab 12.1 Hz, 0.5 x OCtf2Ar), 4.52 (AB, 2 H, 
J a b  11.7 Hz, OCH2Ai), 4.46 (AB, 1 H, 0.5 x OCH2Ai), 4.31 (dd, 1 H, J3>2 3.9 Hz, J3A 9.0 
Hz, H-3), 4.13-4.08 (m, 2 H, H-3’, H-4’), 3.84-3.54 (m, 7 H, H-4, H-5a, H-5b, H-2', H- 
5', H-6 'a, H-6t>), 3.30 (s, 3H, OCH3), 3.18 (s, 3 H, OCH3), 1.53 (s, 3 H, isopropylidene 
CH3), 1.34 (s, 6 H, BDA CH3 and isopropylidene CH3) and 1.30 (s, 3 H, BDA CH3); 13C 
NMR (100 MHz; CDC13) 139.12, 138.34, 138.17 (C-l o f benzyl ether ring), 128.52, 
128.43, 128.30, 127.80, 127.71, 127.66, 127.48 (ArCH), 113.14 (isopropylidene 
C(CH3)2), 104.43 (C-l), 99.90, 99.73 (BDA OCCH3OCH3), 96.10 (C-l'), 78.17, 76.92,
76.45 (3 x CH), 73.82 (OCH2Ar), 73.79 (CH), 72.35 (OCH2Ar), 69.82, 69.65 (2 x CH), 
68.56, 68.12 (C-6 , C-5'), 48.51, 48.32 (2 x OCH3), 27.18, 27.07 (2 x isopropylidene 
CH3) and 18.39, 18.17 (2 x BDA CH3). MS: (FAB) 759.4 [(M+Na)+ 78%), m/z calcd for 
C41H52O 12 [M+Na]+ 759.3356 found m/z 759.3324:
S '^ '- D i - O - a c e t y l ^ ' .S ^ '- t r i - O - b e n z y l - S - O - a - D - g l u c o p y r a n o s y l - l ^ - O -  
i s o p r o p y l id e n e - a - D - r ib o f u r a n o s e  (6 5 ) .
Acceptor (64) (478 mg, 1.7 mmol) and donor (62) (1.0 g, 2.05 
mmol) were dissolved in a mixture o f toluene (8 mL) and 1,4- 
dioxane (24 mL). Activated 4A molecular seives were added and 
the mixture was stirred under argon. NIS (518 mg, 2.3mmol) and a catalytic amount of 
TfOH (15 pL) were added. After stirring for 15 min., TLC (diethyl ether-hexane 2:1) 
showed complete disappearence o f acceptor. The reaction mixture was filtered though 
celite and the filtrate was diluted with ethyl acetate, washed with aq. Na2S2C>3 (15 mL, 1 
M) and satd. aq. NaHCC>3 (15 mL), dried (MgSCU), filtered and concentrated under 
reduced pressure. It was purified by flash chromatography on silica using diethyl ether- 
hexane (1:1) as eluent to give the title compound (810 mg, 68%) which was 
recrystallised from dissopropylether.
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m.p.124-126 °C; Lit m.p 125-127 °C[64]; 'H  NMR (400 MHz; CDCI3) <5h 7.33-7.23 (m, 
15 H, ArCH), 5.82 (d, 1 H, J\,2 3.5 Hz, H -l), 5.37 (dd, 1 H, Jy,v=Jyx 9.8 Hz, H-3'), 5.21 
(d, 1 H, J v z  3.9 Hz, H -l1), 5.09 (dd, 1 H, Jv,y 9.8 Hz, H-4’), 4.72-4.48 (m, 6 H, 2.5 x 
OCH2Ai, H-2), 4.32-4.29 (m, 2 H, H-4, 0.5 x  OCH2Ai), 4.17 (dd, 1 H, J 3.2 4.3 Hz, JiA
10.1 Hz, H-3), 3.83-3.79 (m, 2 H, H-5a, H-5'), 3.71 (dd, 1 H, JsM 3.5 Hz, y5bj5a 11.7, H- 
5b), 3.60 (dd, 1 H, 3.5 Hz, H-2'), 3.34 (dd, 1H, / 6a,5 2.4 Hz, J6a,6b 10.9 Hz, H-
6a), 3.29 (dd, 1 H, J6h,5 3.5 Hz, / 6b.6a 10.9 Hz, H-6b), 2.03 (s, 3 H, C //3CO), 1.88 (s, 3 H, 
CH3CO), 1.53 (s, 3 H, isopropylidene CH3) and 1.36 (s, 3 H, isopropylidene CH{):
'[,2,3',4'-Teira-0-acety\-2',5,6'-0-benzy\-3-0-a-D-g\ucopyranosy\-D- 
r i b o f u r a n o s e  (5 6 ) .
M ethod A (from  65)
65 (750 mg, 1.06 mmol) Was treated with 90% aq. TFA (5 mL) 
acch-V^^x r “T^ oAc an(j for iq  mjn 7 he reaction was quenched by adding
satd. aq. NaHCC>3 (100 mL) and extracted with ethyl acetate(200 
mL), dried (MgS04), filtered and concentrated under reduced pressure. It was stirred in 
a mixture of acetic anhydride (1 mL) and pyridine (7.5 mL) overnight and concentrated 
under reduced pressure. Purification by flash chromatography on silica using ethyl 
acetate-hexane (3:7) as eluent to give the title compound (700 mg, 88%) which was 
crystallised from ethyl acetate-hexane (1:4):
M ethod B (from 67)
The 67 (1.4 g, 1.89 mmol) was heated atreflux in a mixture o f acetic anhydride-H20 -  
ethylene glycol (14:6:3) for 75 min. It was quenched with satd aq. NaHCC>3 (100 mL) 
and extracted with ethyl acetate (3 x 100 mL), dried (MgS04), filtered and concentrated 
under reduced pressure. The crude product was dissolved in a mixture o f acetic 
anhydride (5 mL) and pyridine (10 mL) and stirred overnight. The mixture was diluted 
with toluene and concentrated under reduced pressure. It was purified by flash 
chromatography on silica using ethyl actetate-hexane (3:7) as eluent to yield the title 
compound (600 mg, 42%) which was crystallised from ethyl acetate-hexane (1:4). 
m.p. 104-106 °C; Lit m.p 105-107 °C[64]; *H NMR (400 MHz; CDCI3) Sr 7.32-7.22 (m, 
15 H, ArCtf), 6.12 (s, 1 H, H -l), 5.37 (t, 1 H, Jy,T 9.5 Hz, H-3'), 5.33 (d, 1 H, J2,\ 4.8 Hz, 
H-2), 5.08-5.03 (m, 2 H, H -l', H-4’), 4.66-4.62 (m, 2 H, H-3, 0.5 x OC/72Ar), 4.56-4.47 
(m, 4 H, 2 x OCtf2Ar) 4.39-4.36 (m, 1 H, H-4), 4.29 (AB, 1 H, /ab  12.1 Hz, 0.5 x
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OCi/2Ar), 3.87 (ddd, 1 H, J 3 A  Hz, J  10.2 Hz, J 6  Hz, H-5'), 3.72 (dd, 1 H, J5slA 2.7 Hz, 
J 5a,5b 11.3 Hz, H-5a), 3.63 (dd, 1 H, J5hA 3.5 Hz, J5b,5& 11.3, H-5b), 3.56 (dd, 1 H, JT,y
10.1 Hz, JT,y 3.5 Hz, H-2'), 3.35 (dd, 1 H, Jw  2.3 Hz, J6%6^  10.9 Hz, H-6'a), 3.29 (dd, 1
H, 5' 3.9 Hz, 6'a 10.9 Hz, H-6'b), 1.95 (s, 3 H, CH3CO), 1.93 (s, 3 H, CH3CO),
I.87 (s, 3 H, CH3CO) and 1.86 (s, 3 H, CH3CO):
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7.5.2 Synthesis of adenophostin A
2'-0-Acetyl-3'-0-(3,4-di-0-acetyl-6-0-benzyl-a-D-glucopyranosyl)-6- 
N-benzoyl-5'-0-benzyladenosine (68).
liIHBz A suspension o f A-6-benzoyl-adenine (430 mg, 1.79 mmol) 
(4.5 mL) and pyridine (1.6 mL) was heated at 
N reflux overnight. The reaction mixture was cooled, diluted 
with toluene (5 mL) and concentrated. The residue was 
repeatedly diluted with toluene ( 3 x 5  mL) and concentrated 
under reduced pressure to remove excess HMDS. A mixture o f 56 (500 mg, 0.67 mmol) 
in dichloroethane (10 mL) and a catalytic amount o f TMSOTf (40 pi) was added to the 
silylated N-6-benzoyladenine. After stirring at reflux for 7 h, TLC (toluene-ethyl 
acetate-methanol 36:10:1) showed conversion o f the dissacharide into a lower-running 
product. The reaction was quenched by adding Et3N (1 mL), diluted with 
dichloromethane (20 mL) and poured into satd aq. NaHC03 (10 mL). The organic phase 
was washed with H2O (10 mL), dried (MgS04 ), filtered and concentrated under reduced 
pressure. It was purified by flash chromatography on silica using dichloromethane- 
methanol (99:1) as eluent to give the title compound (630 mg, 88%).
'H  NMR (400 MHz; CDCI3) (5k 9.05 (s, 1 H, NH),8.80 (s, 1 H, H-2), 8.38 (s, 1 H, H-8), 
8.6-8.04 (m, 2 H, H-2 and H-6 o f Bz ring), 7.64-7.60 (m, 1 H, H-4 of Bz ring), 7.55- 
7.52 (m, 2 H, H-3 and H-5 o f Bz ring), 7.47-7.21 (m, 15 H, ArCH), 6.42 (d, 1 H, J V,T 5.5 
Hz, H -l’), 5.73 (t, 1 H, J T,v = T,y 5.5 Hz, H-2’), 5.44 (t, 1 H, «/3vr = 3",2-9.8 Hz, H-3"), 5.04 
(t, 1 H, J r ,y  =  r ,5 ” 9 .8 Hz, H-4"), 4.97 (d, 1 H, J v ,2« 3.5 Hz, H-l"), 4.74 (dd, 1 H, J y ,4-3.9 
Hz, Jy,T 5.5 Hz, H-3'), 4.69, 4.36 (OCtf2Ar), 4.61-4.43 (m, 5 H, H-4', 2 x OCH2Ai), 
4.01-3.97 (m, 1 H, H-5"), 3.73 (dd, 1 H, J y ^ l . l  Hz, Js-a.s-b 10.5 Hz, H-5a'), 3.62 (dd, 1 
H, J 5%A> 2.7 Hz, j y b,5-a 10.5 Hz, H-5'b), 3.56 (dd, 1 H, J r r  3.5 Hz, J r ,y  9.8 Hz, H-2"),




n h 2 Methanol (2 mL) was added to a solution o f LiOH (158 mg, 
^  3.7 mmol) in water (1 mL). 68 (350 mg, 0.37 mL) was 
n dissolved in THF(2 mL). The LiOH solution was added and 
the mixture was stirred overnight. The mixture was diluted 
“ ~o with water (40 mL) and the THF/methanol was removed by
concentrating under reduced pressure. It was extracted with chloroform (3 x 50 mL), 
dried (MgSCU) and concentrated under reduced pressure to leave an oil. This was 
purified by flash chromatography on silica using ethyl acetate-ethanol (14:1) as eluent to 
give to give the title compound as a colourless oil (180 mg, 68%) which was crystallised 
from methanol.
m.p.95-98 °C; lit white solid[60]; *H NMR (400 MHz; CDC13) ^ 8 .2 9  (s, 1 H, H-8), 8.06 
(s, 1 H, H-2), 7.49-7.23 (m, 15 H, ArCH), 6.19 (d, 1 H, J r>T 6.6 Hz, H -l'), 5.86 (br s, 2 
H, NH2), 4.85 (d, 1 H, J r ,r  3.5 Hz, H-l"), 4.71 (AB, 1 H, Jab 11.7 Hz, 0.5 x OCH2Ai), 
4.63-4.44 (m, 9 H, H-2', 2.5 x OCtf2Ar, 3 x OH), 4.40-4.25 (m, 1 H, H-4’), 4.13 (t, H- 
3'), 3.94-3.90 (m, 1 H, H-3") 3.73-3.65 (m, 4 H, H-4", H-5", H-6"a, H-6"b), 3.60 (dd, 1 
H, Jya,4- 2.5 Hz, Jya.s-b 10.5 Hz, H-5'a), 3.54 (dd, 1 H, Jyb)4- 2.7 Hz, J ^ ,  5.a 10.5 Hz, US'b) 
and 3.43 (dd, 1 H, JTy  3.5 Hz, Jr ,y 10.3 Hz, H-2"):
2">5\6"-Tri-0-benzyl-3,-0-a-D-glucopyranosyl)-N-6-dimethoxytrityl-9- 
/^D-ribofuranosidopurine (70).
NHDMTr To a solution o f 69 (150 mg, 0.21 mmol) in dry pyridine (5 
mL) was added DMTrCl (267 mg, 0.75 mmol) and DMAP 
(50 mg) and the mixture was stirred for 48 h. The pyridine 
was removed under reduced pressure and coevaporated 
with toluene to give an oil. The residue was purified by 
flash chromatography on silica using ethyl acetate-hexane-triethylamine (1:1:0.1 then 
1:0:0.1) as eluent to give the title compound (150 mg, 70%) as a yellow oil.
'H  NMR (400 MHz; CDC13) &  8.04 (s, 1 H, H-8), 7.92 (s, 1 H, H-2), 7.36-7.15 (m, 23 
H, ArCH), 6.98-6.78 (m, 5 H, ArCH), 6.25 (d, 1 H, Jy,T 1A  Hz, H -l'), 4.71 (d, 1 H, J y T






4', 2 x OCHjAr), 4.37 (AB, 1 H, J AB 11.7 Hz, 0.5 x O C ftA r), 4.21^1.19 (m, 2 H, H-3', 
H-3"), 3.97-3.93 (m, 1 H, H-5"), 3.78 (s, 6H, 2 x OCH3 o f DMTr), 3.78-3.58 (m, 3 H, 
H-4”, H-6”a, H-6"b), 3.49-3.51 (m, 2 H, H-5'a, H-5’b) and 3.37 (dd, 1 H, Jr ,r  3.5 Hz,




further 20 min, TLC (ethyl acetate-hexane 8:2) indicated conversion o f starting material 
to a single trisphosphite. The reaction mixture was then cooled to -78  °C and mCPBA 
(161 mg, 0.55 mmol) was added. After 10 min, 10 % aq. Na2S03 solution (15 mL) and 
dichloromethane (20 mL) were added and the mixture was allowed to heat up to room 
temperature. The resulting organic layer was washed with sat. aq. NaHCOs solution (15 
mL) and brine (15 mL). The organic layer was dried (MgSCL), filtered and concentrated 
under reduced pressure to leave an oil, which was dissolved in acetic acid (80%, 5 mL) 
and stirred for 40 min. After this time it was diluted with water (20 mL) and 
concentrated under reduced pressure to leave an oil which was purified by flash 
chromatography on silica using chloroform-acetone (4:l)as eluent to give the title 
compound (100 mg, 85%) as a colourless oil.
O P (0 )(O B n )2
n h2 Bis(benzyloxy)(diisopropylamino)phosphine (164
mg, 0.48 mmol) and 177-tetrazole (50 mg, 0.71 
mmol) were stirred together in dichloromethane (3 
mL) for 30 min, the mixture thus obtained was then 
added to the triol (70) (80 mg, 0.079 mmol). After a
H NMR (400 MHz; CDC13) Sa 8.24 (s, 1 H, H-8), 7.89 (s, 1 H, H-2), 7.39-6.95 (m, 45 
H, AxCH), 6.34 (d, 1 H, Jv?  6.6 Hz, H -l'), 5.64-5.58 (m, 3 H, H-2’, NH2\  5.32 (d, 1 H, 
Jv ,r  3.3 Hz, H-l"), 5.04-4.86 (m, 8 H, 3.5 x O C //2Ar, H-3"), 4.79-4.36 (m, 13 H, 5 x 
O C//2Ar, H-31, H-4', H-4"), 4.29 (AB, 1 H , / ab 11.7 Hz, 0.5 x O Ci/2Ar), 3.85-3.79 (m , 
1 H, H-5") and 3.67-3.53 (m, 5 H, H-5'a, H-2", H-5b, H-6"a, H-6"b); 31P NMR (162 





3-O-a-D-Glucopyranosyl adenosine 2 ,,3M,4"-trisphosphate (72)
A mixture o f 71 (60 mg, 0.004 mmol) and Pd(OH)2 on 
carbon (10%, 120 mg) in cyclohexene (3 mL), methanol (6 
mL) and water (0.5 mL) was heated at 65 °C for 3 h. The 
catalyst was filtered and washed well with de-ionised 
water and methanol. The filtrate was concentrated to a 
glassy solid. The residue was dissolved in de-ionised water (1 mL) and applied to a 
Diaion WK-20 resin column (Na+ form), which was developed by water. The eluent was 
concentrated under reduced pressure to give the title trisphosphate (22 mg, 81%) as its 
sodium salt.
*H NMR (400 MHz; D20 )  8.15 (s, 1 H, H-8), 8.04 (s, 1 H, H-2), 6.11 (d, 1 H, Jv,2' 6.6
Hz, H -l'), 5.19 (d, 1 H, J r ,r 3.9 Hz, H-l"), 5.15-5.10 (m, 1 H, H-2'), 4.49-4.47 (1 H, m, 
H-3’), 4.36-4.26 (m, 2 H, H-41, H-3"), 3.89-3.82 (m, 1 H, H-4") and 3.77-3.58 (m, 6 H, 
H-5'a, H^T), H-2", H-5", H-6"a, H-6"b); 31P NMR (162 MHz; D20 ; *H decoupled) & 
2.84, 2.27 and 1.09:
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7.5.3 Synthesis of OMe adenophostin
2,,3n,4,,-Tri-0-acetyl-2",5,,6,,-tri-0-benzyl-3,-0-«-D-glucopyranosyl-6- 
chloro-9-/^D-ribofuranosylpurine (73).
TMSOTf (0.48 mL, 2.65 mmol) was added cautiously
Cl
| dropwise to a stirred solution of 56 (500 mg, 0.66 mmol), 6- 
\  J  chloropurine (113 mg, 0.73 mmol) and DBU (0.3 mL, 2.00 
mmol) in acetonitrile (5 mL) at 0 °C. The mixture was
heated at 60 °C for 1 h, after which it was cooled and
quenched by careful addition of sat. aq. NaHC03 solution 
(25 mL). The mixture was extracted with dichloromethane (3 x 30 mL) and the 
combined extracts were dried (MgS04), filtered and concentrated under reduced pressure 
to leave a yellow oil. Purification by flash chromatography on silica using 
dichloromethane-acetone (40:1) as eluent gave the title compound (500 mg, 89%) as a 
colourless oil.
[a]20D +71.0 (c 1.14,CHC13); !H NMR (400 MHz; CDC13) Sa 8.73 (s, 1 H, H-8), 8.48 (s, 
1 H, H-2), 7.37-7.23 (m, 15 H, ArC//), 6.41 (d, 1 H, JV)T 5.5 Hz, H -l'), 5.69 (t, 1 H, JTtV 
= 2 ,3- 5.5 Hz, H-2 '), 5.44 (t, 1 H, Jr ,r = J 9.8 Hz, H-3"), 5.02 (t, 1 H, Jr ,r =Jr,5- 9.8 
Hz, H-4"), 4.96 (d, 1 H, J v ,r 3.5 Hz, H-l"), 4.71 (dd, 1 H, J 3-,4-3.9 Hz, Jy,T 5.3 Hz, H-3'), 
4.62 (AB, 1 H, Jab 12.1 Hz, 0.5 x O C//2Ar), 4.56-4.48 (m, 5 H, 2 x O C//2Ar, H-4'), 4.34 
(AB, 1 H, Jab 12.1 Hz, 0.5 x OC//2Ar), 4.00-3.96 (m, 1 H, H-5"), 3.70 (dd, 1 H, J5X4. 2.7 
Hz, j y a,5-b 10.9 Hz, H-5'a), 3.60 (dd, 1 H, JyM. 2.7 Hz, Jyb,5'a 10.9 Hz, H-5*b), 3.56 (dd, 1 
H, J r y  3.5 Hz, JT,y 9.8 Hz, H-2"), 3.40-3.36 (m, 2 H, H-6"a, H-6"b), 1.99 (s, 3 H, 
C //3CO), 1.94 (s, 3 H, C //3CO) and 1.87 (s, 3 H, C //3CO); 13C NMR (100 MHz; CDC13) 
169.93, 169.86, 169.42 (3 x OCOCH3), 151.90 (C-4 or C-6), 151.23 (C-2), 150.86 (C-4 
or C-6), 143.49 (C-8), 137.29, 137.14, 136.75 (3 x C-l Bn ether ring), 131.77 (C-5), 
128.45, 128.28, 128.16, 127.94, 127.75, 127.64, 127.58 (ArCH), 97.97 (C-l"), 86.51 (C- 
1'), 83.03 (CH), 77.00 (CH), 76.69 (CH), 76.57 (CH), 74.59 (CH) , 76.63, 73.45, 73.22 
(3 x OCH2Ar), 71.65 (CH), 69.22, 67.89 (C-5', C-6"), 20.91, 20.72, 20.37 (3 x CH3CO);
MS: (FAB) m/z 845.3 [(M), 65%], m/z calcd for C43H44N4Oi2C1 [M+H]+37C1, 847.2771
found m/z 847.2738, [M+H]+ 35C1, 846.2834 found m/z 846.2820; Anal. Calcd for 




A solution of 1 M NaOMe (0.8 mL, 0.8 mmol) was added to 
| e a stirred solution o f 73 (400 mg, 0.4 mmol) in methanol. The 
(  J  J  mixture was stirred for 30 min after which it was neutralised 
with Dowex® 50WX4—50 ion-exchange resin and filtered. 
The filtrate was concentrated under reduced pressure to leave 
an oil, which was purified by flash chromatography on silica 
using ethyl acetate-hexane (4:1) as eluent to give the title compound as a colourless oil 
(250 mg, 74%).
[a]20D +16.7 (c 0.6, CHC13); *H NMR (400 MHz; CDC13) <5k 8.44 (s, 1 H, H-8), 8.22 (s, 
1 H, H-2), 7.37-7.24 (m, 15 H, AiCH), 6.27 (d, 1 H, J v,? 6.6 Hz, H -l'), 4.79 (d, 1 H, 
Jv',r 3.5 Hz, H-l"), 4.69 (AB, 1 H, Jab 11.7 Hz, 0.5 x O C//2Ar), 4.62^1.56 (m, 1 H, H- 
2'), 4.53—4.41 (m, 6 H, 2.5 x OCi/2Ar, H-4'), 4.21-4.19 (m, 4 H, H-3', OCH3), 4.10 (t, 1 
H, Jy,2”=Jy'A"9A Hz, H-3"), 3.96-3.91 (m, 1 H, H-5"), 3.71-3.65 (m, 3 H, H-4", H-6"a, 
H-6"b), 3.60 (dd, 1 H, Jya>4- 2.7 Hz, Jya,5-b 10.5 Hz, H-5'a), 3.54 (dd, 1 H, Jyb>4- 2.7 Hz, 
Jyb, 5'a 10.5 Hz, HS'b) and 3.43 (dd, 1 H, JT,v 3.5 Hz, Jr ,y 9.4 Hz, H-2"); 13C NMR 
(100 MHz; CDCI3) 160.93 (C-4 or C-6), 151.71 (C-2), 151.49 (C-4 or C-6), 140.48 (C- 
8), 137.62, 137.06, 136.51 (3 x C-l Bn ether ring), 128.61, 128.56, 128.46, 128.39,
128.23, 127.91, 127.70, 127.61, 127.53 (ArCH), 121.68 (C-5), 99.60 (C-l"), 88.02 (C- 
1'), 83.07 (CH), 80.56 (CH), 79.04 (CH), 76.05 (CH), 74.02 (CH), 71.82 (CH), 73.69, 
73.60, 72.77 (3 x OCH2Ar), 69.92 (CH), 69.81, 69.34 (C-5', C-6") and 54.33 (OC//3); 




glucopyranosyl- 6-methoxy-9-/?-D- ribofuranosylpurine (75).
Bis(benzyloxy)(diisopropylamino)phosphine (405
added to 74. After a further 20 min, TLC (ethyl
starting material to a single trisphosphite. The reaction mixture was then cooled to -78 
°C and mCPBA (360 mg, 1.25 mmol) was added. After 10 min, 10 % aq. Na2S 0 3 
solution (15 mL) and ethyl acetate (20 mL) were added and the mixture was allowed to 
heat up to room temperature. The resulting organic layer was washed with sat. aq. 
N aH C 03 solution (15 mL) and brine (15 mL). The organic layer was dried (MgS04 ), 
filtered and concentrated under reduced pressure to leave an oil, which was purified by 
flash chromatography on silica using ethyl acetate-hexane (1:1 then 4:1) to give the title
compound (200 mg, 69%) as a colourless oil.
‘H NMR (400 MHz; CDC13) <5h 8.40 (s, 1 H, H-8), 8.07 (s, 1 H, H-2), 7.40-6.94 (m, 45
C-l Bn ether ring), 136.33-135.09 (C-l of bezylphosphoro ring), 128.73, 128.69,
(CH with C-P couplings), 74.70, 73.97, 73.70 (3 x OCH2Ar), 71.92 (CH with C-P 
coupling), 70.45 (CH with C-P coupling), 70.19 (C-5' or C-6"), 70.13-69.49 (POCH2Ar 
with C-P coupling), 68.71 (C-5' or C-6") and 54.52 (OCtf3); 31P NMR (162 MHz;
?Me mg, 1.17 mmol) and 177-tetrazole (123 mg, 1.76 
J  mmol) were stirred together in dichloromethane (3
n
mL) for 30 min, the mixture thus obtained was then
o
acetate methanol, 95:5) indicated conversion of
H, ArC//), 6.40 (d, 1 H, J V,T 6.2 Hz, H -l'), 5.62-5.57 (m, 1 H, H-2'), 5.33 (d, 1 H, JVtT
3.5 Hz, H-l"), 5.06-4.87 (m, 8 H, 3.5 x OC/^A r, H-3"), 4.80-4.35 (m, 13 H, 5 x 
OCZ/2Ar, H-3’, H-4', H-4"), 4.30 (AB, 1 H, /  a b  11-7 Hz, 0.5 x  OC//2Ar), 4.14 (s, 3 H, 
OCH3), 3.86-3.83 (m, 1 H, H-5"), 3.71-3.57 (m, 4 H, H-5'a, H-S'b, H-6"a, H-6"b) and
3.43 (dd, 1 H, J2",r 3.5 Hz, Jr ,y9.1 Hz, H-2"); 13C NMR (100 MHz; CDC13) 161.03 (C- 
4 or C-6), 152.31 (C-2), 152.11 (C-4 or C-6), 138.20 (C-8), 137.84, 137.43, 136.40 (3 x
128.65, 128.54, 128.51, 128.29, 128.27, 128.10, 128.06, 128.00, 127.94, 127.91, 127.86, 
127.80 (ArCH), 121.98 (C-5), 95.68 (C-l"), 85.87 (C-l'), 82.84 (CH), 78.34 (CH), 77.77
CDC13; *H decoupled) ^>-0.37, -0.97, -1.14; MS: (FAB) m/z 1496.0 [(M+H)+, 78%], 




A mixture o f 75 (35 mg, 0.023 mmol) and Pd(OH)2 on
OMe
I carbon (10%, 110 mg) in cyclohexene (3 mL), methanol 
K J  J  (6 mL) and water (0.5 mL) was heated at 65 °C for 31 h.
H O ^  HO^\ o /N N
Y  7  The catalyst was filtered and washed well with de-ionised-o3po
2‘03PO r - \
Hoi/ op032' water and methanol. The filtrate was concentrated under 
o
reduced pressure to a glassy solid. The residue was 
dissolved in de-ionised water (1 mL) and applied to a Diaion WK-20 resin column (Na+ 
form), which was developed by water. The eluent was concentrated under reduced 
pressure to give the title trisphosphate (0.019 mmol, 83%) as its sodium salt.
]H NMR (400 MHz; D20 )  <5k 8.32 (s, 1 H, H-8), 8.28 (s, 1 H, H-2), 6.14 (d, 1 H, J v,T 6.2 
Hz, H -l'), 5.19 (d, 1 H, J r ,2" 3.9 Hz, H-l"), 5.10-5.04 (m, 1 H, H-2’), 4.55-4.48 (1 H, m, 
H-3'), 4.38-4.23 (m, 2 H, H-4’, H-4"), 3.97 (s, 3 H, OCHi) and 3.83-3.52 (m, 7 H, H-5'a, 
H-5'b, H-2", H-3", H-5", H-6"a, H-6"b); 31P NMR (162 MHz; D20 ; lU decoupled) & 
5.64, 4.93 and 4.87; MS: (FAB) m/z 684.1 [(M-H)“, 28%], m/z calcd for C n H ^ O ig P s  
[M -H ]\ 684.0437 found m/z 684.0447:
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A catalytic amount o f NaOMe (30 mg, mmol) was added to 
a stirred solution o f 73 (300 mg, 0.35 mmol) in methanol. 
The mixture was stirred for 1.5 h after which it was 
neutralised with Dowex® 50WX4-50 ion-exchange resin and 
filtered. The filtrate was concentrated under reduced pressure 
to leave an oil, which was purified by flash chromatography on silica using ethyl 
acetate-hexane (7:3) as eluent to give the title compound as a colourless oil (140 mg, 
55%).
'H  NMR (400 MHz; CDC13) <5h  8.65 (s, 1 H, H-8), 8.44 (s, 1 H, H-2), 7.37-7.23 (m, 15 
H, ArC/7), 6.23 (d, 1 H, J vx  6.2 Hz, H -l'), 4.81 (d, 1 H, J r x  3.5 Hz, H-l"), 4.70 (AB, 1 
H, 0.5 x O C//2Ar), 4.68^1.64 (tn, 1 H, H-2'), 4.56-4.40 (m, 7 H, 2.5 x O C//2Ar, H-2’, H- 
4', OH), 4.26 (br s, 1 H, OH), 4.22 (dd, 1 H, Jyv 2.7 Hz, Jy,? 5.5 Hz, H-3’), 4.06 (t 
covered by s, J,-,2-=Jy,r 9.7 Hz, H-3”, OH), 3.92-3.88 (m, 1 H, H-5"), 3.68-3.65 (m, 3 
H, H-4", H-6"a, H-6"b), 3.62 (dd, 1 H, J5%4.2.7 Hz, J y ^  10.9 Hz, H-5'a), 3.55 (dd, 1 H,
J5w  2.3 Hz, / 51),5a 10.9 Hz, H-5b ) and 3.43 (dd, 1 H, J2~,i- 3.5 Hz, J2-,y 9.7 Hz, H-2");
MS: (FAB) m/z 719.1 [(M+H)+, 32%], m/z calcd for C37H39N4O9CI [M+H]+ 37C1, 
721.2454 found m/z 721.2481, [M+H]+35C1, 719.2483 found m/z 719.2478:
2",5',6"-Tri-0-benzyl-3,-0-a-D-glucopyranosyl-6-cyclopentylamino -9- 
/)-D-ribofuranosylpurine (78).
To a stirred solution of 77 (140 mg, 0.19 mmol) in 
ethanol (10 mL), cyclopentylamine (0.04 mL, 0.38 mmol) 
HN and triethylamine (0.03 mL, 0.23 mmol) were added.
The mixture was heated at 80 °C for 3 h, after which time 
it was cooled and concentrated under reduced pressure. 
Water (20 mL) was added to the residue and was 
extracted with ethyl acetate (3 x 25 mL). The combined 






an oil, which was purified by flash chromatography on silica using ethyl acetate-hexane 
(8:2) ethyl acetate-methanol (10:1) to give the title compound (80 mg, 54%) as a 
colourless oil.
'H  NMR (400 MHz; CDC13) <5k 8.44 (s, 1 H, H-8), 8.03 (s, 1 H, H-2), 7.37-7.21 (m, 15 
H, AiCH), 6.28 (d, 1 H, J v,r 5.9 Hz, H -l'), 6.18 (broad s, 1 H, NH), 5.92 (broad s, 1 H, 
OH), A .ll  (d, 1 H, y r ,2- 3.5 Hz, H-l"), 4.66 (AB, 1 H, J  ab 11.7 Hz, 0.5 x O C//2Ar),
4.58-4.42 (m, 7 H, 2.5 x OCH2Ar, H-2', H-3'), 4.19-4.06 (m, 2 H, H-4', H-3"), 3.99-3.96 
(m, 1 H, H-5"), 3.78-3.63 (m, 3 H, H-4", H-6"a, H-6"b), 3.61-3.50 (m, 2 H, H-5’a, H- 
51)), 3.40 (dd, 1 H, J2,1 3.5 Hz, J2,3 9.8 Hz, H-2”), 2.3 (broad s, 2 H, OH), 2.17-2.09 (m, 2 
H, cyclopentyl ring), 1.79-1.63 (m, 4 H, cyclopentyl ring) and 1.59-1.25 (m, 3 H, 
cyclopentyl ring); 13C NMR (100 MHz; CDCI3) 154.46 (C-2), 152.61 (C-4), 137.82,
137.72, 137.33 (3 x C-l Bn ether ring), 136.60 (C-8), 128.67,128.54,128.40, 128.32, 
128.19, 127.78, 127.55, 127.52 (ArCH), 119.70 (C-5), 99.65 (C -l”), 87.63 (C -l1), 83.03,
79.23, 76.23 (3 x CH), 73.89, 73.61, 73.61 (3 x OCH2Ar), 73.58, 72.75 (2 x CH), 72.17 
(C-5* or C-6"), 69.96 (C-51 or C-6"), 69.60 (CH), 60.37 (NCH, cyclopentyl ring) 33.47 (2 
x NCHCH2 o f cyclopentyl ring) and 23.81 (2 x NCHCH2CH2 o f cyclopentyl ring); MS: 




glucopyranosyl- 6- cyclopentylamino - 9 - f i - D -  ribofuranosylpurine (79).
Bis(benzyloxy)(diisopropylamino)phosphine 
(220 mg, 0.6 mmol) and lH-tetrazole (65 mg, 0.9
H N' ^
mmol) were stirred together in dichloromethane
\  (3 mL) for 30 mm, the mixture thus obtained was
BnO^ —  B n O ^ \ n I N 
0)p o ^ ^ \^ -o  \ ]  then added to 78 (80 mg, O.lmmol). After a
Bri0)2(O)PO-X*-,,T*A
Bno 1/ OP(0 )(OBn)2 further 20 min, TLC (ethyl acetate:methanol,
o
95:5) indicated conversion o f starting material to 
a single trisphosphite. The reaction mixture was then cooled to -78  °C and mCPBA (180 
mg, 0.6 mmol) was added. After 10 min, 10 % aq. Na2S03 solution (15 mL) and ethyl 
acetate (20 mL) were added and the mixture was allowed to heat up to room temperature. 
The resulting organic layer was washed with sat.aq. NaHCC>3 solution (15 mL) and brine 
(15 mL). The organic layer was dried (MgS04), filtered and concentrated under reduced
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pressure to leave an oil, which was purified by flash chromatography on silica using
ethyl acetate-hexane (1:1 then 4:1 then 1:0) to give the title compound (40 mg, 25%) as a
colourless oil.
*H NMR (400 MHz; CDC13) Sa 8.48 (s, 1 H, H-8), 8.00 (s, 1 H, H-2), 7.63 (d, 1 H, /  8.9 
Hz, NH), 7.38-6.95 (m, 45 H, ArCtf), 6.29(d, 1 H, J v?  6.3 Hz, H -l’), 5.57-5.52 (m, 1 H, 
H-2') 5.30 (d, 1 H, J r>T 3.5 Hz, H-l"), 5.00-4.85 (m, 8 H, H-3", 3.5 x OCi^Ar), 4.76- 
4.26 (m, 14 H, H-3', H-4', H-4", 5.5 x O C//2Ar) 3.82-3.80 (m, 1 H, H-5"), 3.68-3.48 (m, 
5 H, H-5'a, H-51>, H-2", H-6"a, H-6"b) and 2.19-1.20 (m, 9 H, cyclopentyl ring); 31P 
NMR (162 MHz; CDC13; *H decoupled) S? 0.15, -0.66, -0.79; MS: (FAB) m/z 1564.8




P A mixture of 79 (40 mg, 0.025 mmol) and Pd(OH)2 oncarbon (10%, 110 mg) in cyclohexene (3 mL),
methanol (6 mL) and water (0.5 mL) was heated at 65 
°C for 3 h. The catalyst was filtered and washed well 
2‘o 3p o — \  1 with de-ionised water and methanol. The filtrate was
2-o3p o X ^ H  2_
h o  v 0 P ° 3  concentrated to a glassy solid. The residue was
dissolved in de-ionised water (1 mL) and applied to a Diaion WK-20 resin column (Na+ 
form), which was developed by water. The eluent was concentrated under reduced 
pressure to give the title trisphosphate (0.012 mmol, 46%) as its sodium salt.
' h  NMR (400 MHz; D20 )  <5k 8.02 (s, 1 H, H-8), 8.00 (s, 1 H, H-2), 6.04 (d, 1 H, J vx  6.6 
Hz, H -l'), 5.15 (d, 1 H, J r x  3.9 Hz, H-l"), 5.08-5.03 (m, 1 H, H-2'), 4.55-4.41 (m, 1 H, 
H-3’), 4.32-4.21 (m, 3 H, H-4’, H-4", Ntf), 3.83-3.44 (m, 7 H, H-5'a, H-5'b, H-2", H-3", 
H-5", H-6"a, H-6"b) and 1.99-1.42 (m, 9 H, cyclopentyl ring); 3IP NMR (162 MHz; 
D20 ; ‘H decoupled) <5> 3.28, 2.56 and 1.59; MS: (FAB) m/z 736.2 [(M+H)+, 44%], m/z 
calcd fo rC 2iH34N5O i8P3 [M -H ]'736.1033, found m/z 736.1019:
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7.5.5 Synthesis of 6-methylamino adenophostin
2,,3n>4"-Tri-0-acetyl-2,,,5,>6"-tri-0-benzyl-3,-0-a-D-glucopyranosyl-6- 
methylamino-9-^-D-ribofuranosylpurine (81).
NHMe Methylamine hydrochloride (218 mg, 3.2 mmol) was added
pressure. It was extracted with ethyl acetate (30 mL) and washed with water (20 mL). 
The extracts were dried (MgSC>4), filtered and concentrated under reduced pressure to 
leave an o il,. which was purified by flash chromatography on silica using 
dichloromethane-acetone (40:1) as eluent to give the title compound (260 mg, 67%) as a 
colourless oil.
[a ]20D +40.0 (c 0.60, CHCI3); 'H  NMR (400 MHz; CDC13) A  8.41 (s, 1 H, H-8), 8.04 (s,
CH3CO); 13C NMR (100 MHz; CDCb) 170.05, 169.95, 169.51 (3 x OCOCH3), 155.24
(NCH3) and 20.98, 20.80, 20.53 (3 x CH3CO); MS: (FAB) m/z 840.3 [(M+H)+, 42%], 
m/z calcd for C44H49N5O 12 [M+H] 840.3455 found m/z 840.3469:
to a solution o f 73 (390 mg, 0.46 mmol), triethylamine (0.9 
N n mL, 6.4 mmol) in dichloromethane (5 mL) and ethanol (1
mL). The mixture was heated at 60 °C overnight, after 
3Ac which it was cooled and concentrated under reduced
1 H, H-2), 7.40-7.23 (m, 15 H, AiCH ), 6.30 (d, 1 H, J V,T 5.1 Hz, H -l'), 5.87 (broad s, 1 
H, NT/), 5.71 (t, 1 H, J 2',v=J2',3' 5 A Hz, H-2'), 5.42 ( t , 1 H, Jy^= Jy ,r 9.S Hz, H-3"), 5.03 
(t, 1 H, Jr ,y=Jr,5-9.8 Hz, H-4"), 4.97 (d, 1 H, J r ,y 3.5 Hz, H-l"), 4.75 (t, 1 H, Jy,T =Jy,4<
5.1 Hz, H-3'), 4.61 (AB, 1 H, Jab 12.1 Hz, 0.5 x OCH2Ai \  4.56-4.44 (m, 5 H, H-4', 2 x 
O C//2Ar), 4.41 (AB, 1 H, Jab 12.1 Hz, 0.5 x OC/T2Ar), 3.99-3.95 (m, 1 H, H-5"), 3.74 
(dd, 1 H, j y a,4- 2.7 Hz, jy ^  10.9 Hz, H-5'a), 3.64 (dd, 1 H, J5^  3.1 Hz, J ^  10.9 Hz, 
R S'b), 3.54 (dd, 1 H, Jy,r  3.5 Hz, Jy,y  9.8 Hz, H-2"), 3.39-3.33 (m, 2 H, H-6"a, H-6"b),
3.19 (broad s, 3 H, NCT/3), 1.97 (s, 3 H, CH3CO), 1.93 (s, 3 H, CH3CO) and 1.88 (s, 3 H,
(C-2), 153.21 (C-4), 153.20 (C-6), 138.00 (C-8), 137.43, 137.26, 137.20 (3 x C-l Bn 
ether ring), 128.41, 138.32, 127.82, 127.79, 127.64, 127.60, 127.56 (ArCH), 97.90 (C- 
1"), 86.07 (C-l'), 82.38, 76.69, 76.59, 76.33 (4 x CH), 74.25, 73.58, 73.47 (3 x 




NaOMe (5 mg, cat) was added to a solution o f 81 (100 mg, 
0.12 mmol) and the mixture was stirred for 30 min. It was 
\  J  then concentrated under reduced pressure to leave a white 




oh with chloroform (3 x 20 mL). The combined extracts were
o
dried (MgSCU), filtered and concentrated under reduced 
pressure to give an oil (80 mg, 94%) which was crystallised from methanol, 
m .p.174-175 °C; [cc]20D 0.00 ± 1 (c 0.4, CHC13); *H NMR (400 MHz; CDC13) Sn 8.31 (s, 
1 H, H-8), 8.02 (s, 1 H, H-2), 7.49-7.22 (m, 15 H, ArC//), 6.25 (d, 1 H, JV,T 5.9 Hz, H- 
1’), 6.09 (broad s, 1 H, NH), 5.67 (broad s, 1 H, OH), 4.80 (d, 1 H, 3.5 Hz, H-l"), 
4.70 (AB, 1 H, Jab 11.7 Hz, 0.5 x OCH2Ai), 4.68^1.38 (m, 7 H, H-2’, H-3’, 2.5 x 
OCH2Ai), 4.19—4.18 (m, 1 H, H-4’), 4.11 ( t , 1 H, Jy%r = J y A«9J  Hz, H-3"), 3.96-3.90 
(m, 1 H, H-5"), 3.78-3.60 (m, 3 H, H-4", H-6"a, H-6"b), 3.58-3.47 (m, 2 H, H-5'a, H- 
51)), 3.42 (dd, 1 H, Jr ,r 3.5 Hz, Jr ,y 9.7 Hz, H-2") and 3.18 (broad s, 3 H, NCH3); 13C 
NMR (100 MHz; CDC13) 155.32 (C-6 , C-2), 152.64 (C-4), 137.88, 137.76, 137.30 (3 x 
C-l Bn ether ring), 136.64 (C-8), 128.63, 128.55, 128.40, 128.33, 128.22, 127.78, 127.55 
(ArCH), 119.87 (C-5), 99.50 (C-l"), 87.82 (C -l’), 86.63, 83.03, 79.12, 76.02 (4 x CH), 
73.90, 73.62 (3 x OCH2Ar), 73.43, 72.81 (2 x CH), 71.98 (C-5f or C-6"), 69.93 (CH), 
69.56 (C-5’ or C-6"), and 48.05 (NCH3); MS: (FAB) m/z calcd for C38H43N5O9 [M+H]+ 
714.3139 found m/z 714.3139. Anal. Calcd for C38H43N5O9 C, 63.94; H, 6.07; N 9.81%. 
Found: C, 63.60; H, 6.03; N 9.59%:
2n,5,,6,,-Tri-0-benzyl-2,,3M,4M-tris(dibenzyloxyphosphoryl)-3,-0-a-D- 
glucopyranosyl- 6- methylamino -9-fi-D- ribofuranosylpurine (83).
NHMe Bis(benzyloxy)(diisopropylamino)phosphine (232
mg, 0.67 mmol) and 1/7-tetrazole (71 mg, 1.01 
Bno BnO'-'A 0 mmol) were stirred together in dichloromethane (3
b )  (  mL) for 30 min, the mixture thus obtained was then
B (0 0P(0)(0Bn)2 added to 82 (80 mg, 0.1 mmol). After a further 20
min, TLC (ethyl acetate:methanol, 95:5) indicated conversion of starting material to a
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single trisphosphite. The reaction mixture was then cooled to -78 °C and mCPBA (192 
mg, 0.67 mmol) was added. After 10 min, 10 % aq. Na2SC>3 solution (15 mL) and ethyl 
acetate (20 mL) were added and the mixture was allowed to heat up to room temperature. 
The resulting organic layer was washed with sat. aq. NaHCC>3 solution (15 mL) and 
brine (15 mL). The organic layer was dried (MgSC^), filtered and concentrated under 
reduced pressure to leave an oil, which was purified by flash chromatography on silica 
using ethyl acetate-hexane (1:1 then 4:1) to give the title compound (60 mg, 36%) as a 
colourless oil.
‘H NMR (400 MHz; CDC13) *  8.31 (s , 1 H, H-8), 7.83 (s , 1 H, H-2), 7.52-6.95 (m, 45 
H, AiCH), 6.32 (d, 1 H, J r,x 6.2 Hz, H -l'), 5.73 (br s, 1 H, NH), 5.65-5.60 (m, 1 H, H- 
2'), 5.32 (d, 1 H, J\'\2" 3.5 Hz, H-l"), 5 .05 ^ .8 6  (m, 8 H, H-3", 3.5 x OCH2Ar), 4.76-4.36 
(m, 13 H, H-3', H-4’, H-4", 5 x O C #2Ar), 4.30 (AB, 1 H, 0.5 x OCH2Ar), 3.84-3.82 (m, 
1 H, H-5"), 3.66-3.53 (m, 5 H, H-5’a, H-5 t>, H-2", H-6"a, H-6"b) and 3.16 (s , 3 H, 
NCH3); 31P NMR (162 MHz; CDC13; 'H  decoupled) * -0 .2 4 , -0.91, -1.05; MS: (FAB) 






NHMe A mixture o f 83 (28 mg, 0.018 mmol) and Pd(OH)2 on 
carbon (10%, 45 mg) in cyclohexene (3 mL), methanol 
(6 mL) and water (0.5 mL) was heated at 65 °C for 3 h. 
The catalyst was filtered and washed well with de­
ionised water and methanol. The filtrate was 
concentrated to a glassy solid. The residue was dissolved in de-ionised water (1 mL) and 
applied to a Diaion WK-20 resin column (Na+ form), which was developed by water. 
The eluent was concentrated under reduced pressure to give the title trisphosphate (0.016 
mmol, 80%) as its sodium salt.
*H NMR (400 MHz; D20 )  Sa 8.09 (s, 2 H, H-2, H-8), 6.12 (d, 1 H, JV,T 6.6 Hz, H -l'),
5.20 (d, 1 H, J v ,2" 3.9 Hz, H-l"), 5.17-5.11 (m, 1 H, H-2'), 4 .49^ .48  (m, 1 H, H-3'), 
4.38-4.30 (m, 3 H, H-4', H-3", NH), 3.87 (m, 1 H, H-4"), 3.78-3.59 (m, 6 H, H-5'a, H- 
5*b, H-2", H-5", H-6"a, H-6"b) and 2.92 (s, 3 H, NCH3); 31P NMR (162 MHz; D20 ; *H
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decoupled) 5? 2.45, 2.10 and 0.86; MS: (FAB) m/z 682.1 [(M-H)“, 84%], m/z calcd for 
C17H28N5O18P3 [M -H]' 682.0564 found m/z 682.0567:
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7.5.6 Synthesis of 6-dimethylamino adenophostin
2,,3,,,4,'-Tri-0-acetyl-2",5,,6,'-tri-0-benzyl-3,-0-a-D-glucopyranosyl-6- 
dimethylamino-9-/^D-ribofuranosylpurine (85).
NMe2 Dimethylamine hydrochloride (180 mg, 2.20 mmol) was 
/ T ?  added to a solution o f 73 (300 mg, 0.35 mmol), triethylamine 
(0.62 mL, 4.4 mmol) in dichloromethane (5 mL) and ethanol 
(1 mL). The mixture was heated at 60 °C 2 h, after which it 
was cooled and concentrated under reduced pressure. It was 
extracted with ethyl acetate (30 mL) and washed with water (20 mL). The extracts were 
dried (MgSCU), filtered and concentrated under reduced pressure to leave an oil, which 
was purified by flash chromatography on silica using dichloromethane-acetone (50:1 
then 9:1) as eluent to give the title compound (290 mg, 96%) as a colourless oil.
[a]20D +52.9 (c 0.55,CHC13); !H NMR (400 MHz; CDC13) 8.46 (s, 1 H, H-8), 8.17 (s, 
1 H, H-2), 7.47-7.17 (m, 15 H, AiCH), 6.44 (d, 1 H, JV,T 5.1 Hz, H -l'), 5.82 (t, 1 H, JT,v 
—Ji\y 5.1 Hz, H-2’), 5.53 ( t , 1 H, Jr ,2" =Jy,r  9.8 Hz, H-3"), 5.16 (t, 1 H, J r tr= Jr ,y 9.8 
Hz, H-4"), 5.08 (d, 1 H, Jr ,r  3.5 Hz, H-l"), 4.85 (t, 1 H, Jy?  =JyA> 5.1 Hz, H-3’), 4.74 
(AB, 1 H, A b  12.1 Hz, 0.5 x O C//2Ar), 4.70-4.57 (m, 5 H, H-4', 2 x OC/72Ar), 4.43 
(AB, 1 H, Jab 12.1 Hz, 0.5 x OCtf2Ar), 4.11^1.06 (m, 1 H, H-5"), 3.85 (dd, 1 H, J5%4' 2.7 
Hz, Jy a.s'b 10.9 Hz, H-5'a), 3.75 (dd, 1 H, %  3.1 Hz, A b)5-a 10.9 Hz, H-5T)), 3.67-3.64 
(m, 7 H, H-2", N (C //3)2), 3.52-3.44 (m, 2 H, H-6"a, H-6"b), 2.08 (s, 3 H, C tf3CO), 2.04 
(s, 3 H, C //3CO) and 1.99 (s, 3 H, CH3CO); 13C NMR (100 MHz; CDC13) 170.05, 
169.92, 169.49 (3 x OCOCH3), 154.68 (C-2), 152.39, 150.18 (C-4, C-6), 137.43 (C-8), 
137.25, 137.24, 136.38 (3 x C-l Bn ether ring), 128.36, 128.28, 12.8.18, 127.79, 127.71, 
127.67, 127.61, 127.52 (ArCH), 97.80 (C-l"), 85.93 (C-l'), 82.23, 76.57, 76.16, 76.33 (4 
x CH), 74.13, 73.52, 73.43 (3 xOCH2Ar), 73.21, 71.77 (2 x CH), 69.09, 69.05 (C-5\ C- 
6"), 68.93 (CH), 38.62, 31.01 (NCH3) and 20.95, 20.77, 20.52 (3 x CH3CO); MS: (FAB) 
m/z 854.2 [(M+H)+, 48%], m/z calcd for C45H5oNsOi2 [M+H] 854.3567, found m/z 
854.3619; Anal. Calcd for C45H5oN5Oi2 C, 63.30; H, 5.90; N 8.27%. Found: C, 62.80; 




NMe2 NaOMe (30 mg, cat) was added to a solution o f 85 (290 mg, 
Njj 0.34 mmol) in methanol and the mixture was stirred for 30 
N min. It was then concentrated under reduced pressure to 
leave a white solid, which was washed with water (10 mL) 
and extracted with chloroform (3 x 20 mL). The combined 
extracts were dried (MgSCU), filtered and concentrated under reduced pressure to give an 
oil which was crystallised from methanol (140 mg, 57%).
m.p.153-155 °C; [a]20D +2.2 ± 1 (c 0.45,CHC13); 'H  NMR (400 MHz; CDC13) <Sh 8.26 (s, 
1 H, H-8), 8.02 (s, 1 H, H-2), 7.35-7.24 (m, 15 H, AiCH), 6.20 (d, 1 H, J vx  6.6 Hz, H- 
1'), 4.85 (d, 1 H, J ]",2" 3.5 Hz, H-l"), 4.76-4.38 (m, 8 H, H-2', H-3', 3 x OCtf2Ar), 4.25- 
4.23 (m, 1 H, H-4’), 4.08 ( t , 1 H, JyX =J3-A-9 .8 Hz, H-3"), 3.91-3.88 (m, 1 H, H-5"), 
3.69-3.49 (m, 11 H, H-5'a, H-5'b, H-4", H-6"a, H-6"b, N(CH3)2) and 3.41 (dd, 1 H, JTy
3.5 Hz, Jr ,y 9.8 Hz, H-2"); 13C NMR (100 MHz; CDC13) 154.77 (C-6), 151.72 (C-2), 
150.00 (C-4), 137.76, 137.34, 136.55 (3 x C-l Bn ether ring), 136.26 (C-8), 128.74, 
128.59, 128.41, 128.23, 127.75, 127.58,127.55, 127.52 (ArCH), 120.19 (C-5), 99.55 (C- 
1"), 87.48 (C -l’), 83.07, 80.47, 79.09, 76.25 (4 x CH), 73.84, 73.59, 73.56 (3 xOCH2Ar), 
72.72 (CH), 71.99 (CH), 69.91 (C-5' or C-6"), 69.64 (CH), 69.54 (C-5' or C-6"), 38.86, 
(NCH3); MS: (FAB) m/z calcd for C39H45N50 9 [M+H]+ 728.3250 found m/z 728.3280:
2",5',6"-Tri-0-benzyl-2',3",4"-tris(dibenzyloxyphosphoryl)-3'-0-a-D- 
glucopyranosyl- 6-dimethylamino -9-p-D- ribofuranosylpurine (87).
NMe Bis(benzyloxy)(diisopropylamino)phosphine (110
mg, 0.3 mmol) and l//-tetrazole (35 mg, 0.5 mmol)
were stirred together in dichloromethane (3 mL) for
(BnO M O po^V^^ \  1 30 min, the mixture thus obtained was then added to(Bn6)2(0)P0-A^-^X r ~ \
Bno^ J/ op(0)(OBn)2 mg^  q Q5 mmoi) After a further 20 min, TLC
(ethyl acetate:methanol, 95:5) indicated conversion of starting material to a single 
trisphosphite. The reaction mixture was then cooled to -78  °C and mCPBA (206 mg, 
0.72 mmol) was added. After 10 min, 10 % aq. Na2SC>3 solution (15 mL) and ethyl 





The resulting organic layer was washed with sat. aq. NaHCC>3 solution (15 mL) and 
brine (15 mL). The organic layer was dried (MgS04), filtered and concentrated under 
reduced pressure to leave an oil, which was purified by flash chromatography on silica 
using ethyl acetate-hexane (1:1 then 4:1) to give the title compound (45 mg, 54%) as a 
colourless oil.
'H  NMR (400 MHz; CDC13) <5k 8.26 (s, 1 H, H-8), 7.89 (s, 1 H, H-2), 7.39-6.95 (m, 45 
H, ArCH), 6.37 (d, 1 H, J y,r 6.3 Hz, H -l'), 5.69-5.64 (m, 1 H, H-2'), 5.32 (d, 1 H, Jr ,r
3.5 Hz, H-l"), 5.09 (AB, 1 H, Ja b  11.7 Hz, 0.5 x O C//2Ar), 5.06-4.85 (m, 10 H, H-3",
4.5 x OC/72Ar), 4.47-4.36 (m, 10 H, H-3’, H-4', H-4", 3.5 x OCtf2Ar), 4.29 (AB, 1 H, 
J a b  11.7 Hz, 0.5 x OCffzAr), 3.84-3.82 (m, 1 H, H-5") and 3.65-3.43 (m, 11 H, H-5’a, 
H-5t>, H-2", H-6"a, H-6"b, N(Cff3)2); 31P NMR (162 MHz; CDCI3; 'H  decoupled) S?- 
0.05, -0.66, -0.82; MS: (FAB) m/z 1508.4 [(M+H)+, 79%], m/z calcd for C8iH84N5Oi8P3 
[M+H]+ 1508.5102 found m/z 1508.5068:
3'-0-a-D-Glucopyranosyl-6-methylamino-9-/?-D-ribofuranosylpurine 
2',3",4"-trisphosphate (88).
NMe2 a  mixture o f 87 (20 mg, 0.013 mmol) and Pd(OH)2 on
car'50n ^0 mg) in cyclohexene (3 mL), methanol (6
H0~-\ ho' 'V on/n N mL) and water (0.5 mL) was heated at 70 °C for 2 hours.
2-o 3p o - A - Q  W
2 o3p o 4 - ^ 4  J—\  xhe catalyst was filtered and washed well with de-ionised
HO 1/ op°3
0 water and methanol. The filtrate was concentrated to a
glassy solid. The residue was dissolved in de-ionised water (1 mL) and applied to a 
Diaion WK-20 resin column (Na+ form), which was developed by water. The eluent was 
concentrated under reduced pressure and purified by HPLC to give the title trisphosphate 
(4 pmol, 31%) as the free acid.
'H  NMR (400 MHz; D20 )  <5h 8.29 (s, 1 H, H-8), 8.17 (s, 1 H, H-2), 6.19 (d, 1 H, 6.6 
Hz, H -l'), 5.12 (d, 1 H, Ji-,2- 3.9 Hz, H-l"), 5.10-5.05 (m, 1 H, H-2'), 4.46-4.44 (m, 1 H, 
H-3'), 4.34-4.27 (m, 2 H, H-4', H-3"), 3.93-3.86 (m, 1 H, H 4") and 3.71-3.56 (m, 12 H, 
H-5'a, H-5t>, H-2", H-5", H-6"a, H-6"b, N (C //3)2); 31P NMR (162 MHz; D20 ; 'H  
decoupled) & 4.61 2 x P and 4.52; MS: (FAB) m/z 698.0 [(M+H)+, 40%], m/z calcd for 
Ci8H3oN5Oi8P3 [M + H f 698.0877 found m/z 698.0894:
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7.5.7 Synthesis of 6-cyclohexylamino adenophostin
2 \5 ,,6"-Tri-0-benzyl-3,-0-a-D-glucopyranosyl-6-cyclohexylamino-9->£- 
D-ribofuranosylpurine (90).
(MgSC>4), filtered and concentrated under reduced pressure to leave an oil. The oil was 
dissolved in methanol and NaOMe (30 mg, cat) was added and the mixture was stirred 
for 30 min. It was the concentrated under reduced pressure to leave a white solid, which 
was washed with water (10 mL) and extracted with chloroform (3 x 20 mL). The 
combined extracts were dried (MgS04 ), filtered and concentrated under reduced pressure 
to give an oil which was crystallised from methanol (70 mg, 50%).
m.p. 103-106 °C; [a f°D +0.01 ± 1 (c 0.38,CHC13); 'H  NMR (400 MHz; CDC13) <5k 8.26
cyclohexyl), 1.68-1.66 (m, 1 H, cyclohexyl), 1.52-1.42 (m, 2 H, cyclohexyl) and 1.34—
1.22 (m, 2 H, cyclohexyl); 13C NMR (100 MHz; CDC13) 154.33 (C-2), 152.94 (C-4, C-
72.46 (2 x CH), 70.31 (CH2), 69.91 (CH2 and CH), 33.68, 26.04 and 25.33 (3 x CH2); 
MS: (FAB) m/z 782.3 [(M+H)+, 60%], m/z calcd for C43H51N5O9 [M+H]+, 782.3765
Cyclohexylamine (0.08 mL, 1.06 mmol) was added to a 
solution of 73 (150 mg, 0.17 mmol), triethylamine (0.15 
mL, 1.06 mmol) in dichloromethane (5 mL) and ethanol (1
J  mL). The mixture was heated at 60 °C overnight, after 
which it was cooled and concentrated under reduced 
pressure. It was extracted with ethyl acetate (30 mL) and 
washed with water (20 mL). The extracts were dried
(s, 1 H, H-8), 8.01 (s, 1 H, H-2), 7.37-7.22 (m, 15 H, AiCH), 6.25 (d, 1 H, Jv,x 6.3 Hz, 
H -l'), 5.85 (broad s, 2 H, NH, OH), 4.78 (d, 1 H, Jr ,r  3.5 Hz, H -l"), 4.65 (AB, 1 H, Jab
11.7 Hz, 0.5 x OC//2Ar), 4.59-4.38 (m, 7 H, H-2', H-3', 2.5 x O Ci/2Ar), 4.17-4.09 (m, 3 
H, H-4', H-3", OH), 3.97-3.94 (m, 1 H, H-5"), 3.76-3.64 (m, 3 H, H-4", H-6"a, H-6"b),
3.58-3.51 (m, 2 H, H-5'a, H-5*b), 3.47 (d, 1 H, J 5 A  Hz, cyclohexyl), 3.41 (dd, 1 H, JT,r
3.5 Hz, JT,y 9.9 Hz, H-2"), 2.11-1.91 (m, 3 H, cyclohexyl), 1.91-1.77 (m, 2 H,
6), 138.09 (C-8), 137.95, 137.59, 136.84 (3 x C-l Bn ether ring), 129.06, 128.90, 128.77,
128.72, 128.54, 128.16, 127.94, 127.89 (ArCH), 119.87 (C-5), 99.97 (C-l"), 87.82 (C- 
1’), 83.43, 82.06, 81.05, 79.53, 76.74 (5 x CH), 74.22, 73.97, 73.92 (3 xOCH2Ar), 73.01,
188
found m/z 782.3768. Anal. Calcd for C43H51N5O9 C, 66.05; H, 6.57; N 8.96%. Found: 
C, 65.7; H, 6.52; N 8.83%:
2,,,5,,6"-Tri-0-benzyl-2',3,,J4,,-tris(dibenzyloxyphosphoryl)-3,-0-a-D- 
glucopyranosyl- 6-cyclohexylamino -9-fi-D- ribofuranosylpurine (91).
reaction mixture was then cooled to -78  °C and wiCPBA (103 mg, 0.35 mmol) was 
added. After 10 min, 10 % aq. Na2SC>3 solution (15 mL) and dichloromethane (20 mL) 
were added and the mixture was allowed to heat up to room temperature. The resulting 
organic layer was washed with sat. aq. NaHC03 solution (15 mL) and brine (15 mL). 
The organic layer was dried (MgS04), filtered and concentrated under reduced pressure 
to leave an oil, which was purified by flash chromatography on silica using ethyl 
acetate-hexane (2:3 then 1:1 then 4:1) to give the title compound (55 mg, 68%) as a 
colourless oil.
lH NMR (400 MHz; CDCI3) &  8.28 (s, 1 H, H-8), 7.82 (s, 1 H, H-2), 7.39-6.94 (m, 45
31P NMR (162 MHz; CDC13; 'H  decoupled) * - 0 .2 3 ,  -0.89, -1.05; MS: (FAB) m/z 





mg, 0.3 mmol) and l//-tetrazole (32 mg, 0.46 
mmol) were stirred together in dichloromethane (3 
mL) for 30 min, the mixture thus obtained was then 
added to 90 (40 mg, 0.05 mmol). After a further 20 
min, TLC (ethyl acetate) indicated conversion of 
starting material to a single trisphosphite. The
H, AiCH), 6.32 (d, 1 H, JV,T 6.6 Hz, H -l'), 5.69 (br s, 1 H, NH), 5.64-5.59 (m, 1 H, H- 
2'), 5.31 (d, 1 H, J r ,r  3.5 Hz, H-l"), 5.08-4.30 (m, 21 H, H-3’, H-4', H-3", H-4", 8.5 x 
OC/72Ar,), 4.30 (AB, 1 H, J ab 11.7 Hz, 0.5 x O C//2Ar), 3.89-3.81 (m , 1 H, H-5"), 3.66-






ribofuranosylpurine 2 \3 f\4"-trisphosphate (92).
A mixture of 91 (25 mg, 0.016 mmol) and Pd(OH)2 on 
carbon (10%, 45 mg) in cyclohexene (3 mL), methanol 
(6 mL) and water (0.5 mL) was heated at 70 °C for 2 
hours. The catalyst was filtered and washed well with 
de-ionised water and methanol. The filtrate was 
concentrated under reduced pressure to a glassy solid. 
The residue was dissolved in de-ionised water (1 mL) 
and applied to a Diaion WK-20 resin column (Na+ form), which was developed by water. 
The eluent was concentrated under reduced pressure to give the title trisphosphate 
(15.27 //mol, 95%) as the sodium salt.
!H NMR (400 MHz; D20 ) 8.07 (s, 1 H, H-8), 8.03 (s, 1 H, H-2), 6.09 (d, 1 H, J V,T 6.3
Hz, H -l'), 5.19 (d, 1 H, 3.5 Hz, H-l"), 5.14-5.08 (m, 1 H, H-2'), 4.5£-4.49 (m, 1 H, 
H-3'), 4.35—4.26 (m, 3 H, H-4', H-3", H-4") and 3.89-3.58 (m, 6 H, H-5'a, H-5T), H-2", 
H-5", H-6"a, H-6"b), 1.89-1.82 (m, 2 H, cyclohexyl), 1.73-1.59 (m, 2 H, cyclohexyl), 
1.49-1.45 (m, 1 H, cyclohexyl) and 1.35-1.08 (m, 6 H, cyclohexyl); 31P NMR (162 
MHz; D20 ;  ‘H decoupled) Se 3.31, 2.66 and 1.49; MS: (FAB) m/z 752.1 [(M+H)+, 
60%], w/z calcd for C22H36N50 ,8P3 [M+H]+752.1346 found m/z 752.1361:
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7.5.8 Synthesis of 2,6 disubstituted compounds
2',3,,>4"-Tri-0-acetyl-2,,,5,l6,,-tri-0-benzyl-3,-0-a-D-glucopyranosyl- 
2,6-dichloro-9-^-D-ribofuranosylpurine (93).
TMSOTf (0.6 mL, 3.3 mmol) was added cautiously 
drop wise to a stirred solution o f 56 (500 mg, 0.66 mmol),
 . dmw v u ; ci 2,6-dichloropurine (138 mg, 0.73 mmol) and DBU (0.4
Acaco^ ^ A  ) \ QA mL, 2.67 mmol) in acetonitrile (5 mL) at 0 °C. The
0 mixture was heated at 60 °C for 1 h, after which it was
cooled and quenched by careful addition of sat. aq. NaHCC>3 solution (25 mL). The 
mixture was extracted with dichloromethane (3 x 30 mL) and the combined extracts 
were dried (MgS04), filtered and concentrated under reduced pressure to leave a yellow 
oil. Purification by flash chromatography on silica using ethyl acetate-hexane (3:7) as 
eluent gave the title compound (390 mg, 67%) as a colourless oil.
[a]20D +63.3 (c 0.44, CHCI3); ‘H NMR (400 MHz; CDC13) A  8.45 (s, 1 H, H-8), 7 .37- 
7.16 (m, 15 H, AiCH), 6.37 (d, 1 H, JV2- 5.6 Hz, H -l'), 5.61 (t, 1 H, J2',v=Jz,y 5.6 Hz, H- 
2'), 5.45 (t, 1 H, Jy,4- 9.8 Hz, H-3”), 5.02 (t, 1 H, Jr ,y =J4-,5- 9.8 Hz, H-4"), 4.97 (d,
1 H, J r x  3.5 Hz, H-l"), 4.69 (dd, 1 H, Jy,*3.5 Hz, J 3.2. 5.6 Hz, H-3'), 4.63 (AB, 1 H, Tab
12.1 Hz, 0.5 x OCH2Ar), 4.56-4.42 (m, 5 H, 2 x OCH2Ar, H-4'), 4.36 (AB, 1 H, Jab 12.1 
Hz, 0.5 x OCtf2Ar), 4.02-3.98 (m, 1 H, H-5"), 3.70 (dd, 1 H, J5%v 2.4 Hz, J5X5% 10.9 Hz, 
H-5'a), 3.60-3.55 (m, 2 H, H-2", H-5'b), 3.45-3.38 (m, 2 H, H-6"a, H-6 " b), 1.99 (s, 3 H, 
C //3CO), 1.96 (s, 3 H, CH3CO) and 1.89 (s, 3 H, C //3CO); 13C NMR (100 MHz; CDC13) 
169.88, 169.88, 169.43 (3 x OCOCH3), 152.86 (C-4 or C-6), 152.51 (C-2), 151.48 (C-4 
or C-6), 144.02 (C-8), 137.23, 137.13, 136.59 (3 x C -l Bn ether ring), 130.81 (C-5), 
128.45, 128.27, 128.14, 127.97, 127.82, 127.71, 127.60 (ArCH), 98.12 (C-l"), 86.43 (C- 
1’), 83.46, 76.68, 76.49, 74.96, 74.59 (5 x CH), 73.64, 73.43, 73.15 (3 x OCH2Ar), 
71.61, 69.25 (2 x CH), 67.11 (C-5’ or C-6"), 68.91 (CH), 67.96 (C-51 or C-6”), 20.89, 
20.70, 20.33 (3 x CH3CO); MS: (FAB) m/z 879.1 [(M+H)+, 83%], m/z calcd for 
C43H43N4Oi2C12 [M+H]+37C12 883.2352 found m/z 883.2394, [M+H]+35C1,37C1 881.2381 
found m/z 881.2391, [M+H]+ 35C12 879.2411 found m/z 879.2400; Anal. Calcd for 
C43H43N40 , 2C12 C, 58.64; H, 5.15; N 6.36%. Found: C, 58.80; H, 5.09; N 5.94%:
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7.5.8.1 Synthesis of 2-methoxy-6-methylamino Adenophostin
2,,3,,,4"-Tri-0-acetyl-2",5,,6,,-tri-0-benzyl-3,-0-a-D-glucopyranosyl-2- 
chloro-6-methylamino-9-/?-D-ribofuranosylpurine (94).
reduced pressure. It was extracted with ethyl acetate (30 mL) and washed with water (20 
mL). The extracts were dried (MgSCU), filtered and concentrated under reduced pressure 
to leave an oil, which was purified by flash chromatography on silica using 
dichloromethane-acetone (40:1) as eluent to give the title compound (260 mg, 67%) as a 
colourless oil.
'H  NMR (400 MHz; CDCI3) <5h 7.99 (s, 1 H, H-8), 7.36-7.24 (m, 15 H, ArCH), 6.27 (d,
or C-6"), 31.0 (NCH3), 20.9, 20.8, 20.5 (3 x CH3CO); MS: (FAB) m/z 874.1 [(M+H)+, 
90%], m/z calcd for C44H47N5O 12CI [M+H]+ 37C1 876.2992 found m/z 876.3042, [M+H]+ 
35C1 874.3021 found m/z 874.3043:
NHMe Methylamine hydrochloride (179 mg, 2.6 mmol) was 
added to a solution o f 93 (390 mg, 0.44 mmol),
o
‘ci triethylamine (0.74 mL, 5.3 mmol) in dichloromethane (5 
mL) and ethanol (1 mL). The mixture was heated at 60 °C 
for 4 h, after which it was cooled and concentrated under
1 H, J\\y 5.5 Hz, H -l'), 6.16 (broad s, 1 H, Nfl), 5.61 (t, 1 H, J?,v=JT,y 5.5 Hz, H-2'), 
5.43 (dd , 1 H, J y ^  l0 A J r ,r 9.4 Hz, H-3"), 5.05 (t, 1 H, Jr,y= Jr,5" 9.4 Hz, H-4"), 4.97 
(d, 1 H, JV.,2" 3.5 Hz, H-l"), 4.71 (t, 1 H, J y ,T = J y ,4. 5.5 Hz, H-3'), 4.62 (AB, 1 H, Jab 12.1 
Hz, 0.5 x O C//2Ar), 4.55-4.47 (m, 5 H, H-4', 2 x OCH2Ai), 4.34 (AB, 1 H, Jab 12.1 Hz, 
0.5 x OCH2Ai), 4.00-3.96 (m, 1 H, H-5"), 3.63 (dd, 1 H, 2.7 Hz, J 5-a.s-b 10.9 Hz, H-
5'a), 3.55 (dd, 1 H, J 5<b,4- 3.1 Hz, J 5-b,5'a 10.5 Hz, H-5T)), 3.40 (dd, 1 H, J r r  3.5 Hz, J 2»,y
10.1 Hz, H-2"), 3.36-3.26 (m, 2 H, H-6"a, H-6"b), 3.16 (broad s, 3 H, NCH3), 1.98 (s, 3 
H, C //3CO), 1.94 (s, 3 H, C/ACO) and 1.89 (s, 3 H, CJ/3CO); 13C NMR (100 MHz; 
CDCI3) 170.1, 169.9, 169.5 (3 x OCOCH3), 155.7, 149.4 (C-6 , C-4), 138.3 (C-8), 137.4, 
137.3, 137.2 (3 x C-l Bn ether ring), 132.8 (C-2), 128.4, 128.2, 127.8, 127.7, 127.6, 
127.5, (ArCH), 118.9 (C-5), 98.0 (C-l"), 85.9 (C-l'), 82.7, 76.5, 74.5 (3 x CH), 73.6, 








NaOMe (10 mg, 0.16 mmol) was added to a solution of
NHMe
94 (70 mg, 0.08 mmol) in methanol and the mixture was 
stirred at 65 °C overnight. It was then concentrated under 
reduced pressure to leave a white solid, which was 
washed with water (10 mL) and extracted with 
chloroform (3 x 20 mL). The combined extracts were dried (MgS04), filtered and 
concentrated under reduced pressure to give an oil (50 mg, 84%).
'H  NMR (400 MHz; CDC13) <5h 7.97 (s, 1 H, H-8), 7.37-7.21 (m, 15 H, AiCH), 6.28 (br 
s, 1 H, NH), 6.22 (d, 1 H, J v?  6.3 Hz, H -l'), 4.73 (d, 1 H, J r r  3.5 Hz, H-l"), 4.65 (AB, 
1 H, Jab 11.7 Hz, 0.5 x OCtf2Ar) 4.50-4.38 (m, 7 H, H-2', H-4', 2.5 x OCH2Ai ), 4.16-
4.11 (m, 3 H, H-3', H-3", H-5"), 3.92-3.87 (m, 1 H, H-6"a), 3.74 (t, 1 H, J 3V.= J3V. 10.0
Hz, H-4"), 3.66 (dd, 1 H ,76 V  3.1 Hz, Js%6-d 10.5 Hz, H-6"b), 3.53-3.48 (m, 2 H, H-5'a, 
H-5'b), 3.41 (dd, 1 H, J 2-,r 3.5 Hz, J 2-,3- 10.0 Hz, H-2") and 3.14 (s, 3 H, NC/73); MS: 
(FAB) m/z 748.2 [(M+H)+, 36%], m/z calcd for CsgH^NsOsCl [M+H]+ 37C1 750.2719 
found m/z 750.2754, [M+H]+ 35C1 748.2749 found m/z 748.2759:
2',3",4"-Tri-0-acetyl-2,,,5',6"-tri-0-benzyl-3'-0-a-D-glucopyranosyl-2- 
methoxy-6-methylamino-9-/)-D-ribofu ranosyl purine (96).
NaOMe (61 mg, 1.13 mmol) was added to a solution of
NHMe
95 (100 mg, 0.11 mmol) in methanol (10 mL) and the 
mixture was heated at reflux overnight. It was the 
concentrated under reduced pressure to leave a white 
solid, which was washed with water (10 mL) and 
extracted with chloroform (3 x 20 mL). The combined extracts were dried (MgS04), 
filtered and concentrated under reduced pressure to give an oil which was purified by 
flash chromatography on silica using dichloromethane-acetone (40:1) as eluent to give 
the title compound which was crystallised from methanol (60 mg, 71%). 
m.p. 192-193 °C; [af°D +0.00 ± 1 (c 0.40, CHC13); *H NMR (400 MHz; CDC13) Sn 7.79 
(s, 1 H, H-8), 7.37-7.22 (m, 15 H, ArCH), 6.10 (d, 1 H, J VtT 6.3 Hz, H -l’), 5.93 (br s, 1 






Hz, 0.5 x OCH2Ar), 4.60-4.42 (m, 6 H, H-2', H-3', 2 x OCH2Ar), 4.70 (AB, 1 H, Jab
12.1 Hz, 0.5 x O C //2Ai), 4.31—4.29 (m, 1 H, H-4'), 3.74 ( t , 1 H, Jy,r  =Jr,4~ 9.8 Hz, H- 
3"), 3.97-3.94 (m, 2 H, H-5", OH), 3.79 (dd, 1 H, J5%4. 2.7 Hz, J s v a  10.5 Hz, H-5'a), 
3.68-3.61 (m, 4 H, H-513, H-4", H-6"a, H-6"b), 3.86 (s, 3 H, OCH3), 3.42 (dd, 1 H, J2~,r
3.5 Hz, J 2-,3- 9.8 Hz, H-2") and 3.14 (s, 3 H, NCH3); MS: (FAB) m/z 744.2 [(M+H)+, 
61%], m/z calcd for C39H45N5O 18 [M+H]+ 37C1 744.3244 found m/z 744.3246; Anal. 




glucopyranosyl- 2-methoxy-6-methylamino -9-J3-D- 
ribofuranosylpurine (97).
NHMe Bis(benzyloxy)(diisopropylamino)phosphine (83 
mg, 0.24 mmol) and li/-tetrazole (25 mg, 0.4 
mmol) were stirred together in dichloromethane 
(3 mL) for 30 min, the mixture thus obtained was 
then added to 96 (30 mg, 0.04 mmol). After a 
further 20 min, TLC (ethyl acetate) indicated conversion o f starting material to a single 
trisphosphite. The reaction mixture was then cooled to -78  °C and mCPBA (81 mg, 0.28 
mmol) was added. After 10 min, 10 % aq. Na2SC>3 solution (15 mL) and ethyl acetate 
(20 mL) were added and the mixture was allowed to heat up to room temperature. The 
resulting organic layer was washed with sat. aq. NaHC(>3 solution (15 mL) and brine (15 
mL). The organic layer was dried (MgS(>4), filtered and concentrated under reduced 
pressure to leave an oil, which was purified by flash chromatography on silica using 
ethyl acetate-hexane (2:3 then 1:1 then 4:1) to give the title compound (35 mg, 57%) as 
a colourless oil.
‘H NMR (400 MHz; CDC13) Sh 7.63 (s, 1 H, H-8), 7.37-6.96 (m, 45 H, ArCH), 6.37 (d, 
1 H, J r ,2' 6.3 Hz, H -l'), 5.82 (broad s, 1 H, NH), 5.71-5.61 (m, 1 H, H-2'), 5.33 (d, 1 H, 
J r , 2" 3.5 Hz, H-l"), 5.02-4.87 (m, 8 H, H-3", 3.5 x OCH2Ar), 4.77-4.27 (m, 14 H, H-3', 
H-4’, H-4", 5.5 x OCH2Ar), 3.86-3.80 (m, 1 H, H-5"), 3.70 (s, 3 H, OCH3), 3.69-3.53 
(m, 5 H, H-5'a, H-5'b, H-2", H-6"a, H-6"b) and 3.11 (s, 3 H, NCH3); 31P NMR (162 
MHz; CDC13; 'H  decoupled) <5p 0.04, -0.58, -0 .79; MS: (FAB) m/z 1524.1 [(M), 89%], 





NHMe A mixture o f 97 (20 mg, 0.013 mmol) and Pd(OH)2 
< J  y 0n car^on 50 mg) in cyclohexene (3 mL),
h o ^  ho^\^ov/N n oMe methanol (6 mL) and water (0.5 mL) was heated at
70 °C for 2 h. The catalyst was filtered and washed 
well with de-ionised water and methanol. The filtrate 
was concentratedunder reduced pressure to a glassy solid. The residue was dissolved in 
de-ionised water (1 mL) and applied to a Diaion WK-20 resin column (Na+ form), which 
was developed by water. The eluent was concentrated under reduced pressure and 
purified by HPLC to give the title trisphosphate (6.06 //mol, 46%) as the free acid.
'H  NMR (400 MHz; D20 )  <51,7.82 (s, 1 H, H-8), 5.99 (d, 1 H, J v s  5.1 Hz, H -l'), 5 .28-
5.23 (m, 1 H, H-2'), 5.11 (d, 1 H, 3.5 Hz, H-l"), 4.30-4.18 (m, 3 H, H-3', H-4', H- 
3"), 3.83-3.80 (m, 1 H, H-4"), 3.77 (s, 3 H, OCH3), 3.74-3.31 (m, 6 H, H-5’a, H-5'b, H- 
2", H-5", H-6"a, H-6"b) and 3.12 (s, 3 H, NCH3); 31P NMR (162 MHz; D20 ; 'H  
decoupled) <$> 3.15, 2.28 and 1.33; MS: (FAB) m/z 714.0 [(M+H)+, 69%], m/z calcd for 
C18H30N5O18P3 [M+H]+ 714.0826 found m/z 714.0860:
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7.5.8.2 Synthesis of 6-(3-noradamantylamino) adenophostin
2,l3",4"-Tri-0-acetyl-2">5,,6"-tri-0-benzyl-3'-0-a-D-glucopyranosyl-2- 
chloro-6-(-3-noradamantylamino)-9-^-D-ribofuranosylpurine (99).
3-Noradamantanamine hydrochloride (212 mg, 1.2
mmol) was added to a solution of 93 (179 mg, 0.2
HNr mmol) and triethylamine (0.34 mL, 2.4 mmol) in
dichloromethane (5 mL) and ethanol (1 mL). The
D ^ mixture was heated at 60 °C overnight, after which it
B n O ^ B n O ^ ,  n /  N Cl ^
V 7  was cooled and concentrated under reduced pressure.
bhOq 0Ac It was extracted with ethyl acetate (30 mL) and
washed with water (20 mL). The extracts were dried (MgSCU), filtered and concentrated 
under reduced pressure to leave an oil, which was purified by flash chromatography 
using ethyl acetate-hexane (4:1) as eluent to give the title compound (160 mg, 80%) as a 
colourless oil.
*H NMR (400 MHz; CDC13) &  7.97 (s, 1 H, H-8), 7.36-7.24 (m, 15 H, ArCH), 6.26 (d, 
1 H, J v ?  5.5 Hz, H -l’), 6.16 (br s, 1 H, NH), 5.61 (dd, 1 H, J T,y  5.5 Hz, J ? ,y  5.0 Hz, H- 
2'), 5.43 (t, 1 H, J y ,T = J y A« 9 .9  Hz, H-3"), 5.04 (t, 1 H, J r ,3"= J r ,5"9.9 Hz, H-4"), 4.97 (d, 
1 H, 3.3 Hz, H-l"), 4.72 (t, 1 H, J y ,T = J y A< 5.0 Hz, H-3'), 4.62 (AB, 1 H, Jab 12.1
Hz, 0.5 x OCJJ2Ar), 4.55-4.46 (m, 5 H, H-4’, 2 x O C//2Ar), 4.36 (AB, 1 H, Jab 12.1 Hz,
0.5 x OC7/2Ar), 4.10-3.97 (m, 1 H, H-5"), 3.71 (dd, 1 H, J 5%4- 2.9 Hz, J y ^  10.6 Hz, H- 
5'a), 3.63 (dd, 1 H, J 5 V r 3.3 Hz, J 5-b,5'a 10.6 Hz, H-5T)), 3.54 (dd, 1 H, 3.3 Hz, J T ,y  
9.9 Hz, H-2"), 3.43-3.35 (m, 2 H, H-6"a, H-6"b), 2.65-2.61 (m, 1 H, noradamantane), 
2.35-2.19 (m, 7 H, noradamantane), 2.05-1.94 (m, 1 H, noradamantane), 1.98 (s, 3 H, 
C //3CO), 1.94 (s, 3 H, CJ/3CO), 1.89 (s, 3 H, C //3CO) and 1.69-1.57 (m, 4 H, 
noradamantane); 13C NMR (100 MHz; CDC13) 170.42, 170.26, 169.89 (3 x OCOCH3),
154.69, 154.47, 149.82 (C-2, C-4, C-6), 138.39 (C-8), 137.76, 137.63, 137.50 (3 x C-l 
Bn ether ring), 128.77, 128.67, 128.54, 128.16, 128.04, 127.96, (ArCH), 119.43 (C-5), 
98.34 (C-l"), 86.22 (C-l'), 86.92, 74.84 (2 x CH), 73.95, 73.81, 73.55 (3 xOCH2Ar),
72.11 (CH), 69.63 (C-5' or C-6"), 69.52, 69.27 (2 x CH), 66.29 (C-5' or C-6"), 49.01 
(CH2, noradamantane), 43.57, 37.83 (CH, noradamantane), 35.32 (CH2 noradamantane) 
21.33, 21.14, 20.85 (3 x CH3CO); MS: (FAB) m/z 980.3 [(M+H)+, 80%], m/z calcd for
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NaOMe (5 mg, 0.092 mmol) was added to a solution of 
99 (90 mg, 0.092 mmol) in methanol (4 mL) and the 
HrjJ mixture was stirred for 90 min. It was then concentrated
¥ under reduced pressure to leave a white solid, which 
Il0^ \  Bno-^ \ o^/ ci was washed with water (10 mL) and extracted with
.N
chloroform (3 x 20 mL). The combined extracts were
BnO v  0H
dried (MgS04), filtered and concentrated under reduced 
pressure to give an oil, which was purified by flash chromatography on silica using 
dicloromethane-methanol (20:1) as eluent to give the title compound (65 mg, 84%) as a 
colourless oil.
[a ]20D +6.8 ± 1.0 (c 0.59, CHC13); 'H  NMR (400 MHz; CDCI3) &  7.98 (s, 1 H, H-8),
7.37-7.21 (m, 15 H, ArCH), 6.24 (d, 1 H, Jv?  5.9 Hz, H -l'), 5.84 (br s, 1 H, NH), 4.69 
(d, 1 H, JV3r 3.5 Hz, H -l”), 4.63 (AB, 1 H, Jab 11.7 Hz, 0.5 x OCH2Ar), 4.59^1.36 (m, 7 
H, H-2', H-3’, 2.5 x OCH2Ar), 4.15 ( t , 1 H, J yx= Jr ,4- 9.8 Hz, H-3"), 4.06-4.01 (m, 2 H, 
H-4', H-5"), 3.95 (dd, 1 H, J6 V  2.1 Hz, J 6 W  10.5 Hz, H-6"a), 3.76 (t, 1 H, Jr ,y=Jr,s- 
9.4 Hz, H-4'',) 3.66 (dd, 1 H, J 6-w - 7.4 Hz, Jew *  10.5 Hz H-6"b), 3.51-3.44 (m, 2 H, H- 
5'a, H-Sb), 3.41 (dd, 1 H, J r ,r  3.5 Hz, J 2-,3- 9.8 Hz, H-2"), 2.64-2.61 (m, 1 H, 
noradamantane), 2.35-2.18 (m, 6 H, noradamantane), 2.02-1.94 (m, 2 H, 
noradamantane) and 1.69-1.56 (m, 4 H, noradamantane); 13C NMR (100 MHz; CDCI3)
154.70, 153.74, 149.61 (C-2, C-4, C-6), 138.34 (C-8), 138.16, 137.59, 136.71 (3 x C-l 
Bn ether ring), 129.22, 128.96, 128.79, 128.47, 128.19, 127.96, 127.90, 127.77, 127.70 
(ArCH), 119.27 (C-5), 93.69 (C -l”), 87.97 (C -lf), 84.03, 81.59, 79.77, 77.68 (4 x CH), 
73.92, 73.79 (3 xOCH2Ar), 72.82, 72.77 (2 x CH), 70.66, 70.41 (C-5', C-6”), 68.82 
(CH), 48.92, 48.92 (CH2 noradamantane), 43.58 (CH noradamantane), 43.58 (CH2 
noradamantane), 37.83 (CH noradamantane) and 35.38 (CH2 noradamantane); MS: 
(FAB) m/z 854.2 [(M+H)+, 52%], m/z calcd for C46H52N509C1 [M+H]+ 37C1 857.3535 






mg, 0.28 mmol) and 1/7-tetrazole (29 mg, 0.42
HN mmol) were stirred together in dichloromethane
(  }\ V (3 mL) for 30 min, the mixture thus obtained was
BnCS l3n0r\ / K J  Cl then added to 100 (40 mg, 0.04 mmol). After a
0 )P O '" V ^ c\  V J
Bn6)2('o)PO-A^^X fiirther 20 min, TLC (ethyl acetate methanol,
BnN0 1/ OP(0)(OBn)2 v J
0 95:5) indicated conversion o f starting material to
a single trisphosphite. The reaction mixture was then cooled to -78  °C and mCPBA (95 
mg, 0.33 mmol) was added. After 10 min, 10 % aq. Na2S03 solution (15 mL) and ethyl 
acetate (20 mL) were added and the mixture was allowed to heat up to room temperature. 
The resulting organic layer was washed with sat. aq. NaHCC>3 solution (15 mL) and 
brine (15 mL). The organic layer was dried (MgSCU), filtered and concentrated under 
reduced pressure to leave an oil, which was purified by flash chromatography on silica 
using ethyl acetate-hexane (2:3 then 1:1 then 4:1) to give the title compound (35 mg, 
46%) as a colourless oil. *H NMR (400 MHz; CDC13) 4 17.72 (s, 1 H, H-8), 7.51-6.99 
(m, 45 H, ArCH), 6.24 (d, 1 H, J v,t 6.3 Hz, H -l’), 6.06 (br s, 1 H, Ntf), 5.51-5.46 (m, 1 
H, H-2’), 5.30 (d, 1 H, J r>T 4.3 Hz, H-l"), 5.04-4.33 (m, 21 H, H-3', H-4’, H-3", H-4" 8.5 
x O Ci/2Ar), 4.30 (AB, 1 H, JAB 11.7 Hz, 0.5 x OCH2Ai ), 3.82-3.78 (m, 1 H, H-5"), 
3.72-3.52 (m, 5 H, H-5'a, H-5'b, H-2", H-6"a, H-6"b), 2.63-2.59 (m, 1 H, 
noradamantane), 2.34-2.17 (m, 6 H, noradamantane), 2.09-1.98 (m, 2 H, 
noradamantane) and 1.65-1.56 (m, 4 H, noradamantane); 31P NMR (162 MHz; CDCI3; 
'h  decoupled) Se -0.23, -0.91, -0.11; MS: (FAB) m/z calcd for C g sH ^O ig P sC l 




A mixture o f 101 (10 mg, 0.0061 mmol) and 
Pd(OH)2 on carbon (10%, 30 mg) in cyclohexene (3 
mL), methanol (6 mL) and water (0.5 mL) was 
^  heated at 70 °C for 2 h. The catalyst was filtered and
H0^ ho^\/O s /N n washed well with de-ionised water and methanol.
The filtrate was concentrated under reduced pressure
H o i /  o p °3 2’
0 to a glassy solid. The residue was dissolved in de­
ionised water (1 mL) and applied to a Diaion WK-20 resin column (Na+ form), which
was developed by water. The eluent was concentrated under reduced pressure to give the 
title trisphosphate (3.6 pmol, 59%) as the sodium salt.
]H NMR (400 MHz; D20 )  Sh 8.04 (s, 1 H, H-8), 8.03 (s, 1 H, H-2), 6.05 (d, 1 H, J v,2' 5.5 
Hz, H -l’), 5.19 (d, 1 H, Jr,2" 3.5 Hz, H-l"), 5.06-5.02 (m, 1 H, H-2'), 4.57-4.22 (m, 3 H, 
H-3', H-4', H-3"), 3.83-3.55 (m, 7 H, H-5'a, K S'b, H-2", H-4" H-5", H-6"a, H-6"b),
2.37-2.35 (m, 1 H, noradamantane), 2.18-2.01 (m, 6 H, noradamantane) 1.88-1.86 (m, 2 
H, noradamantane) and 1.45-1.42 (m, 4 H, noradamantane); 31P NMR (162 MHz; D20 ; 
!H decoupled) 5? 3.44, 2.49 and 2.49; MS: (FAB) m/z 788.0 [(M-H)", 100%], m/z 
calcd for C^HsvNsOigPa [M -H]'788.1301 found m/z 788.1336:
199
References
[1] Berridge, M. J., Bootman, M. D., & Lipp, P. (1998) Calcium - a life and death 
signal. Nature (London), 395, 645-648.
[2] Guse, A. H. (2002) Cyclic ADP-ribose (cADPR) and Nicotinic Acid Adenine 
Dinucleotide Phosphate (NAADP): Novel Regulators o f Ca2+ Signalling and Cell 
Function. Curr. Mol. Med., 2,259-268.
[3] Galione, A. (1994) Cyclic ADP-ribose, the ADP-ribosyl cyclase pathway and 
calcium signalling. Mol. Cell. Endocrinol., 98, 125-131.
[4] Gu, Q.-M. & Sih, C. J. (1994) Cyclic ADP-Ribose: Synthesis and Structural 
Assignment. J. Am. Chem. Soc., 116, 7481-7486.
[5] Berridge, M. J. (1983) Rapid accumulation of inositol trisphosphate reveals that 
agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. 
Biochem. J., 212, 849-858.
[6] Rhee, S. G. (2001) Regulation o f phosphoinositide-specific phospholipase C. 
Annu. Rev. Biochem., 70, 281-312.
[7] Clapham, D. E. (1995) Calcium signaling. Cell, 80, 259-268.
[8] Thrower, E. C., Hagar, R. E., & Ehrlich, B. E. (2001) Regulation o f Ins(l,4,5)P3 
receptor isoforms by endogenous modulators. Trends Pharm Sci, 22, 580-586.
[9] Marchant, J. S. & Taylor, C. W. (1998) Rapid activation and partial inactivation 
o f inositol trisphosphate receptors by inositol trisphosphate. Biochem. 37, 
11524-11533.
[10] Hamada, K., Miyata, T., Mayanagi, K., Hirota, J., & Mikoshiba, K. (2002) Two- 
state conformational changes in inositol 1,4,5-trisphosphate receptor regulated by 
calcium. J. Biol. Chem., 277 ,21115-21118.
200
[11] Patel, S., Joseph, S. K., & Thomas ,A. P. (1999) Molecular properties of inositol
1,4,5-trisphosphate receptors. Cell Calcium, 2 5 ,247-264.
[12] Joseph, S. K. (1996) The inositol trisphosphate receptor family. Cell Signal, 8,
1-7.
[13] Yoshikawa, F., Morita, M., Monkawa, T., Michikawa, T., Furuichi, T., & 
Mikoshiba, K. (1996) Mutational analysis o f the ligand binding site o f the 
inositol 1,-4,5-trisphosphate receptor. J. Biol Chem., 271 , 18277-18284.
[14] Newton, C. L., Mignery, G. A., & Sudhof, T. C. (1994) Coexpression in 
vertebrate tissues and cell-lines of multiple inositol 1,4,5-trisphosphate 
Ins(l,4,5)P3 Receptors with distinct affinities for Ins(l,4,5)P3. J. Biol Chem., 
2 69 , 28613-28619.
[15] Nerou, E. P., Riley, A. M., Potter, B. V. L., & Taylor, C. W. (2001) Selective 
recognition o f inositol phosphates by subtypes o f the inositol trisphosphate 
receptor. Biochem. J., 3 5 5 , 59-69.
[16] Wojcikiewicz, R. H. & Luo, S. G. (1998) Differences among type I, II, and III 
inositol-1,4,5-trisphosphate receptors in ligand-binding affinity influence the 
sensitivity o f calcium stores to inositol-1,4,5-trisphosphate. Mol. Pharmacol., 53, 
656-662.
[17] Galvan, D. L., Borrego-Diaz, E., Perez, P. J., & Mignery, G. A. (1999) Subunit 
oligomerization, and topology of the inositol 1,4,5-trisphosphate receptor. J. 
Biol. Chem., 274 , 29483-29492.
[18] Yoshida, Y. & Imai, S. (1997) Structure and function o f inositol 1,4,5- 
trisphosphate receptor. Jpn. J. Pharmacol., 74, 125-137.
[19] Jiang Q-X, Thrower, E. C., Chester, D. W., Ehrlich, B. E., & Sigworth, F. J. 
(2002) Three-dimensional structure o f the type 1 inositol 1,4,5-trisphosphate 
receptor at 24 A resolution. EMBOJ, 2 1 , 3575-3581.
201
[20] Mikoshiba, K. (1997) The Ins(l,4,5)P3 receptor and intracellular Ca2+ signaling. 
Curr. Opin. Neurobiol, 7, 339-345.
[21] Berridge, M. J. (1993) Inositol trisphosphate and calcium signalling. Nature 
(London), 3 6 1 , 315-325.
[22] Potter, B. V. L. & Lampe, D. (1995) Chemistry o f inositol lipid mediated cellular 
signalling. Angew. Chem. Int. Ed. Engl., 34 , 1933-1972.
[23] Balia, T. (2001) Pharmacology o f phosphoinositides, regulators o f multiple 
cellular functions. Curr. Pharm. Des., 7, 475-507.
[24] Wilcox, R. A., Primrose,W.U., Nahorski, S. R., & Challiss, R. A. J. (1998) New 
developments in the pharmacology o f the myoinositol 1,4,5-trisphosphate 
receptor. Trends Pharm Sci, 19, 467-475.
[25] Inoue, T., Kikuchi, K., Hirose, K., lino, M., & Nagano, T. (1999) Synthesis and 
evaluation o f 1-position-modified inositol 1,4,5-trisphosphate analogues. Bioorg. 
Med. Chem. Lett., 9, 1697-1702.
[26] Nakanishi, w., Kikuchi,K., Inoue,T., Hirose,K., Iino,M., & Nagano,T. (2002) 
Hydrophobic modifications at 1-phosphate o f inositol 1,4,5- trisphosphate 
analogues enhance receptor binding. Bioorg. Med. Chem. Lett., 12, 911-913.
[27] Safrany, S. T., Wilcox, R. A., Liu, C., Potter, B. V. L., & Nahorski, S. R. (1992)
3-Position modification o f myo-inositol 1,4,5-trisphosphate: consequences for 
• 2+  •intracellular Ca mobilisation and enzyme recognition. Eur. J. Pharmacol.- 
Molecular Pharmacology Section, 226 , 265 -272.
[28] Safrany, S. T., Wojcikiewicz, R. J. H., Strupish, J., Nahorski, S. R., Dubreuil, D., 
Cleophax, J., Gero, S. D., & Potter, B. V. L. (1991) Interaction o f synthetic D-
• 94 -myo-6-deoxy-inositol 1,4,5-trisphosphate with the Ca 'releasing D-myo-inositol
1,4,5-trisphosphate receptor, and the metabolic enzymes 5-phosphatase and 3- 
kinase. FEBSLett., 2 7 8 ,252 -256.
202
[29] Gawler, D. J., Potter, B. V. L., Gigg, R., & Nahorski, S. R. (1991) Interactions 
between inositol tris- and tetrakis-phosphates. Biochem. J., 276, 163-167.
[30] Wilcox, R. A., Fauq, A. H., Kozikowski, A. P., & Nahorski, S. R. (1997) 
Defining the minimal structural requirements for partial agonism at the type I 
rayo-inositol 1,4,5-trisphosphate receptor. FEES Lett., 4 0 2 ,241-245.
[31] Mezna, M. & Michelangeli, F. (1996) The effects o f inositol 1,4,5-trisphosphate 
analogues on the transient kinetics o f Ca release from cerebellar microsomes. J. 
Biol Chem., 271,31818-31823.
[32] Maruyama, T., Kanaji, T., Nakade, S., Kanno, T., & Mikoshiba, K. (1997) 2APB, 
2-Aminoethoxydiphenyl borate, a membrane penetrable modulator o f 
Ins(l,4,5)P3-induced Ca2+ release. J. Biochem., 1 2 2 ,498-505.
[33] Hurley, J. H. & Meyer, T. (2001) Subcellular targeting by membrane lipids. Curr. 
Opin. Cell Biol., 13, 146-152.
[34] Ellson, C. D., Andrews, S., Stephens, L. R., & Hawkins, P. T. (2002) The PX 
domain: a new phosphoinositide-binding module. J. Cell Sci., 115, 1099-1105.
[35] Maffucci, T. & Falasca, M. (2001) Specificity in pleckstrin homology (PH) 
domain membrane targeting: a role for a phosphoinositide-protein co-operative 
mechanism. FEBS Lett, 506, 173-179.
[36] Bottomley, M. J., Salim, K., & Panayotou, G. (1998) Phospholipid-binding 
protein domains. Biochim. Biophys. Acta, 1436, 165-183.
[37] Ferguson, K. M., Lemmon, M. A., Schlessinger, J., & Sigler, P. B. (1995) 
Structure of the high affinity complex of inositol trisphosphate with a 
phospholipase C pleckstrin homology domain. Cell, 83, 1037-1046.
[38] Hyvonen, M., Macias, M. J., Nilges, M., Oschkinat, H., Saraste, M., & Williams, 
M. (1995) Structure o f the binding site for inositol phosphates in a PH domain. 
EMBOJ., 1 4 ,4676-4685.
203
[39] Hamada, K., Shimizu, T., Matsui, T., Tsukita, S., Tsukita, S., & Hakoshima, T. 
(2002) Structural basis o f the membrane-targeting and unmasking mechanisms of 
the radixin FERM domain. EMBOJ, 19,4449-4462.
[40] Takahashi, M., Kagasaki, T., Hosoya, T., & Takahashi, S. (1993) Adenophostins 
A and B: potent agonists o f inositol-1,4,5-trisphosphate receptor produced by 
Penicillium brevicompactum. J. Antibiot., 4 6 , 1643-1647.
[41] Takahashi, S., Kinoshita, T., & Takahashi, M. (1994) Adenophostins A and B: 
Potent agonists o f inositol-1,4,5-trisphosphate receptor produced by Penicillium 
brevicompactum - Structure elucidation. J. Antibiot., 4 7 , 95-100.
[42] Hotoda, H., Takahashi, M., Tanzawa, K., Takahashi, S., & Kaneko, M. (1995) 
Ins(l,4,5)P3 receptor-ligand. lrSynthesis of adenophostin A. Tetrahedron Lett., 
36 , 5037-5040.
[43] Correa, V., Riley, A. M., Shuto, S., Home, G., Nerou, E. P., Marwood, R. D., 
Potter, B. V. L., & Taylor, C. W. (2001) Structural determinants o f adenophostin 
A activity at inositol trisphosphate receptors. Mol. Pharmacol., 59, 1206-1215.
[44] Takahashi, M., Tanzawa, K., & Takahashi, S. (1994) Adenophostins, Newly 
Discovered Metabolites of Penicillium brevicompactum, Act as Potent Agonists 
o f the Inositol 1,4,5-Trisphosphate Receptor. J. Biol. Chem., 269 , 369-372.
[45] Felemez, M., Marwood, R. D., Potter, B. V. L., & Spiess, B. (1999) 
Intramolecular studies o f the protonation o f adenophostin A: Comparison with 1- 
D-myo-inositol 1,4,5-trisphosphate. Biochem Biophys Res Commun, 266, 334- 
340.
[46] Jenkins, D. J. & Potter, B. V. L. (1996) A Ca2+ -mobilising carbohydrate-based 
polyphosphate: synthesis of 2-hydroxyethyl a-D-glucopyranoside 2’,3,4- 
trisphosphate. Carbohydr. Res., 287 , 169-182.
204
[47] Wilcox, R. A., Emeux, C., Primrose, W. U., Gigg, R., & Nahorski, S. R. (1995) 
2-hydroxyethyl a-D-glucopyranoside 2,3',4'-trisphosphate - a novel metabolically 
resistant adenophostin A and myo-inositol 1,4,5-trisphosphate analogue potently 
interacts with the myo inositol 1,4,5-trisphosphate receptor. Biochem. Soc. 
Trans., 23 , S 420-S 420.
[48] Wilcox, R. A., Emeux, C., Primrose, W. U., Gigg, R., & Nahorski, S. R. (1995)
2-hydroxyethyl a-D-glucopyranoside 2,3',4'-trisphosphate - a novel metabolically 
resistant adenophostin A and myo-inositol 1,4,5-trisphosphate analogue potently 
interacts with the myo inositol 1,4,5-trisphosphate receptor. Mol. Pharmacol., 47, 
1204-1211.
[49] Moitessier, N., Chretien, F., Chapleur, Y., & Humeau, C. (1995) Synthesis and 
biological-activities o f inositol 1,4,5-trisphosphates mimics related to 
xylopyranosides. Tetrahedron Lett., 3 6 , 8023-8026.
[50] Roussel, F., Hilly, M., Chretien, F., Mauger, J. P., & Chapleur, Y. (1999) 
Synthesis and biological evaluation o f (2-hydroxyethyl) 2- deoxy-alpha-D-threo- 
pyranoside 3,4,2 '-trisphosphate, a mimic o f the second messenger inositol 1,4,5- 
trisphosphate. J. Carbohydr Chem, 18, 697-707.
[51] Riley, A. M., Guedat, P., Schlewer, G., Spiess, B., & Potter, B. V. L. (1998) A 
conformationally restricted cyclic phosphate analogue of inositol trisphosphate: 
Synthesis and physicochemical properties. J. Org. Chem., 63, 295-305.
[52] de Kort, M., Regenbogen, A. D., Valentijn, A. R. P. M., Challiss, R. A. J., Iwata, 
Y., Miyamoto, S., van der Marcel, G. A., & van Boom, J .H. (2000) 
Spirophostins: Conformationally restricted analogues of adenophostin A. Chem. 
Eur. J., 6, 2696-2704.
[53] Riley, A. M., Correa, V., Mahon, M. F., Taylor, C. W., & Potter, B. V. L. (2001) 
Bicyclic analogues o f D-myo-inositol 1,4,5-trisphosphate related to adenophostin 
A: Synthesis and biological activity. J. Med. Chem., 44 ,2108-2117.
205
[54] Marchant, J. S., Beecroft, M. D., Riley, A. M., Jenkins, D. J., Marwood, R. D., 
Taylor, C. W., & Potter, B. V. L. (1997) Disaccharide polyphosphates based 
upon adenophostin A activate hepatic D-myoinositol 1,4,5-trisphosphate 
receptors. Biochem. 36, 12780-12790.
[55] Jenkins, D. J., Marwood, R. D., & Potter, B. V. L. (1997) A disaccharide 
polyphosphate mimic of D-myo-inositol 1,4,5-trisphosphate. Chem. Commun., 
449-450.
[56] Shuto, S., Tatani, K., Ueno, Y., & Matsuda, A. (1998) Synthesis o f adenophostin 
mimics lacking the adenine moiety as novel potent Ins(l,4,5)P3 receptor ligands: 
Some structural requirements for the significant activity of adenophostin A. J. 
Org. Chem., 63, 8815-8824.
[57] Marwood, R. D., Riley, A. M., Correa, V., Taylor, C. W., & Potter, B. V. L.
(1999) Simplification o f adenophostin A defines a minimal structure for potent 
glucopyranoside-based mimics o f D-myo-inositol 1,4,5-trisphosphate. Bioorg. 
Med. Chem. Lett., 9 ,453—458.
[58] de Kort, M., Valentijn, G., van der Marel, G. A., & van Boom, J. H. (1997) 
Synthesis o f clustered disaccharide polyphosphate analogues o f adenophostin A. 
Tetrahedron Lett., 38 , 7629-7632.
[59] de Kort, M., Correa, V., Valentijn, A. R. P. M., van der Marel, G. A., Potter, B. 
V. L., Taylor, C. W., & van Boom, J. H. (2000) Synthesis o f potent agonists of 
the D-myo-inositol 1,4,5- trisphosphate receptor based on clustered disaccharide 
polyphosphate analogues o f adenophostin A. J. Med. Chem., 43 , 3295-3303.
[60] Marwood, R. D., Correa, V., Taylor, C. W., & Potter, B. V. L. (2000) Synthesis 
o f adenophostin A. Tetrahedron Asymmetry, 11, 397—403.
[61] van Straten, N. C. R., van der Marel, G. A., & van Boom, J. H. (1996) An 
expeditious route to the synthesis o f adenophostin A. Tetrahedron Lett., 37, 
3599-3602.
206
[62] Hotoda, H., Murayama, K., Miyamoto, S., Iwata, Y., Takahashi, M., Kawase, Y., 
Tanzawa, K., & Kaneko, M. (1999) Molecular recognition of adenophostin, a 
very potent Ca2+ inducer, at the D-myo-inositol 1,4,5-trisphosphate receptor. 
Biochem. 38,9234-9241.
[63] Marwood, R. D., Riley, A. M., Jenkins, D. J., & Potter, B. V. L. (2000) Synthesis 
o f adenophostin A and congeners modified at glucose. J. Chem. Soc., Perkin 
Trans. 7, 1935-1947.
[64] Marwood, R. D., Jenkins, D. J., Correa, V., Taylor, C. W., & Potter, B. V. L. 
(2000) Contribution o f the adenine base to the activity o f adenophostin A 
investigated using a base replacement strategy. J. Med. Chem., 4 3 , 4278-4287.
[65] Shuto, S., Home, G., Marwood, R. D., & Potter, B. V L. (2001) Total synthesis 
of nucleobase-modified adenophostin A mimics. Chem. Eur. J., 7,4937-4946.
[66] van Straten, N. C. R., van der Marel, G. A., & van Boom, J. H. (1997) Synthesis 
o f 2l,3",4"-trisphosphate-containing analogues o f Adenophostin A. Tetrahedron, 
53 , 6523-6538.
[67] van Straten, N. C. R., Kriek, N. M. A. J., Cziria, Z. A. C., van der Marel, G. A., 
& van Boom, J. H. (1997) Synthesis o f 3",4"-bisphosphate-containing analogues 
of Adenophostin A. Tetrahedron, 53 , 6539-6554.
[68] Beecroft, M. D., Marchant, J. S., Riley, A. M., van Straten, N. C. R., van der 
Marel, G. A., van Boom, J. H., Potter, B. V. L., & Taylor, C. W. (1999) 
Acyclophostin: A ribose-modified analogue o f adenophostin A with high affinity 
for inositol 1,4,5-trisphosphate receptors and pH-dependent efficacy. Mol. 
Pharmacol., 1, 109-117.
[69] Roussel, F., Moitessier, N., Hilly, M., Chretien, F., Mauger, J. P., & Chapleur, Y. 
(2002) D-myo-inositol- 1,4,5-trisphosphate and adenophostin A mimics: 
Importance o f the spatial orientation o f a phosphate group on the biological 
activity. Bioorg. Med. Chem., 10, 759-768.
207
[70] de Kort, M., Regenbogen, A. D., Overkleeft, H. S., Challiss, R. A. J., Iwata, Y., 
Miyamoto, S., van der Marel, G. A., & van Boom, J. H. (2000) Synthesis and 
biological evaluation of cyclophostin: A 5 ',6 "-tethered analogue of adenophostin 
A. Tetrahedron, 56, 5915-5928.
[71] de Kort, M., Luijendijk, J., van der Marel, G. A., & van Boom, J. H. (2000) 
Synthesis o f photoaffinity derivatives o f adenophostin A. Eur. J. Org. Chem., 
3085-3092.
[72] Riley, A. M., Murphy, C. T., Lindley, C. J., Westwick, J., & Potter, B. V. L. 
(1996) 6-Deoxy-6-hydroxymethyl scy//o-inositol 1,2.4-trisphosphate: A potent 
agonist at the inositol 1,4,5-trisphosphate receptor. Bioorg. Med. Chem. Lett., 6, 
2197-2200.
[73] Jiang, L. & Chan, T.-H. (1998) Regioselective acylation of hexopyranosides with 
pivaloyl chloride. J. Org. Chem., 63, 6035-6038.
[74] Ley, S. V., Baeschlin, D. K., Dixon, D. J., Foster, A. C., Ince, S. J., Priepke, H. 
W. M., & Reynolds, D. J. (2001) 1,2-diacetals: A new opportunity for organic 
synthesis. Chem. Rev., 101, 53-80.
[75] Buchanan, J. G., Edgar, A. R., Rawson, D. I., Shahidi, P., & Wightman, R. H. 
(1982) Assignment of ring size in isopropylidene acetals by 13C NMR- 
spectroscopy. Carbohydr. Res., 100, 75-86.
[76] Jenkins, D. J. & Potter, B. V. L. (1998) Total synthesis, from D-xylose, o f chiral, 
ring-contracted lD-myo-inositol 1,4,5-trisphosphate and 1,3,4,5-tetrakisphosphate 
analogues with C-2 excised. J. Chem. Soc., Perkin Trans. 1, 41-49.
[77] Rajanbabu, T. V. & Reddy, G. S. (1986) 1-methylene sugars as C-glycoside 
precursors. J. Org. Chem., 51, 5458-5461.
[78] Pine, S. H., Shen, G. S., & Hoang, H. (1991) Ketone methylenation using the 
Tebbe and Wittig reagents-A comparison. Synthesis-Stuttgart, 165-167.
208
[79] Tanaka, T., Tamatsukuri, S., & Ikehara, M. (1986) New approach to the synthesis 
of deoxynucleoside-phosphoramide derivatives. Tetrahedron Lett., 27, 199-202.
[80] Sawyer, D. A. & Potter, B. V. L. (1992) Total Synthesis of fluorinated analogues 
o f inositol and inositol 1,4,5-trisphosphate. J. Chem. Soc. Perkin Trans. 7, 923- 
932.
[81] Shuto, S., Terauchi, M., Yahiro, Y., Abe, H., Ichikawa, S., & Matsuda, A. (2000) 
Stereoselective synthesis o f alpha and beta-C-glucosides via radical cyclization 
with an allylsilyl tether. Control o f the stereoselectivity by changing the 
conformation of the pyranose ring. Tetrahedron Lett., 41,4151—4155.
[82] Shuto, S., Yahiro, Y., Ichikawa, S., & Matsuda, A. (2000) Synthesis o f 3,7- 
anhydro-D-glycero-D-ido-octitol 1,5,6- trisphosphate as an Ins(l,4,5)P3 receptor 
ligand using a radical cyclization reaction with a vinylsilyl tether as the key step. 
Conformational restriction strategy using steric repulsion between adjacent bulky 
protecting groups on a pyranose ring. J. Org. Chem., 65, 5547-5557.
[83] Shuto, S., Fukuoka, M., Abe, H., & Matsuda, A. (2001) Intracellular Ca2+' 
mobilizing adenine nucleotides. Synthesis and biological activity o f cyclic ADP- 
carbocyclic-ribose and C- glycosidic analogue o f adenophostin A. Nucleosides 
Nucleotides Nucleic Acids, 20, 461—470.
[84] Shuto, S., Potter, B. V. L., & Taylor, C. W. (2002) C-glycoside adenophostin A 
analogues. Unpublished.
[85] Rosenberg, H. J., Riley, A. M., Correa, V., Taylor, C. W., & Potter, B. V. L.
(2000) C-glycoside based mimics o f D-wyo-inositol 1,4,5-trisphosphate. 
Carbohydr. Res., 329, 7-16.
[86] Demchenko, A., Stauch, T., & Boons, G.-J. (1997) Solvent and other effects on 
the stereoselectivity o f thioglycoside glycosidations. Synlett, 818-820.
209
[87] Ogawa, T., Takahashi, Y., & Matsui, M. (1982) Glucan synthesis .1. 
regioselective alkylation via trialkylstannylation, methyl alpha D 
glucopyranoside. Carbohydr. Res., 102,207-215.
[88] Felemez, M., Bernard, P., Schlewer, G., & Spiess, B. (2000) Intramolecular 
protonation process o f wyo-inositol 1,4,5- trisphosphate and related compounds: 
Dynamics of the intramolecular interactions. J. Am. Chem. Soc., 122, 3156— 
3165.
[89] Wilcox, R. A., Primrose, W. U., Nahorski, S. R., & Challiss, R. A. J. (1998) New 
developments in the pharmacology o f the myoinositol 1,4,5-trisphosphate 
receptor. Trends Pharmacol. Sci., 19 ,467—475.
[90] Reddy, G. S. & Kinzy, W. (1994) Anomeric oxygen activation for glycoside 
synthesis-the trichloroacetimidate method. Adv Carbohydrate Chem. Biochem., 
50,21-123.
[91] Rosenberg, H. J., Riley, A. M., Marwood, R. D., Correa, V., Taylor, C. W., & 
Potter, B. V. L. (2001) Xylopyranoside-based agonists of D-myoinositol 1,4,5- 
trisphosphate receptors: Synthesis and effect o f stereochemistry on biological 
activity. Carbohydr. Res., 332, 53-66.
[92] Watanabe, Y., Nakamoto, C., & Ozaki, S. (1993) Glycosylation based on 
phosphite chemistry. Synlett, 115-116.
[93] Garegg, P. J. (1997) Thioglycosides as glycosyl donors in oligosaccharide 
synthesis. Adv Carbohydr Chem Biochem, 5 2 ,179-205.
[94] Vorbriiggen, H., Krolikiewicz, K., & Bennua, B. (1981) Nucleoside synthesis 
with trimethysilyl triflate and perchlorate as catalysts. Chem. Ber., 114, 1234- 
1255.
[95] Jacobson, K. A., Vangalen, P. J. M., & Williams, M. (1992) Adenosine receptors 
- Pharmacology, structure-activity- relationships and therapeutic potential. J. 
Med. Chem., 35, 407-422.
210
[96] Kristinsson, H., Nebel, K., O’Sullivan, A. C., Struber, F., Winkler, T., & 
Yamaguchi, Y. (1994) A novel synthesis o f sulfamoyl nucleosides. Tetrahedron, 
50, 6825-6838.
[97] Schaeffer, H. J. & Thomas, H. J. (1958) Synthesis o f Potential Anticancer agents. 
XIV. Ribosides of 2,6-Disubstituted Purines. J. Am. Chem. Soc., 80, 3738-3742.
[98] Adkins, C. E., Wissing, F., Potter, B. V. L., & Taylor, C. W. (2000) Rapid 
activation and partial inactivation o f inositol trisphosphate receptors by 
adenophostin A. Biochem. J., 352, 929-933.
[99] Parekh, A. B., Riley, A. M., & Potter, B. V. L. (2002) Adenophostin A and 
ribophostin, but not inositol 1,4,5- trisphosphate or wa««o-adenophostin, activate 
the Ca2+ release- activated Ca2+ current, I-CRAC, in weak intracellular Ca2+ 
buffer. Biochem. J., 361, 133-141.
[100] Mak, D. O. D., McBride, S., & Foskett, J. K. (2001) ATP-dependent 
adenophostin activation inositol 1,4,5- trisphosphate receptor channel gating - 
Kinetic implications for the durations o f calcium puffs in cells. J. Gen. Physiol., 
117,299-314.
[101] Morris, S. A., Nerou, E. P., Riley, A. M., Potter, B. V. L., & Taylor, C. W. (2002) 
Determinants o f adenophostin A binding to inositol trisphosphate receptors. 
Biochem. J., In press.
[102] Hirata, M., Yanaga, F., Koga, T., Ogasawara, T., Watanabe, Y., & Ozaki, S. 
(1990) Stereospecific recognition of inositol 1,4,5-trisphosphate analogues by the 
phosphatase, kinase and binding proteins. J. Biol. Chem., 265, 8404-8407.
[103] Macchia, M., Salvetti, F., Bertini, S., Di Bussolo, V., Gattuso, L., Gesi, M., 
Hamdan, M., Klotz, K. N., Laragione, T., Lucacchini, A., Minutolo, F., Nencetti, 
S., Papi, C., Tuscano, D., & Martini, C. (2001) 7-Nitrobenzofiirazan (NBD) 
derivatives o f 5 '-N- ethylcarboxamidoadenosine (NECA) as new fluorescent
211
probes for human A(3) adenosine receptors. Bioorg. Med. Chem. Lett., 11, 3023- 
3026.
[104] Ostermann, N., Ahmadian, M. R., Wittinghofer, A., & Goody, R. S. (1999) New 
N-2-labelled fluorescent derivatives o f guanosine nucleotides and their 
interaction with GTP-binding proteins. Nucleosides Nucleotides, 18 ,245-262.
[105] Kramer, R. H. & Karpen, J. W. (1998) Spanning binding sites on allosteric 
proteins with polymer- linked ligand dimers. Nature (London), 395, 710-713.
[106] Katayama, E., Funahashi, H., Michikawa, T., Shiraishi, T., Ikemoto, T., lino, M., 
Hirosawa, K., & Mikoshiba, K. (1996) Native structure and arrangement o f 
inositol-1,4,5- trisphosphate receptor molecules in bovine cerebellar Purkinje 
cells as studied by quick-freeze deep-etch electron microscopy. EMBO J., 15, 
4844-4851.
[107] Kanaseki, T., Ikeuchi, Y., & Tashiro, Y. (1998) Rough surfaced smooth 
endoplasmic reticulum in rat and mouse cerebellar Purkinje cells visualized by 
quick-freezing techniques. Cell Structure and Function, 23, 373-387.
[108] Riley, A. M. & Potter, B. V. L. (2000) Poly(ethylene glycol)-linked dimers o f D - 
wyo-inositol 1,4,5- trisphosphate. Chem. Commun., 983-984.
[109] Contour, M. O., Defaye, J., Little, M., & Wong, E. (1989) Stereoselective 
thiogylocoside synthesis o f 1,2-trans-l- thioglycopyranosides. Carbohydr. Res., 
193, 283-287.
[110] Tino, J. A., Clark, J. M., Field, A. K., Jacobs, G. A., Lis, K. A., Michalik, T. L., 
McGeeverrubin, B., Slusarchyk, W. A., Spergel, S. H., Sundeen, J. E., Tuomri, 
A. V., Weaver, E. R., Young, M. G., & Zahler, R. (1993) Synthesis and antiviral 
activity o f novel isonucleoside analogs. J. Med. Chem.36,1221-1229.
[111] Desai, T., Gigg, J., & Gigg, R. (1996) Synthesis o f 2-(9-allyl-(and 3-O-allyl-) 5- 
0-benzyl-/?-D-ribofuranoside. Carbohydr. Res., 280 ,209-221.
212
